



(86) Date de dépôt PCT/PCT Filing Date: 2001/04/03

(87) Date publication PCT/PCT Publication Date: 2001/10/18

(45) Date de délivrance/Issue Date: 2010/07/13

(85) Entrée phase nationale/National Entry: 2003/02/27

(86) N° demande PCT/PCT Application No.: US 2001/010872

(87) N° publication PCT/PCT Publication No.: 2001/077171

(30) Priorités/Priorities: 2000/04/05 (US60/194,731);
2000/07/28 (US60/222,121)

(51) Cl.Int./Int.Cl. *C12N 15/12* (2006.01),
A61K 38/19 (2006.01), *C07K 14/715* (2006.01),
C07K 16/28 (2006.01), *C12N 15/62* (2006.01),
C12N 5/10 (2006.01), *A61K 38/00* (2006.01)

(72) Inventeurs/Inventors:
SPRECHER, CINDY A., US;
NOVAK, JULIA E., US;
WEST, JAMES W., US;
PRESNELL, SCOTT R., US;
HOLLY, RICHARD D., US;
NELSON, ANDREW J., US

(73) Propriétaire/Owner:
ZYMOGENETICS, INC., US

(74) Agent: OGILVY RENAULT LLP/S.E.N.C.R.L., S.R.L.

(54) Titre : RECEPTEURS DE CYTOKINES ZALPHA11 SOLUBLES

(54) Title: SOLUBLE ZALPHA11 CYTOKINE RECEPTORS

(57) **Abrégé/Abstract:**

Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for soluble zalpha11 receptors that may be used as novel cytokine antagonist, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block zalpha11 Ligand activity in vitro and in vivo, and may be used in conjunction with zalpha11 Ligand and other cytokines to selectively stimulate the immune system. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 October 2001 (18.10.2001)

PCT

(10) International Publication Number
WO 01/77171 A3

(51) International Patent Classification⁷: **C12N 15/12**,
15/62, 5/10, C07K 14/715, 16/28, A61K 38/19

(74) Agent: **JOHNSON, Jennifer, K.**; ZymoGenetics, Inc.,
1201 Eastlake Avenue East, Seattle, WA 98102 (US).

(21) International Application Number: PCT/US01/10872

(22) International Filing Date: 3 April 2001 (03.04.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/194,731 5 April 2000 (05.04.2000) US
60/222,121 28 July 2000 (28.07.2000) US

(71) Applicant: **ZYMOGENETICS, INC.** [US/US]; 1201
Eastlake Avenue East, Seattle, WA 98102 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
16 May 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors: **SPRECHER, Cindy, A.**; 8207 39th Avenue NE, Seattle, WA 98115 (US). **NOVAK, Julia, E.**; 10699 Battle Point Drive Northeast, Bainbridge Island, WA 98110 (US). **WEST, James, W.**; 7539 19th NE, Seattle, WA 98115 (US). **PRESNELL, Scott, R.**; 2902 N. Puget Sound Avenue, Tacoma, WA 98407 (US). **HOLLY, Richard, D.**; 12539 10th Avenue N.W., Seattle, WA 98177 (US). **NELSON, Andrew, J.**; 1829 Northeast 170th Street, Shoreline, WA 98155 (US).

(54) Title: SOLUBLE ZALPHA11 CYTOKINE RECEPTORS

(57) Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for soluble zalpha11 receptors that may be used as novel cytokine antagonist, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block zalpha11 Ligand activity in vitro and in vivo, and may be used in conjunction with zalpha11 Ligand and other cytokines to selectively stimulate the immune system. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.

WO 01/77171 A3



Description

5

SOLUBLE ZALPHA11 CYTOKINE RECEPTORS

BACKGROUND OF THE INVENTION

Hormones and polypeptide growth factors control proliferation and differentiation of cells of multicellular organisms. These diffusable molecules allow
10 cells to communicate with each other and act in concert to form cells and organs, and to repair damaged tissue. Examples of hormones and growth factors include the steroid hormones (e.g. estrogen, testosterone), parathyroid hormone, follicle stimulating hormone, the interleukins, platelet derived growth factor (PDGF), epidermal growth factor (EGF), granulocyte-macrophage colony stimulating factor (GM-CSF),
15 erythropoietin (EPO) and calcitonin.

Hormones and growth factors influence cellular metabolism by binding to receptors. Receptors may be integral membrane proteins that are linked to signaling pathways within the cell, such as second messenger systems. Other classes of receptors are soluble molecules, such as the transcription factors. Of particular interest are
20 receptors for cytokines, molecules that promote the proliferation and/or differentiation of cells. Examples of cytokines include erythropoietin (EPO), which stimulates the development of red blood cells; thrombopoietin (TPO), which stimulates development of cells of the megakaryocyte lineage; and granulocyte-colony stimulating factor (G-CSF), which stimulates development of neutrophils. These cytokines are useful in
25 restoring normal blood cell levels in patients suffering from anemia, thrombocytopenia, and neutropenia or receiving chemotherapy for cancer.

The demonstrated *in vivo* activities of these cytokines illustrate the enormous clinical potential of, and need for, other cytokines, cytokine agonists, and cytokine antagonists or binding partners. The present invention addresses these needs
30 by providing a new cytokine antagonist or binding partner, a soluble hematopoietic cytokine receptor, as well as related compositions and methods.

The present invention provides such polypeptides for these and other uses that should be apparent to those skilled in the art from the teachings herein.

DESCRIPTION OF THE INVENTION

5 Within one aspect, the present invention provides an isolated polynucleotide that encodes a soluble receptor polypeptide comprising a sequence of amino acid residues that is at least 90% identical to the amino acid sequence as shown in SEQ ID NO:6, and wherein the soluble receptor polypeptide encoded by the polynucleotide sequence binds a ligand comprising a polypeptide of SEQ ID NO:10 or
10 SEQ ID NO:47, or antagonizes the ligand activity. In one embodiment, the isolated polynucleotide is as disclosed above, wherein the soluble receptor polypeptide encoded by the polynucleotide forms a homodimeric receptor complex.

 Within another aspect, the present invention provides an isolated polynucleotide that encodes a soluble receptor polypeptide comprising a sequence of
15 amino acid residues that is at least 90% identical to the amino acid sequence as shown in SEQ ID NO:6, wherein the soluble receptor polypeptide encoded by the polynucleotide forms a heterodimeric or multimeric receptor complex. In one embodiment, the isolated polynucleotide is as disclosed above, wherein the soluble receptor polypeptide encoded by the polynucleotide forms a heterodimeric or
20 multimeric receptor complex further comprising a soluble Class I cytokine receptor.

 In one embodiment, the isolated polynucleotide is as disclosed above, wherein the soluble receptor polypeptide encoded by the polynucleotide forms a heterodimeric or multimeric receptor complex further comprising a soluble IL-2R γ receptor polypeptide (SEQ ID NO:4) or a soluble IL-13 α' receptor polypeptide (SEQ ID
25 NO:82). In another embodiment, the isolated polynucleotide is as disclosed above, wherein the polypeptide further comprises a WSXWS motif as shown in SEQ ID NO:13.

 Within another aspect, the present invention provides an isolated polynucleotide that encodes a soluble receptor polypeptide comprising a sequence of
30 amino acid residues as shown in SEQ ID NO:6, wherein the soluble receptor polypeptide encoded by the polynucleotide forms a heterodimeric or multimeric

receptor complex. In one embodiment, the isolated polynucleotide is as disclosed above, wherein the soluble receptor polypeptide encoded by the polynucleotide further comprises a soluble Class I cytokine receptor. In another embodiment, the isolated polynucleotide is as disclosed above, wherein the soluble receptor polypeptide encoded
5 by the polynucleotide forms a heterodimeric or multimeric receptor complex further comprising a soluble IL-2R γ receptor polypeptide (SEQ ID NO:4) or a soluble IL-13 α' receptor polypeptide (SEQ ID NO:82). In another embodiment, the isolated polynucleotide is as disclosed above, wherein the soluble receptor polypeptide is encoded by the polynucleotide as shown in SEQ ID NO:7. In another embodiment, the
10 isolated polynucleotide is as disclosed above, wherein the soluble receptor polypeptide further comprises an affinity tag.

Within a second aspect, the present invention provides an expression vector comprising the following operably linked elements: (a) a transcription promoter; a first DNA segment encoding a soluble receptor polypeptide having an amino acid
15 sequence as shown in SEQ ID NO:6; and a transcription terminator; and (b) a second transcription promoter; a second DNA segment encoding a soluble Class I cytokine receptor polypeptide; and a transcription terminator; and wherein the first and second DNA segments are contained within a single expression vector or are contained within independent expression vectors. In one embodiment, the expression vector disclosed
20 above further comprises a secretory signal sequence operably linked to the first and second DNA segments. In another embodiment, the expression vector is as disclosed above, wherein the second DNA segment encodes a soluble IL-2R γ receptor polypeptide (SEQ ID NO:4) or a soluble IL-13 α' receptor polypeptide (SEQ ID NO:82).

25 Within a third aspect, the present invention provides a cultured cell comprising an expression vector as disclosed above, wherein the cell expresses the polypeptides encoded by the DNA segments. In one embodiment, the cultured cell comprising an expression vector is as disclosed above, wherein the first and second DNA segments are located on independent expression vectors and are co-transfected
30 into the cell, and cell expresses the polypeptides encoded by the DNA segments. In another embodiment, the cultured cell comprising an expression vector is as disclosed

above, wherein the cell expresses a heterodimeric or multimeric soluble receptor polypeptide encoded by the DNA segments. In another embodiment, the cultured cell comprising an expression vector is as disclosed above, wherein the cell secretes a soluble receptor polypeptide heterodimer or multimeric complex. In another
5 embodiment, the cultured cell comprising an expression vector is as disclosed above, wherein the cell secretes a soluble receptor polypeptide heterodimer or multimeric complex that binds a ligand comprising a polypeptide of SEQ ID NO:10 or SEQ ID NO:47, or antagonizes the ligand activity.

Within another aspect, the present invention provides a DNA construct
10 encoding a fusion protein comprising: a first DNA segment encoding a polypeptide having a sequence of amino acid residues as shown in SEQ ID NO:6; and at least one other DNA segment encoding a soluble Class I cytokine receptor polypeptide, wherein the first and other DNA segments are connected in-frame; and wherein the first and other DNA segments encode the fusion protein. In one embodiment, the DNA
15 construct encodes a fusion protein as disclosed above, wherein at least one other DNA segment encodes a soluble IL-2R γ receptor polypeptide (SEQ ID NO:4) or a soluble IL-13 α' receptor polypeptide (SEQ ID NO:82).

Within another aspect, the present invention provides an expression vector comprising the following operably linked elements: a transcription promoter; a
20 DNA construct encoding a fusion protein as disclosed above; and a transcription terminator, wherein the promoter is operably linked to the DNA construct, and the DNA construct is operably linked to the transcription terminator.

Within another aspect, the present invention provides a cultured cell comprising an expression vector as disclosed above, wherein the cell expresses a
25 polypeptide encoded by the DNA construct.

Within another aspect, the present invention provides a method of producing a fusion protein comprising: culturing a cell as disclosed above; and isolating the polypeptide produced by the cell.

Within another aspect, the present invention provides an isolated soluble
30 receptor polypeptide comprising a sequence of amino acid residues that is at least 90% identical to an amino acid sequence as shown in SEQ ID NO:6, and wherein the soluble

receptor polypeptide binds a ligand comprising a polypeptide of SEQ ID NO:10 or SEQ ID NO:47, or antagonizes the ligand activity. In one embodiment, the isolated polypeptide is as disclosed above, wherein the soluble receptor polypeptide forms a homodimeric receptor complex.

5 Within another aspect, the present invention provides an isolated polypeptide comprising a sequence of amino acid residues that is at least 90% identical to an amino acid sequence as shown in SEQ ID NO:6, wherein the soluble receptor polypeptide forms a heterodimeric or multimeric receptor complex. In one embodiment, the isolated polypeptide is as disclosed above, wherein the soluble
10 receptor polypeptide forms a heterodimeric or multimeric receptor complex further comprising a soluble Class I cytokine receptor. In another embodiment, the isolated polypeptide is as disclosed above, wherein the soluble receptor polypeptide forms a heterodimeric or multimeric receptor complex further comprising a soluble IL-2R γ receptor polypeptide (SEQ ID NO:4) or a soluble IL-13 α' receptor polypeptide (SEQ ID
15 NO:82). In another embodiment, the isolated polypeptide is as disclosed above, wherein the polypeptide further comprises a WSXWS motif as shown in SEQ ID NO:13.

 Within another aspect, the present invention provides an isolated soluble receptor polypeptide comprising a sequence of amino acid residues as shown in SEQ ID
20 NO:6, wherein the soluble receptor polypeptide forms a heterodimeric or multimeric receptor complex. In one embodiment, the isolated polypeptide is as disclosed above, wherein the soluble receptor polypeptide forms a heterodimeric or multimeric receptor complex further comprising a soluble Class I cytokine receptor. In another embodiment, the isolated polypeptide is as disclosed above, wherein the soluble receptor polypeptide
25 forms a heterodimeric or multimeric receptor complex comprising a soluble IL-2R γ receptor polypeptide (SEQ ID NO:4) or a soluble IL-13 α' receptor polypeptide (SEQ ID NO:82). In another embodiment, the isolated polypeptide is as disclosed above, wherein the soluble receptor polypeptide further comprises an affinity tag, chemical moiety, toxin, or label.

30 Within another aspect, the present invention provides an isolated heterodimeric or multimeric soluble receptor complex comprising soluble receptor

subunits, wherein at least one of soluble receptor subunits comprises a soluble receptor polypeptide comprising a sequence of amino acid residues as shown in SEQ ID NO:6. In one embodiment, the isolated heterodimeric or multimeric soluble receptor complex disclosed above further comprises a soluble Class I cytokine receptor polypeptide. In
5 another embodiment, the isolated heterodimeric or multimeric soluble receptor complex disclosed above further comprises a soluble IL-2R γ receptor polypeptide (SEQ ID NO:4) or a soluble IL-13 α' receptor polypeptide (SEQ ID NO:82).

Within another aspect, the present invention provides a method of producing a soluble receptor polypeptide that form a heterodimeric or multimeric
10 complex comprising: culturing a cell as disclosed above; and isolating the soluble receptor polypeptides produced by the cell.

Within another aspect, the present invention provides a method of producing an antibody to a soluble receptor polypeptide comprising: inoculating an animal with a soluble receptor polypeptide complex selected from the group consisting
15 of: (a) a polypeptide comprising a homodimeric soluble receptor complex comprising SEQ ID NO:6; (b) a polypeptide comprising a soluble receptor heterodimeric or multimeric receptor complex comprising SEQ ID NO:6; (b) a polypeptide comprising a soluble receptor heterodimeric or multimeric receptor complex comprising SEQ ID NO:6, and further comprising a soluble Class I cytokine receptor polypeptide; (c) a
20 polypeptide comprising a soluble receptor heterodimeric or multimeric receptor complex comprising SEQ ID NO:6, and further comprising a soluble IL-2R γ receptor polypeptide (SEQ ID NO:4); (d) a polypeptide comprising a soluble receptor heterodimeric or multimeric receptor complex comprising SEQ ID NO:6, and further comprising a soluble IL-13 α' receptor polypeptide (SEQ ID NO:82); and wherein the
25 polypeptide complex elicits an immune response in the animal to produce the antibody; and isolating the antibody from the animal.

Within another aspect, the present invention provides an antibody produced by the method as disclosed above, which specifically binds to a homodimeric, heterodimeric or multimeric receptor complex comprising a soluble receptor
30 polypeptide comprising SEQ ID NO:6. In one embodiment the antibody disclosed above is a monoclonal antibody.

6a

Within another aspect, the present invention provides an isolated polynucleotide encoding a heterodimeric or multimeric receptor complex comprising soluble receptor subunits, wherein the receptor complex comprises a sequence of amino acid residues that is at least 90% identical to the amino acid sequence as shown in SEQ ID NO:6, and a soluble IL-2R γ receptor polypeptide as shown in SEQ ID NO:4.

Within another aspect, the present invention provides an expression vector comprising:

(a) a transcription promoter; a first DNA segment encoding a soluble receptor polypeptide having an amino acid sequence as shown in SEQ ID NO:6; and a transcription terminator, wherein the promoter, DNA segment and terminator are operably linked; and

(b) a second transcription promoter; a second DNA segment encoding a soluble IL-2R γ receptor polypeptide as shown in SEQ ID NO:4; and a transcription terminator, wherein the promoter, DNA segment and terminator are operably linked.

Within another aspect, the present invention provides two expression vectors comprising:

(a) a transcription promoter; a first DNA segment encoding a soluble receptor polypeptide having an amino acid sequence as shown in SEQ ID NO:6; and a transcription terminator, wherein the promoter, DNA segment and terminator are operably linked; and

(b) a second transcription promoter; a second DNA segment encoding a soluble IL-2R γ receptor polypeptide as shown in SEQ ID NO:4; and a transcription terminator, wherein the promoter, DNA segment and terminator are operably linked;

wherein the first and second DNA segments are contained within independent expression vectors; and wherein the polypeptides expressed from the DNA segments associate to form a heterodimeric or multimeric receptor complex.

Within another aspect, the present invention provides a cultured cell comprising one or more expression vectors comprising:

6b

(a) a transcription promoter; a first DNA segment encoding a soluble receptor polypeptide having an amino acid sequence as shown in SEQ ID NO:6; and a transcription terminator, wherein the promoter, DNA segment and terminator are operably linked; and

(b) a second transcription promoter; a second DNA segment encoding a soluble
5 IL-2R γ receptor polypeptide as shown in SEQ ID NO:4; and a transcription terminator, wherein the promoter, DNA segment and terminator are operably linked;

wherein the first and second DNA segments are contained within a single expression vector or are contained within independent expression vectors;

and wherein the cell expresses the polypeptides encoded by the DNA segments.

10 Within another aspect, the present invention provides a DNA construct encoding a fusion protein comprising:

a first DNA segment encoding a polypeptide having a sequence of amino acid residues as shown in SEQ ID NO:6; and

at least one other DNA segment encoding a soluble IL-2R γ receptor
15 polypeptide as shown in SEQ ID NO:4,

wherein the first and other DNA segments are connected in-frame; and

wherein the first and other DNA segments encode the fusion protein.

Within another aspect, the present invention provides an expression vector comprising the following operably linked elements:

20 a transcription promoter;

a DNA construct encoding a fusion protein as defined herein; and

a transcription terminator,

wherein the promoter is operably linked to the DNA construct, and the DNA construct is operably linked to the transcription terminator.

25 Within another aspect, the present invention provides a method of producing a fusion protein encoded by a DNA construct as defined herein, comprising:

6c

culturing a cell as defined herein such that the cell expresses the polypeptide encoded by the DNA construct; and

isolating the polypeptide produced by the cell.

5 Within another aspect, the present invention provides an isolated heterodimeric or multimeric receptor complex comprising soluble receptor subunits, wherein at least one of the soluble receptor subunits comprises a sequence of amino acid residues that is at least 90% identical to an amino acid sequence as shown in SEQ ID NO:6, and wherein the receptor complex further comprises a soluble IL-2R γ receptor polypeptide as shown in SEQ ID NO:4.

10 Within another aspect, the present invention provides a method of producing a soluble heterodimeric or multimeric complex comprising:

culturing a cell as defined herein; and

isolating the soluble receptor polypeptides produced by the cell.

15 Within another aspect, the present invention provides a method of producing an antibody to a soluble heterodimeric or multimeric receptor complex, wherein the inoculated soluble heterodimeric or multimeric receptor complex comprises SEQ ID NO:6 and a soluble IL-2R γ receptor polypeptide as shown in SEQ ID NO: 4;

wherein the complex elicits an immune response to produce the antibody; and

20 wherein the antibody specifically binds to a heterodimeric or multimeric receptor complex comprising SEQ ID NO:6 and a soluble IL-2R γ receptor polypeptide as shown in SEQ ID NO:4.

25 Within another aspect, the present invention provides an *in vitro* method for inhibiting a ligand comprising a polypeptide of SEQ ID NO:10 or SEQ ID NO:47, or for antagonizing the ligand activity-induced proliferation of hematopoietic cells and hematopoietic cell progenitors, comprising:

culturing bone marrow or peripheral blood cells with a composition comprising a heterodimeric or multimeric receptor complex comprising soluble receptor subunits, wherein at least one of the subunits comprises a sequence of amino acid residues that is at

6d

least 90% identical to SEQ ID NO:6, and wherein the receptor complex further comprises a soluble IL-2R γ receptor polypeptide as shown in SEQ ID NO:4;

wherein the composition reduces proliferation of the hematopoietic cells in the bone marrow or peripheral blood cells as compared to bone marrow or peripheral blood cells cultured in the absence of soluble receptor complex.

Within another aspect, the present invention provides an *in vitro* method for inhibiting a ligand comprising a polypeptide of SEQ ID NO:10, or for antagonizing the ligand activity-induced proliferation of hematopoietic cells and hematopoietic cell progenitors, comprising:

culturing bone marrow or peripheral blood cells with a composition comprising a soluble receptor, wherein the soluble receptor comprises a heterodimeric receptor complex comprising soluble receptor subunits, wherein the first soluble receptor subunit comprises a soluble receptor polypeptide comprising a sequence of amino acid residues that is at least 90% identical to SEQ ID NO:6, and wherein the second soluble receptor subunit comprises a soluble IL-2R γ receptor polypeptide as shown in SEQ ID NO:4;

wherein the composition reduces proliferation of the hematopoietic cells in the bone marrow or peripheral blood cells as compared to bone marrow or peripheral blood cells cultured in the absence of soluble receptor.

Within another aspect, the present invention provides an *in vitro* method for inhibiting a ligand comprising a polypeptide of SEQ ID NO:10 or antagonizing the ligand activity-induced proliferation of hematopoietic cells and hematopoietic cell progenitors comprising:

culturing bone marrow or peripheral blood cells with a composition comprising a soluble receptor, wherein the soluble receptor comprises a multimeric soluble receptor complex comprising soluble receptor subunits, wherein at least one of soluble receptor subunits comprises a soluble receptor polypeptide comprising a sequence of amino acid residues that is at least 90% identical to SEQ ID NO:6, and wherein at least one other of the soluble receptor subunits comprises a soluble receptor polypeptide comprising soluble IL-2R γ receptor polypeptide as shown in SEQ ID NO:4;

wherein the composition reduces proliferation of the hematopoietic cells in the bone marrow or peripheral blood cells as compared to bone marrow or peripheral blood cells cultured in the absence of soluble receptor.

Within another aspect, the present invention provides use of a soluble
5 heterodimeric or multimeric receptor complex comprising soluble receptor subunits, wherein at least one of the subunits comprises a sequence of amino acids that is at least 90% identical to SEQ ID NO:6, and wherein the receptor complex further comprises a soluble IL-2R γ receptor polypeptide as shown in SEQ ID NO:4, in an acceptable pharmaceutical vehicle, for the manufacture of a medicament for suppressing an immune
10 response in a mammal exposed to an antigen or pathogen.

Within another aspect, the present invention provides use of a soluble heterodimeric or multimeric receptor complex comprising soluble receptor subunits, wherein at least one of the subunits comprises a sequence of amino acids that is at least 90% identical to SEQ ID NO:6, and wherein the receptor complex further comprises a
15 soluble IL-2R γ receptor polypeptide as shown in SEQ ID NO:4, for the manufacture of a medicament for reducing proliferation of neoplastic B or T cells in a mammal with a B or T cell neoplasm.

Within another aspect, the present invention provides use of a soluble heterodimeric or multimeric receptor complex comprising soluble receptor subunits,
20 wherein at least one of the subunits comprises a sequence of amino acids that is at least 90% identical to SEQ ID NO:6, and wherein the receptor complex further comprises a soluble IL-2R γ receptor polypeptide as shown in SEQ ID NO:4, in an acceptable pharmaceutical vehicle, for suppressing an immune response in a mammal exposed to an antigen or pathogen.

25 Within another aspect, the present invention provides use of a soluble heterodimeric or multimeric receptor complex comprising soluble receptor subunits, wherein at least one of the subunits comprises a sequence of amino acids that is at least 90% identical to SEQ ID NO:6, and wherein the receptor complex further comprises a soluble IL-2R γ receptor polypeptide as shown in SEQ ID NO:4, for reducing proliferation
30 of neoplastic B or T cells in a mammal with a B or T cell neoplasm.

Within another aspect, it is provided an isolated heterodimeric or multimeric receptor complex that is capable of intracellular signaling, the receptor complex comprises:

5 (i) a first receptor subunit comprising the extracellular domain of the zalpha11 receptor, as shown in SEQ ID NO:6, and an intracellular domain of a class I cytokine receptor; and

(ii) a second receptor subunit comprising the extracellular domain of the IL-2R γ receptor, as shown in SEQ ID NO: 4, and an intracellular domain from a class I cytokine receptor.

10 In another aspect the first receptor subunit comprises the intracellular domain of the zalpha11 receptor, as shown in residues 256 (Lys) to 538 (Ser) of SEQ ID NO:2.

Alternatively, the second receptor subunit comprises the intracellular domain of the zalpha11 receptor, as shown in residues 256 (Lys) to 538 (Ser) of SEQ ID
15 NO:2.

In another aspect, the first receptor subunit comprises an intracellular domain from a class I cytokine receptor other than the zalpha11 receptor; and the first receptor subunit further comprises a transmembrane domain from either: (i) the zalpha11 receptor, as shown in residues 238 (Leu) to 255 (Leu) of SEQ ID NO:2; or (ii) the
20 class I cytokine receptor other than the zalpha11 receptor.

Within another aspect, the present invention provides an antibody which specifically binds to a homodimeric, heterodimeric or multimeric receptor complex as disclosed above.

Within another aspect, the present invention provides a method for
5 inhibiting a ligand comprising a polypeptide of SEQ ID NO:10 or SEQ ID NO:47, or
antagonizing the ligand activity-induced proliferation of hematopoietic cells and
hematopoietic cell progenitors comprising culturing bone marrow or peripheral blood
cells with a composition comprising an amount of soluble receptor comprising SEQ ID
NO:6 sufficient to reduce proliferation of the hematopoietic cells in the bone marrow or
10 peripheral blood cells as compared to bone marrow or peripheral blood cells cultured in
the absence of soluble receptor. In one embodiment the method is as disclosed above,
wherein the hematopoietic cells and hematopoietic progenitor cells are lymphoid cells.
In another embodiment the method is as disclosed above, wherein the lymphoid cells
are NK cells or cytotoxic T cells.

15 Within another aspect, the present invention provides a method of
reducing proliferation of neoplastic B or T cells comprising administering to a mammal
with a B or T cell neoplasm an amount of a composition of soluble receptor comprising
SEQ ID NO:6 sufficient to reduce proliferation of the neoplastic B or T cells.

Within another aspect, the present invention provides a method of
20 suppressing an immune response in a mammal exposed to an antigen or pathogen
comprising: (1) determining a level of an antigen- or pathogen-specific antibody; (2)
administering a composition of soluble receptor polypeptide comprising SEQ ID NO:6
in an acceptable pharmaceutical vehicle; (3) determining a post administration level of
antigen- or pathogen-specific antibody; (4) comparing the level of antibody in step (1)
25 to the level of antibody in step (3), wherein a lack of increase or a decrease in antibody
level is indicative of suppressing an immune response.

These and other aspects of the invention will become evident upon
reference to the following detailed description of the invention.

Prior to setting forth the invention in detail, it may be helpful to the understanding thereof to define the following terms:

The term "affinity tag" is used herein to denote a polypeptide segment that can be attached to a second polypeptide to provide for purification or detection of the second polypeptide or provide sites for attachment of the second polypeptide to a substrate. In principal, any peptide or protein for which an antibody or other specific binding agent is available can be used as an affinity tag. Affinity tags include a poly-histidine tract, protein A (Nilsson et al., EMBO J. 4:1075, 1985; Nilsson et al., Methods Enzymol. 198:3, 1991), glutathione S transferase (Smith and Johnson, Gene 67:31, 1988), Glu-Glu affinity tag (Grussenmeyer et al., Proc. Natl. Acad. Sci. USA 82:7952-4, 1985), substance P, FlagTM peptide (Hopp et al., Biotechnology 6:1204-10, 1988), streptavidin binding peptide, or other antigenic epitope or binding domain. See, in general, Ford et al., Protein Expression and Purification 2: 95-107, 1991. DNAs encoding affinity tags are available from commercial suppliers (e.g., Pharmacia Biotech, Piscataway, NJ).

The terms "amino-terminal" and "carboxyl-terminal" are used herein to denote positions within polypeptides. Where the context allows, these terms are used with reference to a particular sequence or portion of a polypeptide to denote proximity or relative position. For example, a certain sequence positioned carboxyl-terminal to a reference sequence within a polypeptide is located proximal to the carboxyl terminus of the reference sequence, but is not necessarily at the carboxyl terminus of the complete polypeptide.

The term "complement/anti-complement pair" denotes non-identical moieties that form a non-covalently associated, stable pair under appropriate conditions. For instance, biotin and avidin (or streptavidin) are prototypical members of a complement/anti-complement pair. Other exemplary complement/anti-complement pairs include receptor/ligand pairs, antibody/antigen (or hapten or epitope) pairs, sense/antisense polynucleotide pairs, and the like. Where subsequent dissociation of the complement/anti-complement pair is desirable, the complement/anti-complement pair preferably has a binding affinity of $<10^9 \text{ M}^{-1}$.

The term "complements of a polynucleotide molecule" is a polynucleotide molecule having a complementary base sequence and reverse orientation as compared to a reference sequence. For example, the sequence 5' ATGCACGGG 3' is complementary to 5' CCCGTGCAT 3'.

5 The term "degenerate nucleotide sequence" denotes a sequence of nucleotides that includes one or more degenerate codons (as compared to a reference polynucleotide molecule that encodes a polypeptide). Degenerate codons contain different triplets of nucleotides, but encode the same amino acid residue (i.e., GAU and GAC triplets each encode Asp).

10 The term "expression vector" is used to denote a DNA molecule, linear or circular, that comprises a segment encoding a polypeptide of interest operably linked to additional segments that provide for its transcription. Such additional segments include promoter and terminator sequences, and may also include one or more origins of replication, one or more selectable markers, an enhancer, a polyadenylation signal,
15 etc. Expression vectors are generally derived from plasmid or viral DNA, or may contain elements of both.

 The term "isolated", when applied to a polynucleotide, denotes that the polynucleotide has been removed from its natural genetic milieu and is thus free of other extraneous or unwanted coding sequences, and is in a form suitable for use within
20 genetically engineered protein production systems. Such isolated molecules are those that are separated from their natural environment and include cDNA and genomic clones. Isolated DNA molecules of the present invention are free of other genes with which they are ordinarily associated, but may include naturally occurring 5' and 3' untranslated regions such as promoters and terminators. The identification of
25 associated regions will be evident to one of ordinary skill in the art (see for example, Dynan and Tijan, Nature 316:774-78, 1985).

 An "isolated" polypeptide or protein is a polypeptide or protein that is found in a condition other than its native environment, such as apart from blood and animal tissue. In a preferred form, the isolated polypeptide is substantially free of other
30 polypeptides, particularly other polypeptides of animal origin. It is preferred to provide the polypeptides in a highly purified form, i.e. greater than 95% pure, more preferably

greater than 99% pure. When used in this context, the term "isolated" does not exclude the presence of the same polypeptide in alternative physical forms, such as dimers or alternatively glycosylated or derivatized forms.

The term "operably linked", when referring to DNA segments, indicates
5 that the segments are arranged so that they function in concert for their intended purposes, e.g., transcription initiates in the promoter and proceeds through the coding segment to the terminator.

The term "ortholog" denotes a polypeptide or protein obtained from one species that is the functional counterpart of a polypeptide or protein from a different
10 species. Sequence differences among orthologs are the result of speciation.

"Paralogs" are distinct but structurally related proteins made by an organism. Paralogs are believed to arise through gene duplication. For example, α -globin, β -globin, and myoglobin are paralogs of each other.

A "polynucleotide" is a single- or double-stranded polymer of
15 deoxyribonucleotide or ribonucleotide bases read from the 5' to the 3' end. Polynucleotides include RNA and DNA, and may be isolated from natural sources, synthesized *in vitro*, or prepared from a combination of natural and synthetic molecules. Sizes of polynucleotides are expressed as base pairs (abbreviated "bp"), nucleotides ("nt"), or kilobases ("kb"). Where the context allows, the latter two terms may describe
20 polynucleotides that are single-stranded or double-stranded. When the term is applied to double-stranded molecules it is used to denote overall length and will be understood to be equivalent to the term "base pairs". It will be recognized by those skilled in the art that the two strands of a double-stranded polynucleotide may differ slightly in length and that the ends thereof may be staggered as a result of enzymatic cleavage; thus all
25 nucleotides within a double-stranded polynucleotide molecule may not be paired.

A "polypeptide" is a polymer of amino acid residues joined by peptide bonds, whether produced naturally or synthetically. Polypeptides of less than about 10 amino acid residues are commonly referred to as "peptides".

"Probes and/or primers" as used herein can be RNA or DNA. DNA can
30 be either cDNA or genomic DNA. Polynucleotide probes and primers are single or double-stranded DNA or RNA, generally synthetic oligonucleotides, but may be

generated from cloned cDNA or genomic sequences or its complements. Analytical probes will generally be at least 20 nucleotides in length, although somewhat shorter probes (14-17 nucleotides) can be used. PCR primers are at least 5 nucleotides in length, preferably 15 or more nt, more preferably 20-30 nt. Short polynucleotides can be used when a small region of the gene is targeted for analysis. For gross analysis of genes, a polynucleotide probe may comprise an entire exon or more. Probes can be labeled to provide a detectable signal, such as with an enzyme, biotin, a radionuclide, fluorophore, chemiluminescer, paramagnetic particle and the like, which are commercially available from many sources, such as Molecular Probes, Inc., Eugene, OR, and Amersham Corp., Arlington Heights, IL, using techniques that are well known in the art.

The term "promoter" is used herein for its art-recognized meaning to denote a portion of a gene containing DNA sequences that provide for the binding of RNA polymerase and initiation of transcription. Promoter sequences are commonly, but not always, found in the 5' non-coding regions of genes.

A "protein" is a macromolecule comprising one or more polypeptide chains. A protein may also comprise non-peptidic components, such as carbohydrate groups. Carbohydrates and other non-peptidic substituents may be added to a protein by the cell in which the protein is produced, and will vary with the type of cell. Proteins are defined herein in terms of their amino acid backbone structures; substituents such as carbohydrate groups are generally not specified, but may be present nonetheless.

The term "receptor" is used herein to denote a cell-associated protein, or a polypeptide subunit of such a protein, that binds to a bioactive molecule (the "ligand") and mediates the effect of the ligand on the cell. Binding of ligand to receptor results in a conformational change in the receptor (and, in some cases, receptor multimerization, i.e., association of identical or different receptor subunits) that causes interactions between the effector domain(s) and other molecule(s) in the cell. These interactions in turn lead to alterations in the metabolism of the cell. Metabolic events that are linked to receptor-ligand interactions include gene transcription, phosphorylation, dephosphorylation, cell proliferation, increases in cyclic AMP production, mobilization

of cellular calcium, mobilization of membrane lipids, cell adhesion, hydrolysis of inositol lipids and hydrolysis of phospholipids. Cell-surface cytokine receptors are characterized by a multi-domain structure as discussed in more detail below. These receptors are anchored in the cell membrane by a transmembrane domain characterized
5 by a sequence of hydrophobic amino acid residues (typically about 21-25 residues), which is commonly flanked by positively charged residues (Lys or Arg). In general, receptors can be membrane bound, cytosolic or nuclear; monomeric (e.g., thyroid stimulating hormone receptor, beta-adrenergic receptor) or multimeric (e.g., PDGF receptor, growth hormone receptor, IL-3 receptor, GM-CSF receptor, G-CSF receptor,
10 erythropoietin receptor and IL-6 receptor). The term "receptor polypeptide" is used to denote complete receptor polypeptide chains and portions thereof, including isolated functional domains (e.g., ligand-binding domains).

A "secretory signal sequence" is a DNA sequence that encodes a polypeptide (a "secretory peptide") that, as a component of a larger polypeptide, directs
15 the larger polypeptide through a secretory pathway of a cell in which it is synthesized. The larger peptide is commonly cleaved to remove the secretory peptide during transit through the secretory pathway.

A "soluble receptor" is a receptor polypeptide that is not bound to a cell membrane. Soluble receptors are most commonly ligand-binding receptor polypeptides
20 that lack transmembrane and cytoplasmic domains. Soluble receptors can comprise additional amino acid residues, such as affinity tags that provide for purification of the polypeptide or provide sites for attachment of the polypeptide to a substrate, or immunoglobulin constant region sequences. Many cell-surface receptors have naturally occurring, soluble counterparts that are produced by proteolysis. Soluble receptor
25 polypeptides are said to be substantially free of transmembrane and intracellular polypeptide segments when they lack sufficient portions of these segments to provide membrane anchoring or signal transduction, respectively.

The term "splice variant" is used herein to denote alternative forms of RNA transcribed from a gene. Splice variation arises naturally through use of
30 alternative splicing sites within a transcribed RNA molecule, or less commonly between separately transcribed RNA molecules, and may result in several mRNAs

transcribed from the same gene. Splice variants may encode polypeptides having altered amino acid sequence. The term splice variant is also used herein to denote a protein encoded by a splice variant of an mRNA transcribed from a gene.

5 Molecular weights and lengths of polymers determined by imprecise analytical methods (e.g., gel electrophoresis) will be understood to be approximate values. When such a value is expressed as "about" X or "approximately" X, the stated value of X will be understood to be accurate to $\pm 10\%$.

10 The present invention is based in part upon the discovery of a novel heterodimeric soluble receptor protein having the structure of a class I cytokine receptor. The heterodimeric soluble receptor includes at least one zalphal1 soluble receptor subunit, disclosed in the commonly owned US Patent application No. 09/404,641. A second soluble receptor polypeptide included in the heterodimeric
15 soluble receptor belongs to the receptor subfamily that includes the IL-2 γ -common receptor (IL-2R γ , or γ_c), IL-2 receptor β -subunit, and the β -common receptor (i.e., IL3, IL-5, IL-13, IL-15 and GM-CSF receptor β -subunits), IL-13 α , IL-13 α' , IL-15 receptor subunits, and the like. The soluble human and mouse zalphal1 receptor (IL-21R) monomer and homodimer was shown to antagonize of the activity of the natural ligand
20 for the zalphal1 receptor, zalphal1 Ligand (IL-21) (Parrish-Novak, J. et al., Nature 408:57-63, 2000). The zalphal1 Ligand is disclosed in the commonly owned US Patent application No. 09/522,217. According to the present invention, a heterodimeric soluble zalphal1 receptor, as exemplified by a preferred embodiment of a soluble zalphal1 receptor + soluble IL-2R γ receptor heterodimer (zalphal1/IL-2R γ), was
25 shown to act as a potent antagonist of the zalphal1 Ligand. As disclosed in the examples herein, the preferred zalphal1/IL-2R γ heterodimer was a more effective antagonist zalphal1 Ligand activity, and hence more superior antagonist, than a zalphal1 homodimer or monomer.

Moreover, also contemplated by the present invention are homodimeric
30 and monomeric zalphal1-comprising soluble receptors; as well as homodimeric, heterodimeric, and multimeric zalphal1-comprising receptors that are capable of

intracellular signaling. Such receptors can comprise at least one an extracellular domain of a $\alpha 1$ receptor, and an intracellular domain from $\alpha 1$ or another class I cytokine receptor. The additional heterodimeric or multimeric subunit can comprise the extracellular domain from IL-2R γ receptor (e.g., SEQ ID NO:4), IL-13 α (also known as IL-13RA2; SEQ ID NO:84), IL-13 α' (also known as IL-13RA1; SEQ ID NO:82, IL-15 (SEQ ID NO:86) receptor, or other class I receptor, and an intracellular domain from $\alpha 1$ or another class I cytokine receptor.

The nucleotide sequence of a representative $\alpha 1$ -encoding DNA is described in SEQ ID NO:1 (from nucleotide 1 to 1614), and its deduced 538 amino acid sequence is described in SEQ ID NO:2. In its entirety, the $\alpha 1$ polypeptide (SEQ ID NO:2) represents a full-length polypeptide segment (residue 1 (Met) to residue 538 (Ser) of SEQ ID NO:2). The domains and structural features of the $\alpha 1$ polypeptide are further described below.

Analysis of the $\alpha 1$ polypeptide encoded by the DNA sequence of SEQ ID NO:1 revealed an open reading frame encoding 538 amino acids (SEQ ID NO:2) comprising a predicted secretory signal peptide of 19 amino acid residues (residue 1 (Met) to residue 19 (Gly) of SEQ ID NO:2), and a mature polypeptide of 519 amino acids (residue 20 (Cys) to residue 538 (Ser) of SEQ ID NO:2). In addition to the WSXWS motif (SEQ ID NO:13) corresponding to residues 214 to 218 of SEQ ID NO:2, the receptor comprises a cytokine-binding domain of approximately 200 amino acid residues (residues 20 (Cys) to 237 (His) of SEQ ID NO:2); a domain linker (residues 120 (Pro) to 123 (Pro) of SEQ ID NO:2); a penultimate strand region (residues 192 (Lys) to 202 (Ala) of SEQ ID NO:2); a transmembrane domain (residues 238 (Leu) to 255 (Leu) of SEQ ID NO:2); complete intracellular signaling domain (residues 256 (Lys) to 538 (Ser) of SEQ ID NO:2) which contains a "Box I" signaling site (residues 267 (Ile) to 273 (Pro) of SEQ ID NO:2), and a "Box II" signaling site (residues 301 (Leu) to 304 (Gly) of SEQ ID NO:2). Moreover, there is a STAT3 binding site (YXXQ) located near the C-terminus from residues 519 (Tyr) to 522 (Gln) of SEQ ID NO:2. Those skilled in the art will recognize that these domain boundaries are approximate, and are based on alignments with known proteins and predictions of protein folding. In addition to these domains, conserved receptor features in the

encoded receptor include (as shown in SEQ ID NO:2) a conserved Trp residue at position 138, and a conserved Arg residue at position 201. Moreover the zalpha11 contains conserved Cys residues typical of class I cytokine receptors, shown in residues 25, 35, 65, and 81 of SEQ ID NO:2, and corresponding regions of SEQ ID NO:6 and
5 SEQ ID NO:69 described below. The corresponding polynucleotides encoding the zalpha11 polypeptide regions, domains, motifs, residues and sequences described above are as shown in SEQ ID NO:1. The human zalpha11 soluble receptor polypeptide, comprising residues 20 (Cys) to 237 (His) of SEQ ID NO:2, is shown in SEQ ID NO:6, and the corresponding polynucleotide sequence for the human zalpha11 soluble
10 receptor polypeptide is shown in SEQ ID NO:5.

SEQ ID NO:3 is a polynucleotide sequence comprising a fragment of the human IL-2R γ receptor that encodes a soluble 232 amino acid soluble IL-2R γ receptor polypeptide (SEQ ID NO:4). Those skilled in the art will recognize that these domain boundaries for the IL-2R γ receptor extracellular domain are approximate, and other
15 soluble IL-2R γ receptor polypeptides, such as those including an IL-2R γ receptor polypeptide secretory signal sequence or additional IL-2R γ receptor polypeptide amino acids in the extracellular domain, are encompassed within the scope of the present invention.

A variant form of the human zalpha11 polypeptide was identified
20 (WIPO publication No. WO 00/27822 shown as SEQ ID NO:3 and SEQ ID NO:4 therein) and is shown in the DNA sequence of SEQ ID NO:64; and corresponding polypeptide sequence shown in (SEQ ID NO:65). This particular alternative zalpha11 receptor polypeptide contains 568 amino acids, and comprises a predicted secretory signal peptide of 20 amino acid residues (residue 1 (Met) to residue 20 (Gly) of SEQ ID
25 NO:65), and a mature polypeptide of 548 amino acids (residue 21 (Met) to residue 568 (Ser) of SEQ ID NO:65). In addition to the WSXWS motif (SEQ ID NO:13) corresponding to residues 244 to 248 of SEQ ID NO:65, the receptor comprises a cytokine-binding domain of approximately 200 amino acid residues (residues 21 (Met) to 267 (His) of SEQ ID NO:65); no domain linker; a penultimate strand region
30 (residues 222 (Lys) to 232 (Ala) of SEQ ID NO:65); a transmembrane domain (residues 268 (Leu) to 285 (Leu) of SEQ ID NO:65); complete intracellular signaling domain

(residues 286 (Lys) to 568 (Ser) of SEQ ID NO:65) which contains a "Box I" signaling site (residues 297 (Ile) to 303 (Pro) of SEQ ID NO:65), and a "Box II" signaling site (residues 331 (Leu) to 334 (Gly) of SEQ ID NO:65). Moreover, there is a STAT3 binding site (YXXQ) located near the C-terminus from residues 549 (Tyr) to 552 (Gln) of SEQ ID NO:65. Those skilled in the art will recognize that these domain boundaries are approximate, and are based on alignments with known proteins and predictions of protein folding. In addition to these domains, conserved receptor features in the encoded receptor include (as shown in SEQ ID NO:65) a conserved Trp residue at position 168, and a conserved Arg residue at position 231. The corresponding polynucleotides encoding the zalpha11 polypeptide regions, domains, motifs, residues and sequences described above are as shown in SEQ ID NO:64. This particular human zalpha11 soluble receptor variant polypeptide, comprising residues 21 (Met) to 267 (His) of SEQ ID NO:65 (SEQ ID NO:69) and the corresponding polynucleotide sequence for this particular human zalpha11 soluble receptor polypeptide is shown in SEQ ID NO:68. This variant form of the human zalpha11 receptor is included in the heterodimeric and multimeric zalpha11 receptor complexes of the present invention, disclosed herein.

In addition, other variant forms of zalpha11 receptor are contemplated by the present invention, wherein the extracellular domain of the variant form disclosed above (e.g., 21 (Met) to 267 (His) of SEQ ID NO:65, or SEQ ID NO:69) comprises a domain linker comprising the amino acids PAPP (SEQ ID NO:70) inserted between amino acid 161 (Ser) and 162 (Arg) of SEQ ID NO:65, or the corresponding region of SEQ ID NO:69. A preferred domain linker comprises a sequence of amino acids from preferably 4 to 14 amino acids long, most preferably 14 amino acids long, wherein aside from the PAPP (SEQ ID NO:70) motif sequence any amino acid may be present. For example, a representative linker-containing variant zalpha11 soluble receptor is shown in SEQ ID NO:71. Moreover, other variant zalpha11 sequences can include, in reference to SEQ ID NO:65 a Gly at position 162 rather than an Arg, or the same Arg to Gly substitution in the corresponding region of SEQ ID NO:69 or SEQ ID NO:71, or other variant of SEQ ID NO:65 or SEQ ID NO:69 containing a domain linker as described above. Corresponding DNA sequences that encode such variants can be

readily determined by one of skill in the art upon using the information present in Table 1 and Table 2.

The zalpha11 Ligand is a "short-helix" form secreted four-helical bundle cytokine. The zalpha11 Ligand polynucleotide sequence is shown in SEQ ID NO:9 and
5 corresponding amino acid sequence shown in SEQ ID NO:10. The secretory signal sequence comprises amino acid residues 1 (Met) to 31 (Gly), and the mature polypeptide comprises amino acid residues 32 (Gln) to 162 (Ser) (as shown in SEQ ID NO:10). In general, cytokines are predicted to have a four-alpha helix structure, with helices A, C and D being most important in ligand-receptor interactions, and are more
10 highly conserved among members of the family. Referring to the human zalpha11 Ligand amino acid sequence shown in SEQ ID NO:10, alignment of human zalpha11 Ligand, human IL-15, human IL-4, and human GM-CSF amino acid sequences it is predicted that zalpha11 Ligand helix A is defined by amino acid residues 41-56; helix B by amino acid residues 69-84; helix C by amino acid residues 92-105; and helix D by
15 amino acid residues 135-148; as shown in SEQ ID NO:10. Structural analysis suggests that the A/B loop is long, the B/C loop is short and the C/D loop is parallel long. Conserved cysteine residues within zalpha11 Ligand correspond to amino acid residues 71, 78, 122 and 125 of SEQ ID NO:10. Consistent cysteine placement is further confirmation of the four-helical-bundle structure. Also highly conserved in the family
20 comprising IL-15, IL-2, IL-4, GM-CSF and zalpha11 Ligand is the Glu-Phe-Leu sequence as shown in SEQ ID NO:10 at residues 136-138.

Further analysis of zalpha11 Ligand based on multiple alignments of known cytokines predicts that amino acid residues 44, 47 and 135 (as shown in SEQ ID NO:10) play an important role in zalpha11 Ligand binding to its cognate receptor.
25 Based on comparison between sequences of human and murine zalpha11 Ligand well-conserved residues were found in the regions predicted to encode alpha helices A and D. The corresponding polynucleotides encoding the zalpha11 Ligand polypeptide regions, domains, motifs, residues and sequences described herein are as shown in SEQ ID NO:9. The murine zalpha11 Ligand is shown in SEQ ID NO:46, and corresponding
30 polypeptide sequence shown in SEQ ID NO:47.

The activity of molecules of the present invention can be measured using a variety of assays that measure proliferation of and/or binding to cells expressing the zalpha11 receptor. Of particular interest are changes in zalpha11 Ligand-dependent cells. A suitable cell line was engineered to be zalpha11 Ligand-dependent that
 5 comprises an IL-3-dependent BaF3 cell line (Palacios and Steinmetz, Cell 41: 727-734, 1985; Mathey-Prevot et al., Mol. Cell. Biol. 6: 4133-4135, 1986). Moreover, other suitable cell lines to be engineered to be zalpha11 Ligand-dependent include FDC-P1 (Hapel et al., Blood 64: 786-790, 1984); and MO7e (Kiss et al., Leukemia 7: 235-240, 1993). Growth factor-dependent cell lines can be established according to published
 10 methods (e.g. Greenberger et al., Leukemia Res. 8: 363-375, 1984; Dexter et al., in Baum et al. Eds., Experimental Hematology Today, 8th Ann. Mtg. Int. Soc. Exp. Hematol. 1979, 145-156, 1980).

Zalpha11 Ligand stimulates proliferation, activation, differentiation and/or induction or inhibition of specialized cell function of cells involved homeostasis
 15 of hematopoiesis and immune function. In particular, zalpha11 Ligand polypeptides stimulate proliferation, activation, differentiation, induction or inhibition of specialized cell functions of cells of the hematopoietic lineages, including, but not limited to, T cells, B cells, NK cells, dendritic cells, monocytes, and macrophages, as well as epithelial cells. Proliferation and/or differentiation of hematopoietic cells can be
 20 measured *in vitro* using cultured cells or *in vivo* by administering zalpha11 Ligand to the appropriate animal model. Assays measuring cell proliferation or differentiation are well known in the art and described herein. For example, assays measuring proliferation include such assays as chemosensitivity to neutral red dye (Cavanaugh et al., Investigational New Drugs 8:347-354, 1990),
 25 incorporation of radiolabeled nucleotides (Cook et al., Analytical Biochem. 179:1-7, 1989), incorporation of 5-bromo-2-deoxyuridine (BrdU) in the DNA of proliferating cells (Porstmann et al., J. Immunol. Methods 82:169-179, 1985), and use of tetrazolium salts (Mosmann, J. Immunol. Methods 65:55-63, 1983; Alley et al., Cancer Res. 48:589-601, 1988; Marshall et al., Growth Reg. 5:69-84, 1995; and Scudiero et al., Cancer Res. 48:4827-4833, 1988).
 30 Assays measuring

5

10

15

20

25

3

compositions can further comprise kit ligand or stem cell factor. Thus, the soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ receptors of the present invention can be used as an antagonist or Ligand binding agent to decrease the activity of the zalpha11 Ligand on NK cells.

5 Moreover, the tissue distribution of a receptor for a given cytokine offers a strong indication of the potential sites of action of that cytokine. Northern analysis of zalpha11 receptor revealed transcripts in human spleen, thymus, lymph node, bone marrow, and peripheral blood leukocytes. Specific cell types were identified as expressing zalpha11 receptors, and strong signals were seen in a mixed lymphocyte
10 reaction (MLR) and in the Burkitt's lymphoma Raji. The two monocytic cell lines, THP-1 (Tsuchiya et al., Int. J. Cancer 26:171-176, 1980) and U937 (Sundstrom et al., Int. J. Cancer 17:565-577, 1976), were negative. Zalpha11 receptor is expressed at relatively high levels in the MLR, in which peripheral blood mononuclear cells (PBMNC) from two individuals are mixed, resulting in mutual activation. Detection of
15 high levels of transcript in the MLR but not in resting T or B cell populations suggests that zalpha11 receptor expression may be induced in one or more cell types during activation. Activation of isolated populations of T and B cells can be artificially achieved by stimulating cells with PMA and Ionomycin. When sorted cells were subjected to these activation conditions, levels of zalpha11 receptor transcript increased
20 in both cell types, supporting a role for this receptor and zalpha11 Ligand in immune responses, especially in autocrine and paracrine T and B cell expansions during activation. Zalpha11 Ligand may also play a role in the expansion of more primitive progenitors involved in lymphopoiesis. Thus, the soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ receptors of the
25 present invention can be used as an antagonist or Ligand binding agent to modulate the lymphopoietic activities of the zalpha11 Ligand.

Zalpha11 receptor was found to be present at low levels in resting T and B cells, and was upregulated during activation in both cell types. Interestingly, the B cells also down-regulate the message more quickly than do T cells, suggesting that
30 amplitude of signal and timing of quenching of signal are important for the appropriate regulation of B cell responses.

In addition, a large proportion of intestinal lamina propria cells show positive hybridization signals with zalpha11 receptor. This tissue consists of a mixed population of lymphoid cells, including activated CD4+ T cells and activated B cells. Immune dysfunction, in particular chronic activation of the mucosal immune response, plays an important role in the etiology of Crohn's disease and inflammatory bowel disease (IBD); abnormal response to and/or production of proinflammatory cytokines is also a suspected factor (Braegger et al., Annals Allergy 72:135-141, 1994; Sartor RB Am. J. Gastroenterol. 92:5S-11S, 1997). The zalpha11 Ligand in concert with IL-15 expands NK cells from bone marrow progenitors and augments NK cell effector function. Zalpha11 Ligand also co-stimulates mature B cells stimulated with anti-CD40 antibodies, but inhibits B cell proliferation to signals through IgM. Zalpha11 Ligand enhances T cell proliferation in concert with a signal through the T cell receptor, and over expression in transgenic mice leads to lymphopenia and an expansion of monocytes and granulocytes. These pleiotropic effects of zalpha11 Ligand suggest that molecules that antagonize or bind zalpha11 Ligand, such as the molecules of the present invention, can provide therapeutic utility for a wide range of diseases arising from defects in the immune system, including (but not limited to) systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS), myasthenia gravis, Crohn's Disease, IBD, and diabetes. It is important to note that these diseases are the result of a complex network of immune dysfunction (SLE, for example, is the manifestation of defects in both T and B cells), and that immune cells are dependent upon interaction with one another to elicit a potent immune response. Therefore, zalpha11 Ligand (or an antagonist of the Ligand, such a molecule of the present invention) that can be used to manipulate more than one type of immune cell is an attractive therapeutic candidate for intervention at multiple stages of disease.

Similarly, the tissue distribution of the mRNA corresponding to IL-2R γ receptor cDNA shows expression in hematopoietic and lymphoid cells including CD4+ T-cells, CD8+ T-cells, CD20+ B-cells, CD56+ NK cells, CD14+ monocytes, as well as granulocytes. IL-2R γ receptor cDNA is generally not found in other cell types, including epithelial cells and fibroblast cells. The expression pattern of this receptor correlates with the activities of the zalpha11 Ligand and the localization of the zalpha11

receptor. Moreover, antibodies to the IL-2R γ receptor decrease or ablate the effect of zalpha11 Ligand in B-cells and BaF3/zalpha11 receptor cells, demonstrating that the zalpha11 receptor and IL-2R γ receptor can heterodimerize *in vivo* and *in vitro*.

The zalpha11 Ligand both promotes expansion of NK cell populations
5 from bone marrow and regulates the proliferation of mature T and B cells in response to activating stimuli. The zalpha11 Ligand acts through a receptor complex that includes at least one zalpha11 receptor subunit and the γ_C subunit of IL2R, even though the cytoplasmic domain of zalpha11 receptor is capable of transducing signal in a homodimeric configuration (commonly owned US Patent application No. 09/522,217).
10 IL4R α is also capable of signaling as a homodimer (Kammer, W. et al., J. Biol. Chem. 271:23634-23637, 1996), although the true functional IL4 receptor complex is a IL4R α / γ_C heterodimer. Signaling in BaF3/zalpha11 receptor could have resulted from interactions of the human zalpha11 receptor with endogenous murine γ_C , and Examples herein show that antibodies to the γ_C subunit decrease zalpha11 Ligand signaling in
15 these cells.

Moreover, the IL2 receptor has been studied in detail and is composed of an α - β - γ_C heterotrimer. The β and γ_C subunits are both essential for signal transduction and are members of the hematopoietin receptor superfamily (Cosman, D., Cytokine 5:95-106, 1993), whereas the α subunit appears to primarily be involved in high-affinity
20 binding conversion and is structurally distinct from the hematopoietin receptor family. The γ_C subunit has been shown to participate in forming the receptors for IL4, IL7, IL9, and IL15, in addition to IL2 (for review, see Sugamura, K., et al., Annu. Rev. Immunol. 14:179-205, 1996), and null mutations in the γ_C gene have been shown to cause X-linked severe combined immunodeficiency (X-SCID) (Noguchi, M. et al., Cell 73:147-
25 157, 1993).

Zalpha11 Ligand antagonism of anti-IgM and IL4-induced B cell proliferation (commonly owned US Patent Application No. 09/522,217, and examples herein) could be due to competition for γ_C ; however, it is clear that IL4 can signal through a γ_C -independent receptor (IL4R α + IL13R α') (Murata, T. et al., Blood
30 91:3884-3891, 1998). B cells from human SCID patients proliferate normally in response to anti-IgM and IL4 (Matthews, D.J. et al., Blood 85:38-42, 1995), and IL4

responsiveness in normal human B cells is associated with both IL13 responsiveness and levels of IL13R (Ford, D. et al., J. Immunol. 163:3185-3193, 1999). Similarly, Zalpha11 Ligand may signal through a heterodimeric, heterotrimeric or multimeric complex that includes zalpha11 receptor and a non- γ_C -subunit. As such, the present invention contemplates soluble zalpha11 receptor heterodimeric antagonists and binding agents to the zalpha11 Ligand that do not include the γ_C subunit, but include an additional Class I cytokine subunit, for example, IL13R α' and the like.

The soluble receptors of the present invention are useful as antagonists of the zalpha11 Ligand cytokine. Such antagonistic effects can be achieved by direct neutralization or binding of the zalpha11 Ligand. In addition to antagonistic uses, the soluble receptors of the present invention can bind zalpha11 Ligand and act as carrier proteins for the zalpha11 Ligand cytokine, in order to transport the Ligand to different tissues, organs, and cells within the body. As such, the soluble receptors of the present invention can be fused or coupled to molecules, polypeptides or chemical moieties that direct the soluble-receptor-Ligand complex to a specific site, such as a tissue, specific immune cell, or tumor. Thus, the soluble receptors of the present invention can be used to specifically direct the action of the zalpha11 Ligand. See, Cosman, D. Cytokine 5: 95-106, 1993; and Fernandez-Botran, R. Exp. Opin. Invest. Drugs 9:497-513, 2000.

Moreover, the soluble receptors of the present invention can be used to stabilize the zalpha11 Ligand, to increase the bio-availability, therapeutic longevity, and/or efficacy of the Ligand by stabilizing the Ligand from degradation or clearance, or by targeting the ligand to a site of action within the body. For example the naturally occurring IL-6/soluble IL-6R complex stabilizes IL-6 and can signal through the gp130 receptor. See, Cosman, D. supra., and Fernandez-Botran, R. supra.

For example, the Zalpha11 Ligand will be useful in treating tumorigenesis, and therefore would be useful in the treatment of cancer. Zalpha11 Ligand inhibits IL-4 stimulated proliferation of anti-IgM stimulated normal B-cells and a similar effect is observed in B-cell tumor lines suggesting that there may be therapeutic benefit in treating patients with the zalpha11 Ligand in order to induce the B cell tumor cells into a less proliferative state. The ligand could be administered in combination with other agents already in use including both conventional

chemotherapeutic agents as well as immune modulators such as interferon alpha. Alpha/beta interferons have been shown to be effective in treating some leukemias and animal disease models, and the growth inhibitory effects of interferon-alpha and zalpha11 Ligand are additive for at least one B-cell tumor-derived cell line. Moreover, 5 stabilization of the zalpha11 Ligand or ability to target the Ligand to specific sites of action with the soluble receptors of the present invention would be desirable in this therapeutic endeavor.

The present invention provides a method of reducing proliferation of neoplastic B or T cells comprising administering to a mammal with a B or T cell 10 neoplasm an amount of a composition of zalpha11 Ligand antagonist, such as the soluble receptors of the present invention, sufficient to reduce proliferation of the neoplastic B or T cells. In other embodiments, the composition can comprise at least one other cytokine selected from the group consisting of IL-2, IL-15, IL-4, GM-CSF, Flt3 ligand or stem cell factor. Furthermore, the zalpha11 Ligand antagonist can be a 15 toxic fusion. Similarly, soluble receptor-toxic fusions and soluble receptors of the present invention can be used to reduce proliferation of lymphoid and hematopoietic neoplasms that over-express or grow in response to zalpha11 Ligand. Moreover, indirect effects of the soluble receptors of the present invention can modulate NK cell function induced by zalpha11 Ligand, and hence indirectly enhance tumor cell killing.

20 The present invention provides polynucleotide molecules, including DNA and RNA molecules that encode the heterodimeric zalpha11 receptor polypeptides disclosed herein. Those skilled in the art will recognize that, in view of the degeneracy of the genetic code, considerable sequence variation is possible among these polynucleotide molecules. SEQ ID NO:7 is a degenerate DNA sequence that 25 encompasses all DNAs that encode the soluble zalpha11 receptor polypeptide of SEQ ID NO:6. SEQ ID NO:66 is a degenerate DNA sequence that encompasses all DNAs that encode the soluble zalpha11 receptor polypeptide of SEQ ID NO:69. SEQ ID NO:8 is a degenerate DNA sequence that encompasses all DNAs that encode the soluble human IL-2R γ polypeptide of SEQ ID NO:4. Those skilled in the art will 30 recognize that the degenerate sequence of SEQ ID NO:7, SEQ ID NO:66 and SEQ ID NO:8 also provide all RNA sequences encoding SEQ ID NO:6, SEQ ID NO:69 and

SEQ ID NO:4 respectively by substituting U for T. Thus, zalpha11 polypeptide-encoding polynucleotides comprising nucleotide 1 to nucleotide 654 of SEQ ID NO:7 or comprising nucleotide 1 to nucleotide 741 of SEQ ID NO:66, soluble human IL-2R γ polypeptide-encoding polynucleotides comprising nucleotide 1 to nucleotide 696 of
5 SEQ ID NO:8, and their RNA equivalents are contemplated by the present invention. Table 1 sets forth the one-letter codes used within SEQ ID NO:7, SEQ ID NO:66 and SEQ ID NO:8 to denote degenerate nucleotide positions. "Resolutions" are the nucleotides denoted by a code letter. "Complement" indicates the code for the complementary nucleotide(s). For example, the code Y denotes either C or T, and its
10 complement R denotes A or G, A being complementary to T, and G being complementary to C.

TABLE 1

Nucleotide	Resolution	Complement	Resolution
A	A	T	T
C	C	G	G
G	G	C	C
T	T	A	A
R	A G	Y	C T
Y	C T	R	A G
M	A C	K	G T
K	G T	M	A C
S	C G	S	C G
W	A T	W	A T
H	A C T	D	A G T
B	C G T	V	A C G
V	A C G	B	C G T
D	A G T	H	A C T
N	A C G T	N	A C G T

The degenerate codons used in SEQ ID NO:7, SEQ ID NO:66 and SEQ
5 ID NO:8 encompass all possible codons for a given amino acid, are set forth in Table 2.

TABLE 2

Amino Acid	One Letter Code	Codons	Degenerate Codon
Cys	C	TGC TGT	TGY
Ser	S	AGC AGT TCA TCC TCG TCT	WSN
Thr	T	ACA ACC ACG ACT	ACN
Pro	P	CCA CCC CCG CCT	CCN
Ala	A	GCA GCC GCG GCT	GCN
Gly	G	GGA GGC GGG GGT	GGN
Asn	N	AAC AAT	AAY
Asp	D	GAC GAT	GAY
Glu	E	GAA GAG	GAR
Gln	Q	CAA CAG	CAR
His	H	CAC CAT	CAY
Arg	R	AGA AGG CGA CGC CGG CGT	MGN
Lys	K	AAA AAG	AAR
Met	M	ATG	ATG
Ile	I	ATA ATC ATT	ATH
Leu	L	CTA CTC CTG CTT TTA TTG	YTN
Val	V	GTA GTC GTG GTT	GTN
Phe	F	TTC TTT	TTY
Tyr	Y	TAC TAT	TAY
Trp	W	TGG	TGG
Ter	.	TAA TAG TGA	TRR
Asn Asp	B		RAY
Glu Gln	Z		SAR
Any	X		NNN

One of ordinary skill in the art will appreciate that some ambiguity is introduced in determining a degenerate codon, representative of all possible codons encoding each amino acid. For example, the degenerate codon for serine (WSN) can, in some circumstances, encode arginine (AGR), and the degenerate codon for arginine (MGN) can, in some circumstances, encode serine (AGY). A similar relationship exists between codons encoding phenylalanine and leucine. Thus, some polynucleotides encompassed by the degenerate sequence may encode variant amino acid sequences, but one of ordinary skill in the art can easily identify such variant sequences by reference to the amino acid sequence of SEQ ID NO:6, SEQ ID NO:69 or SEQ ID NO:4. Variant sequences can be readily tested for functionality as described herein.

One of ordinary skill in the art will also appreciate that different species can exhibit "preferential codon usage." In general, see, Grantham, et al., Nuc. Acids Res. 8:1893-912, 1980; Haas, et al. Curr. Biol. 6:315-24, 1996; Wain-Hobson, et al., Gene 13:355-64, 1981; Grosjean and Fiers, Gene 18:199-209, 1982; Holm, Nuc. Acids Res. 14:3075-87, 1986; Ikemura, J. Mol. Biol. 158:573-97, 1982. As used herein, the term "preferential codon usage" or "preferential codons" is a term of art referring to protein translation codons that are most frequently used in cells of a certain species, thus favoring one or a few representatives of the possible codons encoding each amino acid (See Table 2). For example, the amino acid Threonine (Thr) may be encoded by ACA, ACC, ACG, or ACT, but in mammalian cells ACC is the most commonly used codon; in other species, for example, insect cells, yeast, viruses or bacteria, different Thr codons may be preferential. Preferential codons for a particular species can be introduced into the polynucleotides of the present invention by a variety of methods known in the art. Introduction of preferential codon sequences into recombinant DNA can, for example, enhance production of the protein by making protein translation more efficient within a particular cell type or species. Therefore, the degenerate codon sequence disclosed in SEQ ID NO:7, SEQ ID NO:66 and SEQ ID NO:8 serves as a template for optimizing expression of polynucleotides and polypeptides in various cell types and species commonly used in the art and disclosed herein. Sequences containing preferential codons can be tested and optimized for expression in various species, and tested for functionality as disclosed herein.

Within preferred embodiments of the invention the isolated polynucleotides will hybridize to similar sized regions of SEQ ID NO:5, SEQ ID NO:68 or SEQ ID NO:3, or a sequence complementary thereto, under stringent conditions. In general, stringent conditions are selected to be about 5°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Numerous equations for calculating T_m are known in the art, and are specific for DNA, RNA and DNA-RNA hybrids and polynucleotide probe sequences of varying length (see, for example, Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, Second Edition (Cold Spring Harbor Press 1989); Ausubel *et al.*, (eds.), Current Protocols in Molecular Biology (John Wiley and Sons, Inc. 1987); Berger and Kimmel (eds.), Guide to Molecular Cloning Techniques, (Academic Press, Inc. 1987); and Wetmur, Crit. Rev. Biochem. Mol. Biol. 26:227 (1990)). Sequence analysis software such as OLIGO 6.0 (LSR; Long Lake, MN) and *Primer Premier 4.0* (Premier Biosoft International; Palo Alto, CA), as well as sites on the Internet, are available tools for analyzing a given sequence and calculating T_m based on user-defined criteria. Such programs can also analyze a given sequence under defined conditions and identify suitable probe sequences. Typically, hybridization of longer polynucleotide sequences (e.g., >50 base pairs) is performed at temperatures of about 20-25°C below the calculated T_m . For smaller probes (e.g., <50 base pairs) hybridization is typically carried out at the T_m or 5-10°C below. This allows for the maximum rate of hybridization for DNA-DNA and DNA-RNA hybrids. Higher degrees of stringency at lower temperatures can be achieved with the addition of formamide which reduces the T_m of the hybrid about 1°C for each 1% formamide in the buffer solution. Suitable stringent hybridization conditions are equivalent to about a 5 h to overnight incubation at about 42°C in a solution comprising: about 40-50% formamide, up to about 6X SSC, about 5X Denhardt's solution, zero up to about 10% dextran sulfate, and about 10-20 µg/ml denatured commercially-available carrier DNA. Generally, such stringent conditions include temperatures of 20-70°C and a hybridization buffer containing up to 6x SSC and 0-50% formamide; hybridization is then followed by washing filters in up to about

2X SSC. For example, a suitable wash stringency is equivalent to 0.1X SSC to 2X SSC, 0.1% SDS, at 55°C to 65°C. Different degrees of stringency can be used during hybridization and washing to achieve maximum specific binding to the target sequence. Typically, the washes following hybridization are performed at increasing degrees of stringency to remove non-hybridized polynucleotide probes from hybridized complexes. Stringent hybridization and wash conditions depend on the length of the probe, reflected in the T_m , hybridization and wash solutions used, and are routinely determined empirically by one of skill in the art.

As previously noted, the isolated polynucleotides of the present invention include DNA and RNA. Methods for preparing DNA and RNA are well known in the art. In general, RNA is isolated from a tissue or cell that produces large amounts of $\alpha 11$ receptor RNA or the RNA for the heterodimeric component of the receptor, such as IL-2R γ , or other class I cytokine receptor. Such tissues and cells are identified by Northern blotting (Thomas, Proc. Natl. Acad. Sci. USA 77:5201, 1980), and include PBLs, spleen, thymus, and lymph tissues, Raji cells, human erythroleukemia cell lines (e.g., TF-1), acute monocytic leukemia cell lines, other lymphoid and hematopoietic cell lines, and the like, for the $\alpha 11$ receptor. RNA for a heterodimeric component of the receptor, such as IL-2R γ , or other class I cytokine receptor can be isolated from lymphoid cells, such as those described above, and other cells and tissues as is known in the art for these receptors. Total RNA can be prepared using guanidinium isothiocyanate extraction followed by isolation by centrifugation in a CsCl gradient (Chirgwin et al., Biochemistry 18:52-94, 1979). Poly (A)⁺ RNA is prepared from total RNA using the method of Aviv and Leder (Proc. Natl. Acad. Sci. USA 69:1408-12, 1972). Complementary DNA (cDNA) is prepared from poly(A)⁺ RNA using known methods. In the alternative, genomic DNA can be isolated. Polynucleotides encoding $\alpha 11$ polypeptides are then identified and isolated by, for example, hybridization or polymerase chain reaction (PCR) (Mullis, U.S. Patent No. 4,683,202).

The polynucleotides of the present invention can also be synthesized using DNA synthesis machines. Currently the method of choice is the phosphoramidite method. If chemically synthesized double stranded DNA is required for an application

such as the synthesis of a gene or a gene fragment, then each complementary strand is made separately. The production of short polynucleotides (60 to 80 bp) is technically straightforward and can be accomplished by synthesizing the complementary strands and then annealing them. However, for producing longer polynucleotides (>300 bp),
5 special strategies are usually employed, because the coupling efficiency of each cycle during chemical DNA synthesis is seldom 100%. To overcome this problem, synthetic genes (double-stranded) are assembled in modular form from single-stranded fragments that are from 20 to 100 nucleotides in length.

An alternative way to prepare a full-length gene is to synthesize a
10 specified set of overlapping oligonucleotides (40 to 100 nucleotides). After the 3' and 5' short overlapping complementary regions (6 to 10 nucleotides) are annealed, large gaps still remain, but the short base-paired regions are both long enough and stable enough to hold the structure together. The gaps are filled and the DNA duplex is completed via enzymatic DNA synthesis by *E. coli* DNA polymerase I. After the enzymatic synthesis
15 is completed, the nicks are sealed with T4 DNA ligase. Double-stranded constructs are sequentially linked to one another to form the entire gene sequence which is verified by DNA sequence analysis. See Glick and Pasternak, Molecular Biotechnology, Principles & Applications of Recombinant DNA, (ASM Press, Washington, D.C. 1994); Itakura et al., Annu. Rev. Biochem. 53: 323-56, 1984 and Climie et al., Proc. Natl. Acad. Sci.
20 USA 87:633-7, 1990. Moreover, other sequences are generally added that contain signals for proper initiation and termination of transcription and translation.

The present invention further provides counterpart polypeptides and polynucleotides from other species (orthologs). These species include, but are not limited to mammalian, avian, amphibian, reptile, fish, insect and other vertebrate and
25 invertebrate species. Of particular interest are heterodimeric soluble receptor complexes combining soluble α 11 receptor and soluble human IL-2R γ or other soluble Class I cytokine receptor polypeptides from other mammalian species, including murine, porcine, ovine, bovine, canine, feline, equine, and other primate polypeptides. Known and unknown orthologs of human soluble α 11 receptor and
30 soluble human IL-2R γ or other soluble Class I cytokine receptors can be cloned using information and compositions provided by the present invention in combination with

conventional cloning techniques. For example, a cDNA can be cloned using mRNA obtained from a tissue or cell type, such as lymphoid cells, that expresses $\alpha 1$ receptor, human IL-2R γ or other Class I cytokine receptors. Moreover, suitable sources of mRNA can be identified by probing Northern blots with probes
5 designed from the sequences disclosed herein. A library is then prepared from mRNA of a positive tissue or cell line. A $\alpha 1$ -encoding cDNA can then be isolated by a variety of methods, such as by probing with a complete or partial human cDNA or with one or more sets of degenerate probes based on the disclosed sequences. A cDNA can also be cloned using PCR (Mullis, supra.), using primers designed from the
10 representative human $\alpha 1$ sequence, or soluble human IL-2R γ sequence, disclosed herein. Within an additional method, the cDNA library can be used to transform or transfect host cells, and expression of the cDNA of interest can be detected with an antibody to $\alpha 1$ polypeptide. Similar techniques can also be applied to the isolation of genomic clones.

15 Cytokine receptor subunits are characterized by a multi-domain structure comprising an extracellular domain, a transmembrane domain that anchors the polypeptide in the cell membrane, and an intracellular domain. The extracellular domain the $\alpha 1$ receptor is a ligand-binding domain, that binds $\alpha 1$ Ligand, and the intracellular domain is an effector domain involved in signal transduction,
20 although ligand-binding and effector functions can reside on separate subunits of a multimeric receptor. The ligand-binding domain may itself be a multi-domain structure. Multimeric receptors include homodimers (e.g., PDGF receptor $\alpha\alpha$ and $\beta\beta$ isoforms, erythropoietin receptor, MPL, and G-CSF receptor), heterodimers whose subunits each have ligand-binding and effector domains (e.g., PDGF receptor $\alpha\beta$
25 isoform), and multimers having component subunits with disparate functions (e.g., IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-13, IL-15 and GM-CSF receptors). Some receptor subunits are common to a plurality of receptors. For example, the AIC2B subunit, which cannot bind ligand on its own but includes an intracellular signal transduction domain, is a component of IL-3 and GM-CSF receptors. Many cytokine receptors can
30 be placed into one of four related families on the basis of the structure and function. Hematopoietic receptors, for example, are characterized by the presence of a domain

containing conserved cysteine residues and the WSXWS motif (SEQ ID NO:13). Cytokine receptor structure has been reviewed by Urdal, Ann. Reports Med. Chem. 26:221-228, 1991; and Cosman, Cytokine 5:95-106, 1993. Under selective pressure for organisms to acquire new biological functions, new receptor family members likely
5 arise from duplication of existing receptor genes leading to the existence of multi-gene families. Family members thus contain vestiges of the ancestral gene, and these characteristic features can be exploited in the isolation and identification of additional family members. Thus, the cytokine receptor superfamily is subdivided into several families, for example, the immunoglobulin family (including CSF-1, MGF, IL-1, and
10 PDGF receptors); the hematopoietin family (including IL-2 receptor β -subunit, GM-CSF receptor α -subunit, GM-CSF receptor β -subunit; and G-CSF, EPO, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-13 and IL-15 receptors); TNF receptor family (including TNF (p80) TNF (p60) receptors, CD27, CD30, CD40, Fas, and NGF receptor).

Analysis of the $\alpha 11$ receptor sequence suggests that it is a member
15 of the same receptor subfamily as the IL-2 receptor β -subunit, IL-4, and IL-9, receptors. Certain receptors in this subfamily (e.g., EPO-R or MPL) associate to form homodimers that transduce a signal. Other members of the subfamily (e.g., IL-6, IL-11, and LIF receptors) combine with a second subunit (termed a β -subunit) to bind ligand and transduce a signal. Specific β -subunits associate with a plurality of specific cytokine
20 receptor subunits. For example, the β -subunit gp130 (Hibi et al., Cell 63:1149-1157, 1990) associates with receptor subunits specific for IL-6, IL-11, and LIF (Gearing et al., EMBO J. 10:2839-2848, 1991; Gearing et al., U.S. Patent No. 5,284,755). Oncostatin M binds to a heterodimer of LIF receptor and gp130. CNTF binds to trimeric receptors comprising CNTF receptor, LIF receptor, and gp130 subunits. Moreover, IL-4 and IL-
25 13 elicit responses through the IL-4 and IL-13 receptors by acting upon various functional heterodimeric receptor complexes, e.g. with and without the γ_c subunit, and such heterodimeric receptor complexes may affect whether the cytokines act upon hematopoietic or non-hematopoietic cells (Andersson, A. et al., Eur. J. Immunol. 27:1762-1768, 1997; Murata, T. et al., Blood 10:3884-3891, 1998). Moreover, binding
30 affinity of IL-4 on its receptor is increased when the γ_c subunit of the IL4R complex is replaced by an IL-13R α' subunit (Murata, T. et al., supra.). Thus, the soluble receptors

of the present invention include zalpha11 receptor homodimers; and heterodimers that have a zalpha11 receptor component, such as soluble zalpha11/IL-2R γ or soluble zalpha11 receptor heterodimerized with another soluble Class I cytokine receptor, such as IL-13R α (SEQ ID NO:84), IL-13R α ' (SEQ ID NO:82) or an IL-15 (SEQ ID NO:86) receptor subunit.

For example, suitable Class I cytokine soluble receptors that can heterodimerize with a soluble zalpha11 receptor component (e.g., SEQ ID NO:6), include a soluble receptor for IL-13R α as shown in SEQ ID NO:84, IL-13R α ' as shown in SEQ ID NO:82, or IL-15 as shown in SEQ ID NO:86. Moreover, functional sub-fragments, such as minimal cytokine binding fragments, of these Class I cytokine soluble receptors can be used. Such functional fragments include 1 to 322, 7 to 322, and 105 to 322 of SEQ ID NO:82; 1 to 317, 10 to 317, and 105 to 317 of SEQ ID NO:84; and 1 to 173 of SEQ ID NO:86. The corresponding polynucleotide sequences are as shown in SEQ ID NO:81, SEQ ID NO:83 and SEQ ID NO:85 respectively. It is well within the level of one of skill in the art to delineate what sequences of a known class I cytokine sequence comprise the extracellular cytokine binding domain free of a transmembrane domain and intracellular domain.

A polynucleotide sequence for the mouse ortholog of human zalpha11 receptor has been identified and is shown in SEQ ID NO:11 and the corresponding amino acid sequence shown in SEQ ID NO:12. Analysis of the mouse zalpha11 polypeptide encoded by the DNA sequence of SEQ ID NO:11 revealed an open reading frame encoding 529 amino acids (SEQ ID NO:12) comprising a predicted secretory signal peptide of 19 amino acid residues (residue 1 (Met) to residue 19 (Ser) of SEQ ID NO:12), and a mature polypeptide of 510 amino acids (residue 20 (Cys) to residue 529 (Ser) of SEQ ID NO:12). In addition to the WSXWS motif (SEQ ID NO:13) corresponding to residues 214 to 218 of SEQ ID NO:12, the receptor comprises a cytokine-binding domain of approximately 200 amino acid residues (residues 20 (Cys) to 237 (His) of SEQ ID NO:12); a domain linker (residues 120 (Pro) to 123 (Pro) of SEQ ID NO:12); a penultimate strand region (residues 192 (Lys) to 202 (Ala) of SEQ ID NO:12); a transmembrane domain (residues 238 (Met) to 254 (Leu) of SEQ ID NO:12); complete intracellular signaling domain (residues 255 (Lys) to 529 (Ser) of

SEQ ID NO:12) which contains a "Box I" signaling site (residues 266 (Ile) to 273 (Pro) of SEQ ID NO:12), and a "Box II" signaling site (residues 301 (Ile) to 304 (Val) of SEQ ID NO:2). A comparison of the human and mouse amino acid sequences reveals that both the human and orthologous polypeptides contain corresponding structural features described above. The mature sequence for the mouse zalpha11 begins at Cys₂₀ (as shown in SEQ ID NO:12), which corresponds to Cys₂₀ (as shown in SEQ ID NO:2) in the human sequence. There is about 69% identity a between the mouse and human zalpha11 sequences over the extracellular cytokine binding domain corresponding to residues 20 (Cys) to 237 (His) of SEQ ID NO:2 (SEQ ID NO:6) and residues 20 (Cys) to 237 (His) of SEQ ID NO:12. The above percent identities were determined using a FASTA program with ktup=1, gap opening penalty=12, gap extension penalty=2, and substitution matrix=BLOSUM62, with other FASTA program parameters set as default. The corresponding polynucleotides encoding the mouse zalpha11 polypeptide regions, domains, motifs, residues and sequences described above are as shown in SEQ ID NO:11.

The present invention also provides for a heterodimeric soluble receptor, wherein the isolated soluble zalpha11 receptor polypeptide therein is substantially similar to the polypeptides of SEQ ID NO:6 and their orthologs. Moreover, in a preferred embodiment, the present invention also provides for a heterodimeric soluble receptor, wherein an isolated soluble IL-2R γ receptor polypeptide therein is substantially similar to the polypeptides of SEQ ID NO:4 and their orthologs. The term "substantially similar" is used herein to denote polypeptides having at least 70%, more preferably at least 80%, sequence identity to the sequences shown in SEQ ID NO:6 or their orthologs. Such polypeptides will more preferably be at least 90% identical, and most preferably 95% or more identical to SEQ ID NO:6 or SEQ ID NO:4 their orthologs.) Percent sequence identity is determined by conventional methods. See, for example, Altschul et al., Bull. Math. Bio. 48: 603-616, 1986 and Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA 89:10915-10919, 1992. Briefly, two amino acid sequences are aligned to optimize the alignment scores using a gap opening penalty of 10, a gap extension penalty of 1, and the "blosum 62" scoring matrix of Henikoff and

Henikoff (ibid.) as shown in Table 3 (amino acids are indicated by the standard one-letter codes). The percent identity is then calculated as:

$$5 \quad \frac{\text{Total number of identical matches}}{\text{[length of the longer sequence plus the number of gaps introduced into the longer sequence in order to align the two sequences]}} \times 100$$

Table 3

	A	R	N	D	C	Q	E	G	H	I	L	K	M	F	P	S	T	W	Y	V
5	A	4																		
	R	-1	5																	
	N	-2	0	6																
	D	-2	-2	1	6															
	C	0	-3	-3	-3	9														
	Q	-1	1	0	0	-3	5													
10	E	-1	0	0	2	-4	2	5												
	G	0	-2	0	-1	-3	-2	-2	6											
	H	-2	0	1	-1	-3	0	0	-2	8										
	I	-1	-3	-3	-3	-1	-3	-4	-3	4										
	L	-1	-2	-3	-4	-1	-2	-3	-4	-3	2	4								
15	K	-1	2	0	-1	-3	1	1	-2	-1	-3	-2	5							
	M	-1	-1	-2	-3	-1	0	-2	-3	-2	1	2	-1	5						
	F	-2	-3	-3	-3	-2	-3	-3	-3	-1	0	0	-3	0	6					
	P	-1	-2	-2	-1	-3	-1	-1	-2	-2	-3	-3	-1	-2	-4	7				
	S	1	-1	1	0	-1	0	0	0	-1	-2	-2	0	-1	-2	-1	4			
20	T	0	-1	0	-1	-1	-1	-1	-2	-2	-1	-1	-1	-1	-2	-1	1	5		
	W	-3	-3	-4	-4	-2	-2	-3	-2	-2	-3	-2	-3	-1	1	-4	-3	-2	11	
	Y	-2	-2	-2	-3	-2	-1	-2	-3	2	-1	-1	-2	-1	3	-3	-2	-2	2	7
	V	0	-3	-3	-3	-1	-2	-2	-3	-3	3	1	-2	1	-1	-2	-2	0	-3	-1

Sequence identity of polynucleotide molecules is determined by similar methods using a ratio as disclosed above.

Those skilled in the art appreciate that there are many established algorithms available to align two amino acid sequences. The "FASTA" similarity search algorithm of Pearson and Lipman is a suitable protein alignment method for
5 examining the level of identity shared by an amino acid sequence disclosed herein and the amino acid sequence of a putative variant zsig57. The FASTA algorithm is described by Pearson and Lipman, Proc. Nat'l Acad. Sci. USA 85:2444 (1988), and by Pearson, Meth. Enzymol. 183:63 (1990).

10 Briefly, FASTA first characterizes sequence similarity by identifying regions shared by the query sequence (*e.g.*, SEQ ID NO:6) and a test sequence that have either the highest density of identities (if the ktup variable is 1) or pairs of identities (if ktup=2), without considering conservative amino acid substitutions, insertions, or deletions. The ten regions with the highest density of identities are then rescored by
15 comparing the similarity of all paired amino acids using an amino acid substitution matrix, and the ends of the regions are "trimmed" to include only those residues that contribute to the highest score. If there are several regions with scores greater than the "cutoff" value (calculated by a predetermined formula based upon the length of the sequence and the ktup value), then the trimmed initial regions are examined to
20 determine whether the regions can be joined to form an approximate alignment with gaps. Finally, the highest scoring regions of the two amino acid sequences are aligned using a modification of the Needleman-Wunsch-Sellers algorithm (Needleman and Wunsch, J. Mol. Biol. 48:444 (1970); Sellers, SIAM J. Appl. Math. 26:787 (1974)), which allows for amino acid insertions and deletions. Preferred program parameters for
25 FASTA analysis are: ktup=1, gap opening penalty=10, gap extension penalty=1, and substitution matrix=BLOSUM62, with other parameters set as default. These FASTA program parameters can be introduced into a FASTA program by modifying the scoring matrix file ("SMATRIX"), as explained in Appendix 2 of Pearson, Meth. Enzymol. 183:63 (1990).

30 FASTA can also be used to determine the sequence identity of nucleic acid molecules using a ratio as disclosed above. For nucleotide sequence comparisons,

the ktup value can range between one to six, preferably from three to six, most preferably three, with other program parameters set as default.

The BLOSUM62 table (Table 3) is an amino acid substitution matrix derived from about 2,000 local multiple alignments of protein sequence segments, representing highly conserved regions of more than 500 groups of related proteins (Henikoff and Henikoff, *Proc. Nat'l Acad. Sci. USA* 89:10915 (1992)). Accordingly, the BLOSUM62 substitution frequencies can be used to define conservative amino acid substitutions that may be introduced into the amino acid sequences of the present invention. Although it is possible to design amino acid substitutions based solely upon chemical properties (as discussed below), the language "conservative amino acid substitution" preferably refers to a substitution represented by a BLOSUM62 value of greater than -1. For example, an amino acid substitution is conservative if the substitution is characterized by a BLOSUM62 value of 0, 1, 2, or 3. According to this system, preferred conservative amino acid substitutions are characterized by a BLOSUM62 value of at least 1 (e.g., 1, 2 or 3), while more preferred conservative amino acid substitutions are characterized by a BLOSUM62 value of at least 2 (e.g., 2 or 3).

Variant zalpha11 polypeptides or substantially homologous zalpha11 polypeptides are characterized as having one or more amino acid substitutions, deletions or additions. These changes are preferably of a minor nature, that is conservative amino acid substitutions (see Table 4) and other substitutions that do not significantly affect the folding or activity of the polypeptide; small deletions, typically of one to about 30 amino acids; and small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue, a small linker peptide of up to about 20-25 residues, or an affinity tag. The present invention thus includes zalpha11 soluble receptor polypeptides of from about 190 to about 245 amino acid residues that comprise a sequence that is at least 80%, preferably at least 90%, and more preferably 95% or more identical to the corresponding region of SEQ ID NO:6. Polypeptides comprising affinity tags can further comprise a proteolytic cleavage site between the zalpha11 polypeptide and the affinity tag. Suitable sites include thrombin cleavage sites and factor Xa cleavage sites.

Table 4Conservative amino acid substitutions

5	Basic:	arginine
		lysine
		histidine
	Acidic:	glutamic acid
		aspartic acid
10	Polar:	glutamine
		asparagine
	Hydrophobic:	leucine
		isoleucine
		valine
15	Aromatic:	phenylalanine
		tryptophan
		tyrosine
	Small:	glycine
		alanine
20		serine
		threonine
		methionine

The present invention further provides a variety of other polypeptide
 25 fusions and related multimeric proteins comprising one or more polypeptide fusions.
 For example, a soluble zalpha11 receptor or soluble zalpha11 heterodimeric
 polypeptide, such as soluble zalpha11/IL-2R γ can be prepared as a fusion to a
 dimerizing protein as disclosed in U.S. Patents Nos. 5,155,027 and 5,567,584.
 Preferred dimerizing proteins in this regard include immunoglobulin constant region
 30 domains, e.g., IgG γ 1, and the human κ light chain. Immunoglobulin-soluble zalpha11
 receptor or immunoglobulin-soluble zalpha11 heterodimeric polypeptide, such as
 immunoglobulin-soluble zalpha11/IL-2R γ fusions can be expressed in genetically
 engineered cells to produce a variety of multimeric zalpha11 receptor analogs.
 Auxiliary domains can be fused to soluble zalpha11 receptor or soluble zalpha11
 35 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ to target them to specific

cells, tissues, or macromolecules (e.g., collagen, or cells expressing the zalpha11 Ligand). A zalpha11 polypeptide can be fused to two or more moieties, such as an affinity tag for purification and a targeting domain. Polypeptide fusions can also comprise one or more cleavage sites, particularly between domains. See, Tuan et al.,
5 Connective Tissue Research 34:1-9, 1996.

The proteins of the present invention can also comprise non-naturally occurring amino acid residues. Non-naturally occurring amino acids include, without limitation, *trans*-3-methylproline, 2,4-methanoproline, *cis*-4-hydroxyproline, *trans*-4-hydroxyproline, *N*-methylglycine, *allo*-threonine, methylthreonine,
10 hydroxyethylcysteine, hydroxyethylhomocysteine, nitroglutamine, homoglutamine, pipecolic acid, thiazolidine carboxylic acid, dehydroproline, 3- and 4-methylproline, 3,3-dimethylproline, *tert*-leucine, norvaline, 2-azaphenylalanine, 3-azaphenylalanine, 4-azaphenylalanine, and 4-fluorophenylalanine. Several methods are known in the art for incorporating non-naturally occurring amino acid residues into proteins. For example,
15 an *in vitro* system can be employed wherein nonsense mutations are suppressed using chemically aminoacylated suppressor tRNAs. Methods for synthesizing amino acids and aminoacylating tRNA are known in the art. Transcription and translation of plasmids containing nonsense mutations is carried out in a cell-free system comprising an *E. coli* S30 extract and commercially available enzymes and other reagents. Proteins
20 are purified by chromatography. See, for example, Robertson et al., J. Am. Chem. Soc. 113:2722, 1991; Ellman et al., Methods Enzymol. 202:301, 1991; Chung et al., Science 259:806-9, 1993; and Chung et al., Proc. Natl. Acad. Sci. USA 90:10145-9, 1993). In a second method, translation is carried out in *Xenopus* oocytes by microinjection of mutated mRNA and chemically aminoacylated suppressor tRNAs (Turcatti et al., J.
25 Biol. Chem. 271:19991-8, 1996). Within a third method, *E. coli* cells are cultured in the absence of a natural amino acid that is to be replaced (e.g., phenylalanine) and in the presence of the desired non-naturally occurring amino acid(s) (e.g., 2-azaphenylalanine, 3-azaphenylalanine, 4-azaphenylalanine, or 4-fluorophenylalanine). The non-naturally occurring amino acid is incorporated into the protein in place of its natural counterpart.
30 See, Koide et al., Biochem. 33:7470-7476, 1994. Naturally occurring amino acid residues can be converted to non-naturally occurring species by *in vitro* chemical

modification. Chemical modification can be combined with site-directed mutagenesis to further expand the range of substitutions (Wynn and Richards, Protein Sci. 2:395-403, 1993).

5 A limited number of non-conservative amino acids, amino acids that are not encoded by the genetic code, non-naturally occurring amino acids, and unnatural amino acids may be substituted for zalph11 amino acid residues.

Essential amino acids in the polypeptides of the present invention can be identified according to procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, Science 244: 1081-5, 1989; 10 Bass et al., Proc. Natl. Acad. Sci. USA 88:4498-502, 1991). In the latter technique, single alanine mutations are introduced at every residue in the molecule, and the resultant mutant molecules are tested for biological activity (e.g. ligand binding and signal transduction) as disclosed below to identify amino acid residues that are critical to the activity of the molecule. See also, Hilton et al., J. Biol. Chem. 271:4699-4708, 15 1996. Sites of ligand-receptor, protein-protein or other biological interaction can also be determined by physical analysis of structure, as determined by such techniques as nuclear magnetic resonance, crystallography, electron diffraction or photoaffinity labeling, in conjunction with mutation of putative contact site amino acids. See, for example, de Vos et al., Science 255:306-312, 1992; Smith et al., J. Mol. Biol. 224:899-20 904, 1992; Wlodaver et al., FEBS Lett. 309:59-64, 1992. The identities of essential amino acids can also be inferred from analysis of homologies with related receptors.

Determination of amino acid residues that are within regions or domains that are critical to maintaining structural integrity can be determined. Within these regions one can determine specific residues that will be more or less tolerant of change 25 and maintain the overall tertiary structure of the molecule. Methods for analyzing sequence structure include, but are not limited to, alignment of multiple sequences with high amino acid or nucleotide identity and computer analysis using available software (e.g., the Insight II® viewer and homology modeling tools; MSI, San Diego, CA), secondary structure propensities, binary patterns, complementary packing and buried 30 polar interactions (Barton, Current Opin. Struct. Biol. 5:372-376, 1995; and, Cordes et al., Current Opin. Struct. Biol. 6:3-10, 1996). In general, when designing modifications

to molecules or identifying specific fragments determination of structure will be accompanied by evaluating activity of modified molecules.

Amino acid sequence changes are made in soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ , so as to minimize disruption of higher order structure essential to biological activity. For example, where the soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ comprises one or more helices, changes in amino acid residues will be made so as not to disrupt the helix geometry and other components of the molecule where changes in conformation abate some critical function, for example, binding of the molecule to the zalpha11 Ligand, or antagonizing zalpha11 Ligand activity. The effects of amino acid sequence changes can be predicted by, for example, computer modeling as disclosed above or determined by analysis of crystal structure (see, e.g., Lapthorn et al., Nat. Struct. Biol. 2:266-268, 1995). Other techniques that are well known in the art compare folding of a variant protein to a standard molecule (e.g., the native protein). For example, comparison of the cysteine pattern in a variant and standard molecules can be made. Mass spectrometry and chemical modification using reduction and alkylation provide methods for determining cysteine residues which are associated with disulfide bonds or are free of such associations (Bean et al., Anal. Biochem. 201:216-226, 1992; Gray, Protein Sci. 2:1732-1748, 1993; and Patterson et al., Anal. Chem. 66:3727-3732, 1994). It is generally believed that if a modified molecule does not have the same disulfide bonding pattern as the standard molecule folding would be affected. Another well known and accepted method for measuring folding is circular dichroism (CD). Measuring and comparing the CD spectra generated by a modified molecule and standard molecule is routine (Johnson, Proteins 7:205-214, 1990). Crystallography is another well known method for analyzing folding and structure. Nuclear magnetic resonance (NMR), digestive peptide mapping and epitope mapping are also known methods for analyzing folding and structural similarities between proteins and polypeptides (Schaanan et al., Science 257:961-964, 1992).

A Hopp/Woods hydrophilicity profile of the zalpha11 protein sequence as shown in SEQ ID NO:6 can be generated (Hopp et al., Proc. Natl. Acad.

Sci.78:3824-3828, 1981; Hopp, J. Immun. Meth. 88:1-18, 1986 and Triquier et al., Protein Engineering 11:153-169, 1998). The profile is based on a sliding six-residue window. Buried G, S, and T residues and exposed H, Y, and W residues were ignored. For example, in the soluble $\alpha 11$ receptor, hydrophilic regions include amino acid residues 55 through 60 of SEQ ID NO: 2, amino acid residues 56 through 61 of SEQ ID NO: 2, amino acid residues 139 through 144 of SEQ ID NO: 2, and amino acid residues 227 through 232 of SEQ ID NO: 2. The corresponding hydrophilic regions in reference to SEQ ID NO:6 can be made with cross-reference to the above amino acid residues of SEQ ID NO:2.

Those skilled in the art will recognize that hydrophilicity or hydrophobicity will be taken into account when designing modifications in the amino acid sequence of a soluble $\alpha 11$ receptor or soluble $\alpha 11$ heterodimeric polypeptide, such as soluble $\alpha 11$ /IL-2R γ , so as not to disrupt the overall structural and biological profile. Of particular interest for replacement are hydrophobic residues selected from the group consisting of Val, Leu and Ile or the group consisting of Met, Gly, Ser, Ala, Tyr and Trp. For example, residues tolerant of substitution could include such residues as shown in SEQ ID NO:6, SEQ ID NO:69 and SEQ ID NO:4. However, Cysteine residues could be relatively intolerant of substitution.

The identities of essential amino acids can also be inferred from analysis of sequence similarity between Class I cytokine receptor family members with soluble $\alpha 11$ receptor or soluble IL-2R γ receptor. Using methods such as "FASTA" analysis described previously, regions of high similarity are identified within a family of proteins and used to analyze amino acid sequence for conserved regions. An alternative approach to identifying a variant extracellular domain $\alpha 11$ polynucleotide on the basis of structure is to determine whether a nucleic acid molecule encoding a potential variant $\alpha 11$ polynucleotide can hybridize to a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:5, or SEQ ID NO:68 as discussed above. Likewise, variants of soluble class I cytokine receptor contained within a $\alpha 11$ heterodimeric polypeptide, such as the soluble IL-2R γ receptor component in soluble $\alpha 11$ /IL-2R γ , can be identified as described above.

Other methods of identifying essential amino acids in the polypeptides of the present invention are procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, Science 244:1081 (1989), Bass et al., Proc. Natl Acad. Sci. USA 88:4498 (1991), Coombs and
5 Corey, "Site-Directed Mutagenesis and Protein Engineering," in Proteins: Analysis and Design, Angeletti (ed.), pages 259-311 (Academic Press, Inc. 1998)). In the latter technique, single alanine mutations are introduced at every residue in the molecule, and the resultant mutant molecules are tested for biological activity as disclosed below to identify amino acid residues that are critical to the activity of the molecule. See also,
10 Hilton et al., *J. Biol. Chem.* 271:4699 (1996).

The present invention also includes functional fragments of soluble zalpha11 receptor polypeptides or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ polypeptides and nucleic acid molecules encoding such functional fragments. A "functional" soluble zalpha11 receptor polypeptide or soluble
15 zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ polypeptide, or fragment thereof defined herein is characterized by its by its ability to bind to an anti-zalpha11 antibody, or to zalpha11 Ligand (either soluble or immobilized), or to antagonize zalpha11 Ligand activity in, for example, a biological or binding assay. As previously described herein, zalpha11 receptor is characterized by a class I cytokine
20 receptor structure. Thus, the present invention further provides fusion proteins encompassing: (a) homodimeric or multimeric polypeptide molecules comprising an extracellular domain described herein; and (b) functional fragments comprising one or more of these domains. The other polypeptide portion of the fusion protein may be contributed by another class I cytokine receptor, for example, IL-2R γ , IL-2 receptor β -subunit and the β -common receptor (i.e., IL3, IL-5, and GM-CSF receptor β -subunits),
25 IL-13 α , IL-13 α' , or IL-15 receptor subunits, or by a non-native and/or an unrelated secretory signal peptide that facilitates secretion of the soluble fusion protein.

Routine deletion analyses of nucleic acid molecules can be performed to obtain functional fragments of a nucleic acid molecule that encode a soluble zalpha11
30 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ . As an illustration, DNA molecules having the nucleotide sequence of SEQ ID

NO:1 or fragments thereof, can be digested with *Bal31* nuclease to obtain a series of nested deletions. These DNA fragments are then inserted into expression vectors in proper reading frame, and the expressed polypeptides are isolated and tested for antagonizing $\alpha 11$ Ligand biological or $\alpha 11$ Ligand binding activity; or for the ability to bind anti-soluble $\alpha 11$ receptor or anti-soluble $\alpha 11$ heterodimeric polypeptide antibodies; or for the ability to bind $\alpha 11$ Ligand. One alternative to exonuclease digestion is to use oligonucleotide-directed mutagenesis to introduce deletions or stop codons to specify production of a desired polypeptide fragment. Alternatively, particular fragments of a soluble $\alpha 11$ receptor or soluble $\alpha 11$ heterodimeric polypeptide polynucleotide can be synthesized using the polymerase chain reaction.

Standard methods for identifying functional domains, such as Ligand binding domains, are routine for those of skill in the art. For example, studies on the truncation at either or both termini of interferons have been summarized by Horisberger and Di Marco, Pharmac. Ther. 66:507 (1995). Moreover, standard techniques for functional analysis of proteins are described by, for example, Treuter et al., Molec. Gen. Genet. 240:113 (1993); Content et al., "Expression and preliminary deletion analysis of the 42 kDa 2-5A synthetase induced by human interferon," in Biological Interferon Systems, Proceedings of ISIR-TNO Meeting on Interferon Systems, Cantell (ed.), pages 65-72 (Nijhoff 1987); Herschman, "The EGF Receptor," in Control of Animal Cell Proliferation 1, Boynton et al., (eds.) pages 169-199 (Academic Press 1985); Coumailleau et al., J. Biol. Chem. 270:29270 (1995); Fukunaga et al., J. Biol. Chem. 270:25291 (1995); Yamaguchi et al., Biochem. Pharmacol. 50:1295 (1995); and Meisel et al., Plant Molec. Biol. 30:1 (1996).

Multiple amino acid substitutions can be made and tested using known methods of mutagenesis and screening, such as those disclosed by Reidhaar-Olson and Sauer (Science 241:53-57, 1988) or Bowie and Sauer (Proc. Natl. Acad. Sci. USA 86:2152-2156, 1989). Briefly, these authors disclose methods for simultaneously randomizing two or more positions in a polypeptide, selecting for functional polypeptide, and then sequencing the mutagenized polypeptides to determine the spectrum of allowable substitutions at each position. Other methods that can be used

include phage display (e.g., Lowman et al., Biochem. 30:10832-10837, 1991; Ladner et al., U.S. Patent No. 5,223,409; Huse, WIPO Publication WO 92/062045) and region-directed mutagenesis (Derbyshire et al., Gene 46:145, 1986; Ner et al., DNA 7:127, 1988).

5 Variants of the disclosed soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide DNA and polypeptide sequences can be generated through DNA shuffling as disclosed by Stemmer, Nature 370:389-91, 1994, Stemmer, Proc. Natl. Acad. Sci. USA 91:10747-51, 1994 and WIPO Publication WO 97/20078. Briefly, variant DNAs are generated by *in vitro* homologous recombination by random
10 fragmentation of a parent DNA followed by reassembly using PCR, resulting in randomly introduced point mutations. This technique can be modified by using a family of parent DNAs, such as allelic variants or DNAs from different species, to introduce additional variability into the process. Selection or screening for the desired activity, followed by additional iterations of mutagenesis and assay provides for rapid
15 "evolution" of sequences by selecting for desirable mutations while simultaneously selecting against detrimental changes.

Mutagenesis methods as disclosed herein can be combined with high-throughput, automated screening methods to detect zalpha11 Ligand antagonist or binding activity in host cells of cloned, mutagenized soluble zalpha11 receptor or
20 soluble zalpha11 heterodimeric receptor polypeptides. Preferred assays in this regard include cell proliferation assays and biosensor-based ligand-binding assays, which are described below and in the Examples. Mutagenized DNA molecules that encode active receptors or portions thereof (e.g., ligand-binding fragments, and the like) can be recovered from the host cells and rapidly sequenced using modern equipment. These
25 methods allow the rapid determination of the importance of individual amino acid residues in a polypeptide of interest, and can be applied to polypeptides of unknown structure.

The present invention thus provides a series of novel, hybrid molecules in which a segment comprising one or more of the domains of soluble zalpha11
30 receptor is fused to another soluble receptor polypeptide. Fusion is preferably done by splicing at the DNA level to allow expression of chimeric molecules in recombinant

production systems. The resultant molecules are then assayed for such properties as improved solubility, improved stability, prolonged clearance half-life, improved expression and secretion levels, and pharmacodynamics. Such hybrid molecules may further comprise additional amino acid residues (e.g. a polypeptide linker) between the component proteins or polypeptides.

Using the methods discussed herein, one of ordinary skill in the art can identify and/or prepare a variety of polypeptide fragments or variants of SEQ ID NO:6 that retain $\alpha 11$ Ligand binding or antagonist activity. For example, one can make a $\alpha 11$ soluble receptor by preparing a variety of polypeptides that are substantially homologous to the cytokine-binding domain (residues 20 (Cys) to 237 (His) of SEQ ID NO:2 (SEQ ID NO:6), or a subsequence therein that binds $\alpha 11$ Ligand, or allelic variants or species orthologs thereof) and retain ligand-binding activity of the wild-type $\alpha 11$ protein. Such polypeptides may include additional amino acids from, for example, part or all of the signal peptide sequence, transmembrane and intracellular domains. Such polypeptides may also include additional polypeptide segments as generally disclosed herein such as labels, affinity tags, and the like. Similarly, one of ordinary skill in the art can identify and/or prepare a variety of polypeptide fragments or variants of SEQ ID NO:4, or other soluble class I cytokine receptors that form heterodimers with $\alpha 11$ receptor.

For any soluble $\alpha 11$ receptor polypeptide, including variants, and fusion polypeptides or proteins, one of ordinary skill in the art can readily generate a fully degenerate polynucleotide sequence encoding that variant using the information set forth in Tables 1 and 2 above.

The soluble $\alpha 11$ receptor or soluble $\alpha 11$ heterodimeric receptor polypeptides of the present invention, including full-length soluble receptor polypeptides, biologically active fragments, and fusion polypeptides, can be produced in genetically engineered host cells according to conventional techniques. Suitable host cells are those cell types that can be transformed or transfected with exogenous DNA and grown in culture, and include bacteria, fungal cells, and cultured higher eukaryotic cells. Eukaryotic cells, particularly cultured cells of multicellular organisms, are preferred. Techniques for manipulating cloned DNA molecules and introducing

exogenous DNA into a variety of host cells are disclosed by Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989, and Ausubel et al., eds., Current Protocols in Molecular Biology, John Wiley and Sons, Inc., NY, 1987.

5 In general, a DNA sequence encoding a $\alpha 11$ polypeptide is operably linked to other genetic elements required for its expression, generally including a transcription promoter and terminator, within an expression vector. The vector will also commonly contain one or more selectable markers and one or more origins of replication, although those skilled in the art will recognize that within certain
10 systems selectable markers may be provided on separate vectors, and replication of the exogenous DNA may be provided by integration into the host cell genome. Selection of promoters, terminators, selectable markers, vectors and other elements is a matter of routine design within the level of ordinary skill in the art. Many such elements are described in the literature and are available through commercial suppliers.

15 To direct a soluble $\alpha 11$ receptor or soluble $\alpha 11$ heterodimeric polypeptide, such as soluble $\alpha 11/\text{IL-2R}\gamma$ into the secretory pathway of a host cell, a secretory signal sequence (also known as a leader sequence, prepro sequence or pre sequence) is provided in the expression vector. The secretory signal sequence may be that of $\alpha 11$ receptor disclosed herein, the $\text{IL-2R}\gamma$ (amino acid 1 (Met) to 22 (Gly)
20 of SEQ ID NO:18), or may be derived from another secreted protein (e.g., t-PA) or synthesized *de novo*. The secretory signal sequence is operably linked to the $\alpha 11$ DNA sequence, i.e., the two sequences are joined in the correct reading frame and positioned to direct the newly synthesized polypeptide into the secretory pathway of the host cell. Secretory signal sequences are commonly positioned 5' to the DNA sequence
25 encoding the polypeptide of interest, although certain secretory signal sequences may be positioned elsewhere in the DNA sequence of interest (see, e.g., Welch et al., U.S. Patent No. 5,037,743; Holland et al., U.S. Patent No. 5,143,830).

Cultured mammalian cells are suitable hosts within the present invention. Methods for introducing exogenous DNA into mammalian host cells include
30 calcium phosphate-mediated transfection (Wigler et al., Cell 14:725, 1978; Corsaro and Pearson, Somatic Cell Genetics 7:603, 1981; Graham and Van der Eb, Virology 52:456,

1973), electroporation (Neumann et al., EMBO J. 1:841-845, 1982), DEAE-dextran mediated transfection (Ausubel et al., ibid.), and liposome-mediated transfection (Hawley-Nelson et al., Focus 15:73, 1993; Ciccarone et al., Focus 15:80, 1993, and viral vectors (Miller and Rosman, BioTechniques 7:980-90, 1989; Wang and Finer, Nature Med. 2:714-716, 1996). The production of recombinant polypeptides in cultured mammalian cells is disclosed, for example, by Levinson et al., U.S. Patent No. 4,713,339; Hagen et al., U.S. Patent No. 4,784,950; Palmiter et al., U.S. Patent No. 4,579,821; and Ringold, U.S. Patent No. 4,656,134. Suitable cultured mammalian cells include the COS-1 (ATCC No. CRL 1650), COS-7 (ATCC No. CRL 1651), BHK (ATCC No. CRL 1632), BHK 570 (ATCC No. CRL 10314), 293 (ATCC No. CRL 1573; Graham et al., J. Gen. Virol. 36:59-72, 1977) and Chinese hamster ovary (e.g. CHO-K1; ATCC No. CCL 61) cell lines. Additional suitable cell lines are known in the art and available from public depositories such as the American Type Culture Collection, Rockville, Maryland. In general, strong transcription promoters are preferred, such as promoters from SV-40 or cytomegalovirus (CMV). See, e.g., U.S. Patent No. 4,956,288. Other suitable promoters include those from metallothionein genes (U.S. Patent Nos. 4,579,821 and 4,601,978) and the adenovirus major late promoter.

Drug selection is generally used to select for cultured mammalian cells into which foreign DNA has been inserted. Such cells are commonly referred to as "transfectants". Cells that have been cultured in the presence of the selective agent and are able to pass the gene of interest to their progeny are referred to as "stable transfectants." A preferred selectable marker is a gene encoding resistance to the antibiotic neomycin. Selection is carried out in the presence of a neomycin-type drug, such as G-418 or the like. Selection systems can also be used to increase the expression level of the gene of interest, a process referred to as "amplification." Amplification is carried out by culturing transfectants in the presence of a low level of the selective agent and then increasing the amount of selective agent to select for cells that produce high levels of the products of the introduced genes. A preferred amplifiable selectable marker is dihydrofolate reductase, which confers resistance to methotrexate. Other drug resistance genes (e.g. hygromycin resistance, multi-drug resistance, puromycin

acetyltransferase) can also be used. Alternative markers that introduce an altered phenotype, such as green fluorescent protein, or cell surface proteins such as CD4, CD8, Class I MHC, placental alkaline phosphatase may be used to sort transfected cells from untransfected cells by such means as FACS sorting, flow cytometry, or magnetic
5 bead separation technology.

Other higher eukaryotic cells can also be used as hosts, including plant cells, insect cells and avian cells. The use of *Agrobacterium rhizogenes* as a vector for expressing genes in plant cells has been reviewed by Sinkar et al., J. Biosci. (Bangalore) 11:47-58, 1987. Transformation of insect cells and production of foreign polypeptides
10 therein is disclosed by Guarino et al., U.S. Patent No. 5,162,222 and WIPO publication WO 94/06463. Insect cells can be infected with recombinant baculovirus, commonly derived from *Autographa californica nuclear polyhedrosis virus* (AcNPV). See, King, L.A. and Possee, R.D., The Baculovirus Expression System: A Laboratory Guide, London, Chapman & Hall; O'Reilly, D.R. et al., Baculovirus Expression Vectors: A
15 Laboratory Manual, New York, Oxford University Press., 1994; and, Richardson, C. D., Ed., Baculovirus Expression Protocols. Methods in Molecular Biology, Totowa, NJ, Humana Press, 1995. A second method of making recombinant zalpha11 baculovirus utilizes a transposon-based system described by Luckow (Luckow, V.A, et al., J Virol 67:4566-79, 1993). This system, which utilizes transfer vectors, is sold in the Bac-to-
20 Bac™ kit (Life Technologies, Rockville, MD). This system utilizes a transfer vector, pFastBac1™ (Life Technologies) containing a Tn7 transposon to move the DNA encoding the zalpha11 polypeptide into a baculovirus genome maintained in *E. coli* as a large plasmid called a "bacmid." See, Hill-Perkins, M.S. and Possee, R.D., J Gen Virol 71:971-6, 1990; Bonning, B.C. et al., J Gen Virol 75:1551-6, 1994; and, Chazenbalk,
25 G.D., and Rapoport, B., J Biol Chem 270:1543-9, 1995. In addition, transfer vectors can include an in-frame fusion with DNA encoding an epitope tag at the C- or N-terminus of the expressed zalpha11 polypeptide, for example, a Glu-Glu epitope tag (Grussenmeyer, T. et al., Proc. Natl. Acad. Sci. 82:7952-4, 1985). Using a technique known in the art, a transfer vector containing zalpha11 is transformed into *E. Coli*, and
30 screened for bacmids which contain an interrupted lacZ gene indicative of recombinant baculovirus. The bacmid DNA containing the recombinant baculovirus genome is

isolated, using common techniques, and used to transfect *Spodoptera frugiperda* cells, e.g. Sf9 cells. Recombinant virus that expresses zalpha11 is subsequently produced. Recombinant viral stocks are made by methods commonly used in the art.

The recombinant virus is used to infect host cells, typically a cell line
5 derived from the fall armyworm, *Spodoptera frugiperda*. See, in general, Glick and
Pasternak, Molecular Biotechnology: Principles and Applications of Recombinant
DNA, ASM Press, Washington, D.C., 1994. Another suitable cell line is the High
FiveO™ cell line (Invitrogen) derived from *Trichoplusia ni* (U.S. Patent No.
5,300,435). Commercially available serum-free media are used to grow and maintain
10 the cells. Suitable media are Sf900 II™ (Life Technologies) or ESF 921™ (Expression
Systems) for the Sf9 cells; and Ex-cello405™ (JRH Biosciences, Lenexa, KS) or
Express FiveO™ (Life Technologies) for the *T. ni* cells. Procedures used are generally
described in available laboratory manuals (King, L. A. and Possee, R.D., ibid.; O'Reilly,
D.R. et al., ibid.; Richardson, C. D., ibid.). Subsequent purification of the zalpha11
15 polypeptide from the supernatant can be achieved using methods described herein.

Fungal cells, including yeast cells, can also be used within the present
invention. Yeast species of particular interest in this regard include *Saccharomyces
cerevisiae*, *Pichia pastoris*, and *Pichia methanolica*. Methods for transforming *S.
cerevisiae* cells with exogenous DNA and producing recombinant polypeptides
20 therefrom are disclosed by, for example, Kawasaki, U.S. Patent No. 4,599,311;
Kawasaki et al., U.S. Patent No. 4,931,373; Brake, U.S. Patent No. 4,870,008; Welch et
al., U.S. Patent No. 5,037,743; and Murray et al., U.S. Patent No. 4,845,075.
Transformed cells are selected by phenotype determined by the selectable marker,
commonly drug resistance or the ability to grow in the absence of a particular nutrient
25 (e.g., leucine). A preferred vector system for use in *Saccharomyces cerevisiae* is the
POT1 vector system disclosed by Kawasaki et al. (U.S. Patent No. 4,931,373), which
allows transformed cells to be selected by growth in glucose-containing media.
Suitable promoters and terminators for use in yeast include those from glycolytic
enzyme genes (see, e.g., Kawasaki, U.S. Patent No. 4,599,311; Kingsman et al., U.S.
30 Patent No. 4,615,974; and Bitter, U.S. Patent No. 4,977,092) and alcohol
dehydrogenase genes. See also U.S. Patents Nos. 4,990,446; 5,063,154; 5,139,936 and

4,661,454. Transformation systems for other yeasts, including *Hansenula polymorpha*, *Schizosaccharomyces pombe*, *Kluyveromyces lactis*, *Kluyveromyces fragilis*, *Ustilago maydis*, *Pichia pastoris*, *Pichia methanolica*, *Pichia guilliermondii* and *Candida maltosa* are known in the art. See, for example, Gleeson et al., J. Gen. Microbiol. 132:3459-3465, 1986 and Cregg, U.S. Patent No. 4,882,279. *Aspergillus* cells may be utilized according to the methods of McKnight et al., U.S. Patent No. 4,935,349. Methods for transforming *Acremonium chrysogenum* are disclosed by Sumino et al., U.S. Patent No. 5,162,228. Methods for transforming *Neurospora* are disclosed by Lambowitz, U.S. Patent No. 4,486,533.

The use of *Pichia methanolica* as host for the production of recombinant proteins is disclosed in WIPO Publications WO 97/17450, WO 97/17451, WO 98/02536, and WO 98/02565. DNA molecules for use in transforming *P. methanolica* will commonly be prepared as double-stranded, circular plasmids, which are preferably linearized prior to transformation. For polypeptide production in *P. methanolica*, it is preferred that the promoter and terminator in the plasmid be that of a *P. methanolica* gene, such as a *P. methanolica* alcohol utilization gene (*AUG1* or *AUG2*). Other useful promoters include those of the dihydroxyacetone synthase (DHAS), formate dehydrogenase (FMD), and catalase (CAT) genes. To facilitate integration of the DNA into the host chromosome, it is preferred to have the entire expression segment of the plasmid flanked at both ends by host DNA sequences. A preferred selectable marker for use in *Pichia methanolica* is a *P. methanolica* *ADE2* gene, which encodes phosphoribosyl-5-aminoimidazole carboxylase (AIRC; EC 4.1.1.21), which allows *ade2* host cells to grow in the absence of adenine. For large-scale, industrial processes where it is desirable to minimize the use of methanol, it is preferred to use host cells in which both methanol utilization genes (*AUG1* and *AUG2*) are deleted. For production of secreted proteins, host cells deficient in vacuolar protease genes (*PEP4* and *PRB1*) are preferred. Electroporation is used to facilitate the introduction of a plasmid containing DNA encoding a polypeptide of interest into *P. methanolica* cells. It is preferred to transform *P. methanolica* cells by electroporation using an exponentially decaying, pulsed electric field having a field strength of from 2.5 to 4.5 kV/cm,

preferably about 3.75 kV/cm, and a time constant (t) of from 1 to 40 milliseconds, most preferably about 20 milliseconds.

Prokaryotic host cells, including strains of the bacteria *Escherichia coli*, *Bacillus* and other genera are also useful host cells within the present invention.

5 Techniques for transforming these hosts and expressing foreign DNA sequences cloned therein are well known in the art (see, e.g., Sambrook et al., *ibid.*). When expressing a α 11 polypeptide in bacteria such as *E. coli*, the polypeptide may be retained in the cytoplasm, typically as insoluble granules, or may be directed to the periplasmic space by a bacterial secretion sequence. In the former case, the cells are lysed, and the

10 granules are recovered and denatured using, for example, guanidine isothiocyanate or urea. The denatured polypeptide can then be refolded and dimerized by diluting the denaturant, such as by dialysis against a solution of urea and a combination of reduced and oxidized glutathione, followed by dialysis against a buffered saline solution. In the latter case, the polypeptide can be recovered from the periplasmic space in a soluble

15 and functional form by disrupting the cells (by, for example, sonication or osmotic shock) to release the contents of the periplasmic space and recovering the protein, thereby obviating the need for denaturation and refolding.

Transformed or transfected host cells are cultured according to conventional procedures in a culture medium containing nutrients and other

20 components required for the growth of the chosen host cells. A variety of suitable media, including defined media and complex media, are known in the art and generally include a carbon source, a nitrogen source, essential amino acids, vitamins and minerals. Media may also contain such components as growth factors or serum, as required. The growth medium will generally select for cells containing the exogenously

25 added DNA by, for example, drug selection or deficiency in an essential nutrient which is complemented by the selectable marker carried on the expression vector or co-transfected into the host cell. *P. methanolica* cells are cultured in a medium comprising adequate sources of carbon, nitrogen and trace nutrients at a temperature of about 25°C to 35°C. Liquid cultures are provided with sufficient aeration by conventional means,

30 such as shaking of small flasks or sparging of fermentors. A preferred culture medium for *P. methanolica* is YEPD (2% D-glucose, 2% Bacto™ Peptone (Difco Laboratories,

Detroit, MI), 1% Bacto™ yeast extract (Difco Laboratories), 0.004% adenine and 0.006% L-leucine).

Mammalian cells suitable for use in assaying antagonist activity of the novel soluble receptors of the present invention express a α 11 receptor or receptor fusion capable of signaling and transducing a receptor-mediated signal of the α 11 Ligand. Such cells include cells that express a β -subunit, such as gp130, IL-2R γ and cells that co-express receptors (Gearing et al., EMBO J. 10:2839-2848, 1991; Gearing et al., U.S. Patent No. 5,284,755). In this regard it is generally preferred to employ a cell that is responsive to other cytokines that bind to receptors in the same subfamily, such as IL-6 or LIF, because such cells will contain the requisite signal transduction pathway(s). Preferred cells of this type include the human TF-1 cell line (ATCC number CRL-2003) and the DA-1 cell line (Branch et al., Blood 69:1782, 1987; Broudy et al., Blood 75:1622-1626, 1990). In the alternative, suitable host cells can be engineered to produce a β -subunit or other cellular component needed for the desired cellular response. For example, the murine cell line BaF3 (Palacios and Steinmetz, Cell 41:727-734, 1985; Mathey-Prevot et al., Mol. Cell. Biol. 6: 4133-4135, 1986) has been used to produce a cell line responsive to the α 11 Ligand (see Examples). Other such lines include a baby hamster kidney (BHK) cell line, or the CTLL-2 cell line (ATCC TIB-214) can be transfected to express an IL-2R γ subunit in addition to α 11 receptor. It is generally preferred to use a host cell and receptor(s) from the same species, however this approach allows cell lines to be engineered to express multiple receptor subunits from any species, thereby overcoming potential limitations arising from species specificity. In the alternative, species homologs of the human receptor cDNA can be cloned and used within cell lines from the same species, such as a mouse cDNA in the BaF3 cell line. Cell lines that are dependent upon one hematopoietic growth factor, such as IL-3, can thus be engineered to become dependent upon a α 11 ligand. Such cells can be used as described herein in the presence of α 11 Ligand to assess the antagonist activity of soluble α 11 receptor or soluble α 11 heterodimeric polypeptide, such as soluble α 11/IL-2R γ on α 11 Ligand signaling and proliferative activity.

Cells expressing functional soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ are used within screening assays. A variety of suitable assays are known in the art. These assays are based on the detection of a biological response in the target cell to the zalpha11 Ligand in the presence or absence of the soluble receptors of the present invention. One such assay is a cell proliferation assay. Cells are cultured in the presence or absence of zalpha11 Ligand with or without the addition other cytokines or proliferative agents, and cell proliferation is detected by, for example, measuring incorporation of tritiated thymidine or by colorimetric assay based on the metabolic breakdown of Alamar BlueTM (AccuMed, Chicago, IL) or 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) (Mosman, *J. Immunol. Meth.* 65: 55-63, 1983). An alternative assay format uses cells that are further engineered to express a reporter gene. The reporter gene is linked to a promoter element that is responsive to the receptor-linked pathway, and the assay detects activation of transcription of the reporter gene. DNA response elements can include, but are not limited to, cyclic AMP response elements (CRE), hormone response elements (HRE) insulin response element (IRE) (Nasrin et al., *Proc. Natl. Acad. Sci. USA* 87:5273-7, 1990) and serum response elements (SRE) (Shaw et al. *Cell* 56: 563-72, 1989). Cyclic AMP response elements are reviewed in Roestler et al., *J. Biol. Chem.* 263 (19):9063-6; 1988 and Habener, *Molec. Endocrinol.* 4 (8):1087-94; 1990. Hormone response elements are reviewed in Beato, *Cell* 56:335-44; 1989. A preferred promoter element in this regard is a serum response element, or SRE (see, for example, Shaw et al., *Cell* 56:563-572, 1989). A preferred such reporter gene is a luciferase gene (de Wet et al., *Mol. Cell. Biol.* 7:725, 1987). Expression of the luciferase gene is detected by luminescence using methods known in the art (e.g., Baumgartner et al., *J. Biol. Chem.* 269:19094-29101, 1994; Schenborn and Goiffin, *Promega Notes* 41:11, 1993). Luciferase assay kits are commercially available from, for example, Promega Corp., Madison, WI. Target cell lines of this type can be used to screen libraries of chemicals, cell-conditioned culture media, fungal broths, soil samples, water samples, and the like for antagonist activity. Such cells can be used as described herein in the presence of zalpha11 Ligand in a competitive inhibition type assay to assess the antagonist activity of soluble zalpha11

receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ on zalpha11 Ligand signaling and proliferative activity.

T-and B-cell proliferation assay methods can also be used to assess the antagonist activity of soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ on zalpha11 Ligand signaling and proliferative activity in the presence of other cytokines, for example, IL-15, Flt3 and the like. Such assays are described in the examples herein, and are known in the art. Briefly, using flow cytometry, mature or immature subsets of T-cells or B-cells are isolated based on the presence or absence of various cell surface molecules (e.g., CD4, CD8, CD19, CD3, CD40, CD28, etc.). Cells can be selected prior to or after exposure to zalpha11 Ligand, depending on the cell type being studied, and the effect of zalpha11 Ligand thereon. The soluble receptors or antibodies of the present invention can be added at a range of concentrations to assess the antagonistic or binding activity on the Ligand in the T-cell or B-cell proliferation assay. Such assays are well known in the art, and described herein.

Moreover, a secretion trap method employing soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides can be used to isolate transfected cells that express zalpha11 Ligand. For the method, see, Aldrich, et al, Cell 87: 1161-1169, 1996. A cDNA expression library prepared from a known or suspected ligand source is transfected into COS-7 cells. The cDNA library vector generally has an SV40 origin for amplification in COS-7 cells, and a CMV promoter for high expression. The transfected COS-7 cells are grown in a monolayer and then fixed and permeabilized. Tagged or biotin-labeled soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides, described herein, is then placed in contact with the cell layer and allowed to bind cells in the monolayer that express an anti-complementary molecule, i.e., a zalpha11 Ligand. A cell expressing a ligand will thus be bound with receptor molecules. An anti-tag antibody (anti-Ig for Ig fusions, M2 or anti-FLAG for FLAG-tagged fusions, streptavidin, and the like) which is conjugated with horseradish peroxidase (HRP) is used to visualize these cells to which the tagged or biotin-labeled soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides has bound. The HRP catalyzes deposition of a tyramide reagent, for

example, tyramide-FITC. A commercially-available kit can be used for this detection (for example, Renaissance TSA-Direct™ Kit; NEN Life Science Products, Boston, MA). Cells which express zalpha11 receptor Ligand will be identified under fluorescence microscopy as green cells and picked for subsequent cloning of the ligand using procedures for plasmid rescue as outlined in Aldrich, et al, supra., followed by subsequent rounds of secretion trap assay until single clones are identified.

Moreover, histologic and immunohistochemical methods employing soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides can be used to identify cells and tissues cells that express zalpha11 Ligand. Such methods are known in the art and described herein.

Additional assays to detect the antagonist or binding activity of soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides provided by the present invention include the use of hybrid receptor polypeptides. These hybrid polypeptides fall into two general classes. Within the first class, the intracellular domain of zalpha11, comprising approximately residues 256 (Lys) to 528 (Ser) of SEQ ID NO:2, is joined to the ligand-binding domain of a second receptor. It is preferred that the second receptor be a hematopoietic cytokine receptor, such as mpl receptor (Souyri et al., Cell 63:1137-1147, 1990). The hybrid receptor will further comprise a transmembrane domain, which may be derived from either receptor. A DNA construct encoding the hybrid receptor is then inserted into a host cell. Cells expressing the hybrid receptor are cultured in the presence of a ligand for the binding domain and assayed for a response. This system provides a means for analyzing signal transduction mediated by zalpha11 while using readily available ligands. This system can also be used to determine if particular cell lines are capable of responding to signals transduced by zalpha11. A second class of hybrid receptor polypeptides comprise the extracellular (ligand-binding) domain of zalpha11 (approximately residues 20 (Cys) to 237 (His) of SEQ ID NO:2) (SEQ ID NO:6) with a cytoplasmic domain of a second receptor, preferably a cytokine receptor, and a transmembrane domain. The transmembrane domain may be derived from either receptor. Such hybrid receptors are expressed in cells known to be capable of responding to signals transduced by the receptor comprising the extracellular domain, such as in the presence of the zalpha11 Ligand.

Addition of the soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides, in the presence of the zalpha11 Ligand, is used to assess the zalpha11 Ligand antagonist or binding activity of the soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides to the zalpha11 Ligand.

5 The tissue specificity and biological activities of zalpha11 Ligand expression suggest a role in early NK cell and thymocyte development, mature B-cell expansion, general immune response stimulation, and immune response regulation. These processes involve stimulation of cell proliferation and differentiation in response to the binding of the zalpha11 Ligand to its cognate receptor, comprising at least one
10 zalpha11 receptor subunit. In view of the biological activity observed for this Ligand, antagonists have enormous potential in both *in vitro* and *in vivo* applications. As antagonists of the zalpha11 Ligand, soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides can find utility in the suppression of the immune system, such as in the treatment of autoimmune diseases, including rheumatoid arthritis,
15 multiple sclerosis, diabetes mellitus, inflammatory bowel disease, Crohn's disease, and the like. Immune suppression can also be used to reduce rejection of tissue or organ transplants and grafts and to treat B-cell malignancies, T-cell specific leukemias or lymphomas by inhibiting proliferation of the affected cell type.

 Soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor
20 polypeptides may also be used within diagnostic systems for the detection of circulating levels of zalpha11 Ligand. Within a related embodiment, antibodies or other agents that specifically bind to soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides can be used to detect circulating receptor polypeptides. Elevated or depressed levels of Ligand or receptor polypeptides may be indicative of pathological
25 conditions, including cancer. Soluble receptor polypeptides may contribute to pathologic processes and can be an indirect marker of an underlying disease. For example, elevated levels of soluble IL-2 receptor in human serum have been associated with a wide variety of inflammatory and neoplastic conditions, such as myocardial infarction, asthma, myasthenia gravis, rheumatoid arthritis, acute T-cell leukemia, B-
30 cell lymphomas, chronic lymphocytic leukemia, colon cancer, breast cancer, and ovarian cancer (Heaney et al., Blood 87:847-857, 1996).

A ligand-binding polypeptide of a $\alpha 11$ receptor, such as soluble $\alpha 11$ receptor or soluble $\alpha 11$ heterodimeric polypeptide, such as soluble $\alpha 11/\text{IL-2R}\gamma$ can be prepared by expressing a truncated DNA encoding the $\alpha 11$ cytokine binding domain (approximately residue 20 (Cys) through residue 237 (His) of the human receptor (SEQ ID NO:2) (SEQ ID NO:6)) or the corresponding region of a non-human receptor (e.g., SEQ ID NO:12). A soluble $\alpha 11$ heterodimeric polypeptide, such as soluble $\alpha 11/\text{IL-2R}\gamma$ can be prepared by co-expressing a truncated DNA encoding the $\alpha 11$ cytokine binding domain (SEQ ID NO:6) and the truncated DNA encoding the extracellular domain of another class I cytokine receptor, such as $\text{IL-2R}\gamma$ (SEQ ID NO:4). It is preferred that the extracellular domains of the soluble $\alpha 11$ homodimer or heterodimer be prepared in a form substantially free of transmembrane and intracellular polypeptide segments. Moreover, ligand-binding polypeptide fragments within the soluble $\alpha 11$ receptor or soluble $\alpha 11$ heterodimeric polypeptide (e.g., soluble $\alpha 11/\text{IL-2R}\gamma$), or cytokine-binding domain, described above, can also serve as $\alpha 11$ soluble receptors for uses described herein. To direct the export of a receptor polypeptide from the host cell, the receptor DNA is linked to a second DNA segment encoding a secretory peptide, such as a t-PA secretory peptide, secretory peptide from another cytokine receptor, other secreted molecule, or a $\alpha 11$ receptor secretory peptide. To facilitate purification of the secreted receptor polypeptide, a C-terminal extension, such as a poly-histidine tag, substance P, FlagTM peptide (Hopp et al., Bio/Technology 6:1204-1210, 1988; available from Eastman Kodak Co., New Haven, CT), Glu-glu tag (SEQ ID NO:14) or another polypeptide or protein for which an antibody or other specific binding agent is available, can be fused to the soluble receptor polypeptide.

In an alternative approach, a receptor extracellular domain can be expressed as a fusion with immunoglobulin heavy chain constant regions, typically an F_C fragment, which contains two constant region domains and lacks the variable region. Such fusions are typically secreted as multimeric molecules wherein the F_C portions are disulfide bonded to each other and two receptor polypeptides are arrayed in close proximity to each other. Fusions of this type can be used to affinity purify the cognate ligand from solution, as an *in vitro* assay tool, to block signals *in vitro* by specifically

titrating out Ligand, and as antagonists *in vivo* by administering them parenterally to bind circulating ligand and clear it from the circulation. To purify ligand, a zalpha11-Ig chimera (e.g., Zalpha11-Fc4 described herein), is added to a sample containing the ligand (e.g., cell-conditioned culture media or tissue extracts) under conditions that
5 facilitate receptor-ligand binding (typically near-physiological temperature, pH, and ionic strength). The chimera-ligand complex is then separated by the mixture using protein A, immobilized on a solid support (e.g., insoluble resin beads). The ligand is then eluted using conventional chemical techniques, such as with a salt or pH gradient. In the alternative, the chimera itself can be bound to a solid support, with binding and
10 elution carried out as above. Collected fractions can be re-fractionated until the desired level of purity is reached.

Moreover, soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides, such as soluble zalpha11/IL-2R γ , can be used as a "ligand sink," i.e., antagonist, to bind ligand *in vivo* or *in vitro* in therapeutic or other applications
15 where the presence of the ligand is not desired. For example, in cancers that are expressing large amounts of bioactive zalpha11 Ligand, soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides, such as soluble zalpha11/IL-2R γ can be used as a direct antagonist of the ligand *in vivo*, and may aid in reducing progression and symptoms associated with the disease, and can be used in conjunction
20 with other therapies (e.g., chemotherapy) to enhance the effect of the therapy in reducing progression and symptoms, and preventing relapse. Moreover, soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides, such as soluble zalpha11/IL-2R γ can be used to slow the progression of cancers that over-express zalpha11 receptors, by binding ligand *in vivo* that would otherwise enhance
25 proliferation of those cancers.

Moreover, soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides, such as soluble zalpha11/IL-2R γ can be used *in vivo* or in diagnostic applications to detect zalpha11 Ligand-expressing cancers *in vivo* or in tissue samples. For example, the soluble zalpha11 receptor or soluble zalpha11 heterodimeric
30 receptor polypeptides, such as soluble zalpha11/IL-2R γ can be conjugated to a radio-label or fluorescent label as described herein, and used to detect the presence of the

zalpha11 Ligand in a tissue sample using an *in vitro* ligand-receptor type binding assay, or fluorescent imaging assay. Moreover, a radiolabeled soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides, such as soluble zalpha11/IL-2R γ could be administered *in vivo* to detect Ligand-expressing solid tumors through a radio-imaging method known in the art.

It is preferred to purify the polypeptides of the present invention to $\geq 80\%$ purity, more preferably to $\geq 90\%$ purity, even more preferably $\geq 95\%$ purity, and particularly preferred is a pharmaceutically pure state, that is greater than 99.9% pure with respect to contaminating macromolecules, particularly other proteins and nucleic acids, and free of infectious and pyrogenic agents. Preferably, a purified polypeptide is substantially free of other polypeptides, particularly other polypeptides of animal origin.

Expressed recombinant soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides, such as soluble zalpha11/IL-2R γ (or zalpha11 chimeric or fusion polypeptides) can be purified using fractionation and/or conventional purification methods and media. Ammonium sulfate precipitation and acid or chaotrope extraction may be used for fractionation of samples. Exemplary purification steps may include hydroxyapatite, size exclusion, FPLC and reverse-phase high performance liquid chromatography. Suitable chromatographic media include derivatized dextrans, agarose, cellulose, polyacrylamide, specialty silicas, and the like. PEI, DEAE, QAE and Q derivatives are preferred. Exemplary chromatographic media include those media derivatized with phenyl, butyl, or octyl groups, such as Phenyl-Sepharose FF (Pharmacia), Toyopearl butyl 650 (Toso Haas, Montgomeryville, PA), Octyl-Sepharose (Pharmacia) and the like; or polyacrylic resins, such as Amberchrom CG 71 (Toso Haas) and the like. Suitable solid supports include glass beads, silica-based resins, cellulosic resins, agarose beads, cross-linked agarose beads, polystyrene beads, cross-linked polyacrylamide resins and the like that are insoluble under the conditions in which they are to be used. These supports may be modified with reactive groups that allow attachment of proteins by amino groups, carboxyl groups, sulfhydryl groups, hydroxyl groups and/or carbohydrate moieties. Examples of coupling chemistries include cyanogen bromide activation, N-hydroxysuccinimide activation, epoxide activation, sulfhydryl activation, hydrazide activation, and carboxyl and amino

derivatives for carbodiimide coupling chemistries. These and other solid media are well known and widely used in the art, and are available from commercial suppliers. Methods for binding receptor polypeptides to support media are well known in the art. Selection of a particular method is a matter of routine design and is determined in part
5 by the properties of the chosen support. See, for example, Affinity Chromatography: Principles & Methods, Pharmacia LKB Biotechnology, Uppsala, Sweden, 1988.

The polypeptides of the present invention can be isolated by exploitation of their biochemical, structural, and biological properties. For example, immobilized metal ion adsorption (IMAC) chromatography can be used to purify histidine-rich
10 proteins, including those comprising polyhistidine tags. Briefly, a gel is first charged with divalent metal ions to form a chelate (Sulkowski, Trends in Biochem. 3:1-7, 1985). Histidine-rich proteins will be adsorbed to this matrix with differing affinities, depending upon the metal ion used, and will be eluted by competitive elution, lowering the pH, or use of strong chelating agents. Other methods of purification include
15 purification of glycosylated proteins by lectin affinity chromatography and ion exchange chromatography (Methods in Enzymol., Vol. 182, "Guide to Protein Purification", M. Deutscher, (ed.), Acad. Press, San Diego, 1990, pp.529-39). Within additional embodiments of the invention, a fusion of the polypeptide of interest and an affinity tag (e.g., maltose-binding protein, an immunoglobulin domain) may be
20 constructed to facilitate purification. Moreover zalpha11 Ligand affinity columns can be used to purify soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides, such as soluble zalpha11/IL-2R γ . Such affinity chromatography methods are well known in the art.

Moreover, using methods described in the art, polypeptide fusions, or
25 hybrid zalpha11 proteins, are constructed using regions or domains of the inventive zalpha11 in combination with those of other human cytokine receptor family proteins, or heterologous proteins (Sambrook et al., ibid., Altschul et al., ibid., Picard, Cur. Opin. Biology, 5:511-5, 1994, and references therein). These methods allow the determination of the biological importance of larger domains or regions in a
30 polypeptide of interest. Such hybrids may alter reaction kinetics, binding, constrict or

expand the substrate specificity, or alter tissue and cellular localization of a polypeptide, and can be applied to polypeptides of unknown structure.

Soluble receptor fusion polypeptides or proteins can be prepared by methods known to those skilled in the art by preparing each component of the fusion protein and chemically conjugating them. Alternatively, a polynucleotide encoding one or more components of the fusion protein in the proper reading frame can be generated using known techniques and expressed by the methods described herein. For example, part or all of a domain(s) conferring a biological function may be swapped between zalpha11 of the present invention with the functionally equivalent domain(s) from another cytokine family member. Such domains include, but are not limited to, the extracellular cytokine binding domain, ligand binding domain and residues, transmembrane domain, , as disclosed herein. Such fusion proteins would be expected to have a biological functional profile that is the same or similar to polypeptides of the present invention or other known family proteins, depending on the fusion constructed. Moreover, such fusion proteins may exhibit other properties as disclosed herein.

Standard molecular biological and cloning techniques can be used to swap the equivalent domains between the zalpha11 polypeptide and those polypeptides to which they are fused. Generally, a DNA segment that encodes a domain of interest, e.g., a zalpha11 domain described herein, is operably linked in frame to at least one other DNA segment encoding an additional polypeptide (for instance a domain or region from another cytokine receptor, such as the IL-2R γ receptor), and inserted into an appropriate expression vector, as described herein. Generally DNA constructs are made such that the several DNA segments that encode the corresponding regions of a polypeptide are operably linked in frame to make a single construct that encodes the entire fusion protein, or a functional portion thereof. For example, a DNA construct would encode from N-terminus to C-terminus a fusion protein comprising a signal polypeptide followed by a cytokine-binding domain. Such fusion proteins can be expressed, isolated, and assayed for activity as described herein.

Soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides, such as soluble zalpha11/IL-2R γ polypeptides, or fragments thereof may also be prepared through chemical synthesis. Such polypeptides may be monomers or

multimers; glycosylated or non-glycosylated; pegylated or non-pegylated; and may or may not include an initial methionine amino acid residue.

Polypeptides of the present invention can also be synthesized by exclusive solid phase synthesis, partial solid phase methods, fragment condensation or classical solution synthesis. Methods for synthesizing polypeptides are well known in the art. See, for example, Merrifield, J. Am. Chem. Soc. 85:2149, 1963; and Kaiser et al., Anal. Biochem. 34:595, 1970. After the entire synthesis of the desired peptide on a solid support, the peptide-resin is with a reagent that cleaves the polypeptide from the resin and removes most of the side-chain protecting groups. Such methods are well established in the art.

The activity of molecules of the present invention can be measured using a variety of assays that measure cell differentiation and proliferation. Such assays are well known in the art and described herein.

Proteins of the present invention are useful for example, in treating lymphoid, immune, hematopoietic, inflammatory disorders and the like, and can be measured *in vitro* using cultured cells or *in vivo* by administering molecules of the claimed invention to the appropriate animal model. For instance, host cells expressing a soluble $\alpha 11$ receptor or soluble $\alpha 11$ heterodimeric receptor polypeptides, such as soluble $\alpha 11/\text{IL-2R}\gamma$ can be embedded in an alginate environment and injected (implanted) into recipient animals. Alginate-poly-L-lysine microencapsulation, permselective membrane encapsulation and diffusion chambers are a means to entrap transfected mammalian cells or primary mammalian cells. These types of non-immunogenic "encapsulations" permit the diffusion of proteins and other macromolecules secreted or released by the captured cells to the recipient animal. Most importantly, the capsules mask and shield the foreign, embedded cells from the recipient animal's immune response. Such encapsulations can extend the life of the injected cells from a few hours or days (naked cells) to several weeks (embedded cells). Alginate threads provide a simple and quick means for generating embedded cells.

The materials needed to generate the alginate threads are known in the art. In an exemplary procedure, 3% alginate is prepared in sterile H_2O , and sterile filtered. Just prior to preparation of alginate threads, the alginate solution is again

filtered. An approximately 50% cell suspension (containing about 5×10^5 to about 5×10^7 cells/ml) is mixed with the 3% alginate solution. One ml of the alginate/cell suspension is extruded into a 100 mM sterile filtered CaCl_2 solution over a time period of ~15 min, forming a "thread". The extruded thread is then transferred into a solution of 50 mM CaCl_2 , and then into a solution of 25 mM CaCl_2 . The thread is then rinsed with deionized water before coating the thread by incubating in a 0.01% solution of poly-L-lysine. Finally, the thread is rinsed with Lactated Ringer's Solution and drawn from solution into a syringe barrel (without needle). A large bore needle is then attached to the syringe, and the thread is intraperitoneally injected into a recipient in a minimal volume of the Lactated Ringer's Solution.

Adenoviral and other viral systems, such as vaccinia virus can be used to express and produce the proteins of the present invention. For example, using adenovirus vectors where portions of the adenovirus genome are deleted, inserts are incorporated into the viral DNA by direct ligation or by homologous recombination with a co-transfected plasmid. In an exemplary system, the essential E1 gene has been deleted from the viral vector, and the virus will not replicate unless the E1 gene is provided by the host cell (the human 293 cell line is exemplary). If the adenoviral delivery system has an E1 gene deletion, the virus cannot replicate in human cells, but will express and process (and, if a secretory signal sequence is present, secrete) the heterologous protein. Moreover, by deleting the entire adenovirus genome, very large inserts of heterologous DNA can be accommodated. Generation of so called "gutless" adenoviruses where all viral genes are deleted are particularly advantageous for insertion of large inserts of heterologous DNA. For review, see Yeh, P. and Perricaudet, M., FASEB J. 11:615-623, 1997.

The adenovirus system can be used for protein production *in vitro*. By culturing adenovirus-infected non-293 cells under conditions where the cells are not rapidly dividing, the cells can produce proteins for extended periods of time. For instance, BHK cells are grown to confluence in cell factories, are exposed to the adenoviral vector encoding the secreted protein of interest. The cells are then grown under serum-free conditions, which allows infected cells to survive for several weeks without significant cell division. Alternatively, adenovirus vector infected 293 cells can

be grown as adherent cells or in suspension culture at relatively high cell density to produce significant amounts of protein (See Garnier et al., Cytotechnol. 15:145-55, 1994). With either protocol, an expressed, secreted heterologous protein can be repeatedly isolated from the cell culture supernatant, lysate, or membrane fractions depending on the disposition of the expressed protein in the cell. Within the infected 293 cell production protocol, non-secreted proteins may also be effectively obtained.

Soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides, such as soluble zalpha11/IL-2R γ receptor antagonists can be used in vitro in an assay to measure a decrease in stimulation of colony formation by zalpha11 Ligand from isolated primary bone marrow cultures. Such assays are disclosed herein and are well known in the art.

Zalpha11 Ligand antagonists and binding agents are also useful as research reagents for characterizing sites of ligand-receptor interaction. Inhibitors of zalpha11 Ligand activity (zalpha11 Ligand antagonists) include anti-soluble zalpha11 receptor or anti-soluble zalpha11 heterodimeric receptor polypeptide antibodies, such as anti-soluble zalpha11/IL-2R γ antibodies and soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides, such as soluble zalpha11/IL-2R γ receptors, as well as other peptidic and non-peptidic agents (including ribozymes).

A soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides, such as soluble zalpha11/IL-2R γ ligand-binding polypeptide of the present invention, can also be used for purification of zalpha11 Ligand. The polypeptide is immobilized on a solid support, such as beads of agarose, cross-linked agarose, glass, cellulosic resins, silica-based resins, polystyrene, cross-linked polyacrylamide, or like materials that are stable under the conditions of use. Methods for linking polypeptides to solid supports are known in the art, and include amine chemistry, cyanogen bromide activation, N-hydroxysuccinimide activation, epoxide activation, sulfhydryl activation, and hydrazide activation. The resulting medium will generally be configured in the form of a column, and fluids containing ligand are passed through the column one or more times to allow ligand to bind to the receptor polypeptide. The ligand is then eluted using changes in salt concentration, chaotropic agents (guanidine HCl), or pH to disrupt ligand-receptor binding.

An assay system that uses a ligand-binding receptor (or an antibody, one member of a complement/ anti-complement pair) or a binding fragment thereof, and a commercially available biosensor instrument may be advantageously employed (e.g., BIAcore™, Pharmacia Biosensor, Piscataway, NJ; or SELDI™ technology, CIPHERGEN, Inc., Palo Alto, CA). Such receptor, antibody, member of a complement/anti-complement pair or fragment is immobilized onto the surface of a receptor chip. Use of this instrument is disclosed by Karlsson, J. Immunol. Methods 145:229-240, 1991 and Cunningham and Wells, J. Mol. Biol. 234:554-63, 1993. A receptor, antibody, member or fragment is covalently attached, using amine or sulfhydryl chemistry, to dextran fibers that are attached to gold film within the flow cell. A test sample is passed through the cell. If a ligand, epitope, or opposite member of the complement/anti-complement pair is present in the sample, it will bind to the immobilized receptor, antibody or member, respectively, causing a change in the refractive index of the medium, which is detected as a change in surface plasmon resonance of the gold film. This system allows the determination of on- and off-rates, from which binding affinity can be calculated, and assessment of stoichiometry of binding.

Ligand-binding receptor polypeptides, such as those of the present invention, can also be used within other assay systems known in the art. Such systems include Scatchard analysis for determination of binding affinity (see Scatchard, Ann. NY Acad. Sci. 51: 660-672, 1949) and calorimetric assays (Cunningham et al., Science 253:545-48, 1991; Cunningham et al., Science 245:821-25, 1991).

Soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2Rγ polypeptides can also be used to prepare antibodies that bind to epitopes, peptides, or polypeptides contained within the antigen. The zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2Rγ polypeptides or a fragment thereof serves as an antigen (immunogen) to inoculate an animal and elicit an immune response. One of skill in the art would recognize that antigenic, epitope-bearing polypeptides contain a sequence of at least 6, preferably at least 9, and more preferably at least 15 to about 30 contiguous amino acid residues of a zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2Rγ polypeptides (e.g., SEQ ID NO:2, SEQ ID NO:6, SEQ ID

NO:4). Polypeptides comprising a larger portion of a $\alpha 11$ receptor or soluble $\alpha 11$ heterodimeric polypeptide, such as soluble $\alpha 11/\text{IL-2R}\gamma$ polypeptides i.e., from 30 to 100 residues up to the entire length of the amino acid sequence are included. Antigens or immunogenic epitopes can also include attached tags, adjuvants and carriers, as described herein. Suitable antigens include the $\alpha 11$ polypeptide encoded by SEQ ID NO:2 from amino acid number 20 (Cys) to amino acid number 237 (His) (SEQ ID NO:6), or a contiguous 9 to 218 AA amino acid fragment thereof. Preferred peptides to use as antigens are the cytokine binding domain, disclosed herein, and $\alpha 11$ hydrophilic peptides such as those predicted by one of skill in the art from a hydrophobicity plot, determined for example, from a Hopp/Woods hydrophilicity profile based on a sliding six-residue window, with buried G, S, and T residues and exposed H, Y, and W residues ignored. For example, $\alpha 11$ hydrophilic peptides include peptides comprising amino acid sequences selected from the group consisting of: (1) amino acid number 51 (Trp) to amino acid number 61 (Glu) of SEQ ID NO:2; (2) amino acid number 136 (Ile) to amino acid number 143 (Glu) of SEQ ID NO:2; (3) amino acid number 187 (Pro) to amino acid number 195 (Ser) of SEQ ID NO:2; and (4) amino acid number 223 (Phe) to amino acid number 232 (Glu) of SEQ ID NO:2. The corresponding hydrophilic regions in reference to SEQ ID NO:6 can be made with cross-reference to the above amino acid residues of SEQ ID NO:2. Moreover, antigenic epitope-bearing polypeptides as predicted by a Jameson-Wolf plot, e.g., using DNASTAR Protean program (DNASTAR, Inc., Madison, WI) are suitable antigens. In addition, conserved motifs, and variable regions between conserved motifs of $\alpha 11$ soluble receptor are suitable antigens. Suitable antigens also include the $\alpha 11$ polypeptides disclosed above in combination with another class I cytokine extracellular domain, such as those that form soluble $\alpha 11$ heterodimeric polypeptides, such as soluble $\alpha 11/\text{IL-2R}\gamma$. Moreover, corresponding regions of the mouse soluble $\alpha 11$ receptor polypeptide (residues 20 (Cys) to 237 (His) SEQ ID NO:12) can be used to generate antibodies against the soluble mouse $\alpha 11$ receptor. In addition Antibodies generated from this immune response can be isolated and purified as described herein. Methods for preparing and isolating polyclonal and monoclonal antibodies are well known in the art. See, for example, Current Protocols in

Immunology, Cooligan, et al. (eds.), National Institutes of Health, John Wiley and Sons, Inc., 1995; Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, NY, 1989; and Hurrell, J. G. R., Ed., Monoclonal Hybridoma Antibodies: Techniques and Applications, CRC Press, Inc., Boca Raton, FL, 1982.

As would be evident to one of ordinary skill in the art, polyclonal antibodies can be generated from inoculating a variety of warm-blooded animals such as horses, cows, goats, sheep, dogs, chickens, rabbits, mice, and rats with a soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ polypeptide or a fragment thereof. The immunogenicity of a zalpha11 polypeptide may be increased through the use of an adjuvant, such as alum (aluminum hydroxide) or Freund's complete or incomplete adjuvant. Polypeptides useful for immunization also include fusion polypeptides, such as fusions of zalpha11 or a portion thereof with an immunoglobulin polypeptide or with maltose binding protein. The polypeptide immunogen may be a full-length molecule or a portion thereof. If the polypeptide portion is "hapten-like", such portion may be advantageously joined or linked to a macromolecular carrier (such as keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA) or tetanus toxoid) for immunization.

As used herein, the term "antibodies" includes polyclonal antibodies, affinity-purified polyclonal antibodies, monoclonal antibodies, and antigen-binding fragments, such as F(ab')₂ and Fab proteolytic fragments. Genetically engineered intact antibodies or fragments, such as chimeric antibodies, Fv fragments, single chain antibodies and the like, as well as synthetic antigen-binding peptides and polypeptides, are also included. Non-human antibodies may be humanized by grafting non-human CDRs onto human framework and constant regions, or by incorporating the entire non-human variable domains (optionally "cloaking" them with a human-like surface by replacement of exposed residues, wherein the result is a "veneered" antibody). In some instances, humanized antibodies may retain non-human residues within the human variable region framework domains to enhance proper binding characteristics. Through humanizing antibodies, biological half-life may be increased, and the potential for adverse immune reactions upon administration to humans is reduced.

Antibodies are considered to be specifically binding if: 1) they exhibit a threshold level of binding activity, and 2) they do not significantly cross-react with related polypeptide molecules. A threshold level of binding is determined if anti-soluble zalpha11 receptor or anti-soluble zalpha11 heterodimeric polypeptide, such as anti-soluble zalpha11/IL-2R γ antibodies herein bind to a soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ polypeptide, peptide or epitope with an affinity at least 10-fold greater than the binding affinity to control (non-soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ) polypeptide. It is preferred that the antibodies exhibit a binding affinity (K_a) of $10^6 M^{-1}$ or greater, preferably $10^7 M^{-1}$ or greater, more preferably $10^8 M^{-1}$ or greater, and most preferably $10^9 M^{-1}$ or greater. The binding affinity of an antibody can be readily determined by one of ordinary skill in the art, for example, by Scatchard analysis (Scatchard, G., Ann. NY Acad. Sci. 51: 660-672, 1949).

Whether anti-soluble zalpha11 receptor or anti-soluble zalpha11 heterodimeric polypeptide, such as anti-soluble zalpha11/IL-2R γ antibodies do not significantly cross-react with related polypeptide molecules is shown, for example, by the antibody detecting soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ polypeptide but not known related polypeptides using a standard Western blot analysis (Ausubel et al., ibid.). Examples of known related polypeptides are those disclosed in the prior art, such as known orthologs, and paralog, and similar known members of a protein family. Screening can also be done using non-human soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ , and soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ mutant polypeptides. Moreover, antibodies can be "screened against" known related polypeptides, to isolate a population that specifically binds to the soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ polypeptides. For example, antibodies raised to soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ are adsorbed to related polypeptides adhered to insoluble matrix; antibodies

specific to soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ will flow through the matrix under the proper buffer conditions. Screening allows isolation of polyclonal and monoclonal antibodies non-crossreactive to known closely related polypeptides (Antibodies: A Laboratory Manual, 5 Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press, 1988; Current Protocols in Immunology, Cooligan, et al. (eds.), National Institutes of Health, John Wiley and Sons, Inc., 1995). Screening and isolation of specific antibodies is well known in the art. See, Fundamental Immunology, Paul (eds.), Raven Press, 1993; Getzoff et al., *Adv. in Immunol.* 43: 1-98, 1988; Monoclonal Antibodies: Principles and Practice, 10 Goding, J.W. (eds.), Academic Press Ltd., 1996; Benjamin et al., Ann. Rev. Immunol. 2: 67-101, 1984. Specifically binding anti-soluble zalpha11 receptor or anti-soluble zalpha11 heterodimeric polypeptide, such as anti-soluble zalpha11/IL-2R γ antibodies can be detected by a number of methods in the art, and disclosed below.

A variety of assays known to those skilled in the art can be utilized to 15 detect antibodies that bind to soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ proteins or polypeptides. Exemplary assays are described in detail in Antibodies: A Laboratory Manual, Harlow and Lane (Eds.), Cold Spring Harbor Laboratory Press, 1988. Representative examples of such assays include: concurrent immunoelectrophoresis, radioimmunoassay, 20 radioimmuno-precipitation, enzyme-linked immunosorbent assay (ELISA), dot blot or Western blot assay, inhibition or competition assay, and sandwich assay. In addition, antibodies can be screened for binding to wild-type versus mutant soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ protein or polypeptide.

25 Alternative techniques for generating or selecting antibodies useful herein include *in vitro* exposure of lymphocytes to soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ protein or peptide, and selection of antibody display libraries in phage or similar vectors (for instance, through use of immobilized or labeled soluble zalpha11 receptor or soluble 30 zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ protein or peptide). Genes encoding polypeptides having potential binding domains for soluble

zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ polypeptide, can be obtained by screening random peptide libraries displayed on phage (phage display) or on bacteria, such as *E. coli*. Nucleotide sequences encoding the polypeptides can be obtained in a number of ways, such as

5 through random mutagenesis and random polynucleotide synthesis. These random peptide display libraries can be used to screen for peptides which interact with a known target which can be a protein or polypeptide, such as a ligand or receptor, a biological or synthetic macromolecule, or organic or inorganic substances. Techniques for creating and screening such random peptide display libraries are known in the art

10 (Ladner et al., US Patent NO. 5,223,409; Ladner et al., US Patent NO. 4,946,778; Ladner et al., US Patent NO. 5,403,484 and Ladner et al., US Patent NO. 5,571,698) and random peptide display libraries and kits for screening such libraries are available commercially, for instance from Clontech (Palo Alto, CA), Invitrogen Inc. (San Diego, CA), New England Biolabs, Inc. (Beverly, MA) and Pharmacia LKB Biotechnology

15 Inc. (Piscataway, NJ). Random peptide display libraries can be screened using the soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ sequences disclosed herein to identify proteins which bind to soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ . These "binding polypeptides" which interact with soluble

20 zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ polypeptides can be used for tagging cells; for isolating homolog polypeptides by affinity purification; they can be directly or indirectly conjugated to drugs, toxins, radionuclides and the like. These binding polypeptides can also be used in analytical methods such as for screening expression libraries and neutralizing

25 activity, e.g., for blocking interaction between ligand and receptor, or viral binding to a receptor. The binding polypeptides can also be used for diagnostic assays for determining circulating levels of soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ polypeptides; for detecting or quantitating soluble zalpha11 receptor or soluble zalpha11 heterodimeric

30 polypeptide, such as soluble zalpha11/IL-2R γ polypeptides as marker of underlying pathology or disease. These binding polypeptides can also act as zalpha11 receptor or

zalpha11 heterodimeric polypeptide, such as zalpha11/IL-2R γ "antagonists" to block zalpha11 receptor or zalpha11 heterodimeric polypeptide, such as zalpha11/IL-2R γ binding and signal transduction *in vitro* and *in vivo*. Again, these anti-soluble zalpha11 receptor or anti-soluble zalpha11 heterodimeric polypeptide, such as anti-soluble zalpha11/IL-2R γ binding polypeptides would be useful for inhibiting zalpha11 Ligand activity, as well as receptor activity or protein-binding. Antibodies raised to the heterodimer or multimeric combinations of the present invention are preferred embodiments, as they may act more specifically against the zalpha11 Ligand, or more potently than antibodies raised to only one subunit. Moreover, the antagonistic and binding activity of the antibodies of the present invention can be assayed in the zalpha11 Ligand proliferation and other biological assays described herein.

Antibodies to soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ may be used for tagging cells that express zalpha11 receptor or zalpha11 heterodimeric polypeptides, such as zalpha11/IL-2R γ ; for isolating soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ polypeptide by affinity purification; for diagnostic assays for determining circulating levels of soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ polypeptides; for detecting or quantitating soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ as marker of underlying pathology or disease; in analytical methods employing FACS; for screening expression libraries; for generating anti-idiotypic antibodies; and as neutralizing antibodies or as antagonists to block zalpha11 receptor or zalpha11 heterodimeric polypeptide, such as zalpha11/IL-2R γ , or zalpha11 Ligand activity *in vitro* and *in vivo*. Suitable direct tags or labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent markers, chemiluminescent markers, magnetic particles and the like; indirect tags or labels may feature use of biotin-avidin or other complement/anti-complement pairs as intermediates. Antibodies herein may also be directly or indirectly conjugated to drugs, toxins, radionuclides and the like, and these conjugates used for *in vivo* diagnostic or therapeutic applications. Moreover, antibodies to soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-

2R γ or fragments thereof may be used *in vitro* to detect denatured or non-denatured soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ or fragments thereof in assays, for example, Western Blots or other assays known in the art.

5 Antibodies to soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ are useful for tagging cells that express the corresponding receptors and assaying their expression levels, for affinity purification, within diagnostic assays for determining circulating levels of soluble receptor polypeptides, analytical methods employing fluorescence-activated cell
10 sorting. Moreover, divalent antibodies, and anti-idiotypic antibodies may be used as agonists to mimic the effect of the zalpha11 Ligand.

 Antibodies herein can also be directly or indirectly conjugated to drugs, toxins, radionuclides and the like, and these conjugates used for *in vivo* diagnostic or therapeutic applications. For instance, antibodies or binding polypeptides which
15 recognize soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ polypeptides of the present invention can be used to identify or treat tissues or organs that express a corresponding anti-complementary molecule (i.e., a zalpha11 receptor, or zalpha11 heterodimeric receptor, such as
zalpha11/IL-2R γ). More specifically, anti- soluble zalpha11 receptor or anti-soluble
20 zalpha11 heterodimeric polypeptide, such as anti-soluble zalpha11/IL-2R γ antibodies, or bioactive fragments or portions thereof, can be coupled to detectable or cytotoxic molecules and delivered to a mammal having cells, tissues or organs that express the zalpha11 receptor or a zalpha11 heterodimeric receptor, such as zalpha11/IL-2R γ receptor molecules.

25 Suitable detectable molecules may be directly or indirectly attached to polypeptides that bind soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ ("binding polypeptides," including binding peptides disclosed above), antibodies, or bioactive fragments or portions thereof. Suitable detectable molecules include radionuclides, enzymes, substrates,
30 cofactors, inhibitors, fluorescent markers, chemiluminescent markers, magnetic particles and the like. Suitable cytotoxic molecules may be directly or indirectly

attached to the polypeptide or antibody, and include bacterial or plant toxins (for instance, diphtheria toxin, *Pseudomonas* exotoxin, ricin, abrin and the like), as well as therapeutic radionuclides, such as iodine-131, rhenium-188 or yttrium-90 (either directly attached to the polypeptide or antibody, or indirectly attached through means of a chelating moiety, for instance). Binding polypeptides or antibodies may also be conjugated to cytotoxic drugs, such as adriamycin. For indirect attachment of a detectable or cytotoxic molecule, the detectable or cytotoxic molecule can be conjugated with a member of a complementary/ anticomplementary pair, where the other member is bound to the binding polypeptide or antibody portion. For these purposes, biotin/streptavidin is an exemplary complementary/ anticomplementary pair.

In another embodiment, binding polypeptide-toxin fusion proteins or antibody-toxin fusion proteins can be used for targeted cell or tissue inhibition or ablation (for instance, to treat cancer cells or tissues). Alternatively, if the binding polypeptide has multiple functional domains (i.e., an activation domain or a ligand binding domain, plus a targeting domain), a fusion protein including only the targeting domain may be suitable for directing a detectable molecule, a cytotoxic molecule or a complementary molecule to a cell or tissue type of interest. In instances where the fusion protein including only a single domain includes a complementary molecule, the anti-complementary molecule can be conjugated to a detectable or cytotoxic molecule. Such domain-complementary molecule fusion proteins thus represent a generic targeting vehicle for cell/tissue-specific delivery of generic anti-complementary-detectable/ cytotoxic molecule conjugates.

In another embodiment, soluble $\alpha 11$ receptor or soluble $\alpha 11$ heterodimeric polypeptide, such as soluble $\alpha 11$ /IL-2R γ binding polypeptide-cytokine or antibody-cytokine fusion proteins can be used for enhancing *in vivo* killing of target tissues (for example, blood, lymphoid, colon, and bone marrow cancers), if the binding polypeptide-cytokine or anti-soluble $\alpha 11$ receptor or anti-soluble $\alpha 11$ heterodimeric polypeptide, such as anti-soluble $\alpha 11$ /IL-2R γ antibody targets the hyperproliferative cell (See, generally, Hornick et al., Blood 89:4437-47, 1997). The described fusion proteins enable targeting of a cytokine to a desired site of action, thereby providing an elevated local concentration of cytokine. Suitable anti- $\alpha 11$

homodimer and heterodimer antibodies target an undesirable cell or tissue (i.e., a tumor or a leukemia), and the fused cytokine mediates improved target cell lysis by effector cells. Suitable cytokines for this purpose include interleukin 2 and granulocyte-macrophage colony-stimulating factor (GM-CSF), for instance.

5 Alternatively, soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ binding polypeptide or antibody fusion proteins described herein can be used for enhancing *in vivo* killing of target tissues by directly stimulating a zalpha11 receptor-modulated apoptotic pathway, resulting in cell death of hyperproliferative cells expressing zalpha11 receptor or a
10 zalpha11 heterodimeric receptor, such as soluble zalpha11/IL-2R γ receptor.

 Four-helix bundle cytokines that bind to cytokine receptors as well as other proteins produced by activated lymphocytes play an important biological role in cell differentiation, activation, recruitment and homeostasis of cells throughout the body. Therapeutic utility includes treatment of diseases that require immune regulation
15 including autoimmune diseases, such as, rheumatoid arthritis, multiple sclerosis, myasthenia gravis, systemic lupus erythomatosus and diabetes. Zalpha11 Ligand antagonists, including soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ , may be important in the regulation of inflammation, and therefore would be useful in treating rheumatoid arthritis, asthma,
20 ulcerative colitis, inflammatory bowel disease, Crohn's disease, and sepsis. There may be a role of zalpha11 Ligand antagonists, including soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ , in mediating tumorigenesis, and therefore would be useful in the treatment of cancer. Zalpha11 Ligand antagonists, including soluble zalpha11 receptor or soluble zalpha11
25 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ , may be a potential therapeutic in suppressing the immune system that would be important for reducing graft rejection. Soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ may have usefulness in prevention of graft vs. host disease.

30 Alternatively, zalpha11 Ligand antagonists, including soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-

2R γ receptors in conjunction with other cytokines may enable selective activation, enhancement, or selective suppression, of the immune system in conjunction with zalpha11 Ligand on other cytokines which would be important in boosting immunity to infectious diseases, treating immunocompromised patients, such as HIV+ patient, or in improving vaccines. In particular, zalpha11 antagonists, including soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ , could prevent the expansion of a subset of the immune system involving zalpha11 Ligand (e.g., NK cells and mature B-cells), while enabling expansion of progenitors induced by other cytokines (e.g., T-cells), and would provide therapeutic value in treatment of viral infection and other infection. For example, with Dengue virus infection, which causes dengue hemorrhagic fever/Dengue Shock syndrome (DHF/DSS) it is believed that severe DHF/DSS occurs as a result of "immune enhancement" i.e., enhanced replication of the virus in the presence of pre-existing antibodies against another serotype. In the second infection by a different Dengue virus serotype, the immune system raises antibodies against the first virus that cross-react but do not neutralize the virus, and that potentially aid its entry into macrophages. Thus, suppression of the antibody immune response, or B cell response, during a second or third Dengue infection may help the immune system react appropriately in the second infection to neutralize the virus by suppressing the "enhancing" antibodies from the first serotype infection, and consequently avoiding severe DHF/DSS. For review, see White, D.O. and Fenner F.J. (Eds.) Medical Virology, 3rd ed., Academic Press, Orlando Fl, 1986, pages 479-508). Similarly, suppression of maternal antibody responses against fetal antigens by soluble receptors of the present invention can aid in preventing birth defects and spontaneous abortion. Moreover, in such applications the soluble receptors of the present invention can be used in conjunction with other cytokines to suppress some immune system activities (e.g., B-cell proliferation, using the soluble receptors) but allowing others to increase, e.g., in the presence of other cytokines described herein and known in the art.

The bioactive binding polypeptide or antibody conjugates described herein can be delivered orally, intravenously, intraarterially or intraductally, or may be introduced locally at the intended site of action. For pharmaceutical use, the soluble

zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ receptor polypeptides of the present invention are formulated for parenteral, particularly intravenous or subcutaneous, delivery according to conventional methods. Intravenous administration will be by bolus injection or infusion over a
5 typical period of one to several hours. In general, pharmaceutical formulations will include a zalpha11 soluble receptor polypeptide in combination with a pharmaceutically acceptable vehicle, such as saline, buffered saline, 5% dextrose in water or the like. Formulations may further include one or more excipients, preservatives, solubilizers, buffering agents, albumin to prevent protein loss on vial surfaces, etc. Methods of
10 formulation are well known in the art and are disclosed, for example, in Remington: The Science and Practice of Pharmacy, Gennaro, ed., Mack Publishing Co., Easton, PA, 19th ed., 1995. Therapeutic doses will generally be in the range of 0.1 to 100 μ g/kg of patient weight per day, preferably 0.5-20 mg/kg per day, with the exact dose determined by the clinician according to accepted standards, taking into account the nature and
15 severity of the condition to be treated, patient traits, etc. Determination of dose is within the level of ordinary skill in the art. The proteins may be administered for acute treatment, over one week or less, often over a period of one to three days or may be used in chronic treatment, over several months or years. In general, a therapeutically effective amount of zalpha11 soluble receptor polypeptide is an amount sufficient to
20 produce a clinically significant effect.

The invention is further illustrated by the following non-limiting examples.

25 EXAMPLES

Example 1

Construction of Expression Vector Expressing Full-length zalpha11

The entire zalpha11 receptor was isolated from a plasmid containing zalpha11 receptor cDNA (SEQ ID NO:1) using PCR with primers ZC19,905 (SEQ ID
30 NO:19) and ZC19,906 (SEQ ID NO:20). The reaction conditions were as follows: 95°C for 1 min; 35 cycles at 95°C for 1 min, 55°C for 1 min, 72°C for 2 min; followed

by 72°C at 10 min; then a 10°C soak. The PCR product was run on a 1% low melting point agarose (Boehringer Mannheim) gel and the approximately 1.5 kb zalpha11 cDNA isolated using Qiaquick™ gel extraction kit (Qiagen) as per manufacturer's instructions.

5 The purified zalpha11 cDNA was digested with BamHI (Boehringer Mannheim) and EcoRI (BRL) as per manufacturer's instructions. The entire digest was run on a 1% low melting point agarose (Boehringer Mannheim) gel and the cleaved zalpha11 fragment was purified the using Qiaquick™ gel extraction kit as per manufacturer's instructions. The resultant cleaved zalpha11 fragment was inserted into
10 an expression vector as described below.

 Recipient expression vector pZP-5N was digested with BamHI (Boehringer Mannheim) and EcoRI (BRL) as per manufacturer's instructions, and gel purified as described above. This vector fragment was combined with the BamHI and EcoRI cleaved zalpha11 fragment isolated above in a ligation reaction using T4 Ligase
15 (BRL). The ligation was incubated at 15°C overnight. A sample of the ligation was electroporated in to DH10B electroMAX™ electrocompetent *E. coli* cells (25μF, 200Ω, 2.3V). Transformants were plated on LB+Ampicillin plates and single colonies screened by PCR to check for the zalpha11 sequence using ZC19,905 (SEQ ID NO:19) and ZC19,906 (SEQ ID NO:20) using the PCR conditions as described above.
20 Confirmation of the zalpha11 sequence was made by sequence analysis. The insert was approximately 1.6 kb, and was full-length.

Example 2

Zalpha11 Based Proliferation in BAF3 Assay Using Alamar Blue

25 BaF3 cells expressing the full-length zalpha11 receptor were constructed, using the zalpha11 expression vector, described in Example 1. The BaF3 cells expressing the zalpha11 receptor mRNA were designated BaF3/zalpha11. These cells provide an assay system for detecting zalpha11 Ligand activity as described in numerous Examples below. Conversely, these cells provide also an assay system for
30 detecting zalpha11 Ligand antagonist or inhibitory activity by the soluble receptors and antibodies of the present invention.

A. Construction of BaF3 Cells Expressing human $\alpha 11$ receptor

BaF3, an interleukin-3 (IL-3) dependent pre-lymphoid cell line derived from murine bone marrow (Palacios and Steinmetz, Cell 41: 727-734, 1985; Mathey-Prevot et al., Mol. Cell. Biol. 6: 4133-4135, 1986), was maintained in complete media (RPMI medium (JRH Bioscience Inc., Lenexa, KS) supplemented with 10% heat-inactivated fetal calf serum, 2ng/ml murine IL-3 (mIL-3) (R & D, Minneapolis, MN), 2mM L-glutaMax-1™ (Gibco BRL), 1 mM Sodium Pyruvate (Gibco BRL), and PSN antibiotics (GIBCO BRL)). Prior to electroporation, pZP-5N/ $\alpha 11$ plasmid DNA (Example 1) was prepared and purified using a Qiagen Maxi Prep kit (Qiagen) as per manufacturer's instructions. BaF3 cells for electroporation were washed once in RPMI media and then resuspended in RPMI media at a cell density of 10^7 cells/ml. One ml of resuspended BaF3 cells was mixed with 30 μ g of the pZP-5N/ $\alpha 11$ plasmid DNA and transferred to separate disposable electroporation chambers (GIBCO BRL). Following a 15 minute incubation at room temperature the cells were given two serial shocks (800 IFad/300 V.; 1180 IFad/300 V.) delivered by an electroporation apparatus (CELL-PORATOR™; GIBCO BRL). After a 5 minute recovery time, the electroporated cells were transferred to 50 ml of complete media and placed in an incubator for 15-24 hours (37°C, 5% CO₂). The cells were then spun down and resuspended in 50 ml of complete media containing Geneticin™ (Gibco) selection (500 μ g/ml G418) in a T-162 flask to isolate the G418-resistant pool. Pools of the transfected BaF3 cells, hereinafter called BaF3/ $\alpha 11$ cells, were assayed for signaling capability as described below.

B. Testing the signaling capability of the BaF3/ $\alpha 11$ cells using an Alamar Blue Proliferation Assay

BaF3/ $\alpha 11$ cells were spun down and washed in the complete media, described above, but without mIL-3 (hereinafter referred to as "mIL-3 free media"). The cells were spun and washed 3 times to ensure the removal of the mIL-3. Cells were then counted in a hemacytometer. Cells were plated in a 96-well format at 5000 cells per well in a volume of 100 μ l per well using the mIL-3 free media.

Proliferation of the BaF3/zalpa11 cells was assessed using conditioned media from zalpa11 Ligand-expressing cells diluted with mIL-3 free media to 50%, 25%, 12.5%, 6.25%, 3.125%, 1.5%, 0.75% and 0.375% concentrations; or purified zalpa11 Ligand (commonly owned US Patent application No. 09/522,217) diluted with mIL-3 free media to 500 ng/ml, 250ng/ml, 125 ng/ml, 62 ng/ml, 30 ng/ml, 15 ng/ml, 7.5 ng/ml, 3.75 ng/ml, 1.8 ng/ml, 0.9 ng/ml, 0.5 ng/ml and 0.25 ng/ml concentrations. 100 µl of the diluted mTPO was added to the BaF3/zalpa11 cells. The total assay volume is 200 µl. Negative controls were run in parallel using mIL-3 free media only. The assay plates were incubated at 37°C, 5% CO₂ for 3 days at which time Alamar Blue (Accumed, Chicago, IL) was added at 20µl/well. Alamar Blue gives a fluourometric readout based on the metabolic activity of cells, and is thus a direct measurement of cell proliferation in comparison to a negative control. Plates were again incubated at 37°C, 5% CO₂ for 24 hours. Plates were read on the Fmax™ plate reader (Molecular Devices Sunnyvale, CA) using the SoftMax™ Pro program, at wavelengths 544 (Excitation) and 590 (Emmission). Results confirmed the signaling capability of the zalpa11 receptor, as the zalpa11 Ligand significantly induced proliferation over over background levels.

Example 3

Screening for zalpa11 Ligand Using BaF3/Zalpa11 Cells Using an Alamar Blue Proliferation Assay

A. Activation of primary Monkey splenocytes to test for presence of zalpa11 Ligand

Monkey splenocytes were stimulated *in vitro* to produce conditioned media to test for the presence of zalpa11 Ligand activity as described below. Monkey spleens were obtained from 8 year old female *M. nesestrian* monkeys. The spleens were teased part to produce a single cell suspension. The mononuclear cells were isolated by Ficoll-Paque® PLUS (Pharmacia Biotech, Uppsala, Sweden) density gradient. The mononuclear cells were seeded at 2×10^6 cells/ml in RPMI-1640 media supplemented with 10% FBS and activated with with 5 ng/ml Phorbol-12-myristate-13-acetate (PMA) (Calbiochem, San Diego, CA), and 0.5mg/ml Ionomycin™

(Calbiochem) for 48 h. The supernatant from the stimulated monkey spleen cells was used to assay proliferation of the BaF3/zalpha11 cells as described below.

5 B. Screening for zalpha11 Ligand using BaF3/Zalpha11 cells using an Alamar Blue Proliferation Assay

BaF3/Zalpha11 cells were spun down and washed in mIL-3 free media. The cells were spun and washed 3 times to ensure the removal of the mIL-3. Cells were then counted in a hemacytometer. Cells were plated in a 96-well format at 5000 cells per well in a volume of 100 µl per well using the mIL-3 free media.

10 Proliferation of the BaF3/Zalpha11 cells was assessed using conditioned media from activated monkey spleen (see Example 3A). Conditioned media was diluted with mIL-3 free media to 50%, 25%, 12.5%, 6.25%, 3.125%, 1.5%, 0.75% and 0.375% concentrations. 100 µl of the diluted conditioned media was added to the BaF3/Zalpha11 cells. The total assay volume is 200 µl. The assay plates were
15 incubated at 37°C, 5% CO₂ for 3 days at which time Alamar Blue (Accumed, Chicago, IL) was added at 20 µl/well. Plates were again incubated at 37°C, 5% CO₂ for 24 hours. Plates were read on the Fmax™ plate reader (Molecular devices) as described above (Example 2).

Results confirmed the proliferative response of the BaF3/Zalpha11 cells
20 to a factor present in the activated monkey spleen conditioned media. The response, as measured, was approximately 4-fold over background at the 50% concentration. The untransfected BaF3 cells did not proliferate in response to this factor, showing that this factor is specific for the Zalpha11 receptor.

25 C. Human Primary Source used to isolate zalpha11 Ligand

100 ml blood draws were taken from each of six donors. The blood was drawn using 10X 10 ml vacutainer tubes containing heparin. Blood was pooled from six donors (600ml), diluted 1:1 in PBS, and separated using a Ficoll-Paque® PLUS (Pharmacia Biotech). The isolated primary human cell yield after separation on the
30 ficoll gradient was 1.2×10^9 cells.

Cells were suspended in 9.6 ml MACS buffer (PBS, 0.5% EDTA, 2mM EDTA). 1.6 ml of cell suspension was removed and 0.4 ml CD3 microbeads (Miltenyi Biotec, Auburn, CA) added. The mixture was incubated for 15 min. at 4°C. These cells labeled with CD3 beads were washed with 30 ml MACS buffer, and then
5 resuspended in 2 ml MACS buffer.

A VS+ column (Miltenyi) was prepared according to the manufacturer's instructions. The VS+ column was then placed in a VarioMACS™ magnetic field (Miltenyi). The column was equilibrated with 5 ml MACS buffer. The isolated primary human cells were then applied to the column. The CD3 negative cells were allowed to
10 pass through. The column was rinsed with 9 ml (3 X 3 ml) MACS buffer. The column was then removed from the magnet and placed over a 15 ml falcon tube. CD3+ cells were eluted by adding 5 ml MACS buffer to the column and bound cells flushed out using the plunger provided by the manufacturer. The incubation of the cells with the CD3 magnetic beads, washes, and VS+ column steps (incubation through elution)
15 above were repeated five more times. The resulting CD3+ fractions from the six column separations were pooled. The yield of CD3+ selected human cells were 3×10^8 total cells.

A sample of the pooled CD3+ selected human cells was removed for staining and sorting on a fluorescent antibody cell sorter (FACS) to assess their purity.
20 The human CD3+ selected cells were 91% CD3+ cells.

The human CD3+ selected cells were activated by incubating in RPMI + 5% FBS + PMA 10 ng/ml and Ionomycin 0.5 µg/ml (Calbiochem) for 13 hours 37°C. The supernatant from these activated CD3+ selected human cells was tested for zalpha11 Ligand activity as described below. Moreover, the activated CD3+ selected
25 human cells were used to prepare a cDNA library, as described in commonly owned US Pat. Application No. 09/522,217.

D. Testing supernatant from activated CD3+ selected human cells for zalpha11 Ligand using BaF3/Zalpa11 cells and an Alamar Blue Proliferation Assay

30 BaF3/Zalpa11 cells were spun down and washed in mIL-3 free media. The cells were spun and washed 3 times to ensure the removal of the mIL-3. Cells were

then counted in a hemacytometer. Cells were plated in a 96-well format at 5000 cells per well in a volume of 100 μ l per well using the mIL-3 free media.

Proliferation of the BaF3/Zalpa11 cells was assessed using conditioned media from activated CD3+ selected human cells (see Example 5C) diluted with mIL-3 free media to 50%, 25%, 12.5%, 6.25%, 3.125%, 1.5%, 0.75% and 0.375% concentrations. 100 μ l of the diluted conditioned media was added to the BaF3/Zalpa11 cells. The total assay volume is 200 μ l. The assay plates were incubated and assayed as described in Example 5B.

Results confirmed the proliferative response of the BaF3/Zalpa11 cells to a factor present in the activated CD3+ selected human cell conditioned media. The response, as measured, was approximately 10-fold over background at the 50% concentration. The untransfected BaF3 cells did not proliferate in response to this factor, showing that this factor is specific for the Zalpa11 receptor. Moreover soluble zalpa11 receptor blocked this proliferative activity in the BaF3/Zalpa11 cells (see, Example 16).

Example 4

Construction of Mammalian Expression Vectors That Express zalpa11 Soluble Receptors: zalpa11CEE, zalpa11CFLG, zalpa11CHIS and zalph11-Fc4

A. Construction of zalpa11 Mammalian Expression Vector containing zalph11CEE, zalph11CFLG and zalph11CHIS

An expression vector was prepared for the expression of the soluble, extracellular domain of the zalpa11 polypeptide, pC4zalph11CEE, wherein the construct is designed to express a zalpa11 polypeptide comprised of the predicted initiating methionine and truncated adjacent to the predicted transmembrane domain, and with a C-terminal Glu-Glu tag (SEQ ID NO:14).

A 700 bp PCR generated zalpa11 DNA fragment was created using ZC19,931 (SEQ ID NO:21) and ZC19,932 (SEQ ID NO:22) as PCR primers to add Asp718 and BamHI restriction sites. A plasmid containing the zalpa11 receptor cDNA (SEQ ID NO:1) was used as a template. PCR amplification of the zalpa11 fragment was performed as follows: Twenty five cycles at 94C for 0.5 minutes; five

cycles at 94°C for 10 seconds, 50°C for 30 seconds, 68°C for 45 seconds, followed by a 4°C hold. The reaction was purified by chloroform/phenol extraction and isopropanol precipitation, and digested with Asp718 and BamHI (Gibco BRL) following manufacturer's protocol. A band of the predicted size, 700 bp, was visualized by 1% agarose gel electrophoresis, excised and the DNA was purified using a QiaexII™ purification system (Qiagen) according the manufacturer's instructions.

The excised DNA was subcloned into plasmid pC4EE which had been cut with BamHI and Asp718. The pC4zalph11CEE expression vector uses the native zalph11 signal peptide and attaches the Glu-Glu tag (SEQ ID NO:14) to the C-terminus of the zalph11 polypeptide-encoding polynucleotide sequence. Plasmid pC4EE, is a mammalian expression vector containing an expression cassette having the mouse metallothionein-1 promoter, multiple restriction sites for insertion of coding sequences, a stop codon and a human growth hormone terminator. The plasmid also has an *E. coli* origin of replication, a mammalian selectable marker expression unit having an SV40 promoter, enhancer and origin of replication, a DHFR gene and the SV40 terminator.

About 30 ng of the restriction digested zalph11 insert and about 12 ng of the digested vector were ligated overnight at 16°C. One microliter of each ligation reaction was independently electroporated into DH10B competent cells (GIBCO BRL, Gaithersburg, MD) according to manufacturer's direction and plated onto LB plates containing 50 mg/ml ampicillin, and incubated overnight. Colonies were screened by restriction analysis of DNA prepared from 2 ml liquid cultures of individual colonies. The insert sequence of positive clones was verified by sequence analysis. A large scale plasmid preparation was done using a QIAGEN® Maxi prep kit (Qiagen) according to manufacturer's instructions.

The same process was used to prepare the zalph11 soluble receptors with a C-terminal his tag, composed of 6 His residues in a row; and a C-terminal flag (SEQ ID NO:23) tag, zalph11CFLAG. To construct these constructs, the aforementioned vector has either the HIS or the FLAG® tag in place of the glu-glu tag (SEQ ID NO:14).

B. Mammalian Expression Construction of Soluble zalpha11 receptor zalpha11-Fc4

An expression plasmid containing all or part of a polynucleotide encoding zalpha11 was constructed via homologous recombination. A fragment of zalpha11 cDNA was isolated using PCR that includes the polynucleotide sequence from extracellular domain of the zalpha11 receptor. The two primers used in the production of the zalpha11 fragment were: (1) The primers for PCR each include from 5' to 3' end: 40 bp of the vector flanking sequence (5' of the insert) and 17 bp corresponding to the 5' end of the zalpha11 extracellular domain (SEQ ID NO:24); and (2) 40 bp of the 5' end of the Fc4 polynucleotide sequence (SEQ ID NO:25) and 17 bp corresponding to the 3' end of the zalpha11 extracellular domain (SEQ ID NO:26). The fragment of Fc4 for fusion with the zalpha11 was generated by PCR in a similar fashion. The two primers used in the production of the Fc4 fragment were: (1) a 5' primer consisting of 40 bp of sequence from the 3' end of zalpha11 extracellular domain and 17 bp of the 5' end of Fc4 (SEQ ID NO:27); and (2) a 3' primer consisting of 40 bp of vector sequence (3' of the insert) and 17 bp of the 3' end of Fc4 (SEQ ID NO:28).

PCR amplification of the each of the reactions described above was performed as follows: one cycle at 94°C for 2 minutes; twenty-five cycles at 94°C for 30 seconds, 60°C for 30 seconds, 72°C for 1 minute; one cycle at 72°C for 5 minutes; followed by a 4°C hold. Ten µl of the 100 µl PCR reaction was run on a 0.8% LMP agarose gel (Seaplaque GTG) with 1 x TBE buffer for analysis. The remaining 90 µl of PCR reaction is precipitated with the addition of 5 µl 1 M NaCl and 250 µl of absolute ethanol. The expression vector used was derived from the plasmid pCZR199 (deposited at the American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209, designated No. 98668), and was cut with SmaI (BRL). The expression vector was derived from the plasmid pCZR199, and is a mammalian expression vector containing an expression cassette having the CMV immediate early promoter, a consensus intron from the variable region of mouse immunoglobulin heavy chain locus, multiple restriction sites for insertion of coding sequences, a stop codon and a human growth hormone terminator. The expression vector also has an *E. coli* origin of

replication, a mammalian selectable marker expression unit having an SV40 promoter, enhancer and origin of replication, a DHFR gene and the SV40 terminator. The expression vector used was constructed from pCZR199 by the replacement of the metallothionein promoter with the CMV immediate early promoter.

5 One hundred microliters of competent yeast cells (*S. cerevisiae*) were combined with 10 μ l containing approximately 1 μ g each of the zalpha11 and Fc4 inserts, and 100 ng of SmaI (BRL) digested expression vector and transferred to a 0.2 cm electroporation cuvette. The yeast/DNA mixtures were electropulsed at 0.75 kV (5 kV/cm), "infinite" ohms, 25 μ F. To each cuvette is added 600 μ l of 1.2 M sorbitol and
10 the yeast was plated in two 300 μ l aliquots onto two URA-D plates and incubated at 30°C.

 After about 48 hours, the Ura⁺ yeast transformants from a single plate were resuspended in 1 ml H₂O and spun briefly to pellet the yeast cells. The cell pellet was resuspended in 1 ml of lysis buffer (2% Triton X-100, 1% SDS, 100 mM NaCl, 10
15 mM Tris, pH 8.0, 1 mM EDTA). Five hundred microliters of the lysis mixture was added to an Eppendorf tube containing 300 μ l acid washed glass beads and 200 μ l phenol-chloroform, vortexed for 1 minute intervals two or three times, followed by a 5 minute spin in a Eppendorf centrifuge at maximum speed. Three hundred microliters of the aqueous phase was transferred to a fresh tube, and the DNA precipitated with 600 μ l
20 ethanol (EtOH), followed by centrifugation for 10 minutes at 4°C. The DNA pellet was resuspended in 100 μ l H₂O.

 Transformation of electrocompetent *E. coli* cells (DH10B, GibcoBRL) is done with 0.5-2 ml yeast DNA prep and 40 μ l of DH10B cells. The cells were electropulsed at 2.0 kV, 25 mF and 400 ohms. Following electroporation, 1 ml SOC
25 (2% Bacto® Tryptone (Difco, Detroit, MI), 0.5% yeast extract (Difco), 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl₂, 10 mM MgSO₄, 20 mM glucose) was plated in 250 μ l aliquots on four LB AMP plates (LB broth (Lennox), 1.8% Bacto Agar (Difco), 100 mg/L Ampicillin).

 Individual clones harboring the correct expression construct for
30 zalpha11-Fc4 were identified by restriction digest to verify the presence of the zalpha11-Fc4 insert and to confirm that the various DNA sequences have been joined

correctly to one another. The insert of positive clones were subjected to sequence analysis. Larger scale plasmid DNA is isolated using the Qiagen Maxi kit (Qiagen) according to manufacturer's instructions.

5

Example 5

Transfection And Expression Of Zalpha11 Soluble Receptor Polypeptides

BHK 570 cells (ATCC No. CRL-10314), passage 27, were plated at 1.2×10^6 cells/well (6-well plate) in 800 μ l of serum free (SF) DMEM media (DMEM, Gibco/BRL High Glucose) (Gibco BRL, Gaithersburg, MD). The cells were
10 transfected with expression plasmids containing zalpha11CEE, zalpha11CFLG or zalpha11CHIS described above (see, Example 4), using Lipofectin™ (Gibco BRL), in serum free (SF) DMEM. Three micrograms of zalpha11CEE, zalpha11CFLG or zalpha11CHIS each were separately diluted into 1.5 ml tubes to a total final volume of 100 μ l SF DMEM. In separate tubes, 15 μ l of Lipofectin™ (Gibco BRL) was mixed
15 with 100 μ l of SF DMEM. The Lipofectin™ mix was incubated at room temperature for 30-45 minutes then the DNA mix was added and allowed to incubate approximately 10-15 minutes at room temperature.

The entire DNA: Lipofectin™ mixture was added to the plated cells and distributed evenly over them. The cells were incubated at 37°C for approximately five
20 hours, then transferred to separate 150 mm MAXI plates in a final volume of 30 ml DMEM/5% fetal bovine serum (FBS) (Hyclone, Logan, UT). The plates were incubated at 37°C, 5% CO₂, overnight and the DNA: Lipofectin™ mixture was replaced with selection media (5% FBS/DMEM with 1 μ M methotrexate (MTX) the next day.

25 Approximately 10-12 days post-transfection, the plates were washed with 10 ml SF DMEM. The wash media was aspirated and replaced with 7.25 ml serum-free DMEM. Sterile Teflon meshes (Spectrum Medical Industries, Los Angeles, CA) pre-soaked in SF DMEM were then placed over the clonal cell colonies. A sterile nitrocellulose filter pre-soaked in SF DMEM was then placed over the mesh.
30 Orientation marks on the nitrocellulose were transferred to the culture dish. The plates were then incubated for 5-6 hours in a 37°C, 5% CO₂ incubator.

Following incubation, the filters/meshes were removed, and the media aspirated and replaced with 5% FBS/DMEM with 1 μ M MTX. The filters were then blocked in 10% nonfat dry milk/Western A buffer (Western A: 50mM Tris pH 7.4, 5 mM EDTA, 0.05% NP-40, 150 mM NaCl and 0.25% gelatin) for 15 minutes at room temperature on a rotating shaker. The filters were then incubated with an anti-Glu-Glu, anti-FLAG®, or anti-HIS antibody-HRP conjugates, respectively, in 2.5% nonfat dry milk/Western A buffer for one hour at room temperature on a rotating shaker. The filters were then washed three times at room temperature with Western A for 5-10 minutes per wash. The filters were developed with ultra ECL reagent (Amersham Corp., Arlington Heights, IL) according the manufacturer's directions and visualized on the Lumi-Imager (Roche Corp.)

Positive expressing clonal colonies were mechanically picked to 12-well plates in one ml of 5%FCS/DMEM with 5 μ M MTX, then grown to confluence. Conditioned media samples were then tested for expression levels via SDS-PAGE and Western anlaysis. The three highest expressing clones for each construct were picked; two out of three were frozen down as back up and one was expanded for mycoplasma testing and large-scale factory seeding.

B. Mammalian Expression of soluble zalpha11 receptor zalpha11-Fc4

BHK 570 cells (ATCC NO: CRL-10314) were plated in 10 cm tissue culture dishes and allowed to grow to approximately 50 to 70% confluency overnight at 37°C, 5% CO₂, in DMEM/FBS media (DMEM, Gibco/BRL High Glucose, (Gibco BRL, Gaithersburg, MD), 5% fetal bovine serum (Hyclone, Logan, UT), 1 mM L-glutamine (JRH Biosciences, Lenexa, KS), 1 mM sodium pyruvate (Gibco BRL)). The cells were then transfected with the plasmid containing zalpha11-Fc4 (see, Example 9), using LipofectamineTM (Gibco BRL), in serum free (SF) media formulation (DMEM, 10 mg/ml transferrin, 5 mg/ml insulin, 2 mg/ml fetuin, 1% L-glutamine and 1% sodium pyruvate). The plasmid containing zalpha11-Fc4 was diluted into 15 ml tubes to a total final volume of 640 ml with SF media. 35 ml of LipofectamineTM (Gibco BRL) was mixed with 605 ml of SF medium. The LipofectamineTM mix was added to the DNA mix and allowed to incubate approximately 30 minutes at room temperature. Five

milliliters of SF media was added to the DNA:LipofectamineTM mixture. The cells were rinsed once with 5 ml of SF media, aspirated, and the DNA:LipofectamineTM mixture is added. The cells were incubated at 37°C for five hours, then 6.4 ml of DMEM/10% FBS, 1% PSN media was added to each plate. The plates were incubated at 37°C overnight and the DNA:LipofectamineTM mixture was replaced with fresh 5% FBS/DMEM media the next day. On day 2 post-transfection, the cells were split into the selection media (DMEM/FBS media from above with the addition of 1 mM methotrexate (Sigma Chemical Co., St. Louis, Mo.)) in 150 mm plates at 1:10, 1:20 and 1:50. The media on the cells was replaced with fresh selection media at day 5 post-transfection. Approximately 10 days post-transfection, two 150 mm culture dishes of methotrexate resistant colonies from each transfection were trypsinized and the cells are pooled and plated into a T-162 flask and transferred to large scale culture.

Example 6

15. Purification of zalpha11 Soluble Rreceptors From BHK 570 Cells

A. Purification of zalpha11CEE polypeptide from BHK 570

Unless otherwise noted, all operations were carried out at 4°C. The following procedure was used for purifying zalpha11 polypeptide containing C-terminal GluGlu (EE) tags. Thirty liters of cell factory conditioned media was concentrated to 1.6 liters with an Amicon S10Y3 spiral cartridge on a ProFlux A30. A Protease inhibitor solution was added to the concentrated 1.6 liters of cell factory conditioned media from transfected BHK 570 cells (Example 5) to final concentrations of 2.5 mM ethylenediaminetetraacetic acid (EDTA, Sigma Chemical Co. St. Louis, MO), 0.003 mM leupeptin (Boehringer-Mannheim, Indianapolis, IN), 0.001 mM pepstatin (Boehringer-Mannheim) and 0.4 mM Pefabloc (Boehringer-Mannheim). Samples were removed for analysis and the bulk volume was frozen at -80°C until the purification was started. Total target protein concentrations of the concentrated cell factory conditioned media was determined via SDS-PAGE and Western blot analysis with the anti-EE HRP conjugated antibody.

30 A 100 ml column of anti-EE G-Sepharose (prepared as described below) was poured in a Waters AP-5, 5 cm x 10 cm glass column. The column was flow

packed and equilibrated on a BioCad Sprint (PerSeptive BioSystems, Framingham, MA) with phosphate buffered saline (PBS) pH 7.4. The concentrated cell factory conditioned media was thawed, 0.2 micron sterile filtered, pH adjusted to 7.4, then loaded on the column overnight with 1 ml/minute flow rate. The column was washed with 10 column volumes (CVs) of phosphate buffered saline (PBS, pH 7.4), then plug eluted with 200 ml of PBS (pH 6.0) containing 0.5 mg/ml EE peptide (Anaspec, San Jose, CA) at 5 ml/minute. The EE peptide used has the sequence EYMPME (SEQ ID NO:14). The column was washed for 10 CVs with PBS, then eluted with 5 CVs of 0.2M glycine, pH 3.0. The pH of the glycine-eluted column was adjusted to 7.0 with 2 CVs of 5X PBS, then equilibrated in PBS (pH 7.4). Five ml fractions were collected over the entire elution chromatography and absorbance at 280 and 215 nM were monitored; the pass through and wash pools were also saved and analyzed. The EE-polypeptide elution peak fractions were analyzed for the target protein via SDS-PAGE Silver staining and Western Blotting with the anti-EE HRP conjugated antibody. The polypeptide elution fractions of interest were pooled and concentrated from 60 ml to 5.0 ml using a 10,000 Dalton molecular weight cutoff membrane spin concentrator (Millipore, Bedford, MA) according to the manufacturer's instructions.

To separate α 11CEE from other co-purifying proteins, the concentrated polypeptide elution pooled fractions were subjected to a POROS HQ-50 (strong anion exchange resin from PerSeptive BioSystems, Framingham, MA) at pH 8.0. A 1.0 x 6.0 cm column was poured and flow packed on a BioCad Sprint. The column was counter ion charged then equilibrated in 20mM TRIS pH 8.0 (Tris (Hydroxymethyl Aminomethane)). The sample was diluted 1:13 (to reduce the ionic strength of PBS) then loaded on the Poros HQ column at 5 ml/minute. The column was washed for 10 CVs with 20mM Tris pH 8.0 then eluted with a 40 CV gradient of 20 mM Tris/ 1 M sodium chloride (NaCl) at 10 ml/minute. 1.5 ml fractions were collected over the entire chromatography and absorbance at 280 and 215 nM were monitored. The elution peak fractions were analyzed via SDS-PAGE Silver staining. Fractions of interest were pooled and concentrated to 1.5-2 ml using a 10,000 Dalton molecular weight cutoff membrane spin concentrator (Millipore, Bedford, MA) according to the manufacturer's instructions.

To separate zalpha11CEE polypeptide from free EE peptide and any contaminating co-purifying proteins, the pooled concentrated fractions were subjected to chromatography on a 1.5 x 90 cm Sephadex S200 (Pharmacia, Piscataway, NJ) column equilibrated and loaded in PBS at a flow rate of 1.0 ml/min using a BioCad Sprint. 1.5 ml fractions were collected across the entire chromatography and the absorbance at 280 and 215 nM were monitored. The peak fractions were characterized via SDS-PAGE Silver staining, and only the most pure fractions were pooled. This material represented purified zalpha11CEE polypeptide.

This purified material was finally subjected to a 4 ml ActiClean Etox (Sterogene) column to remove any remaining endotoxins. The sample was passed over the PBS equilibrated gravity column four times then the column was washed with a single 3 ml volume of PBS, which was pooled with the "cleaned" sample. The material was then 0.2 micron sterile filtered and stored at -80°C until it was aliquoted.

On Western blotted, Coomassie Blue and Silver stained SDS-PAGE gels, the zalpha11CEE polypeptide was one major band of an apparent molecular weight of 50,000 Daltons. The mobility of this band was the same on reducing and non-reducing gels.

The protein concentration of the purified material was performed by BCA analysis (Pierce, Rockford, IL) and the protein was aliquoted, and stored at -80°C according to our standard procedures. On IEF (isoelectric focusing) gels the protein runs with a PI of less than 4.5. The concentration of zalpha11CEE polypeptide was 1.0 mg/ml.

Purified zalpha11CEE polypeptide was prepared for injection into rabbits and sent to R & R Research and Development (Stanwood, WA) for antibody production. Rabbits were injected to produce anti-huzalpa11-CEE-BHK serum (Example 10, below).

To prepare anti-EE Sepharose, a 100 ml bed volume of protein G-Sepharose (Pharmacia, Piscataway, NJ) was washed 3 times with 100 ml of PBS containing 0.02% sodium azide using a 500 ml Nalgene 0.45 micron filter unit. The gel was washed with 6.0 volumes of 200 mM triethanolamine, pH 8.2 (TEA, Sigma, St. Louis, MO), and an equal volume of EE antibody solution containing 900 mg of

antibody was added. After an overnight incubation at 4°C, unbound antibody was removed by washing the resin with 5 volumes of 200 mM TEA as described above. The resin was resuspended in 2 volumes of TEA, transferred to a suitable container, and dimethylpimilimidate-2HCl (Pierce, Rockford, IL) dissolved in TEA, was added to a
5 final concentration of 36 mg/ml of protein G-Sepharose gel. The gel was rocked at room temperature for 45 min and the liquid was removed using the filter unit as described above. Nonspecific sites on the gel were then blocked by incubating for 10 min. at room temperature with 5 volumes of 20 mM ethanolamine in 200 mM TEA. The gel was then washed with 5 volumes of PBS containing 0.02% sodium azide and
10 stored in this solution at 4°C.

B. Purification of zalpha11CFLAG polypeptide from BHK 570

Unless otherwise noted, all operations were carried out at 4°C. The following procedure was used for purifying zalpha11 polypeptide containing C-terminal
15 FLAG® (FLG) (Sigma-Aldrich Co.) tags. Thirty liters of cell factory conditioned media was concentrated to 1.7 liters with an Amicon S10Y3 spiral cartridge on a ProFlux A30. A Protease inhibitor solution was added to the 1.7 liters of concentrated cell factory conditioned media from transfected BHK 570 cells (see, Example 5) to
20 final concentrations of 2.5 mM ethylenediaminetetraacetic acid (EDTA, Sigma Chemical Co. St. Louis, MO), 0.003 mM leupeptin (Boehringer-Mannheim, Indianapolis, IN), 0.001 mM pepstatin (Boehringer-Mannheim) and 0.4 mM Pefabloc (Boehringer-Mannheim). Samples were removed for analysis and the bulk volume was frozen at -80°C until the purification was started. Total target protein concentrations of the cell factory conditioned media was determined via SDS-PAGE and Western blot
25 analysis with the anti-FLAG® (Kodak) HRP conjugated antibody. A 125 ml column of anti- FLAG® M2-Agarose affinity gel (Sigma-Aldrich Co.) was poured in a Waters AP-5, 5 cm x 10 cm glass column. The column was flow packed and equilibrated on a BioCad Sprint (PerSeptive BioSystems, Framingham, MA) with phosphate buffered saline (PBS) pH 7.4. The concentrated cell factory conditioned media was thawed, 0.2
30 micron sterile filtered, pH adjusted to 7.4, then loaded on the column overnight with 1 ml/minute flow rate. The column was washed with 10 column volumes (CVs) of

phosphate buffered saline (PBS, pH 7.4), then plug eluted with 250 ml of PBS (pH 6.0) containing 0.5 mg/ml FLAG® (Sigma-Aldrich Co.) peptide at 5 ml/minute. The FLAG® peptide used has the sequence DYKDDDDK (SEQ ID NO:23). The column was washed for 10 CVs with PBS, then eluted with 5 CVs of 0.2M glycine, pH 3.0. 5 The pH of the glycine-eluted column was adjusted to 7.0 with 2 CVs of 5X PBS, then equilibrated in PBS (pH 7.4). Five ml fractions were collected over the entire elution chromatography and absorbance at 280 and 215 nM were monitored; the pass through and wash pools were also saved and analyzed. The FLAG®-polypeptide elution peak fractions were analyzed for the target protein via SDS-PAGE Silver staining and 10 Western Blotting with the anti-FLAG HRP conjugated antibody. The polypeptide elution fractions of interest were pooled and concentrated from 80 ml to 12 ml using a 10,000 Dalton molecular weight cutoff membrane spin concentrator (Millipore, Bedford, MA) according to the manufacturer's instructions.

To separate zalpha11CFLG from other co-purifying proteins, the 15 polypeptide elution pooled fractions were subjected to a POROS HQ-50 (strong anion exchange resin from PerSeptive BioSystems, Framingham, MA) at pH 8.0. A 1.0 x 6.0 cm column was poured and flow packed on a BioCad Sprint. The column was counter ion charged then equilibrated in 20mM TRIS pH 8.0 (Tris (Hydroxymethyl Aminomethane)). The sample was diluted 1:13 (to reduce the ionic strength of PBS) 20 then loaded on the Poros HQ-50 column at 5 ml/minute. The column was washed for 10 column volumes (CVs) with 20mM Tris pH 8.0 then eluted with a 40 CV gradient of 20 mM Tris/ 1 M sodium chloride (NaCl) at 10 ml/minute. 1.5 ml fractions were collected over the entire chromatography and absorbance at 280 and 215 nM were monitored. The elution peak fractions were analyzed via SDS-PAGE Silver staining. 25 Fractions of interest were pooled and concentrated to 1.5-2 ml using a 10,000 Dalton molecular weight cutoff membrane spin concentrator (Millipore, Bedford, MA) according to the manufacturer's instructions.

To separate zalpha11CFLG polypeptide from free FLAG® peptide and any contaminating co-purifying proteins, the pooled concentrated fractions were 30 subjected to chromatography on a 1.5 x 90 cm Sephacryl S200 (Pharmacia, Piscataway, NJ) column equilibrated and loaded in PBS at a flow rate of 1.0 ml/min using a BioCad

Sprint. 1.5 ml fractions were collected across the entire chromatography and the absorbance at 280 and 215 nm were monitored. The peak fractions were characterized via SDS-PAGE Silver staining, and only the most pure fractions were pooled. This material represented purified zalpha11CFLG polypeptide.

5 This purified material was finally subjected to a 4 ml ActiClean Etox (Sterogene) column to remove any remaining endotoxins. The sample was passed over the PBS equilibrated gravity column four times then the column was washed with a single 3 ml volume of PBS, which was pooled with the "cleaned" sample. The material was then 0.2 micron sterile filtered and stored at -80°C until it was aliquoted.

10 On Western blotted, Coomassie Blue and Silver stained SDS-PAGE gels, the zalpha11CFLG polypeptide was one major band of an apparent molecular weight of 50,000 Daltons. The mobility of this band was the same on reducing and non-reducing gels.

The protein concentration of the purified material was performed by
15 BCA analysis (Pierce, Rockford, IL) and the protein was aliquoted, and stored at -80°C according to our standard procedures. On IEF (isoelectric focusing) gels the protein runs with a PI of less than 4.5. The concentration of zalpha11CFLG polypeptide was 1.2 mg/ml.

20 C. Purification of zalpha11-Fc4 polypeptide from transfected BHK 570 cells

Unless otherwise noted, all operations were carried out at 4°C. The following procedure was used for purifying zalpha11 polypeptide containing C-terminal fusion to human IgG/Fc (zalpha11-Fc4; Examples 4 and 5). 12,000 ml of conditioned media from BHK 570 cells transfected with zalpha11-Fc4 (Example 5) was filtered
25 through a 0.2 mm sterilizing filter and then supplemented with a solution of protease inhibitors, to final concentrations of 0.001 mM leupeptin (Boehringer-Mannheim, Indianapolis, IN), 0.001 mM pepstatin (Boehringer-Mannheim) and 0.4 mM Pefabloc (Boehringer-Mannheim). A protein G sepharose (6 ml bed volume, Pharmacia Biotech) was packed and washed with 500 ml PBS (Gibco/BRL) The supplemented conditioned
30 media was passed over the column with a flow rate of 10 ml/minute, followed by washing with 1000 ml PBS (BRL/Gibco). zalpha11-Fc4 was eluted from the column

with 0.1 M Glycine pH 3.5 and 2 ml fractions were collected directly into 0.2 ml 2M Tris pH 8.0, to adjust the final pH to 7.0 in the fractions.

The eluted fractions were characterized by SDS-PAGE and western blotting with anti-human Fc (Amersham) antibodies. Western blot analysis of reducing SDS-PAGE gels reveal an immunoreactive protein of 80,000 KDa in fractions 2-10. Silver stained SDS-PAGE gels also revealed an 80,000 KDa zalpha11:Fc polypeptide in fractions 2-10. Fractions 2-10 were pooled.

The protein concentration of the pooled fractions was performed by BCA analysis (Pierce, Rockford, IL) and the material was aliquoted, and stored at -80°C according to our standard procedures. The concentration of the pooled fractions was 0.26 mg/ml.

Example 7

Assay Using zalpha11 Soluble Receptor zalpha11CEE, zalpha11CFLG and zalpha11-Fc4 Soluble Receptors in Competitive Inhibition Assay

BaF3/Zalpha11 cells were spun down and washed in mIL-3 free media. The cells were spun and washed 3 times to ensure the removal of the mIL-3. Cells were then counted in a hemacytometer. Cells were plated in a 96-well format at 5000 cells per well in a volume of 100 µl per well using the mIL-3 free media.

Both media from the monkey spleen cell activation and the CD3+ selected cells, described in Example 3, were added in separate experiments at 50%, 25%, 12.5%, 6.25%, 3.125%, 1.5%, 0.75% and 0.375% concentrations, with or without zalpha11 soluble receptors (CEE, C-flag, and Fc4 constructs; See, Example 6) at 10µg/ml. The total assay volume was 200 µl.

The assay plates were incubated 37°C, 5% CO₂ for 3 days at which time Alamar Blue (Accumed) was added at 20µl/well. Plates were again incubated at 37°C, 5% CO₂ for 24 hours. Plates were read on the Fmax™ plate reader (Molecular Devices) as described above (Example 2). Results demonstrated complete inhibition of cell growth from each of the different zalpha11 soluble receptor constructs at 10µg/ml, confirming that the factor in each sample was specific for the zalpha11 receptor.

Titration curves, diluting out the soluble receptors, were also run using the above stated assay. Both the zalpha11CEE and zalpha11CFLG soluble zalpha11 receptors were able to completely inhibit growth as low as 20 ng/ml. The zalpha11-Fc4 soluble zalpha11 receptor was only as effective at 1.5 µg/ml.

5

Example 8

Expression of Human zalpha11 Soluble Receptor in *E. coli*

A. Construction of expression vector pCZR225 that expresses huzalpa11/MBP-6H fusion polypeptide

10 An expression plasmid containing a polynucleotide encoding a human zalpha11 soluble receptor fused C-terminally to maltose binding protein (MBP) was constructed via homologous recombination. The polynucleotide sequence for the MBP-zalpa11 soluble receptor fusion polypeptide is shown in SEQ ID NO:29, with the corresponding protein sequence shown in SEQ ID NO:30. The fusion polypeptide,
15 designated huzalpa11/MBP-6H, in Example 9, contains an MBP portion (amino acid 1 (Met) to amino acid 388 (Ser) of SEQ ID NO:30) fused to the human zalpha11 soluble receptor (amino acid 389 (Cys) to amino acid 606 (His) of SEQ ID NO:30). A fragment of human zalpha11 cDNA (SEQ ID NO:31) was isolated using PCR. Two primers were used in the production of the human zalpha11 fragment in a PCR reaction:
20 (1) Primer ZC20,187 (SEQ ID NO:32), containing 40 bp of the vector flanking sequence and 25 bp corresponding to the amino terminus of the human zalpha11, and (2) primer ZC20,185 (SEQ ID NO:33), containing 40 bp of the 3' end corresponding to the flanking vector sequence and 25 bp corresponding to the carboxyl terminus of the human zalpha11. The PCR Reaction conditions were as follows: 25 cycles of 94°C for
25 30 seconds, 50°C for 30 seconds, and 72°C for 1 minute; followed by 4°C soak, run in duplicate. Two µl of the 100 µl PCR reaction was run on a 1.0% agarose gel with 1 x TBE buffer for analysis, and the expected approximately 660 bp fragment was seen. The remaining 90 µl of PCR reaction was combined with the second PCR tube precipitated with 400 µl of absolute ethanol. The precipitated DNA used for
30 recombining into the SmaI cut recipient vector pTAP98 to produce the construct encoding the MBP-zalpa11 fusion, as described below.

Plasmid pTAP98 was derived from the plasmids pRS316 and pMAL-c2. The plasmid pRS316 is a *Saccharomyces cerevisiae* shuttle vector (Hieter P. and Sikorski, R., Genetics 122:19-27, 1989). pMAL-C2 (NEB) is an *E. coli* expression plasmid. It carries the tac promoter driving *MalE* (gene encoding MBP) followed by a His tag, a thrombin cleavage site, a cloning site, and the *rrnB* terminator. The vector pTAP98 was constructed using yeast homologous recombination. 100ng of EcoR1 cut pMAL-c2 was recombined with 1µg Pvu1 cut pRS316, 1µg linker, and 1µg Sca1/EcoR1 cut pRS316. The linker consisted of oligos ZC19,372 (SEQ ID NO:34) (100 pmol): ZC19,351 (SEQ ID NO:35) (1 pmol): ZC19,352 (SEQ ID NO:36) (1 pmol), and ZC19,371 (SEQ ID NO:37) (100 pmol) combined in a PCR reaction. PCR reaction conditions were as follows: 10 cycles of 94°C for 30 seconds, 50°C for 30 seconds, and 72°C for 30 seconds; followed by 4°C soak. PCR products were concentrated via 100% ethanol precipitation.

One hundred microliters of competent yeast cells (*S. cerevisiae*) were combined with 10 µl of a mixture containing approximately 1 µg of the human α 11 receptor PCR product above, and 100 ng of SmaI digested pTAP98 vector, and transferred to a 0.2 cm electroporation cuvette. The yeast/DNA mixture was electropulsed at 0.75 kV (5 kV/cm), infinite ohms, 25 µF. To each cuvette was added 600 µl of 1.2 M sorbitol and the yeast was then plated in two 300 µl aliquots onto two - URA D plates and incubated at 30°C.

After about 48 hours, the Ura⁺ yeast transformants from a single plate were resuspended in 1 ml H₂O and spun briefly to pellet the yeast cells. The cell pellet was resuspended in 1 ml of lysis buffer (2% Triton X-100, 1% SDS, 100 mM NaCl, 10 mM Tris, pH 8.0, 1 mM EDTA). Five hundred microliters of the lysis mixture was added to an Eppendorf tube containing 300 µl acid washed glass beads and 200 µl phenol-chloroform, vortexed for 1 minute intervals two or three times, followed by a 5 minute spin in a Eppendorf centrifuge at maximum speed. Three hundred microliters of the aqueous phase was transferred to a fresh tube, and the DNA precipitated with 600 µl ethanol (EtOH), followed by centrifugation for 10 minutes at 4°C. The DNA pellet was resuspended in 100 µl H₂O.

Transformation of electrocompetent *E. coli* cells (MC1061, Casadaban et. al. J. Mol. Biol. 138, 179-207) was done with 1 µl yeast DNA prep and 40 µl of MC1061 cells. The cells were electropulsed at 2.0 kV, 25 µF and 400 ohms. Following electroporation, 0.6 ml SOC (2% Bacto™ Tryptone (Difco, Detroit, MI), 0.5% yeast extract (Difco), 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl₂, 10 mM MgSO₄, 20 mM glucose) was plated in one aliquot on MM/CA +AMP 100 mg/L plates (Pryor and Leiting, Protein Expression and Purification 10:309-319, 1997).

Cells harboring the correct expression construct for human zalpha11 receptor were identified by expression. Cells were grown in MM/CA with 100 µg/ml Ampicillin for two hours, shaking, at 37°C. 1ml of the culture was induced with 1mM IPTG. 2-4 hours later the 250 µl of each culture was mixed with 250 µl acid washed glass beads and 250 µl Thorner buffer with 5% βME and dye (8M urea, 100 mM Tris pH7.0, 10% glycerol, 2mM EDTA, 5% SDS). Samples were vortexed for one minute and heated to 65°C for 10 minutes. 20 µl were loaded per lane on a 4%-12% PAGE gel (NOVEX). Gels were run in 1XMES buffer. The positive clones were designated pCZR225 and subjected to sequence analysis. The polynucleotide sequence of MBP-zalpha11 fusion is shown in SEQ ID NO:50.

B. Bacterial Expression of human huzalpa11/MBP-6H fusion polypeptide

One microliter of sequencing DNA was used to transform strain BL21. The cells were electropulsed at 2.0 kV, 25 µF and 400 ohms. Following electroporation, 0.6 ml MM/CA with 100 mg/L Ampicillin.

Cells were grown in MM/CA with 100µg/ml Ampicillin for two hours, shaking, at 37°C. 1ml of the culture was induced with 1mM IPTG. 2-4 hours later the 250 µl of each culture was mixed with 250µl acid washed glass beads and 250 µl Thorner buffer with 5% βME and dye (8M urea, 100 mM Tris pH7.0, 10% glycerol, 2mM EDTA, 5% SDS). Samples were vortexed for one minute and heated to 65°C for 10 minutes. 20µl were loaded per lane on a 4%-12% PAGE gel (NOVEX). Gels were run in 1XMES buffer. The positive clones were used to grow up for protein purification of the huzalpa11/MBP-6H fusion protein (Example 9, below).

Example 9Purification of huzalpha11/MBP-6H Soluble Receptor From E.coli Fermentation

Unless otherwise noted, all operations were carried out at 4°C. The following procedure was used for purifying huzalpha11/MBP-6H soluble receptor polypeptide. *E. coli* cells containing the pCZR225 construct and expressing huzalpha11/MBP-6H soluble receptor (Example 8) were grown up in SuperBroth II (12 g/L Casien, 24 g/L Yeast Extract, 11.4 g/L di-potassium phosphate, 1.7 g/L Mono-potassium phosphate; Becton Dickenson, Cockeysville, MD), and frozen in 0.5% glycerol. Twenty grams of the frozen cells in SuperBroth II + Glycerol were used to purify the protein. The frozen cells were thawed and diluted 1:10 in a protease inhibitor solution (Extraction buffer) prior to lysing the cells and releasing the huzalpha11/MBP-6H soluble receptor protein. The diluted cells contained final concentrations of 20 mM Tris (JT Baker, Philipsburg, NJ) 100 mM Sodium Chloride (NaCl, Mallinkrodt, Paris, KY), 0.5 mM phenylmethylsulfonyl fluoride (PMSF, Sigma Chemical Co., St. Louis, MO), 2 µg/ml Leupeptin (Fluka, Switzerland), and 2 µg/ml Aprotinin (Sigma). A French Press cell breaking system (Constant Systems Ltd., Warwick, UK) with temperature of -7 to -10°C and 30K PSI was used to lyse the cells. The diluted cells were checked for breakage by A₆₀₀ readings before and after the French Press. The lysed cells were centrifuged @ 18,000G for 45 minutes to remove the broken cell debris, and the supernatant used to purify the protein. Total target protein concentrations of the supernatant was determined via BCA Protein Assay (Pierce, Rockford, IL), according to manufacturer's instructions.

A 25 ml column of Talon Metal Affinity resin (Clontech, Palo Alto, CA) (prepared as described below) was poured in a Bio-Rad, 2.5 cm D x 10 cm H glass column. The column was packed and equilibrated by gravity with 10 column volumes (CVs) of Talon Equilibration buffer (20mM Tris, 100mM NaCl, pH 8.0). The supernatant was batch loaded to Talon metal affinity resin and was rocked overnight. The resin was poured back into the column and was washed with 10 CV's of Talon Equilibration buffer by gravity, then gravity eluted with 140 ml of Elution buffer (Talon Equilibration buffer + 200mM Imidazole-Fluka Chemical). The talon column was cleaned with 5 CVs of 20mM 2-(N-Morpholino) ethanesulfonic acid pH 5.0 (MES,

Sigma), 5 CVs of distilled H₂O, then stored in 20% Ethanol/0.1% Sodium Azide. Fourteen ml fractions were collected over the entire elution chromatography and the fractions were read with absorbance at 280 and 320 nM and BCA protein assay; the pass through and wash pools were also saved and analyzed. The protein elution
5 fractions of interest were pooled and loaded straight to Amylose resin (New England Biolabs, Beverly, MA).

To obtain more pure huzalpha11/MBP-6H polypeptide, the talon affinity elution pooled fractions were subjected to Amylose resin (22mls) at pH 7.4. A 2.5 cm D x 10 cm H Bio-Rad column was poured, packed and equilibrated in 10 CVs of
10 Amylose equilibration buffer-20mM Tris (JT Baker), 100mM NaCl (Mallinkrodt), 1mM PMSF (Sigma), 10mM *beta*-Mercaptoethanol (BME, ICN Biomedicals Inc., Aurora, OH) pH 7.4. The sample was loaded by gravity flow rate of 0.5 ml/min. The column was washed for 10 CVs with Amylose equilibration buffer, then eluted with ~2 CV of Amylose equilibration buffer + 10 mM Maltose (Fluka Biochemical,
15 Switzerland) by gravity. 5 ml fractions were collected over the entire chromatography and absorbance at 280 and 320 nM were read. The Amylose column was regenerated with 1 CV of distilled H₂O, 5 CVs of 0.1% (w/v) SDS (Sigma), 5 CVs of distilled H₂O, and then 5 CVs of Amylose equilibration buffer.

Fractions of interest were pooled and dialyzed in a Slide-A-Lyzer
20 (Pierce) with 4 x 4L PBS pH 7.4 (Sigma) to remove low molecular weight contaminants, buffer exchange and desalt. After the changes of PBS, the material harvested represented the purified huzalpha11/MBP-6H polypeptide. The purified huzalpha11/MBP-6H polypeptide was analyzed via SDS-PAGE Coomassie staining and Western blot analysis with the anti-rabbit HRP conjugated antibody (Rockland,
25 Gilbertsville, PA). The concentration of the huzalpha11/MBP-6H polypeptide was 1.92 mg/ml as determined by BCA analysis.

Purified huzalpha11/MBP-6H polypeptide was prepared for injection into rabbits and sent to R & R Research and Development (Stanwood, WA) for antibody production. Rabbits were injected to produce anti anti-huzalpha11/MBP-6H
30 serum (Example 10, below).

Example 10

Zalpha11 Soluble Receptor Polyclonal Antibodies

Polyclonal antibodies were prepared by immunizing two female New Zealand white rabbits with the purified huzalpha11/MBP-6H polypeptide (Example 9),
5 or the purified recombinant zalpha11CEE soluble receptor (Example 6A). Corresponding polyclonal antibodies were designated rabbit anti-huzalpha11/MBP-6H and rabbit anti-huzalpha11-CEE-BHK respectively. The rabbits were each given an initial intraperitoneal (IP) injection of 200 mg of purified protein in Complete Freund's Adjuvant (Pierce, Rockford, IL) followed by booster IP injections of 100 mg purified
10 protein in Incomplete Freund's Adjuvant every three weeks. Seven to ten days after the administration of the third booster injection, the animals were bled and the serum was collected. The rabbits were then boosted and bled every three weeks.

The zalpha11-specific polyclonal antibodies were affinity purified from the rabbit serum using an CNBr-SEPHAROSE 4B protein column (Pharmacia LKB)
15 that was prepared using 10 mg of the purified huzalpha11/MBP-6H polypeptide (Example 9) per gram CNBr-SEPHAROSE, followed by 20X dialysis in PBS overnight. Zalpha11-specific antibodies were characterized by an ELISA titer check using 1 mg/ml of the appropriate protein antigen as an antibody target. The lower limit of detection (LLD) of the rabbit anti-huzalpha11/MBP-6H affinity purified antibody is a
20 dilution of 500 pg/ml. The LLD of the rabbit anti-huzalpha11-CEE-BHK affinity purified antibody is a dilution of 50 pg/ml.

Example 11

Identification of Cells Expressing zalpha11 Receptor Using RT-PCR

25 Specific human cell types were isolated and screened for zalpha11 expression by RT-PCR. B-cells were isolated from fresh human tonsils by mechanical disruption through 100 µm nylon cell strainers (Falcon™; Bectin Dickenson, Franklin Lakes, NJ). The B-cell suspensions were enriched for CD19+ B-cells by positive selection with VarioMACS VS+ magnetic column and CD19 microbeads (Miltenyi
30 Biotec, Auburn, CA) as per manufacturer's instructions. T-cells and monocytes were isolated from human apheresed blood samples. CD3+ T-cells were purified by CD3

microbead VarioMACS positive selection and monocytes were purified by VarioMACS negative selection columns (Miltenyi) as per manufacturer's instructions. Samples from each population were stained and analyzed by fluorescent antibody cell sorting (FACS) (Bectin Dickinson, San Jose, CA) analysis to determine the percent enrichment and
5 resulting yields. CD19+ B-cells were approximately 96%, purified CD3+ T-cells were approximately 95% purified, and monocytes were approximately 96% purified.

RNA was prepared, using a standard method in the art, from all three cell types that were either resting or activated. RNA was isolated from resting cells directly from the column preparations above. The CD19+ and CD3+ cells were
10 activated by culturing at 500,000 cells/ml in RPMI + 10%FBS containing PMA 5ng/ml (Calbiochem, La Jolla, CA) and Ionomycin 0.5ug/ml (Calbiochem) for 4 and 24 hours. The monocytes were activated by culturing in RPMI + 10% FBS containing LPS 10ng/ml (Sigma St. Louis MO) and rhIFN- γ 10 ng/ml (R&D, Minneapolis, MN) for 24 hours. Cells were harvested and washed in PBS. RNA was prepared from the cell
15 pellets using RNeasy Midiprep™ Kit (Qiagen, Valencia, CA) as per manufacturer's instructions and first strand cDNA synthesis was generated with Superscript II™ Kit (GIBCO BRL, Grand Island, NY) as per manufacturer's protocol.

Oligos ZC19907 (SEQ ID NO:38) and ZC19908 (SEQ ID NO:39) were used in a PCR reaction to screen the above described samples for a 1.2 kb fragment
20 corresponding to $\alpha 11$ message. PCR amplification was performed with Taq Polymerase (BRL Grand Island NY), and conditions as follows: 35 cycles of 95°C for 1 min., 60°C for 1 min., 72°C for 30 sec.; 1 cycle at 72°C for 10 min.; and 4°C soak. 10ul of each 50 μ l reaction volume was run on a 2% agarose 1XTAE gel to identify resultant products. PCR products were scored as (-) for no product, (+) for band
25 visible, (++) increased presence of band and (+++) being the most predominant band, with results shown in Table 5 below.

Table 5

cDNA Source	Activation	PCR Product
CD19+ cells	0hr resting	+
	4hr activated	++
	24hr activated	+++
CD3+ cells	0hr resting	-
	4hr activated	++
	24hr activated	-
monocytes	0hr resting	-
	24hr activated	-

These results indicated that zalpha11 message is present in resting human CD19+ B-cells and increases with mitogenic activation. It also appears to be expressed by human CD3+ T-cells only after 4 hour activation. There was no apparent message in either resting or activated human monocytes.

Example 12

Zalpha11 Immunohistochemistry

A. Cell and tissue preparations

Positive controls consisted of BaF3 cells transfected with zalpha11 receptor (Example 2) and lymphoid tissues known to express zalpha11 receptor including mouse lymph node, spleen and thymus received from HSD (Harlan Sprague Dawley, Indianapolis, IN), monkey lymph node and spleen received from Regional Primate Research Center (University of Washington, Seattle, WA), human lymph node and spleen received from CHTN (Cleveland, OH). Negative controls performed on each sample included: (1) untransfected BaF3 cells, (2) liver and brain tissue from mouse and human known not to express zalpha11 receptor, (3) staining with antibody dilution buffer (Ventann Biotech Systems, Tucson AZ) in the absence of primary antibody, and (4) using zalpha11 soluble receptor protein in competition experiments.

Other cell samples were examined. Both non-stimulated and stimulated HL60 cells were assayed. HL60 cells are a promyelocytic cell line, which can be

differentiated into myeloid or granulocyte lineages with different reagents. Stimulated HL60 samples were prepared as follows: (1) HL60 cells were treated with 10ng/ml of phorbol-myristate-acetate (PMA) (Sigma, St. Louis, MO) for 48 hours to differentiate into monocyte lineage cells; and (2) HL60 cells treated with 1.25% DMSO (Sigma) for 4 days to differentiate into neutrophil-like cells. In addition, human polymorphonuclear (PMN) cells, human granulocytes, human peripheral blood lymphocytes (PBL) and human monocytes from fresh human blood were examined (prepared in house using routine methods in the art). The cells and tissues described above were fixed overnight in 10% NBF (Surgipath, Richmond, IL), and embedded in paraplast X-tra (Oxford Scientific, St. Louis, MO), and sectioned at 5 μ m with a Reichart-Jung 2050 microme (Leica Instruments GmbH, Nussloch, Germany).¹

B. Immunohistochemistry

Tissue slides were deparaffinized, hydrated to buffer (water), and subjected to steam HIER treatment in Antigen Retrieval Citra buffer (BioGenex, San Roman, CA) for 20 minutes. 5% normal goat serum (Vector, Burlingame, CA) was used to block non-specific binding for 10 minutes. Immunocytochemical screening analyses were performed using polyclonal antibodies to zalpha11 soluble receptor protein (rabbit anti-huzalpa11-MBP-6H and rabbit anti-huzalpa11-CEE-BHK; Example 10) as the primary antibodies, at dilutions of 1:200 and 1:400 respectively. Biotin conjugated goat anti-rabbit IgG (Vector; Cat. No. BA-1000, 1.5 mg/ml) was used as the secondary antibody at dilution of 1:200. In separate samples, protein competition was performed by using additional zalpha11CEE soluble receptor protein (in 10X fold excess) (Example 6A) to the primary antibody to pre-block primary antibody immunoreaction. This competition was used as a control for the rabbit polyclonal antibody specificity to zalpha11. Detection was performed on the Ventana ChemMate 500 instrument using a ChemMate DAB Kit (labeled Streptavidin-Biotin Kit with application of a streptavidin-horseradish peroxidase conjugate, and DAB substrate) according to manufacturer's instruction and using the manufacturer's hematoxylin counterstain for 30 seconds (Ventana Biotek Systems, Tucson, AZ).

High expression of zalpha11 was observed in the PMA-activated HL60 cells. Low level expression was observed in PBL and HL60 cells without stimulation. A subset of cells in the spleen, thymus and lymph node of mouse showed positive staining. Lymph node and spleen of both human and monkey, and HL60 cells with DMSO stimulation showed minimal or no staining. The signal seen in the cells and tissues was mostly competed out by using the excess zalpha11 soluble receptor protein. The negative control tissues of brain and liver showed no staining.

Example 13

Identifying Peripheral Blood Mononuclear Cells (PBMNC's) That Express zalpha11 Receptor Using Polyclonal Rabbit Anti-sera to zalpha11 Soluble Receptor

200 ml fresh heparinized blood was obtained from a normal donor. Blood was diluted 1:1 in PBS, and separated using a Ficoll-Paque PLUS gradient (Pharmacia Biotech, Uppsala, Sweden), and the lymphocyte interface collected. Cells were washed 2X in PBS and resuspended in RPMI + 5% FBS media at a concentration of 2×10^6 cells/ml.

In order to determine whether expression of zalpha11 receptor is affected by the activation state of the lymphocyte cells, i.e., between resting and activated cells several stimulation conditions were used: 1) unstimulated, i.e., media alone (RPMI + 5% FBS media); 2) stimulated with PMA 10 ng/ml + Ionomycin 0.5 μ g/ml (both from Calbiochem); and 3) PHA activation (phytohemagglutinin-P, Difco/VWR). The cells were incubated at 37°C for 17 hours then collected for staining to detect expression of zalpha11 receptor.

An indirect staining protocol was used. Briefly, the human lymphocyte cells were suspended in staining buffer (PBS + 0.02% NaN₃ + BSA 1% normal human serum 2%) and plated at 2×10^5 cells in 50 μ l/well in a 96 well plate. Antibodies to the zalpha11CEE soluble receptor (Example 15) were used to determine whether they co-stained with a B-cell (CD19), T-cell (CD3) or monocyte marker (CD14) on the isolated human lymphocytes. A rabbit polyclonal sera to zalpha11 soluble receptor (Rb anti-huzalpa11-CEE-BHK) (Example 10) at 10 μ g/ml was used as the antibody to identify zalpha11 on the lymphocytes. A secondary antibody, goat anti-rabbit Ig-FITC

(Biosource, Camarillo, CA), was used to visualize the Rb anti-hu α 11-CEE-BHK antibody binding to the α 11 receptors. Other antibodies were simultaneously used to stain T cells (CD3-PE; PharMingen, San Diego, CA), B cells (CD19-PE) (PharMingen), and monocytes (CD14-PE) (PharMingen) in order to identify co-staining of the anti- α 11 receptor antibody on these cell types. Various controls were used to determine non-specific binding and background levels of staining: (1) an irrelevant rabbit polyclonal sera was used as a non-specific control; and (2) secondary antibody alone was used to determine background binding of that reagent. Purified, α 11CEE soluble receptor (Example 6) was used in about a 10-fold excess as a competitive inhibitor to verify the specificity of the rabbit anti-hu α 11-CEE-BHK antibody to α 11 soluble receptor.

After plating the cells and adding the primary and co-staining antibodies, the cells were incubated on ice for 30 minutes, washed 2X with staining buffer, and stained with the secondary antibody, goat anti-rabbit Ig-FTTC (Biosource), for 30 minutes on ice. Cells were washed 2X staining buffer, and resuspended at 200 μ l per well in staining buffer containing the viability stain 7AAD at about 1 μ g/ml final concentration (Sigma, St. Louis, MO). Samples were read on the FACS-Caliber (Becton-Dickinson, San Jose, CA) and viable cells analyzed.

The rabbit polyclonal to α 11 receptor stained resting B cells. The signal on resting B cells was brighter than the signal achieved using the irrelevant rabbit sera, and the signal was diminished to a greater extent on B cells than on T cells with the addition of excess α 11-CEE soluble receptor. This experiment was repeated using separated B and T cells, and the results were very similar. Again the staining with the polyclonal rabbit anti-hu α 11-CEE-BHK antibody to α 11 receptor was highest on resting B cells.

Example 14Zalpa11 Receptor Expression in Various Tissues Using Real-Time Quantitative
RT/PCRA. Primers and Probes for Quantitative RT-PCR-

5 Real-time quantitative RT-PCR using the ABI PRISM 7700 Sequence
Detection System (PE Applied Biosystems, Inc., Foster City, CA) has been previously
described (See, Heid, C.A. et al., Genome Research 6:986-994, 1996; Gibson, U.E.M.
et al., Genome Research 6:995-1001, 1996; Sundaresan, S. et al., Endocrinology
139:4756-4764, 1998. This method incorporates use of a gene specific probe
10 containing both reporter and quencher fluorescent dyes. When the probe is intact the
reporter dye emission is negated due to the close proximity of the quencher dye.
During PCR extension using additional gene-specific forward and reverse primers, the
probe is cleaved by 5' nuclease activity of Taq polymerase which releases the reporter
dye from the probe resulting in an increase in fluorescent emission.

15 The primers and probes used for real-time quantitative RT-PCR analyses
of zalpa11 receptor expression were designed using the primer design software Primer
Express™ (PE Applied Biosystems, Foster City, CA). Primers for human zalpa11
receptor were designed spanning an intron-exon junction to eliminate amplification of
genomic DNA. The forward primer, ZC22,277 (SEQ ID NO:40) and the reverse
20 primer, ZC22,276 (SEQ ID NO:41) were used in a PCR reaction (below) at about 300
nM concentration to synthesize a 143 bp product. The corresponding zalpa11
TaqMan® probe, designated ZG31 (SEQ ID NO:42) was synthesized and labeled by PE
Applied Biosystems. The ZG31 probe was labeled at the 5' end with a reporter
fluorescent dye (6-carboxy-fluorescein) (FAM) (PE Applied Biosystems) and at the 3'
25 end with a quencher fluorescent dye (6-carboxy-tetramethyl-rhodamine) (TAMRA) (PE
Applied Biosystems).

As a control to test the integrity and quality of RNA samples tested, all
RNA samples (below) were screened for rRNA using a primer and probe set ordered
from PE Applied Biosystems (cat No. 4304483). The kit contains an rRNA forward
30 primer (SEQ ID NO:43) and the rRNA reverse primer (SEQ ID NO:44), rRNA
TaqMan® probe (SEQ ID NO:45) The rRNA probe was labeled at the 5'end with a

reporter fluorescent dye VIC (PE Applied Biosystems) and at the 3' end with the quencher fluorescent dye TAMRA (PE Applied Biosystems). The rRNA results also serve as an internal control and allow for the normalization of the zalpha11 mRNA expression results seen in the test samples.

5 RNA samples from human CD3, CD19 and monocyte cell types were prepared and described as per Example 11 above. Control RNA was prepared, using RNeasy Miniprep™ Kit (Qiagen, Valencia, CA) as per manufacturer's instructions, from approximately 10 million BaF3 cells expressing human zalpha11 receptor (Example 2A).

10 B. Real-time quantitative RT-PCR

Relative levels of zalpha11 mRNA were determined by analyzing total RNA samples using the one-step RT-PCR method (PE Applied Biosystems). Total RNA from BaF3 cells expressing human zalpha11 receptor was isolated by standard
15 methods and used to generate a standard curve used for quantitation. The curve consisted of 10-fold serial dilutions ranging from $2.5-2.5 \times 10^{-4}$ ng/ μ l for the rRNA screen and 250-0.025 ng/ μ l for the zalpha11 screen with each standard curve point analyzed in triplicate. The total RNA samples from the cells were also analyzed in triplicate for human zalpha11 receptor transcript levels and for levels of rRNA as an
20 endogenous control. In a total volume of 25 μ l, each RNA sample was subjected to a One-Step RT-PCR reaction containing: approximately 25 ng of total RNA in buffer A (50 mM KCL, 10 mM Tris-HCL); the internal standard dye, carboxy-x-rhodamine (ROX); appropriate primers (approximately 50 nM rRNA primers (SEQ ID NO:43 and SEQ ID NO:44) for the rRNA samples; and approximately 300 nM ZC22,277 (SEQ ID
25 NO:40) and ZC22,276 (SEQ ID NO:41) primers for zalpha11 samples); the appropriate probe (approximately 50 nM rRNA TaqMan® probe (SEQ ID NO:45) for rRNA samples, approximately 100 nM ZG31 (SEQ ID NO:42) probe for zalpha11 samples); 5.5 mM MgCl₂; 300 μ M each d-CTP, d-ATP, and d-GTP and 600 μ M of d-UTP; MuLV reverse transcriptase (0.25 U/ μ l); AmpliTaq™ Gold DNA polymerase (0.025
30 U/ μ l) (PE Applied Biosystems); and RNase Inhibitor (0.4 U/ μ l) (PE Applied Biosystems). PCR thermal cycling conditions were as follows: an initial reverse

transcription (RT) step of one cycle at 48°C for 30 minutes; followed by an AmpliTaq Gold™ (PE Applied Biosystems) activation step of one cycle at 95°C for 10 minutes; followed by 40 cycles of amplification at 95°C for 15 seconds and 60°C for 1 minute.

Relative zalpha11 RNA levels were determined by using the Standard Curve Method as described by the manufacturer, PE Biosystems (User Bulletin No.2: ABI Prism 7700 Sequence Detection System, Relative Quantitation of Gene Expression, December 11, 1997). The rRNA measurements were used to normalize the zalpha11 levels and the resting CD3+ RNA sample was used as a calibrator. Resting CD3 was arbitrarily chosen as the calibrator and given a value of 1.00. The rest of the samples were compared relative to the calibrator. Data are shown in Table 6 below.

Table 6

Sample	Resting	4hr Stimulation	24hr Stimulation
CD3	1.00	15.27	16.70
CD19	20.14	65.08	25.42
Monocytes	0.05	no data	0.26

There was a 15-fold increase in zalpha11 receptor expression in CD3+ at 4 and 24 hrs. Resting CD19 had 20 fold increase in receptor expression relative to resting CD3+. There was a 3 fold increase with 4 hr stimulation that fell back to resting levels by 24 hrs. Monocytes showed no detectable zalpha11 receptor expression in this assay.

C. Purified Human T, NK, and B cells as a Primary Source used to assess human zalpha11 receptor Expression

Whole blood (150 ml) was collected from a healthy human donor and mixed 1:1 with PBS in 50ml conical tubes. Thirty ml of diluted blood was then underlayered with 15 ml of Ficoll Paque Plus (Amersham Pharmacia Biotech, Uppsala, Sweden). These gradients were centrifuged 30 min at 500 g and allowed to stop without braking. The RBC-depleted cells at the interface (PBMC) were collected and

washed 3 times with PBS. The isolated human PBMC yield was 200×10^6 prior to selection described below.

The PBMCs were suspended in 1.5 ml MACS buffer (PBS, 0.5% EDTA, 2mM EDTA) and 3×10^6 cells were set aside for control RNA and for flow cytometric analysis. The 0.25 ml anti-human CD8 microbeads (Miltenyi Biotec) were added and the mixture was incubated for 15 min at 4 degrees C. These cells labeled with CD8 beads were washed with 30 ml MACS buffer, and then resuspended in 2 ml MACS buffer.

A VS+ column (Miltenyi) was prepared according to the manufacturer's instructions. The VS+ column was then placed in a VarioMACS magnetic field (Miltenyi). The column was equilibrated with 5 ml MACS buffer. The isolated primary mouse cells were then applied to the column. The CD8 negative cells were allowed to pass through. The column was rinsed with 9 ml (3 X 3 ml) MACS buffer. The column was then removed from the magnet and placed over a 15 ml falcon tube. CD8+ cells were eluted by adding 5 ml MACS buffer to the column and bound cells flushed out using the plunger provided by the manufacturer. The yield of CD8+ selected human peripheral T cells was 51×10^6 total cells. The CD8-negative flow through cells were collected, counted, stained with anti-human CD4 coated beads, then incubated and passed over a new VS+ column at the same concentrations as described above. The yield of CD4+ selected human peripheral T cells was 42×10^6 total cells.

A sample of each of the CD8+ and CD4+ selected human T cells was removed for staining and sorting on a fluorescence activated cell sorter (FACS) to assess their purity. A PE-conjugated anti-human CD4 antibody, an anti-human CD8-FITC Ab, and an anti-human CD19-CyChrome Ab (all from PharMingen) were used for staining the CD8+ and CD4+ selected cells. The CD8-selected cells in this first experiment were 80% CD8+, and the CD4-selected cells were 85% CD4+. In 2 subsequent experiments (Example 14B), the CD8+ purified cells were 84% and 81% pure, and the CD4+ cells were 85% and 97% pure, respectively. In one experiment, we stained the non-binding (flow-through) cells with anti-human CD19-coated beads (Miltenyi) and ran them over a third magnetic bead column to isolate CD19+ B cells (these were 92% pure).

The human CD8+, CD4+ and CD19+ selected cells were activated by incubating 0.5×10^6 cells/ml in RPMI + 5% human ultraserum (Gemini Bioproducts, Calabasas, CA) + PMA 10 ng/ml and Ionomycin 0.5 μ g/ml (Calbiochem) for 4, 16, or 24 hours at 37°C. The T-cells (2.5×10^6 /well) were alternately stimulated in 24-well plates pre-coated overnight with 0.5 μ g/ml plate-bound anti-CD3 mAb UCHT1 (PharMingen) with or without soluble anti-CD28 mAb (PharMingen) at 5 μ g/ml. At each timepoint, the cells were harvested, pelleted, washed once with PBS, and pelleted again. The supernatant was removed and the pellets were snap-frozen in a dry ice/ethanol bath, then stored at -80°C for RNA preparation at a later date.

In a separate experiment, human NK cells were enriched from Ficoll PBMC by negative selection using the human NK enrichment system (consisting of antibodies to CD3, CD4, CD14, CD19, CD66b, and glycophorin A) from Stem Cell Technologies (Vancouver, B.C., Canada). Cell pellets were prepared from freshly isolated NK cells from 2 different donors, or from NK cells cultured 24 hours in media only or in media supplemented with 20 ng/ml IL-15. RNA from a human NK cell line derived from a malignant non-Hodgkin's lymphoma and designated NK-92 (ATCC No. CRL-2407) was also tested. As positive controls, RNA was isolated from the human B cell lines CESS (ATCC No. TIB-190), IM-9 (ATCC No. CCL-159), and HS-Sultan (CRL-1484).

Real Time-PCR was performed on these human NK, CD8+, CD4+ and CD19+ selected cells as described above for assessing human α 11 receptor expression. Relative levels of α 11 receptor RNA were determined by analysis of total RNA samples using the One-Step RT-PCR method (PE Applied Biosystems). RNA from BaF3 cells expressing human α 11 receptor was used to generate appropriate control for standard curves for the real-time PCR described in Example 14C above. Results of the experiments analyzing the expression of the α 11 Ligand and α receptor in stimulated and unstimulated cells are as described in Example 14D-E below.

D. Expression of human $\alpha 11$ Receptor and Ligand in CD4+, CD8+ and CD19+ cells

The first experiment used RT-PCR, described above, to assess $\alpha 11$ receptor expression in unstimulated and anti-CD3 stimulated CD4+ and CD8+ samples at timepoints of 0h (unstimulated ("resting") cells), and at 4h, 15.5h and 24h, after stimulatoin. The resting CD4+ sample was arbitrarily chosen as the calibrator and given a value of 1.00. There was approximately a 4-fold increase in receptor expression in unstimulated CD4+ cells from 4h to 24h of culture and about an 8-fold increase over the same time period in anti-CD3 stimulated CD4+ cells. The CD8+ cells showed a 7-fold increase in $\alpha 11$ receptor expression that peaked at 4hrs and decreased over time. With anti-CD3 stimulation, the CD8+ cells had a constant 8-fold increase in receptor expression.

The second experiment used RT-PCR to assess $\alpha 11$ receptor expression in anti-CD3-stimulated, PMA + Ionomycin-stimulated and unstimulated CD4+ and CD8+ samples at timepoints of 0 h, and at 3.5 h, 16 h and 24 h after activation. The resting CD8+ sample was arbitrarily chosen as the calibrator and given a value of 1.00. The resting CD4+ and CD8+ cells did not have significant amounts of receptor expression. The expression was about 3 fold higher in the PMA + Ionomycin-stimulated CD4+ samples at 3.5 h, 16 h and 24 h after stimulation. The expression in anti-CD3 activated CD4+ cells peaked at 10-fold above background levels at 3.5 h after stimulation, then fell back to levels 4-fold above background at 16 h after stimulation. The CD8+ cells showed a 4-fold expression increase at 3.5 h after PMA + Ionomycin stimulation, with expression decreasing at subsequent timepoints. As in the first experiment, the anti-CD3 stimulated CD8+ cells again exhibited an 8-fold above background induction of receptor expression.

The final experiment used RT-PCR to assess $\alpha 11$ receptor expression in anti-CD3- and anti-CD3/anti-CD28-stimulated and unstimulated CD4+ and CD8+ samples at timepoints of 0 h, and at 2 h, 4 h, and 16 h after stimulation. CD19+ cells activated with PMA + Ionomycin were also screened for receptor expression at the same time intervals. The resting CD4+ sample was arbitrarily chosen as the calibrator and given a value of 1.00. The 2h anti-CD3 stimulated CD4+ cells

only had a 4-fold induction of receptor, compared to the 10-fold induction seen at 3.5h in the previous experiment. The combination of anti-CD3 and anti-CD28 increased expression to 8-fold above background. The 16 h anti-CD3/anti-CD28 stimulated CD8+ cells had very low receptor expression levels, as seen in the CD8+ cells in previous experiments (above). The CD19+ cells stimulated with PMA + Ionomycin had the most significant receptor expression with a 19-fold increase at 2h, but the expression levels decreased back to those of resting cells by 16h.

A certain amount of variation was expected between blood draws (i.e. multiple samples at different times from the same patient and between multiple patients). Therefore, data trends were analyzed within each study or from a single blood sample and the three experiments above were compared for an overall conclusion. The trend from the Real Time PCR experiments described above is that of all the cell types tested, CD19+ B cells activated with PMA + ionomycin expressed the highest levels of zalpha11 receptor RNA. CD4+ and CD8+ cells can also be stimulated to express receptor, but at lower levels than in B cells.

E. Expression of human zalpha11 Receptor in human NK cells

Real Time PCR was also performed on human NK cells, purified as described in Example 14C, above. The NK-92 sample was arbitrarily chosen as the calibrator and given a value of 1.00. There was approximately a 4.5-fold increase in receptor expression in the positive control CESS cells, a 1.5-fold increase in IM-9 cells, and no increase in the HS-Sultan cells (0.9-fold relative to NK-92). The NK cells, either fresh or cultured overnight with or without IL-15, expressed very similar levels of zalpha11 Receptor as NK-92 (with values ranging from 0.9–1.2-fold different relative to NK-92).

Example 15

Identification of Cells Expressing zalpha11 Receptor Using *in situ* Hybridization

Specific human tissues were isolated and screened for zalpha11 expression by *in situ* hybridization. Various human tissues prepared, sectioned and subjected to *in situ* hybridization included thymus, spleen, tonsil, lymph node and lung.

The tissues were fixed in 10% buffered formalin and blocked in paraffin using standard techniques. Tissues were sectioned at 4 to 8 microns. Tissues were prepared using a standard protocol ("Development of non-isotopic *in situ* hybridization" at <http://dir.niehs.nih.gov/dirlep/ish.html>). Briefly, tissue sections were deparaffinized with HistoClear (National Diagnostics, Atlanta, GA) and then dehydrated with ethanol. Next they were digested with Proteinase K (50 µg/ml) (Boehringer Diagnostics, Indianapolis, IN) at 37°C for 2 to 20 minutes. This step was followed by acetylation and re-hydration of the tissues.

Two *in situ* probes generated by PCR were designed against the human zalpha11 sequence. Two sets of oligos were designed to generate probes for separate regions of the zalpha11 cDNA: (1) Oligos ZC23,684 (SEQ ID NO:60) and ZC23,656 (SEQ ID NO:61) were used to generate a 413 bp probe for zalpha11; and (2) Oligos ZC23,685 (SEQ ID NO:62) and ZC23,657 (SEQ ID NO:63) were used to generate a 430 bp probe for zalpha11. The second probe is 1500 bp 3' of the first zalpha11 probe. The antisense oligo from each set also contained the working sequence for the T7 RNA polymerase promoter to allow for easy transcription of antisense RNA probes from these PCR products. The PCR reaction conditions were as follows: 30 cycles at 94°C for 30 sec, 60°C for 1 min., 72°C for 1.5 min. The PCR products were purified by Qiagen spin columns followed by phenol/chloroform extraction and ethanol precipitation. Probes were subsequently labeled with digoxigenin (Boehringer) or biotin (Boehringer) using an *In Vitro* transcription System (Promega, Madison, WI) as per manufacturer's instruction.

In situ hybridization was performed with a digoxigenin- or biotin-labeled zalpha11 probe (above). The probe was added to the slides at a concentration of 1 to 5 pmol/ml for 12 to 16 hours at 55-60°C. Slides were subsequently washed in 2XSSC and 0.1XSSC at 50°C. The signals were amplified using tyramide signal amplification (TSA) (TSA, *in situ* indirect kit; NEN) and visualized with Vector Red substrate kit (Vector Lab) as per manufacturer's instructions. The slides were then counter-stained with hematoxylin (Vector Laboratories, Burlingame, CA).

A signal was seen in the thymus, tonsil, lung, and lymph node. The positive-staining cells appeared to be lymphocytes.

Example 16

Secretion Trap Assay

A secretion trap assay was used to identify the cDNA for the zalpha11
5 Ligand. The positive DNA pools obtained from the expression cloning effort were described in commonly owned US Patent application No. 09/522,217.

Conditioned medium from DNA clones transfected into BHK cells in
96-well format, were put into the proliferation assay using BaF3/zalpha11 cells
described in Example 2. Several DNA pools gave positive activities that were repeated
10 and neutralized with zalpha11 soluble receptors (Example 6). One positive DNA pool was transfected into COS cells in 12-well format, using the Lipofectamine™ method described below.

A secretion trap assay was then performed using zalpha11 soluble
receptors (C-terminal Glu-Glu tagged either with or without biotinylation; C-terminal
15 Flag tagged; or Fc4 zalpha11 soluble receptor fusions) (Example 6) to test the direct binding between the zalpha11 Ligand in the positive pool and zalpha11 soluble receptors (see below). The result was positive, enabling the detection and isolation of clones expressing the zalpha11 Ligand. Plates were shaken at 37°C for 24 hours, and then DNA minipreps (QiaPrep™ 96 Turbo Miniprep Kit; Qiagen) were prepared in 96-
20 well format using a TomTech Quadra 9600. The plasmid DNA was then pooled in the format of rows and columns, transfected into COS cells, and then the positive pools were determined by secretion trap as described below.

COS Cell Transfections

25 The COS cell transfection was performed as follows: Mix 3ul pooled DNA and 5ul Lipofectamine™ in 92ul serum free DMEM media (55mg sodium pyruvate, 146mg L-glutamine, 5mg transferrin, 2.5mg insulin, 1μg selenium and 5mg fetuin in 500ml DMEM), incubate at room temperature for 30 minutes and then add 400ul serum free DMEM media. Add this 500ul mixture onto 1.5×10^5 COS cells/well
30 plated on 12-well tissue culture plate and incubate for 5 hours at 37°C. Add 500ul 20%

FBS DMEM media (100 ml FBS, 55 mg sodium pyruvate and 146mg L-glutamine in 500ml DMEM) and incubate overnight.

Secretion Trap Assay

5 The secretion trap was performed as follows: Media was rinsed off cells with PBS and then fixed for 15 minutes with 1.8% Formaldehyde in PBS. Cells were then washed with TNT (0.1M Tris-HCL, 0.15M NaCl, and 0.05% Tween-20 in H₂O), and permeated with 0.1% Triton-X in PBS for 15 minutes, and again washed with TNT. Cells were blocked for 1 hour with TNB (0.1M Tris-HCL, 0.15M NaCl and 0.5%
10 Blocking Reagent (NEN Renaissance TSA-Direct Kit) in H₂O), and washed again with TNT. If using the biotinylated protein, the cells were blocked for 15 minute incubations with Avidin and then Biotin (Vector Labs), washing in-between with TNT. Depending on which soluble receptor was used, the cells were incubated for 1 hour with: (A) 1-3 µg/ml zalpha11 soluble receptor zalpha11-Fc4 fusion protein (Example
15 6); (B) 3 µg/ml zalpha11 soluble receptor C-terminal FLAG tagged, zalpha11CFLG (Example 6); (C) 3 µg/ml zalpha11 soluble receptor C-terminal GluGlu tagged, zalpha11CEE (Example 6); or (D) 3 µg/ml biotinylated zalpha11 soluble receptor zalpha11CEE (Example 6) in TNB. Cells were then washed with TNT. Depending on which soluble receptor was used, cells were incubated for another hour with: (A) 1:200
20 diluted goat-anti-human Ig-HRP (Fc specific); (B) 1:1000 diluted M2-HRP; (C) 1:1000 diluted anti-GluGlu antibody-HRP; or (D) 1:300 diluted streptavidin-HRP (NEN kit) in TNB. Again cells were washed with TNT.

 Positive binding was detected with fluorescein tyramide reagent diluted 1:50 in dilution buffer (NEN kit) and incubated for 4-6 minutes, and washed with TNT.
25 Cells were preserved with Vectashield Mounting Media (Vector Labs Burlingame, CA) diluted 1:5 in TNT. Cells were visualized using a FITC filter on fluorescent microscope.

Example 17Mouse zalpha11 Ligand Binds to Human zalpha11 Soluble Receptor in
Secretion Trap Assay

5 A plasmid containing DNA encoding the mouse zalpha11 Ligand (SEQ ID NO:47) was transfected into COS cells, and the binding of human zalpha11 soluble receptor zalpha11-Fc4 (Example 6C) to the transfected COS cells was tested by a secretion trap assay (Example 16). The assay confirmed that the mouse zalpha11 Ligand binds to human zalpha11 soluble receptor.

10 The COS cell transfection was performed as per Example 16 using 0.7 µg of the plasmid in 3 µl. The secretion trap was performed as as per Example 16 using 1 µg/ml zalpha11 soluble receptor Fc4 fusion protein (Example 6C) in TNB, and 1:200 diluted goat-anti-human Ig-HRP (Fc specific) in TNB for the detectable antibody. Positive binding of the soluble human zalpha11 receptor to the prepared fixed cells was detected with fluorescein tyramide reagent, preserved and visualized according to
15 Example 16. The positive result indicated the mouse zalpha11 Ligand binds to human zalpha11 soluble receptor.

Example 18Mouse zalpha11 Ligand Activates Human zalpha11 Receptor in BaF3 AassayUsing Alamar Blue

20 BaF3/Zalpha11 cells were spun down, washed and plated in mL-3 free media as described in Example 2. Proliferation of the BaF3/Zalpha11 cells was assessed using serum-free conditioned media from BHK cells expressing mouse zalpha11 Ligand (SEQ ID NO:47). Conditioned media was diluted with mL-3 free
25 media to: 50%, 25%, 12.5%, 6.25%, 3.125%, 1.5%, 0.75% and 0.375% concentrations. The proliferation assay was performed as per Example 2. Results confirmed the proliferative response of the BaF3/Zalpha11 cells to mouse zalpha11 Ligand. The response, as measured, was approximately 5-fold over background at the 50% concentration.

Example 19Zalpa11 Ligand Activates Human zalpa11 Receptor in Luciferase AssayA. Construction of BaF3/KZ134/zalpa11 cell line

5 The KZ134 plasmid was constructed with complementary oligonucleotides ZC12,749 (SEQ ID NO:48) and ZC12,748 (SEQ ID NO:49) that contain STAT transcription factor binding elements from 4 genes. A modified c-fos Sis inducible element (m67SIE, or hSIE) (Sadowski, H. et al., Science 261:1739-1744, 1993), the p21 SIE1 from the p21 WAF1 gene (Chin, Y. et al., Science 272:719-722, 1996), the mammary gland response element of the β -casein gene (Schmitt-Ney, M. et al., Mol. Cell. Biol. 11:3745-3755, 1991), and a STAT inducible element of the Fcg RI gene, (Seidel, H. et al., Proc. Natl. Acad. Sci. 92:3041-3045, 1995). These oligonucleotides contain Asp718-XhoI compatible ends and were ligated, using standard methods, into a recipient firefly luciferase reporter vector with a c-fos promoter (Poulsen, L.K. et al., J. Biol. Chem. 273:6229-6232, 1998) digested with the same enzymes and containing a neomycin selectable marker. The KZ134 plasmid was used to stably transfect BaF3 cells, using standard transfection and selection methods, to make the BaF3/KZ134 cell line.

A stable BaF3/KZ134 indicator cell line, expressing the full-length zalpa11 receptor was constructed as per Example 1, using about 30 μ g of the zalpa11 expression vector. Clones were diluted, plated and selected using standard techniques. Clones were screened by luciferase assay (see Example 19B, below) using the human zalpa11 Ligand conditioned media as an inducer. Clones with the highest luciferase response (via STAT luciferase) and the lowest background were selected. A stable transfectant cell line was selected. The cell line was called BaF3/KZ134/zalpa11.

25 B. Human and mouse Zalpa11 Ligand activates human zalpa11 receptor in BaF3/KZ134/Zalpa11 luciferase assay

BaF3/KZ134/Zalpa11 cells were spun down and washed in mIL-3 free media. The cells were spun and washed 3 times to ensure removal of mIL-3. Cells were then counted in a hemacytometer. Cells were plated in a 96-well format at about 30,000 cells per well in a volume of 100 μ l per well using the mIL-3 free media. The

same procedure was used for untransfected BaF3/KZ134 cells for use as a control in the subsequent assay.

STAT activation of the BaF3/KZ134/Zalpha11 cells was assessed using conditioned media from (1) BHK570 cells transfected with an expression vector encoding the human zalpha11 Ligand (SEQ ID NO:10) or (2) BHK570 cells transfected with an expression vector encoding the mouse zalpha11 Ligand (SEQ ID NO:47), or (3) mIL-3 free media to measure media-only control response. Conditioned media was diluted with RPMI mIL-3 free media to 50%, 25%, 12.5%, 6.25%, 3.125%, 1.5%, 0.75% and 0.375% concentrations. 100 µl of the diluted conditioned media was added to the BaF3/KZ134/Zalpha11 cells. The assay using the conditioned media was done in parallel on untransfected BaF3/KZ134 cells as a control. The total assay volume was 200 µl. The assay plates were incubated at 37°C, 5% CO₂ for 24 hours at which time the cells were pelleted by centrifugation at 2000 rpm for 10 min., and the media was aspirated and 25 µl of lysis buffer (Promega) was added. After 10 minutes at room temperature, the plates were measured for activation of the STAT reporter construct by reading them on a luminometer (Labsystems Luminoskan, model RS) which added 40 µl of luciferase assay substrate (Promega) at a five second integration.

Results confirmed the STAT reporter response of the BaF3/KZ134/Zalpha11 cells to the human zalpha11 Ligand. The response, as measured, was approximately 50 fold over media-only control at the 50% concentration. STAT activation in response to human zalpha11 Ligand was absent in the untransfected BaF3/KZ134 control cells, showing that the response is mediated through the Zalpha11 receptor.

Results also confirmed the STAT reporter response of the BaF3/KZ134/Zalpha11 cells to the mouse zalpha11 Ligand. The response, as measured, was approximately 40 fold over media-only control at the 50% concentration. Moreover, STAT activation in response to mouse zalpha11 Ligand was evident (about 5-fold) on the untransfected BaF/KZ134 control cells, suggesting that the murine BaF3 cells may have endogenous mouse receptor.

Example 20Mouse zalpha11 Ligand is Active in Mouse Bone Marrow AssayA. Isolation of Non-adherent Low Density Marrow Cells:

Fresh mouse femur aspirate (marrow) was obtained from 6-10 week old male Balb/C or C57BL/6 mice. The marrow was then washed with RPMI+10% FBS (JRH, Lenexa KS; Hyclone, Logan UT) and suspended in RPMI+10% FBS as a whole marrow cell suspension. The whole marrow cell suspension was then subjected to a density gradient (Nycoprep, 1.077, Animal; Gibco BRL) to enrich for low density, mostly mononuclear, cells as follows: The whole marrow cell suspension (About 8 ml) was carefully pipeted on top of about 5 ml Nycoprep gradient solution in a 15 ml conical tube, and then centrifuged at 600X g for 20 minutes. The interface layer, containing the low density mononuclear cells, was then removed, washed with excess RPMI+10% FBS, and pelleted by centrifugation at 400X g for 5-10 minutes. This pellet was resuspended in RPMI +10% FBS and plated in a T-75 flask at approximately 10^6 cells/ml, and incubated at 37°C 5% CO₂ for approximately 2 hours. The resulting cells in suspension were Non-Adherent Low Density (NA LD) Marrow Cells.

B. 96-Well Assay

NA LD Mouse Marrow Cells were plated at 25,000 to 45,000 cells/well in 96 well tissue culture plates in RPMI +10% FBS + 1ng/mL mouse Stem Cell Factor (mSCF) (R&D Systems, Minneapolis, MN), plus 5% conditioned medium from one of the following: (1) BHK 570 cells expressing mouse zalpha11 Ligand (SEQ ID NO:47), (2) BHK 570 cells expressing human zalpha11 Ligand (SEQ ID NO:10), or (3) control BHK 570 cells containing vector and not expressing either Ligand. These cells were then subjected to a variety of cytokine treatments to test for expansion or differentiation of hematopoietic cells from the marrow. To test, the plated NA LD mouse marrow cells were subjected to human Interleukin-15 (hIL-15) (R&D Systems), or one of a panel of other cytokines (R&D Systems). Serial dilution of hIL-15, or the other cytokines, were tested, with 2-fold serial dilution from about 50 ng/ml down to about 6025 ng/ml concentration. After 8 to 12 days the 96-well assays were scored for cell proliferation by Alamar blue assay as described in Example 2.

C. Results from the 96-well NA LD Mouse Marrow assay

Conditioned media from the BHK cells expressing both mouse and human $\alpha 11$ Ligand acted in synergy with hIL-15 to promote the expansion of a population of hematopoietic cells in the NA LD mouse marrow. This expansion of hematopoietic cells was not shown with control BHK conditioned medium plus IL-15. The population hematopoietic cells expanded by the mouse $\alpha 11$ Ligand with hIL-15, and those hematopoietic cells expanded by the human $\alpha 11$ Ligand with hIL-15, were further propagated in cell culture. These hematopoietic cells were stained with a Phycoerythrin labeled anti-Pan NK cell antibody (Pharmingen) and subjected to flow cytometry analysis, which demonstrated that the expanded cells stained positively for this natural killer (NK) cell marker.

The same 96-well assay was run, using fresh human marrow cells bought from Poietic Technologies, Gaithersburg, MD. Again, in conjunction with IL-15, the mouse and human $\alpha 11$ Ligand expanded a hematopoietic cell population that stained positively for the NK cell marker using the antibody disclosed above.

The soluble $\alpha 11$ receptor or soluble $\alpha 11$ heterodimeric polypeptide, such as soluble $\alpha 11$ /IL-2R γ can be used in this assay to measure binding, antagonist or inhibitory effects of the soluble $\alpha 11$ receptor or soluble $\alpha 11$ heterodimeric polypeptide, such as soluble $\alpha 11$ /IL-2R γ on the $\alpha 11$ Ligand.

Example 21

Purification of $\alpha 11$ -MBP Receptor

Unless otherwise stated, all operations were carried out at 4°C. The following procedure was used for purifying human (or mouse) $\alpha 11$ -MBP soluble receptor fusions from *E. coli* (Example 8). Pre-spun frozen *E. coli* paste was thawed and diluted into 2 liters of Buffer B (0.02 M TRIS (EM Science); 0.2 M NaCl (Mallincrodt); 0.01 M 2-mercapto-ethanol (EM Science); pH 8.0; with 5 mg/l Pepstatin A (Boehringer Mannheim); 5 mg/l Aprotinin (Boehringer Mannheim); and 1 mg/l PMSF (Fluka)) plus 1-2 ml of an anti-foaming reagent AF289 antifoam (Sigma). The

mixture was processed in a pre-chilled French Press cell disrupter (Constant Systems LTD) with 20-30 kPSI.

The lysate was then centrifuged at 18,000 x g for 45 minutes at 4°C and the supernatant retained. A 200 ml slurry of Amylose resin (New England BioLabs),
5 pre-equilibrated in Buffer A (0.02 M TRIS (EM Science); 0.2 M NaCl (Mallincrodt); 0.01 M 2-mercapto-ethanol (EM Science); pH 8.0), was added to the lysate supernatant and incubated overnight in 2l roller bottles to allow for maximum batch absorption of the MBP fusion protein. The resin was washed in batch column format for ≥ 5 column volumes with Buffer A, then batch eluted with Buffer C (Buffer A with 0.02 M Maltose
10 (Sigma). Crude fractions were collected and monitored by absorbance 280 nm.

The eluted protein was analyzed by SDS NuPAGE (NOVEX) Coomassie (Sigma) staining. Sample and bulk protein were stored at -80°C.

Example 22

15 Activity of Human and Mouse α 1.1 Ligand Expanded Cells and Mature Murine NK Cells in NK Cell Cytotoxicity Assays

A. NK cell assay

NK cell-mediated target cytolysis was examined by a standard ^{51}Cr -release assay. Target cells (K562 cells (ATCC No. CCL-243) in human assays, and
20 YAC-1 cells (ATCC No. TIB-160) in mouse assays) lack expression of major histocompatibility complex (MHC) molecules, rendering them susceptible to NK cell-mediated lysis. A negative control target cell line in mouse assays is the MHC⁺ thymoma EL4 (ATCC No. TIB-39). We grew K562, EL4, and YAC-1 cells in RP10 medium (standard RPMI 1640 (Gibco/BRL, Grand Island, NY) supplemented with
25 10% FBS (Hyclone, Logan, UT), as well as 4 mM glutamine (Gibco/BRL), 100 I.U./ml penicillin+100 MCG/ml streptomycin (Gibco/BRL), 50 μM β -mercaptoethanol (Gibco/BRL) and 10mM HEPES buffer (Gibco/BRL). On the day of assay, $1-2 \times 10^6$ target cells were harvested and resuspended at $2.5-5 \times 10^6$ cells/ml in RP10 medium. We added 50-100 μl of 5 mCi/ml ^{51}Cr -sodium chromate (NEN, Boston, MA) directly to the
30 cells and incubated them for 1 hour at 37°C, then washed them twice with 12 ml of PBS and resuspended them in 2 ml of RP10 medium. After counting the cells on a

hemacytometer, the target cells were diluted to $0.5-1 \times 10^5$ cells/ml and 100 μ l ($0.5-1 \times 10^4$ cells) were mixed with effector cells as described below.

In human assays, effector cells were prepared from selected and expanded human CD34⁺ BM cells which were harvested, washed, counted, mixed at various concentrations with ⁵¹Cr-labeled target cells in 96-well round bottomed plates, and incubated for 4 hours at 37°C. After co-incubation of effector cells and the labeled target cells, half of the supernatant from each well was collected and counted in a gamma counter for 1 min/sample. The percentage of specific ⁵¹Cr release was calculated from the formula $100 \times (X-Y)/(Z-Y)$, where X is ⁵¹Cr release in the presence of effector cells, Y is the spontaneous release in the absence of effectors, and Z is the total ⁵¹Cr release from target cells incubated with 0.5% Triton X-100. Data were plotted as the % specific lysis versus the effector-to-target ratio in each well.

B. Activity of human zalpha11 Ligand expanded cells

Isolated CD34⁺ human HPCs cultured with flt3 +/- zalpha11 Ligand and flt3 +IL-15 +/- zalpha11 Ligand, were harvested the cells on day 15 to assess their capacity to lyse MHC⁻ K562 cells in a standard ⁵¹Cr-release assay as described above, and to analyze their surface phenotype by flow cytometry. As expected from previous reports (Mrozek, E et al., Blood 87:2632-2640, 1996; and Yu, H et al., Blood 92:3647-3657, 1998), simultaneous addition of IL-15 and flt3L did induce the outgrowth of a small population of CD56⁺ cells. Interestingly, although BM cells cultured simultaneously with zalpha11 Ligand and flt3L did not expand significantly, there was a significant increase in total cell numbers in cultures containing a combination of flt3L, zalpha11 Ligand and IL-15.

For an assessment of the surface phenotype of these human BM cultures, we stained small aliquots of the cells for 3-color flow cytometric analysis with anti-CD3-FITC, anti-CD56-PE and anti-CD16-CyChrome mAbs (all from PharMingen, San Diego, CA) and analyzed them on a FACSCalibur using CellQuest software (Becton Dickinson, Mountain View, CA). This flow cytometric analysis confirmed that the cells growing out of these cultures were differentiated NK cells, as they were large and granular and expressed both CD56 and CD16, and were CD3⁻ (Lanier, LL Annu. Rev.

Immunol. 16:359-393, 1998). Furthermore, these cells exhibited significantly higher effector function than those cells grown with IL-15 and flt3. More specifically, cells grown in all three cytokines lysed more than 40% of the K562 targets at an effector-to-target ratio (E:T) of 1.5, whereas cells grown in IL-15+flt3L lysed fewer than 5% of the targets at an E:T of 2. These data demonstrate that, in combination with IL-15, zalpha11 Ligand (commonly owned US Pat. Application No. 09/522,217) stimulates the differentiation of NK cells from CD34⁺ BM cells.

C. Activity of mouse zalpha11 Ligand expanded cells

To test the effects of mouse zalpha11 Ligand (commonly owned US Pat. Application No. 09/522,217) on murine hematopoietic progenitor cells, purified Lineage-negative (Lin⁻) bone marrow cells from C57Bl/6 mice were expanded in flt3+IL-15+/- zalpha11 Ligand. On day 6 of culture, the cells ("effectors") were harvested and counted, then resuspended in 0.4 ml of RP10 medium (Example 22A). Two aliquots (0.15 ml each) of each sample expanded with or without zalpha11 Ligand (Example 22A) were diluted serially 3-fold in duplicate in 96-well round bottomed plates, for a total of 6 wells of 100 µl each. The remaining 100 µl of cells were stained for NK cell surface markers with FITC-anti-2B4 and PE-anti-DX5 mAbs (PharMingen) and analyzed by flow cytometry. Each group of cells exposed to flt3+IL-15 with or without the presence of mouse zalpha11 Ligand had similar fractions of 2B4+DX5+ cells, ranging from 65-75% positive for both NK markers.

For the NK lysis assay, target cells (YAC-1 and EL4) were labeled with ⁵¹Cr as described above. After counting the target cells on a hemacytometer, the target cells were diluted to 0.5-1x10⁵ cells/ml and 100 µl of YAC-1 or EL4 (0.5-1x10⁴ cells) were mixed with 100 µl effector cells and incubated for 4 hours at 37°C. Specific lysis was determined for each well as described above.

We found that cells grown in the presence of flt3+IL-15+zalpa11 Ligand exhibited enhanced lytic activity (roughly 2-fold) against the YAC-1 targets (but did not kill the MHC⁺ control cell line EL4). At an effector-to-target ratio (E:T) of 5, NK cells generated in the presence of all 3 cytokines (zalpa11 Ligand+flt3+IL-15) lysed 12% of the YAC-1 cells, whereas those NK cells expanded with flt3+IL-15 lysed

6% of the YAC-1 targets. Subsequent experiments confirmed this trend.

In a second approach to determine the biological activity of zalpha11 Ligand on murine NK cells, we isolated immature CD4⁻CD8⁻ ("double negative", DN) mouse thymocytes using routine methods and cultured them with IL-15+flt3+IL-7 or IL-15+flt3+IL-2, with or without zalpha11 Ligand. On day 6 of culture, the cells were harvested and assayed for NK lytic activity on YAC-1 and EL4 cells as described above. We found that cells cultured in the presence of zalpha11 Ligand had the greatest lytic activity in this assay, with enhanced lytic activity over those cells cultured in the presence of the other cytokines. Specifically, DN thymocytes grown with IL-15+flt3+IL-7 killed 18% of the YAC-1 cells at E:T of 24 while cells grown in the presence of IL-15+flt3+IL-7 plus zalpha11 Ligand killed 48% of the targets at the same E:T. DN thymocytes grown in IL-15+flt3+IL-2 killed 15% of the YAC-1 targets at an E:T of 6, whereas cells grown with these 3 cytokines and zalpha11 Ligand killed 35% of the YAC-1 cells at an E:T of 9. Flow cytometry was performed on the cultured cells one day before the NK lysis assay. As was true for the bone marrow cultures, despite the proliferative effect of zalpha11 Ligand (cell numbers increase approximately 2-fold when zalpha11 Ligand is added), it did not significantly enhance the fraction of DX5⁺ cells (17-20% of total cells in the cultures with IL-7, and 35-46% of total in cultures with IL-2). These data imply that zalpha11 Ligand, in combination with IL-15 and flt3, enhances the lytic activity of NK cells generated from murine bone marrow or thymus.

D. Activity of mouse zalpha11 Ligand on Mature murine NK cells

In order to test the effects of mouse zalpha11 Ligand on mature NK cells, we isolated spleens from four 5-week old C57Bl/6 mice (Jackson Laboratories, Bar Harbor, ME) and mashed them with frosted-end glass slides to create a cell suspension. Red blood cells were removed by hypotonic lysis as follows: cells were pelleted and the supernatant removed by aspiration. We disrupted the pellet with gentle vortexing, then added 900 µl of sterile water while shaking, followed quickly (less than 5 sec later) by 100 µl of 10X HBSS (Gibco/BRL). The cells were then resuspended in 10 ml of 1X HBSS and debris was removed by passing the cells over a nylon mesh-lined cell strainer (Falcon). These RBC-depleted spleen cells were then pelleted and

resuspended in MACS buffer (PBS+1%BSA+2mM EDTA) and counted. We stained 300×10^6 of the cells with anti-DX5-coated magnetic beads (Miltenyi Biotec) and positively selected DX5⁺ NK cells over a MACS VS+ separation column, according to the manufacturer's instructions, leading to the recovery of 8.4×10^6 DX5⁺ cells and 5 251×10^6 DX5⁻ cells. Each of these groups of cells were cultured in 24-well plates (0.67×10^6 cells/well, 2 wells per treatment condition) in RP10 medium (Example 22A) alone or with 1) 30 ng/ml mouse zalpha11 Ligand (commonly owned US Pat. Application No. 09/522,217), 2) 30 ng/ml recombinant mouse IL-2 (R&D Systems, Inc., Minneapolis, MN), 3) 30 ng/ml recombinant human IL-15 (R&D), 4) 30 ng/ml 10 each of mouse zalpha11 Ligand and hIL-15, or 5) 30 ng/ml each of mIL-2 and hIL-15. The cells were harvested after 21 hours, washed, and resuspended in RP10 medium and counted. The cells were then assayed for their ability to lyse ⁵¹Cr-labeled YAC-1 or EL4 targets cells, as described in Example 22A.

In general, there was little NK activity from the DX5⁻ (non-NK cells) 15 groups, but the DX5⁻ cells cultured with zalpha11 Ligand and hIL-15 did lyse 25% of the YAC-1 target cells at an E:T of 82. By comparison, DX5⁻ cells cultured with hIL-15 alone lysed 14% of the YAC-1 targets at an E:T of 110. This suggests that zalpha11 Ligand and IL-15 are acting together on the residual NK1.1⁺ NK cells in this cell preparation. As for the DX5⁺ cell preparation, treatment with mouse zalpha11 Ligand 20 alone did not significantly increase their effector function (their lysis of YAC-1 cells was similar to the untreated group). As expected, both IL-2 and IL-15 significantly improved NK activity. The highest level of lysis, however, was detected in the group treated with zalpha11 Ligand and hIL-15 (65% lysis of YAC-1 cells at an E:T of 3.3, vs. 45% lysis at an E:T of 4 for the hIL-15 treatment group). Taken together, these 25 results suggest that although zalpha11 Ligand alone may not increase NK cell lysis activity, it does enhance NK lysis activity of mature NK cells, when administered with IL-15.

The soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ can be used in this assay to measure 30 binding, antagonist or inhibitory effects of the soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R γ on the zalpha11

Ligand.

Example 23

Zalpha11 Ligand Proliferation of Human and Mouse T-cells in a

5

T-cell Proliferation Assay

A. Murine Zalpha11 Ligand Proliferation of Mouse T-cells

T cells from C57Bl/6 mice (Jackson Laboratories, Bar Harbor, ME) were isolated from pooled splenocytes and lymphocytes from axillary, brachial, inguinal, cervical, and mesenteric lymph nodes (LNs). Spleens were mashed with
10 frosted-end glass slides to create a cell suspension. LNs were teased apart with forceps and passed through a cell strainer to remove debris. Pooled splenocytes and LN cells were separated into CD8⁺ and CD4⁺ subsets using two successive MACS magnetic separation columns, according to the manufacturer's instructions (Miltenyi Biotec, Auburn, CA). Whole thymocytes were collected from the same mice.

15

Cells were cultured at 3x10⁵ cells/well (thymocytes) or 10⁵ cells/well (mature T cells) with increasing concentrations of purified murine zalpha11 Ligand (0-30 ng/ml) (commonly owned US Patent Application No. 09/522,217) in 96-well flat bottomed plates pre-coated overnight at 4°C with various concentrations of anti-CD3 mAb 2C11 (PharMingen) for 3 days at 37°C. The anti-CD3 antibody served to activate
20 the murine T-cells through the T-cell receptor. Each well was pulsed with 1μCi ³H-thymidine on day 2 and plates were harvested and counted 16 hours later to assess proliferation.

25

When we tested zalpha11 Ligand in T cell proliferation assays, we found that it co-stimulated anti-CD3-activated murine thymocytes, leading to an accelerated
outgrowth of CD8⁺CD4⁻ cells (the majority of the thymocytes cultured with anti-CD3+zalpha11 Ligand were CD8⁺CD4⁻ by day 3 of culture, while cells cultured with anti-CD3 alone did not significantly skew to this phenotype until day 5). We did not observe significant levels of proliferation of thymocytes to zalpha11 Ligand in the absence of anti-CD3.

30

Interestingly, when we assayed mature peripheral murine T cells for their ability to respond to zalpha11 Ligand+anti-CD3, we found that only the CD8⁺, but not

the CD4⁺ subset, responded in a dose-dependent manner to zalpha11 Ligand. We also observed weak but reproducible proliferation of CD8⁺ cells (but not CD4⁺ cells) in response to zalpha11 Ligand alone. Interestingly, this was not observed for human T cells (see Example 22B, below).

5

B. Human Zalpha11 Ligand Proliferation of Human T-cells

Human CD4⁺ and CD8⁺ T cells were isolated from PBMC as described in Example 14. Cells were cultured at about 10⁵ cells/well with increasing concentrations of purified human zalpha11 Ligand (0-50 ng/ml) (commonly owned US Patent Application No. 09/522,217) in 96-well flat bottomed plates pre-coated overnight at 4°C with various concentrations of anti-human CD3 mAb UCHT1 (PharMingen) for 3 days at 37°C. Each well was pulsed with 1uCi ³H-thymidine on day 2 and plates were harvested and counted 16 hours later. Unlike our results with mouse T cells, our preliminary data suggests that human zalpha11 Ligand co-stimulates CD4⁺, but not CD8⁺, human T cells in a dose-dependent fashion.

10
15

The soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2Rγ can be used in this assay to measure binding, antagonist or inhibitory effects of the soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2Rγ on the zalpha11 Ligand

20

Example 24

Human zalpha11 Receptor Monoclonal Antibodies

Zalpha11 receptor Monoclonal antibodies were prepared by immunizing 5 male BalbC mice (Harlan Sprague Dawley, Indianapolis, IN) with the purified recombinant protein, huzalpha11-CEE-BHK (Example 6). The mice were each given an initial intraperitoneal (IP) injection of 20 mg of purified protein in Complete Freund's Adjuvant (Pierce, Rockford, IL) followed by booster IP injections of 10 mg purified protein in Incomplete Freund's Adjuvant every two weeks. Seven to ten days after the administration of the third booster injection, the animals were bled and the serum was collected.

25
30

The mouse sera samples raised to the huzalpha11-CEE-BHK were characterized by an ELISA titer check using purified recombinant CHO huzalpha11-Fc protein (Example 10C) as an antibody target. One mouse serum sample had titer to the specific antibody target at a dilution of 1:1,000,000 (1:1E6). Four mouse serum samples had titer to the specific antibody target at a dilution of 1:100,000 (1:1E5).

Splenocytes were harvested from the 4 high-titer mice and fused to murine SP2/0 myeloma cells using PEG 1500 (Boehringer Mannheim, UK) in two separate fusion procedures using a 4:1 fusion ratio of splenocytes to myeloma cells (Antibodies: A Laboratory Manual, E. Harlow and D. Lane, Cold Spring Harbor Press). Following 10 days growth post-fusion, specific antibody-producing hybridomas were identified by ELISA using purified recombinant BHK human zalpha11-Fc4 protein (Example 6C) as an antibody target and by FACS using Baf3 cells expressing the huzalpha11 sequence (Example 2) as an antibody target. The resulting 4 hybridomas positive by both methods were cloned three times by limiting dilution. The antibodies were designated: 249.28.2.1.2.2; 247.10.2.15.4.6; 249.19.2.2.3.5; and 249.15.2.4.2.7.

Example 25

Zalpha11 Receptor Purified Recombinant Human Protein

Dose-Response Study in Normal Mice

A. Summary

Normal nine week old female C57Bl/6 (Harlan Sprague Dawley, Indianapolis, IN) mice were treated by intraperitoneal injection once daily for seven days with one of three dose levels of purified recombinant human zalpha11-Fc4 soluble receptor (Example 6C) (5, 50 or 250µg/mouse/day) or PBS vehicle plus 250µg per dose of BSA. Body weights were monitored every other day. On day seven the five mice from the highest dose group and five of the vehicle control group were sacrificed. Blood, bone marrow and tissues were harvested and analyzed. The remaining mice were sacrificed and harvests done the following day. Potential perturbations in lymphoid tissues were examined, as well as general physiologic and toxicologic parameters.

There was no clinical evidence of toxicity. Liver, kidney, spleen, thymus and brain were weighed, and there were no differences between the treatment groups in organ weights. No histologic changes were found in the examined tissues.

B. Dosing solution preparation

5 Purified recombinant human zalpha11 receptor-FC4 fusion protein (zalpha11-FC4) (Example 6C) was diluted into sterile phosphate buffered saline (PBS) (GibcoBRL, Grand Island, NY) at concentrations to deliver 5, 50 or 250 micrograms of protein in 0.1 ml of PBS vehicle. Bovine serum albumin (BSA) (Sigma, St. Louis, MO) was dissolved in PBS to make a 250µg dose per 0.1ml then filtered through an
10 0.2µm syringe-tip filter for the vehicle control treatment. The solutions for daily dosing were made on Day 0, aliquotted and frozen in a frosty -20°C freezer for use. On the day of administration the appropriate aliquots were thawed and 0.1 ml of solution was injected intraperitoneally at approximately mid-morning each day for seven days.

C. Study design

15 The mice were nine weeks old at the start of the study. Each zalpha11-FC4 treatment group consisted of five mice; the control group had 10 mice. The mice in the highest dose and half of the control mice were sacrificed the day after the last of seven treatments (Day 7). The two lower dose and remaining control groups were sacrificed the following day (Day 8).

20 The body weights of the mice were recorded every other day during treatment. There was no difference in weight gain between the treatment groups over the week of treatment.

 At sacrifice, tissues harvested to assess lymphocyte populations by FACS analysis included bone marrow, thymus and spleen. Flow Cytometry analysis of
25 the lymphoid organs and bone marrow was performed with the FACSCalibur, (Becton Dickinson, Mansfield, MA). The tissues harvested for histologic examination for signs of toxicity of the protein included: spleen, thymus, liver, kidney, adrenal gland, mesenteric lymph node, duodenum, pancreas, jejunum, sternum, uterus, ovaries, urinary and gall bladders, salivary gland, heart and lungs. All tissues fixed for histology were
30 kept at 4°C overnight in 10% Normal Buffered Saline (Surgipath, Richmond, IL). The

following day the NBF was replaced with 70% ethanol and the tissues returned to 4°C until processing for histology.

The tissues were processed and stained for H&E analysis in house, then sent to the contract pathologist, David Fairchild. Blood was collected for complete blood cell counts and serum chemistry profiles. The CBC's were done in-house with the Cell Dyn 3500 Hematology Analyzer (Abbott Diagnostics Division, Abbott Park, IL). The serum was kept frozen in a frosty -20°C freezer until submission to Phoenix Central Laboratory (Everett, WA) for complete serum chemistry panels. To compare myeloid:erythroid ratios between the 250µg dose groups of zalpha11R and BSA, an aliquot of the bone marrow from one femur was applied to CytoSpin slides (CYTOSPIN 3 CYTOCENTRIFUGE and CYTO SLIDES, Shandon, Pittsburgh,PA). The bone marrow slides were analyzed at Phoenix Central Laboratories.

D. Study results

There were no apparent clinical indications of physiologic effects or of toxicity of rh-zalpha11R-FC4 fusion protein at doses tested (250µg/day or lower). Body weights remained normal for the duration of the treatments. Red blood cell and platelet counts were normal. There were two mice in the 250µg dose zalpha11-FC4 group whose differential WBC count revealed a possible elevation in the percentage of monocytes, however the other three mice in the group had monocyte percentages equivalent to the average of the control mice. The differential white blood cell monocyte count difference is not considered a significant finding. There were no other differences in complete blood counts. The bone marrow cytology did not reveal a shift in the myeloid and erythroid progenitor populations, and all cell types present appeared normal. All the standard serum chemistry parameters were in normal ranges. There were no differences between the treatment groups in the weights of the thymus, spleen, kidney, liver or brain. Histologic evaluation of the following tissues showed no evidence of abnormalities: thymus, spleen, liver, kidney, adrenal gland, duodenum, pancreas, jejunum, caecum, colon, mesenteric lymph nodes, uterus, ovaries, salivary gland, heart, trachea, lung and brain. The absence of physiologic effects in normal mice indicates that the zalpha11 soluble receptor has low toxicity *in vivo*, which is desirable for a therapeutic agent.

Example 26Zalpa11 Ligand-dependent Proliferation of B-cell Cells StimulatedAnti-CD40 or Anti-IgM5 A. Purification of Human B cells

A vial containing 1×10^8 frozen, apheresed human peripheral blood mononuclear cells (PBMCs) was quickly thawed in a 37°C water bath and resuspended in 25 ml B cell medium (RPMI Medium 1640 (JRH Biosciences, Lenexa, KS), 10% Heat inactivated fetal bovine serum, 5% L-glutamine, 5% Pen/Strep) (Gibco BRL)) in a
10 50 ml tube (Falcon VWR, Seattle, WA). Cells were tested for viability using Trypan Blue (Gibco BRL). Ten milliliters of Ficoll/Hypaque Plus (Pharmacia LKB Biotechnology Inc., Piscataway, NJ) was layered under the cell suspension and spun for 30 minutes at 1800 rpm and allowed to stop with the brake off. The interface was then removed and transferred to a fresh 50 ml Falcon tube, brought up to a final volume of
15 40 ml with PBS and spun for 10 minutes at 1200 rpm with the brake on. The viability of the isolated cells was tested using Trypan Blue. Alternately fresh drawn human blood was diluted 1:1 with PBS (Gibco BRL) and layered over Ficoll/Hypaque Plus (Pharmacia), spun and washed as above. Cells isolated from either fresh or frozen sources gave equivalent results.

20 B cells were purified from the Ficoll floated peripheral blood cells of normal human donors (above) with anti-CD19 magnetic beads (Miltenyi Biotec, Auburn, CA) following the manufacturer's instructions. The purity of the resulting preparations was monitored by flow cytometric analysis with anti-CD22 FITC Ab (Pharmingen, SanDiego, CA). B cell preparations were typically >90% pure.

25

B. Purification of Murine B cells

A suspension of murine splenocytes was prepared by teasing adult C57Bl/6 mouse (Charles River Laboratories, Wilmington, MA) spleens apart with bent needles in B cell medium. RBCs were removed by hypotonic lysis. CD43 positive cells
30 were removed with CD43 magnetic beads (Miltenyi Biotec) following the manufacturer's instructions. The purity of the resulting preparations was monitored by

flow cytometric analysis with anti-CD45R FITC Ab (Pharmingen). B cell preparations were typically >90% pure.

5 C. Proliferation of anti-CD40-stimulated B-Cells in the presence of human or murine zalpha11 Ligand

10 The B cells from either the human or mouse source were resuspended at a final concentration of 1×10^6 cells/ml in B cell medium and plated at 100 μ l/well in a 96 well U bottom plate (Falcon, VWR) containing various stimulation conditions to bring the final volume to 200 μ l/well. For anti-CD40 stimulation human cultures were
15 supplemented with 1 μ g/ml anti-human CD40 (Genzyme, Cambridge, MA) and mouse cultures were supplemented with 1 μ g/ml anti-murine CD40 (Serotec, UK). Human or murine zalpha11 Ligand (commonly owned US Pat. Application No. 09/522,217) was added at dilutions ranging from 1 pg/ml-100 ng/ml as appropriate. The specificity of the effect of zalpha11 Ligand was confirmed by inhibition of zalpha11 Ligand with
20 25mg/ml soluble human zalpha11CEE (Example 6A). All treatments were performed in triplicate. The cells were then incubated at 37°C in a humidified incubator for 120 hours (human) or 72 hours (mouse). Sixteen hours prior to harvesting, 1 μ Ci ^{3} H-thymidine (Amersham, Piscataway, NJ) was added to all wells to assess whether the B-cells had proliferated. The cells were harvested into a 96 well filter plate (UniFilter GF/C, Packard, Meriden, CT) using a cell harvester (Packard) and collected according to manufacturer's instructions. The plates were dried at 55°C for 20-30 minutes and the bottom of the wells were sealed with an opaque plate sealer. To each well was added 0.25 ml of scintillation fluid (Microscint-O, Packard) and the plate was read using a TopCount Microplate Scintillation Counter (Packard).

25 Incubation with Zalpha11 Ligand at concentrations of 3 ng/ml or more enhanced the proliferation induced by soluble anti-CD40 in a dose dependent manner in both murine and human B cells by as much as 30 fold. The murine and human B cells responded equally as well to their respective zalpha11 Ligand. In both species, the stimulation was specific to zalpha11 Ligand, as it was reversed by the presence of
30 soluble zalpha11 receptor in the culture.

D. Proliferation of anti-IgM-stimulated B-Cells in the presence of human or murine zalpha11 Ligand

The B cells from either human or mouse source as described above (parts A and B) were plated as described above (part C). For anti-IgM stimulation of human cells the plates were pre-coated overnight with 10mg/ml F(ab')₂ anti-human IgM Abs (Southern Biotech Associates, Birmingham, Alabama) and washed with sterile media just prior to use. The cultures were supplemented with 0-10 ng/ml hu rIL-4 (R&D Systems, Minneapolis, MN). For anti-IgM stimulation of murine cells soluble anti-IgM (Biosource, Camarillo, CA) was added to the cultures at 10 mg/ml. To each of the preceding anti-IgM/IL-4 conditions, human or murine Zalpha11 ligand was added at dilutions ranging from 1 pg/ml-100 ng/ml as described above. The specificity of the effect of zalpha11 Ligand was confirmed by inhibition with soluble human zalpha11 receptor as described above (Part C). All treatments were performed in triplicate. The cells were incubated, labeled with ³H-thymidine, harvested, and analyzed as described in part C above.

Incubation with Zalpha11 ligand at concentrations of 0.3 ng/ml or more inhibited the proliferation induced by insoluble anti-IgM (mouse) or anti-IgM and IL-4 (human) in a dose-dependent manner. This inhibition was specific to zalpha11 Ligand, as it was reversed by the presence of soluble zalpha11 receptor in the culture.

20

E. Anti-CD40 B Cell proliferation requires IL-2 receptor gamma

Murine B-cells were purified and stimulated with anti-CD40 monoclonal antibody as described in Example 26B and C above. The co-stimulation induced by murine zalpha11 Ligand was completely blocked by the addition of anti-IL-2 receptor gamma (IL-2R γ) monoclonal antibodies that block IL-2 γ utilization. The antibodies 3E12 and TUG/m2 (PharMingen, San Diego, CA) were included in the proliferation assay at 50 μ g/ml. These results demonstrate that the IL-2R γ in B cells is physiologically involved with the zalpha11 Ligand stimulation of B cells. Moreover, these results provide indirect functional support *in vivo* for the finding that the IL-2R γ heterodimerizes with the zalpha11 receptor *in vitro* (Example 27, below).

30

F. The effects of zalpha11 Ligand on B cells are inhibited by soluble zalpha11 receptor constructs

Murine B-cells were purified and stimulated with anti-CD40 monoclonal antibody or anti-IgM antibodies as described in Example 26C and D above. The effect induced by murine zalpha11 Ligand was completely blocked by the addition of either purified hu-zalpha11R: IL-2R γ a heterodimeric soluble receptor (Example 28), or a mu-zalpha11-Fc, a homodimeric soluble receptor (Example 6C). Again, these results provide further functional support for the finding that the IL-2R γ heterodimerizes with the zalpha11 receptor (Example 27, below), and acts as an antagonist to the zalpha11 Ligand's effect on B-cells.

Example 27

Human Zalpha11 Receptor Heterodimerizes With IL-2 Receptor Gamma

A. Assay using conditioned media from transfected BHK-570 cells expressing human zalpha11 Ligand

Soluble human zalpha11 receptor zalpha11CFLAG (Example 6B), or gp130 (Hibi, M. et al., Cell 63:1149-1157, 1990) were biotinylated by reaction with a five-fold molar excess of sulfo-NHS-LC-Biotin (Pierce, Inc., Rockford, IL) according to the manufacturer's protocol. Soluble zalpha11 receptor and soluble IL-2 receptor- γ (sIL-2R γ) (R&D Systems, Minneapolis, MN) were labeled with a five fold molar excess of Ru-BPY-NHS (Igen, Inc., Gaithersburg, MD) according to manufacturer's protocol. The biotinylated and Ru-BPY-NHS-labeled forms of the soluble zalpha11 receptor were respectively designated Bio-zalpha11 receptor and Ru-zalpha11; the biotinylated and Ru-BPY-NHS-labeled forms of the soluble IL-2R γ were respectively designated Bio- IL2R γ and Ru- IL2R γ .

For initial receptor binding characterization of human zalpha11 Ligand, conditioned media from transfected BHK-570 cells expressing human zalpha11 Ligand or control media from untransfected BHK-570 cells was used to determine if zalpha11 Ligand could mediate homodimerization of zalpha11 receptor and if it could mediate the heterodimerization of zalpha11 receptor with IL-2R γ or gp130. To do this, 50 μ l of conditioned media, from control cells or conditioned media from cells expressing

zalpha11 Ligand, was combined with 50 µl of TBS-B (20 mM Tris, 150 mM NaCl, 1 mg/ml BSA, pH 7.2) containing 400 ng/ml of Ru-zalpha11 receptor and Bio-zalpha11, or 400 ng/ml of Ru-zalpha11 receptor and Bio-gp130, or 400 ng/ml of Ru-IL2Rγ and Bio-zAlph11. Following incubation for one hour at room temperature, 30 µg of streptavidin coated, 2.8 mm magnetic beads (Dyna1, Inc., Oslo, Norway) were added and the reaction incubated an additional hour at room temperature. 200 µl ORIGEN assay buffer (Igen, Inc., Gaithersburg, MD) was then added and the extent of receptor association measured using an M8 ORIGEN analyzer (Igen, Inc.).

Conditioned media containing zalpha11 Ligand caused the heterodimerization of Bio-zalpha11 receptor with Ru-IL2Rγ. No receptor dimerization was observed in the presence of control media. Conditioned media containing zalpha11 Ligand did not cause the homodimerization of RU-zalpha11 receptor with Bio-zalpha11 receptor, nor the heterodimerization of Ru-zalpha11 receptor with Bio-gp130.

15 B. Assay using purified human zalpha11 Ligand

To assess the ligand specificity of the heterodimerization of zalpha11 receptor and IL2Rγ, 50 µl of TBS-B containing 400 ng/ml of Ru-zalpha11 receptor and Bio-zAlph11, or 400 ng/ml Ru-IL2Rγ and Bio-zAlph11 was combined 50 µl of TBS-B containing IL-2, IL-4, IL-15 or purified human zalpha11 Ligand (commonly owned US Patent Application No. 09/522,217) at concentrations from 133 pg/ml to 300 ng/ml. Following incubation for one hour a room temperature, 3 µg of streptavidin coated, 2.8 mm magnetic beads (Dyna1, Inc.) were added and the reaction incubated an additional hour at room temperature. 200 µl Origlo assay buffer (Igen, Inc.) was then added and the extent of receptor association measured using an M8 Origen analyzer (Igen, Inc.).

25 The human zalpha11 Ligand caused the heterodimerization of Bio-zalpha11 receptor with Ru-IL-2Rγ in a dose dependent manner with a half maximal concentration of 10 ng/ml. No homodimerization of Ru-zalpha11 receptor with Bio-zalpha11 receptor was observed at any concentration of zalpha11 Ligand tested. No homodimerization of Ru-zalpha11 receptor with Bio-zalpha11 receptor or heterodimerization of Bio-zalpha11 receptor with Ru-IL2Rγ was observed with IL-2, IL-4 or IL-15, at any of the

30 concentrations tested. Thus, the results show that the human zalpha11 receptor

heterodimerizes specifically with the IL-2 receptor- γ in the presence of human $\alpha 11$ Ligand, and that the $\alpha 11$ receptor does not homodimerize or heterodimerize in the presence of other cytokines tested.

5

Example 28

Construct for Generating Human $\alpha 11$ Receptor/ IL-2R γ Heterodimer

A vector expressing a secreted human $\alpha 11$ /hIL2R γ heterodimer was constructed. In this construct, the extracellular domain of $\alpha 11$ was fused to the heavy chain of IgG gamma 1 (IgG $\gamma 1$) (SEQ ID NO:16), while the
10 extracellular portion of hIL-2R γ was fused to a human kappa light chain (human κ light chain) (SEQ ID NO:18).

A. Construction of IgG gamma 1 and human κ light chain fusion vectors

The heavy chain of IgG $\gamma 1$ was cloned into the Zem229R mammalian expression vector (ATCC deposit No. 69447) such that any extracellular portion of a
15 receptor having a 5' EcoRI and 3' NheI site can be cloned in resulting in an N-terminal extracellular domain-C-terminal IgG $\gamma 1$ fusion. The IgG $\gamma 1$ fragment used in this construct was made by using PCR to isolate the IgG $\gamma 1$ sequence from a Clontech hFetal Liver cDNA library as a template. A PCR reaction using oligos ZC11,450 (SEQ ID NO:50) and ZC11,443 (SEQ ID NO:51) was run as follows: 40 cycles of 94°C for 60
20 sec., 53°C for 60 sec., and 72°C for 120 sec.; and 72°C for 7 min.. PCR products were separated by agarose gel electrophoresis and purified using a QiaQuick™ (Qiagen) gel extraction kit. The isolated, 990 bp, DNA fragment was digested with Mlu I and EcoRI (Boehringer-Mannheim), ethanol precipitated and ligated with oligos ZC11,440 (SEQ ID NO:52) and ZC11,441 (SEQ ID NO:53), which comprise an MluI/EcoRI linker, into
25 Zem229R previously digested with and EcoRI using standard molecular biology techniques disclosed herein. This generic cloning vector was called Vector#76 hIgGgamma1 w/ Ch1 #786 Zem229R (Vector #76). The polynucleotide sequence of the extracellular domain of $\alpha 11$ fused to the heavy chain of IgG gamma 1 is shown in SEQ ID NO:15 and the corresponding polypeptide sequence shown in SEQ
30 ID NO:16.

The human κ light chain was cloned in the Zem228R mammalian expression vector (ATCC deposit No. 69446) such that any extracellular portion of a receptor having a 5' EcoRI site and a 3' KpnI site can be cloned in resulting in a N-terminal extracellular domain-C-terminal human κ light chain fusion. The human κ light chain fragment used in this construct was made by using PCR to isolate the human κ light chain sequence from the same Clontech hFetal Liver cDNA library used above. A PCR reaction using oligos ZC11,501 (SEQ ID NO:54) and ZC11,451 (SEQ ID NO:55) was run under conditions described above. PCR products were separated by agarose gel electrophoresis and purified using a QiaQuick™ (Qiagen) gel extraction kit. The isolated, 315 bp, DNA fragment was digested with MluI and EcoRI (Boehringer-Mannheim), ethanol precipitated and ligated with the MluI/EcoRI linker described above, into Zem228R previously digested with and EcoRI using standard molecular biology techniques disclosed herein. This generic cloning vector was called Vector #77 hKlight #774 Zem228R (Vector #77). The polynucleotide sequence of the extracellular portion of hIL-2R γ was fused to a human kappa light chain is shown in SEQ ID NO:17 and the corresponding polypeptide sequence shown in SEQ ID NO:18.

B. Insertion of zalpha11 receptor or IL-2R γ extracellular domains into fusion vector constructs

Using the construction vectors above, a construct having human zalpha11 fused to IgG γ 1 was made. This construction was done by PCRing human zalpha11 receptor from a CD4+ bone marrow library (selected, and made in house) with oligos ZC24,052 (SEQ ID NO:56) and ZC24,053 (SEQ ID NO:57), under conditions described as follows: 30 cycles of 94°C for 60 sec., 57°C for 60 sec., and 72°C for 120 sec.; and 72°C for 7 min.. The resulting PCR product was digested with EcoRI and NheI, gel purified, as described herein, and ligated into a previously EcoRI and NheI digested and band-purified Vector#76 (above). The resulting vector was sequenced to confirm that the human zalpha11/IgG gamma 1 fusion (hzalpha11/Ch1 IgG) was correct. The hzalpha11/Ch1 IgG gamma1 vector was called Vector #190.

A separate construct having IL-2R γ fused to κ light was also constructed. The IL-2R γ /human κ light chain construction was performed as above by

141

PCRing from the same CD4+ library mentioned above with oligos ZC12,834 (SEQ ID NO:58) and ZC12,831 (SEQ ID NO:59), digesting the resulting band with EcoRI and KpnI and then ligating this product into a previously EcoRI and KpnI digested and band-purified Vec#77 (above). The resulting vector was sequenced to confirm that the human IL-2R γ / human κ light chain fusion (hIL-2R γ /Klight) was correct. This hIL-2gamma/Klight #1052 Zem228R vector was called Vector #101.

D. Co-expression of the human α 11 and human IL-2R γ receptors

Approximately 16 μ g of each of Vectors #190 and #101, above, were co-transfected into BHK-570 cells (ATCC No. CRL-10314) using LipofectaminePlusTM reagent (Gibco/BRL), as per manufacturer's instructions. The transfected cells were selected for 10 days in DMEM + 5%FBS (Gibco/BRL) containing 1 μ M of methotrexate (MTX) (Sigma, St. Louis, MO) and 0.5 mg/ml G418 (Gibco/BRL) for 10 days. The resulting pool of transfectants was selected again in 10 μ M of MTX and 0.5 mg/ml G418 for 10 days.

The resulting pool of doubly-selected cells was used to generate protein. Three Factories (Nunc, Denmark) of this pool were used to generate 10 L of serum free conditioned medium. This conditioned media was passed over a 1 ml protein-A column and eluted in (10) 750 microliter fractions. 4 of these fractions found to have the highest concentration were pooled and dialyzed (10 kD MW cutoff) against PBS. Finally the dialyzed material was submitted for amino acid analysis (AAA) and found to have a concentration of 227.17 μ g/ml AAA. A total of 681.5 μ g was obtained from this 10 L purification. The purified soluble human α 11 receptor/IL-2R γ receptor was used to assess its ability to compete with the human α 11 Ligand a BaF3 proliferation assay (Example 29, below).

Example 29

Soluble Human α 11 Receptor/Human IL2 Gamma Receptor-Fc as a α 11

Ligand Antagonist

BaF3 cells stably expressing the human α 11 receptor (Example 2) were plated at 5500 cells per well in standard 96-well tissue culture plates in base

medium plus 3 ng/ml human zalpha11 Ligand. Base medium is 500 ml RPMI 1640 (JRH Biosciences), 5 ml 100x Sodium Pyruvate (Gibco BRL), 5 ml 100x L-glutamine (Gibco BRL), and 50 ml heat-inactivated Fetal Bovine Serum (FBS) (Hyclone Laboratories). To the cells, a decreasing dose of either purified soluble human zalpha11 receptor-Fc homodimer (Example 6C) or purified soluble human zalpha11 receptor/human IL2 gamma receptor-Fc heterodimer (Example 27) were added. An Alamar Blue proliferation assay was run and fluorimetry performed as per Example 2B.

The zalpha11 receptor/ IL2 gamma receptor-Fc heterodimer inhibited human zalpha11 Ligand activity in a dose dependent manner, with 0.312 µg/ml able to completely inhibit the activity of 3 ng/ml human zalpha11 Ligand. The soluble zalpha11 receptor-Fc homodimer also was able to inhibit zalpha11 Ligand activity in a dose dependent manner, however it required about 10 µg/ml of soluble homodimer to completely inhibit the activity of 3 ng/ml zalpha11 Ligand. These data suggested the zalpha11 receptor/ IL2 gamma receptor-Fc heterodimer soluble receptor is approximately 30 to 100 fold more potent than the homodimeric soluble zalpha11 receptor in inhibiting human zalpha11 Ligand.

Example 30

Zalpha11 Receptor Distribution

To assess zalpha11 receptor distribution on various cells types, we generated both rabbit polyclonal and mouse monoclonal antibodies (mAbs) directed against the human receptor (Example 24 and Example 10) and conjugated these antibodies to biotin for use in flow cytometry. We initially used the polyclonal antibodies, which were of relatively low affinity, to stain a panel of cell lines: IL-3 dependent murine pre-B cell line wild-type BaF3 cells (Palacios and Steinmetz, *ibid.*; Mathey-Prevot et al., *ibid.*); BaF3 cells transfected with human zalpha11 (Example 2); human Burkitt's lymphoma cell lines Raji (ATCC No. CCL-86), Ramos (ATCC No. CRL-1596), RPMI 8226 (ATCC No. CCL-155), and Daudi (ATCC No. CCL-213); human T cell leukemia cell line Jurkat (ATCC No. TIB-152); human myelomonocytic leukemia cell lines Thp-1 (ATCC No. TIB-202) and U937 (ATCC No. CRL-1593.2); human pro-myelomonocytic cells HL-60 (ATCC No. CCL-240); murine B cell

lymphoma cell line A20 (ATCC No TIB-208); and murine thymoma cell line EL4 (ATCC No. TIB-39).

The cells were harvested, washed once with FACS wash buffer with serum (WBS). WBS consisted of Hank's balanced salt solution (Gibco/BRL) + 10mM
5 HEPES (Gibco/BRL) + 1% BSA (Sigma) + 10% normal goat serum (Gemini Bioproducts, Woodland, CA) + 10% normal rabbit serum (Sigma); wash buffer (WB) was identical to WBS except that it is serum free. After washing, the cells were resuspended in 100 μ l WB containing 10 μ g/ml rabbit anti-zalpa11 polyclonal antibodies (Example 10). The cells were kept on ice with Ab for 20 min, then washed
10 with WB and resuspended in WB containing goat anti-rabbit-FITC (BioSource, International), incubated another 20 min on ice, then washed and resuspended in 400 μ l WB for analysis on a FACSCalibur flow cytometer (Becton Dickinson). Control samples were stained with the secondary goat anti-rabbit-FITC Ab only. Positive staining was defined as a shift above the staining with secondary alone. Although the
15 polyclonal antibodies were of low affinity, we were reasonably confident that we detected zalpa11 expression on the BaF3/zalpa11 transfectant, on all four human Burkitt's lymphomas (Raji, Ramos, Daudi, and RPMI 8226), and on Jurkat T cells. Our data with the monocytic cell lines were more ambiguous. Resting (undifferentiated) HL-60 cells did not bind the anti-zalpa11 antibodies, but we did
20 detect a positive signal on HL-60 cells activated for 24 hours with PMA (Calbiochem, La Jolla, CA) which induces HL-60 cell differentiation into a monocyte-like cell. We also saw a positive signal on U937 and Thp-1 cells, although this signal may have been due to non-specific binding. The polyclonal antibodies weakly cross-reacted on the mouse B cell line A20, but we saw no staining of the EL4 murine thymoma.

25 The four anti-zalpa11 monoclonal antibodies (Example 24) were conjugated to biotin, and a subset of the cells described above were screened for zalpa11 receptor expression (BaF3, BaF3/zalpa11, Raji, Jurkat, and resting HL-60). Cells were harvested, washed, then resuspended in 100 μ l WB containing 15 μ g/ml of one of each of the 4 biotinylated mAbs. The cells were incubated with mAb for 20 min
30 on ice, then washed with 1.5 ml WB and pelleted in a centrifuge. The supernatant was removed by aspiration and the pellets were resuspended in 100 μ l of CyChrome-

conjugated streptavidin (CyC-SA; PharMingen), then incubated on ice for another 20 min and washed and pelleted as before. Control tubes contained cells stained only with CyC-SA. Pellets were resuspended in 400 μ l WB and flow cytometry performed as above. Positive staining was defined as a signal exceeding the background level of staining with CyC-SA alone. Using the BaF3/zalpa11 transfectant as a control, we were able to rank the 4 mAbs in terms of their respective mean fluorescence intensities (MFI), which can reflect antibody affinity and/or the extent of biotinylation of the mAbs. The mAbs were ranked as follows, from highest to lowest MFI: 249.28.2.1.2.2, 247.10.2.15.4.6, 249.19.2.2.3.5, and 249.15.2.4.2.7. This pattern was essentially the same on both Raji and Jurkat cells, indicating that zalpa11 is expressed on these B and T cell lines. The staining patterns on non-activated HL60 cells were identical for all the mAbs, and the signal was very weak. We speculate that this does not reflect actual expression of zalpa11 by this cell line, but rather is a function of non-specific binding of the mouse mAbs to the human cells, probably via Fc-receptors.

Example 31

Reconstitution of Human zalpa11 Receptor *in vitro*

To identify components involved in the zalpa11-signaling complex, receptor reconstitution studies were performed as follows. BHK 570 cells (ATCC No. CRL-10314) transfected, using standard methods described herein, with the KZ134 luciferase reporter plasmid (Example 19) served as a bioassay cell line to measure signal transduction response from a transfected zalpa11 receptor complex to the luciferase reporter in the presence of zalpa11 Ligand. BHK cells do not endogenously express the zalpa11 receptor. The bioassay cell line was transfected with zalpa11 receptor alone, or co-transfected with zalpa11 receptor along with one of a variety of other known receptor subunits. Each receptor subunit was cloned using PCR followed by ligation into appropriate expression vectors; correct sequence of each construct was confirmed before transfection. Cell lines were tested for receptor expression by RT/PCR prior to assays. Receptor complexes tested included: zalpa11 receptor alone; zalpa11 receptor with IL-2R γ ; zalpa11 receptor with IL-2R γ and IL-2R β ; zalpa11 receptor with IL-2R γ and IL-13R α ; zalpa11 receptor with IL-2R γ and IL-2R α ; and

zalpha11 receptor with IL-2R γ and IL-4R α . Each independent receptor complex cell line was assayed in the presence of human zalpha11 Ligand and luciferase activity measured as described in Example 19. The untransfected bioassay cell line served as a control for the background luciferase activity, and was used as a baseline to compare signaling by the various receptor complex combinations. In each cell line containing both zalpha11 receptor and IL-2R γ , maximal luciferase activity was about two-fold over background in the presence of zalpha11 Ligand. No increase in signal was observed in the presence of any other receptor subunit tested (IL-2R β , IL-2R α , IL-4R α , or IL-13R α).

Other zalpha11 receptor complexes that can be assessed by this method include combinations of zalpha11 receptor with one or more of the IL-4/IL-13 receptor family receptor components (IL-13R α'), as well as other Interleukin receptors (e.g., IL-15 R α , IL-7R α , IL-9R α).

15

Example 32

¹²⁵I-labeled Human zalpha11 Ligand Binding Study in Cell Lines

25 micrograms of purified human zalpha11 Ligand (commonly owned US Patent Application No. 09/522,217) was labeled with 2 mCi ¹²⁵I using iodobeads (Pierce, Rockford Illinois), according to manufacturer's instructions. This labeled protein was used to assess human zalpha11 Ligand binding to human Raji cells (ATCC No. CCL-86), using binding to wild-type murine BaF3 cells, and BaF3 cells transfected with zalpha11 receptor (BaF3/hzalpha11 cells) as controls. Zalpha11 Ligand binding to BaF3/hzalpha11 cells was expected (positive control), while no binding to wild-type BaF3 cells was expected (negative control), based on proliferation assay results (Example 2). About 5X10⁵ Raji cells/well, 1X10⁶ BaF3/hzalpha11 and 1X10⁶ BaF3 cells/well, were each plated in 96-well plates. Ten ng/ml of labeled human zalpha11 Ligand was added in duplicate to wells, with a dilution series of unlabeled human zalpha11 Ligand competitor added from 250 fold molar excess in 1:4 dilutions down to .061 fold molar excess. Each point was run in duplicate. After the labeled human zalpha11 Ligand was added to wells, it was allowed to incubate at 4°C for 2 h to allow for binding of Ligand to the cells. The cells were then washed 3X in binding

buffer (RPMI-1710 (JRH Biosciences) with 1% BSA (Sigma)), and counted on the COBRA II AUTO-GAMMA gamma counter (Packard Instrument Company, Meriden, CT).

5 Binding of the labeled zalpha11 Ligand to cells was evident in the Raji and the BaF3/hzalpha11 cells. In addition, for Raji cells, an average 250 fold molar excess of unlabeled zalpha11 Ligand decreased binding 3 fold in the presence of a non-specific unlabeled competitor (Interferon Gamma from R&D Systems, Minneapolis, MN), and 3.7 fold relative to no competitor. Competition was observed in a dose dependent fashion for the specific unlabeled competitor, human zalpha11 Ligand.
10 Thus, the zalpha11 Ligand binding to Raji cells was specific. Similarly, for positive control BaF3/zalpa11 cells, the 250 fold molar excess of unlabeled zalpha11 Ligand decreased binding 2 fold relative to the non-specific competitor and 3.06 fold relative to no competitor. Thus, the zalpha11 Ligand binding to BaF3/zalpa11 cells also was specific. No competable binding was observed with the wild-type BaF3 cells. Thus,
15 the zalpha11 Ligand was shown to bind specifically to Raji cells, and to Baf3/hzalpa11 cells, but not to the negative control Baf3 cells.

The bound radiolabeled zalpha11 Ligand is then cross-linked to the molecule to which it binds on the cell surface of Raji cells using standard cross-linking methods, to identify the receptor complex to which it binds on these cells. Moreover,
20 anti-zalpa11 receptor antibodies (Example 24 and Example 10), and other anti-cytokine receptor subunit antibodies are employed to assess which subunit components comprise a functional hzalpa11 receptor complex, for example, on the Raji cells and other cell lines to which zalpa11 Ligand binds. Such antibodies can be used to compete for zalpa11 Ligand in a binding assay as described above, and hence show
25 which receptor subunits are present of the Raji cell surface, and on other cell lines to which zalpa11 Ligand binds. Moreover, such antibodies can be used to immunoprecipitate radiolabeled zalpa11 Ligand cross-linked material using methods known in the art and described herein. In addition anti-zalpa11 Ligand antibodies (commonly owned US Patent Application No. 09/522,217) can be used to
30 immunoprecipitate radiolabeled zalpa11 Ligand cross-linked material.

Example 33Zalpa11 Receptor Expression On Human Blood CellsA. Preparation and Culture of Human Peripheral Blood Cells

5 Fresh drawn human blood was diluted 1:1 with PBS (GIBCO BRL) and layered over Ficoll/Hypaque Plus (Pharmacia LKB Biotechnology Inc., Piscataway, NJ) and spun for 30 minutes at 1800 rpm and allowed to stop with the brake off. The interface layer was removed and transferred to a fresh 50 ml Falcon tube (Falcon, VWR, Seattle, WA), brought up to a final volume of 40 ml with PBS and spun for 10 minutes at 1200 rpm with the brake on. The viability of the isolated cells was tested
10 using Trypan Blue (GIBCO BRL) and the cells were resuspended at a final concentration of 1×10^6 cells/ml cell medium (RPMI Medium 1640, 10% Heat inactivated fetal bovine serum, 5% L-glutamine, 5% Pen/Strep) (GIBCO BRL).

Cells were cultured in 6 well plates (Falcon, VWR) for 0, 4 or 24 hours with a variety of different stimuli described below. Anti-IgM, anti-CD40 and anti-CD3
15 stimulation were done as in Example 26. Phorbol myristate acetate (PMA) and ionomycin (Sigma, St. Louis, MO) were added to appropriate wells at 10 ng/ml and 0.5 mg/ml respectively. The cells were incubated at 37°C in a humidified incubator for various times.

20 B. Antibody Staining and Analysis

Cells were collected out of the plates, washed and resuspended in ice cold staining media (HBSS, 1% fetal bovine serum, 0.1% sodium azide) at a concentration of about ten million cells per milliliter. Blocking of Fc receptor and non-specific binding of antibodies to the cells was achieved by adding 10% normal goat
25 serum (Gemini Bioproducts, Woodland, CA) and 10% normal human serum (Ultraserum, Gemini) to the cell suspension. Aliquots of the cell suspensions were mixed with a FITC labeled monoclonal antibody against one of the lineage markers CD3, CD19 or CD14 (PharMingen, La Jolla, CA) and a biotinylated monoclonal antibody against the human zalpa11 receptor (hu-zalpa11) (Example 24). After
30 incubation on ice for 60 minutes the cells were washed twice with ice cold staining media and resuspended in 50 ml staining media containing streptavidin-PE (Caltag,

Burlingame, CA). After a 30 minute incubation on ice, the cells were washed twice with ice cold wash buffer (PBS, 1% fetal bovine serum, 0.1% sodium azide) and resuspended in wash buffer containing 1mg/ml 7-AAD (Molecular Probes, Eugene, OR) as a viability marker. Flow data was acquired on living cells using a FACSCalibur flow cytometer (BD Immunocytometry Systems, San Jose, CA). Both acquisition and analysis were performed using CellQuest software (BD Immunocytometry Systems).

Results showed that the human $\alpha 11$ receptor is expressed on human peripheral blood cells expressing either CD3, CD19 or CD14. Activation of either T cells with anti-CD3 or B cells with anti-CD40 resulted in an increased level of cell surface $\alpha 11$ at 24 hours. No increase in the level of expression of $\alpha 11$ was seen at 4 hours with any stimulus on either cell population. Treatment of the cells with $\alpha 11$ ligand resulted in a decrease of $\alpha 11$ staining on CD3 positive and CD19 positive cells but not CD14 positive cells at both 4 and 24 hours.

15

Example 34

Human $\alpha 11$ Ligand Activity is Blocked With Anti- IL-2R γ Antibodies in a BaF3/ $\alpha 11$ Proliferation Assay

The role of the IL-2 γ receptor was investigated using anti- IL-2 γ receptor monoclonal antibodies to assess whether they would block $\alpha 11$ Ligand activity in a BaF3/ $\alpha 11$ proliferation assay (Example 2). Conditioned-media from BHK570 cells transfected with the human $\alpha 11$ Ligand was added to the assay at 5%, 2.5%, 1.25% and 0.625% concentrations, with or without IL-2 receptor antibodies.

The following mouse anti-IL-2 receptor monoclonal antibodies from PharMingen International, San Diego, California were added at 50 μ g/ml each: (a) 4G3 + TUGm2 or (b) TM- $\beta 1$. 4G3 and TUGm2 are purified rat anti-mouse γ_c chain antibodies, TM- $\beta 1$ is a purified rat anti-mouse CD122 (IL-2 receptor β chain) antibody. Assay results demonstrated almost complete inhibition of the $\alpha 11$ Ligand response with the 4G3 + TUGm2 antibody combination in comparison to the no-antibody control. The TM- $\beta 1$ antibody had no effect. These results suggest a role for the IL-2 γ receptor in the $\alpha 11$ Ligand proliferative response, and further supports that the IL-2R γ heterodimerizes with the $\alpha 11$ receptor to elicit that response.

Example 35Post-translational Mannosylation of zalpha11 Receptor Polypeptide on a
Highly Conserved Trp Residue

5 Mannosylation of the human zalpha11 receptor was assessed using the method for C-2 mannosylation of Tryptophan as described in Hofsteenge, J et al., Biochemistry 33:13524-13530, 1994, and Loeffler, A et al., Biochemistry 35:12005-14, 1996. Moreover, these investigators showed that in a motif of amino acids, WXXW (SEQ ID NO:67), that Trp can be mannosylated.

10 A soluble zalpha11 receptor bearing a C-terminal Glu-Glu (CEE) (SEQ ID NO:14) or FLAG (SEQ ID NO:23) tag was expressed in BHK cells and purified by anti-Flag or anti-EE affinity chromatography (Example 4A). A soluble zalpha11 receptor C-terminally tagged with an Fc4 tag (SEQ ID NO:25) and expressed in CHO cells was affinity purified by anti-Fc4 affinity chromatography (Example 4B). These
15 polypeptides were enzymatically cleaved to generate peptide fragments for the study.

All enzymatic digestions were performed overnight at a protein concentration of 1.0 mg/ml. PNGaseF (Oxford GlycoSciences, Abingdon, Oxford UK) digestion was performed by diluting each soluble zalpha11 receptor polypeptide into a 50 mM EDTA, 20 mM Na-Phosphate pH 7.5 buffer and incubating it with 0.4 U of
20 enzyme per µg of protein. Glu-C (Roche Molecular Biochemicals, Indianapolis, Indiana) digestion was performed at a 1:50 ratio of enzyme to protein by buffer exchanging the sample into 25 mM NH₄HCO₃ pH 7.8 and incubating it at 25°C, except for the Fc4 tagged material, which was digested in 50 mM Na-Phosphate pH 7.8 + 5% Acetonitrile (EM Science, Darmstadt, Germany) at 37°C. The Glu-C digestion
25 generated a zalpha11 WSXWS-containing peptide as shown from amino acid 178 (Leu) to amino acid 199 (Ser) of SEQ ID NO:6 (197 (Leu) to amino acid 218 (Ser) of SEQ ID NO:2). Asp-N (Roche Molecular Biochemicals, Indianapolis, Indiana) digestion was performed by buffer exchanging the protein into 50 mM Na-Phosphate pH 7.7 and incubating it at 37°C with enzyme at a 1:50 ratio to zalpha11 receptor polypeptide. The
30 Asp-N digestion generated a zalpha11 WSXWS-containing peptide as shown from

amino acid 179 (Glu) to amino acid 210 (Ser) of SEQ ID NO:6 (198 (Leu) to amino acid 229 (Glu) of SEQ ID NO:2).

LCMS and LCMS-MS analyses were performed on a Magic HPLC (Michrom Bioresources, Auburn, CA) connected in-line to a Finnigan LCQ mass spectrometer (Finnigan MAT, San Jose, CA). LC separation was done on a Vydac C4 5 μ 300Å column (Michrom Bioresources) with an elution gradient of 20% - 80% solvent B over 80 minutes where solvent A was 2% Acetonitrile + 0.1 % TFA and solvent B was 90% Acetonitrile + 0.095% TFA (EM Science; Sigma, St. Louis, MO). The LCQ mass spectrometer was set to collect MS spectra for the duration of the run. LCMS-MS analysis of polypeptide digests was performed on the same instrument system using a Vydac C18 5 μ 300Å column (Michrom Bioresources) with an elution gradient of 5-65% solvent B over 80 minutes with the same solvent system described for LCMS analysis above. The LCQ mass spectrometer was configured to collect MS, zoom-scan and MS-MS spectra for each ion over a minimum threshold.

The extent of tryptophan mannosylation was estimated by comparing ion intensities for the 2+ and 3+ ions of the peptides containing the WSXWS motif (SEQ ID NO:13) from both Glu-C and Asp-N digestion described above. Peak composition was first determined utilizing the MS data and a peptide map was generated. Next, an average spectrum was created starting approximately 1 minute before the early eluting mannosylated WSXWS (SEQ ID NO:13) containing peptide and ending approximately 1 minute after its later eluting non-mannosylated companion peptide. The normalized intensities of the ions corresponding to mannosylated and non-mannosylated peptide were compared and used to generate a percentage occupancy number. Values generated for both 2+ and 3+ charge states were averaged to generate a percent occupancy value for each digest. This value was then averaged with the value from the companion digest for each lot of protein to generate a final value.

Table 7 below summarizes the data that were calculated for each Peptide-tag and host cell used for zalpha11 soluble receptor expression.

Table 7

C-terminal-Tag	Expression Host	% WSXWS Mannosylated
Glu-Glu	BHK	~46%
FLAG	BHK	~35%
Fc4	CHO	~11%

One of skill in the art would appreciate that mannosylation or non-mannosylation of the $\alpha 11$ receptor WSXWS motif (SEQ ID NO:13) can affect the ability of the $\alpha 11$ receptor or $\alpha 11$ soluble receptor to homodimerize, heterodimerize, and/or its ability to bind the $\alpha 11$ Ligand. As the mannosylation on $\alpha 11$ receptor appears to differ depending on the cell type in which the receptor is expressed, optimization of the expression and production of $\alpha 11$ receptor and soluble receptor polypeptides may take into consideration whether the $\alpha 11$ receptor produced by the cell is mannosylated or non-mannosylated. As such, one of skill in the art would appreciate that the polypeptides of the present invention can be either mannosylated or non-mannosylated.

As the mannosylation event is within the WSXWS motif (SEQ ID NO:13) of the $\alpha 11$ class I cytokine receptor, the mannosylation of the Trp or the lack thereof can affect the polypeptide functionally. For example, insertions or deletions in the WSXWS motif (SEQ ID NO:13) of the EPOR can abrogate cell surface expression, destroy or reduce proliferative response, decrease receptor internalization, and affect EPO binding (Yoshimura, A et al., *J. Biol. Chem.* 267:11619-11625, 1992; Quelle, DE et al., *Mol. Cell. Biol.* 12:4553-4561, 1992; Hilton, DJ et al., *Proc. Natl. Acad. Sci. USA* 92:190-194, 1995). However, mutation in the WSXWS motif (SEQ ID NO:13) can also result in more efficient export from the ER and greater expression of the receptor on the cell surface (Hilton, DJ et al., *supra.*). Effects on cell surface expression, ligand binding and stimulatory response have also been seen with studies on WSXWS motif (SEQ ID NO:13) and related motifs in mutational analysis on IL-2R β , GM-CSFR, and GHR (Miyazaki, et al., *EMBO J.* 10:3191-3197, 1991; Ronco, L.V. et al., *J. Biol. Chem.* 269:277-283, 1994; Baumgartner, JW et al., *J. Biol. Chem.* 269:29094-29101, 1994).

Similarly, mannosylation of the first Trp residue in the WSXWS motif (SEQ ID NO:13) of zalpha11 receptor polypeptides, including full-length and soluble receptors described herein, can have important structural and functional implications such as having affects on the overall stability of the receptor, rate of proteolysis, intracellular processing, antigenicity, cell surface expression, dimerization or multimerization, co-receptor binding, signaling or internalization, affects on zalpha11 Ligand binding and stability of receptor-ligand interaction. Comparison of mannosylated and non-mannosylated zalpha11 receptors can be made using X-ray crystallography or NMR on purified zalpha11 polypeptides (e.g., soluble receptors), or functional studies comparing zalpha11 expressed in cell lines that either mannosylated (e.g., BHK or other cell line) or are defective or reduced in mannosylation (e.g., CHO or other cell line) and comparing the receptors in the various assays described herein.

Example 36
BHK Transfectant Binding Studies

Purified human zalpha11 Ligand (25µg) protein (commonly owned US Patent Application No. 09/522,217) was iodinated with ^{125}I (Amersham) using iodo-beads (Pierce) and purified on a Sephadex G25 PD-10 column (Pharmacia). BHK transfectants (Example 31) expressing either human zalpha11 alone or human zalpha11 + human IL-2R γ receptor were plated at 30K/well in a 24-well dish 24 hours prior to the binding study. BHK transfectants were incubated for 2 hours at 4°C with 2.5 ng (0.147 pMoles) ^{125}I zalpha11 Ligand (specific activity 6.4×10^7 cpm/ug) in the presence of various concentrations of cold zalpha11 Ligand (in a range from about a 10,884 fold excess to no competition in 15, 4-fold dilutions). Cells were washed three times with binding buffer before lysis in 0.8M NaOH, followed by gamma emission counting. Analysis of these data yielded an affinity of approximately 1 nM for the zalpha11 transfectants and approximately 0.1nM for the human zalpha11 + human IL-2R γ receptor transfectants. This result suggested that zalpha11 Ligand has high affinity on both the homodimeric human zalpha11 or heterodimeric human zalpha11 + human IL-2R γ receptor, and that the affinity is higher for the heterodimer.

Example 37Murine Homodimeric zalpha11Receptor-mG2a Fusion Protein

The expression vector pEZE2 was used to express the murine
5 zalpha11receptor-murine IgGamma2a Fc fusion protein (zalpha11m-mG2a). The
mouse zalpha11 extracellular domain murine immunoglobulin gamma 2a heavy chain
Fc region fusion protein (zalpha11m-mG2a) DNA sequence is shown in SEQ ID
NO:72, and the corresponding polypeptide sequence is shown in SEQ ID NO:73.

The pEZE2 vector is a plasmid derived from pDC312 (Immunex Corp.,
10 Seattle, WA), and contains an EASE segment as described in WIPO Publication WO
97/25420. The presence of the EASE segment in an expression vector can improve
expression of recombinant proteins about two to eight fold in stable cell pools. The
pEZE2 plasmid is a dicistronic expression vector that can be used to express two
different proteins in mammalian cells, such as Chinese Hamster Ovary (CHO) cells.
15 The pEZE2 expression unit contains a CMV enhancer/promoter; an adenovirus
tripartite leader sequence; a multiple cloning site (MCS) for insertion of the coding
region for the recombinant protein of interest; an encephalomyocarditis virus internal
ribosome entry site; a coding segment for mouse dihydrofolate reductase; and the SV40
transcription terminator. In addition, pEZE2 contains an *E. coli* origin of replication
20 and the bacterial beta lactamase gene.

The zalpha11m-mG2a fusion protein is a disulfide-linked homodimer
consisting of two chains of the mouse zalpha11 extracellular domain fused to a wild
type murine immunoglobulin gamma 2a Fc region. The murine immunoglobulin
gamma 2a Fc confers effector functions, FcγRI binding and C1q complement fixation.
25 The mouse zalpha11 extracellular domain murine immunoglobulin gamma 2a Fc
constant region fusion construct was generated by overlap PCR of three separate DNA
fragments, each generated by separate PCR amplification reactions. The first fragment
contained an optimized tPA (tissue plasminogen activator) signal sequence (SEQ ID
NO:80). The optimized tPA (otPA) signal sequence was amplified using
30 oligonucleotide primers ZC26,644 (SEQ ID NO:74) and ZC26,641 (SEQ ID NO:75)
using an in-house previously generated expression vector as the template. PCR reaction

mix contained 20 pmoles of each primer, 10 ng template cDNA, 20 μ M each dNTP, 1 X Taq buffer (Life Technologies, Gaithersburg, MD), 0.5 μ l Taq polymerase in a 100 μ l reaction. PCR conditions: 1 cycle, 94°C, 2 minutes, 25 cycles, 94°C, 30 seconds, 60°C, 30 seconds, 72°C, 30 seconds, 1 cycle, 72°C, 5 minutes. The second fragment
5 contained the mouse zalpha11 extracellular domain coding region of amino acids 20 to 257 of SEQ ID NO:12. Oligonucleotide primers ZC26,642 (SEQ ID NO:76) and ZC26,662 (SEQ ID NO:77) were used to amplify this mouse zalpha11 segment using a previously generated clone of mouse zalpha11 (SEQ ID NO:11) as the template. This PCR fragment was made using the same PCR reaction mix specified above. PCR
10 reaction conditions were as follows: 1 cycle, 94°C, 2 minutes, 25 cycles, 94°C, 30 seconds, 50°C, 30 seconds, 72°C, 45 seconds, 1 cycle, 72°C, 5 minutes.

The murine gamma 2a heavy chain Fc region was generated from a previously generated clone of murine Ig gamma 2a heavy chain cDNA. The segment containing the hinge, C_H2, and C_H3 domains of the murine immunoglobulin gamma 2a
15 heavy chain constant region was generated by PCR amplification using oligonucleotide primers ZC26,643 (SEQ ID NO:78) and ZC26,645 (SEQ ID NO:79). This PCR fragment was made using the same reaction mix specified above. PCR conditions were as follows: 1 cycle, 94°C, 2 minutes, 25 cycles, 94°C, 30 seconds, 60°C, 30 seconds, 72°C, 30 seconds, 1 cycle, 72°C, 5 minutes.

20 To prepare the fusion protein-coding segment, three protein coding domains were linked by overlap PCR using oligonucleotides ZC26,644 (SEQ ID NO:74) and ZC26,662 (SEQ ID NO:77) to link the first two PCR products and ZC26,644 (SEQ ID NO:74) and ZC26,645 (SEQ ID NO:79) to link in the Fc region. Two reactions were set up: The first ran 25 cycles of 94°C for 2 min., 55°C for 30 sec.
25 and 72°C for 1 min. 30 sec.. The other reaction ran 25 cycles of 94 degrees C for 2 min., 60°C for 30 sec and 72°C for 1 min. and 30 sec.. The PCR products in the two reactions were pooled and purified by using the QIAquick PCR purification kit (Qiagen) as per manufacturer's protocol. The product was eluted in 60 μ l of buffer. 30 μ l of this eluate was digested with Fse1 and Asc1 restriction enzymes in diluted NEB
30 10x buffer No. 4 (New England Biolabs, Beverly, MA) as per manufacturer's directions. The material was then run on a 1% TAE agarose gel and the approximately

1500 bp band was excised and the DNA purified using a Qiagen Agarose gel extraction kit (Qiagen) as per manufacturers instructions. The fragment was eluted in 30 µl H₂O.

To prepare the recipient vector for the insert, about 3 µg of pEZE2 vector was digested w/ AscI and FseI in the same manner as above, with the exception of 1 µl of Calf Intestinal Phosphatase (CIP) (New England Biolabs) added after restriction enzyme digest (the reaction was allowed to proceed an additional 2hrs). The vector was then run on an agarose gel and purified as per above. The material was eluted in 30 µl of H₂O.

The fusion protein-coding segment was cloned into the MCS of pEZE2 from the FseI site to the AscI site in the polylinker, and ligated in 20 µl using standard molecular biological reagents and procedures. The ligation reaction was incubated O/N at 16 °C. About 4µl of this ligation mix was electroporated into 50 µl of DH12s *E. coli* electrocompetent cells (Life Technologies, Rockville, MD) and the cells rescued in 1 ml of LB media and allowed to shake/incubate for 1hr. and 100 µl spread on Amp 100 agar plates. The plates were allowed to incubate o/n at 37°C. A single colony was sequence analyzed. A mutation was found that would result in a change from Glu to Lys at position 25 in SEQ ID NO:73. This amino acid substitution is within the otPA leader, and may have resulted in improper processing of the signal peptide, as N-terminal showed that the leader sequence was incompletely cleaved and started at a pyroglutamine residue upstream of the predicted start. However, this homodimeric construct was still active in inhibiting the zalpha11 Ligand (Example 40).

A large prep was created using the Qiagen Maxi prep kit (Qiagen) as per manufacturers instructions. The plasmid was used to transfect CHO cells. The cells were selected in medium without hypoxanthine or thymidine and the transgene was amplified using methotrexate (Example 38). The presence of protein was assayed by Western blotting using anti human gamma 1heavy chain constant region and anti human kappa light chain antibodies (Rockland Immunochemicals, Gilbertsville PA).

Example 38Production of zAlpha11m-mG2A in DG-44 CHO Cells

20 μ g of a zAlpha11m-mG2A/pEZE2 construct (Example 37) was digested with 40 units of Pvu I at 37°C for three hours and was then precipitated with isopropanol and pelleted in a 1.5 mL microfuge tube. The supernatant was aspirated away from the pellet and the pellet was resuspended in 100 μ l of water. About 200 μ g (20 μ l) of sheared salmon sperm DNA was added to the digested zAlpha11m-mG2A/pEZE2 construct. The DNA mixture was co-precipitated using 0.1 volumes of sodium acetate (pH 5.2) and 2.2 volumes of ethanol. The tube was placed on dry ice for 15 minutes then was spun down in a microfuge at 14,000 RPM for 15 minutes forming a DNA pellet. The supernatant was aspirated off the pellet, and the pellet was washed with 1 mL of 70% ethanol and allowed to incubate for 5 minutes at room temperature. The tube was spun in a microfuge for 10 minutes at 14,000 RPM and the supernatant was aspirated off the pellet. The pellet was allowed to air dry for 30 minutes. The pellet was then resuspended in 100 μ l of water and allowed to incubate at room temperature for 10 minutes. 500 μ l containing about 5×10^6 DG-44 CHO cells was added to the DNA in the microfuge tube, then the DNA/cell mixture was placed in a 0.4 cm gap cuvette and electroporated using the following parameters: 1,070 μ F, high capacitance and 376 V. The contents of the cuvette were then removed and diluted to 25 mLs with EX-CELL™ 325 PF-CHO Protein Free Media (JRH Biosciences, Lenexa, KS) with 3 mM L-Glutamine and placed in a 125 mL shake flask. The flask was placed in an incubator on a shaker at 37°C, 6% CO₂ and shaking at 120 RPM.

The DG-44 CHO zAlpha11m-mG2A culture was amplified with methotrexate (MTX) using standard methods to a final MTX level of 50 nM MTX. The culture was dilution-cloned and screened using a series of western blots. A final clone was chosen and further selected in MTX to a level of 200 nM MTX and was then scaled up for production. Production of each lot of the clone was accomplished by seeding 8X 4L spinner flasks with 2 L of culture at approximately 5×10^5 cells/mL. Cultures were spun at 70 RPM, maintained at 37°C, 6% CO₂ and allowed to incubate for either 72 or 96 hours. The cells were spun down and the supernatants were 0.2 μ m

filtered. A sufficient number of cells were recovered to seed the next series of flasks. Four total lots were produced in this manner for protein purification (Example 39).

Example 39

5 Purification of the homodimeric zalpha11m-mG2a soluble receptor protein

All procedures performed at 4°C, unless otherwise noted. Conditioned media (Example 38) was directly captured on an appropriately sized POROS 50 A (coupled protein A; PerSeptive BioSystems, Framingham, MA) column at an optimal capture flow rate. The column was washed with 20 column volumes (CV) of loading
10 buffer, then rapidly eluted with 3 CV of 0.1 M Glycine pH 2.5. The collected fractions had a predetermined volume of 2M TRIS pH 8.0 added prior to the elution to neutralize the pH to about 7.2.

Brilliant Blue (Sigma) stained NuPAGE gels were ran to analyze the elution. Fractions of interested were pooled and concentrated against a 30 kD MWCO
15 centrifugal concentrator to a nominal volume. The concentrated Protein A pool was injected onto an appropriately sized Pharmacia Sephacryl 200 column (Pharmacia) to remove aggregates and to buffer exchange the protein into PBS pH 7.2.

Brilliant Blue (Sigma) stained NuPAGE gels (NOVEX) were again used to analyze the elution. Fractions were pooled and concentrated as before to ~1-2
20 mgs/ml. Western and Brilliant Blue (Sigma) stained NuPAGE gels (NOVEX) were ran to confirm purity and content. In addition, the protein was submitted for amino acid analysis (AAA), and N-terminal sequencing for further analysis.

Example 40

25 Soluble homodimeric zalpha11m-mg2a fusion protein as a zalpha11 Ligand Antagonist

BaF3 cells stably expressing the mouse zalpha11 receptor (constructed as per Example 2 using primers to SEQ ID NO:11) were plated at 5500 cells per well in standard 96-well tissue culture plates in base medium plus 3 ng/ml human zalpha11
30 Ligand. Base medium is 500 ml RPMI 1640 (JRH Biosciences), 5 ml 100x Sodium Pyruvate (Gibco BRL), 5 ml 100x L-glutamine (Gibco BRL), and 50 ml heat-inactivated Fetal Bovine Serum (FBS) (Hyclone Laboratories). To the cells, a

decreasing dose of either purified homodimeric zalpha11m-mg2a (Example 39) was added. An Alamar Blue proliferation assay was run and fluorimetry performed as per Example 2B.

5 The homodimeric zalpha11m-mG2a fusion protein inhibited human zalpha11 Ligand activity in a dose dependent manner, with 1-5 $\mu\text{g/ml}$ able to inhibit the activity of 1.25 ng/ml human zalpha11 Ligand.

10 From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

158a

SEQUENCE LISTING

<110> ZymoGenetics, Inc.

<120> SOLUBLE ZALPHA11 CYTOKINE RECEPTORS

<130> 14577-66CA FC/gc

<150> PCT/US01/10872

<151> 2001-04-03

<150> US 60/194,731

<151> 2000-04-05

<150> US 60/222,121

<151> 2000-07-28

<160> 86

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 1614

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)...(1614)

<400> 1

atg ccg cgt ggc tgg gcc gcc ccc ttg ctc ctg ctg ctg ctc cag gga	48
Met Pro Arg Gly Trp Ala Ala Pro Leu Leu Leu Leu Leu Leu Gln Gly	
1 5 10 15	
ggc tgg ggc tgc ccc gac ctc gtc tgc tac acc gat tac ctc cag acg	96
Gly Trp Gly Cys Pro Asp Leu Val Cys Tyr Thr Asp Tyr Leu Gln Thr	
20 25 30	
gtc atc tgc atc ctg gaa atg tgg aac ctc cac ccc agc acg ctc acc	144
Val Ile Cys Ile Leu Glu Met Trp Asn Leu His Pro Ser Thr Leu Thr	
35 40 45	
ctt acc tgg caa gac cag tat gaa gag ctg aag gac gag gcc acc tcc	192
Leu Thr Trp Gln Asp Gln Tyr Glu Glu Leu Lys Asp Glu Ala Thr Ser	
50 55 60	
tgc agc ctc cac agg tcg gcc cac aat gcc acg cat gcc acc tac acc	240
Cys Ser Leu His Arg Ser Ala His Asn Ala Thr His Ala Thr Tyr Thr	
65 70 75 80	
tgc cac atg gat gta ttc cac ttc atg gcc gac gac att ttc agt gtc	288
Cys His Met Asp Val Phe His Phe Met Ala Asp Asp Ile Phe Ser Val	
85 90 95	

158b

aac atc aca gac cag tct ggc aac tac tcc cag gag tgt ggc agc ttt Asn Ile Thr Asp Gln Ser Gly Asn Tyr Ser Gln Glu Cys Gly Ser Phe 100 105 110	336
ctc ctg gct gag agc atc aag ccg gct ccc cct ttc aac gtg act gtg Leu Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Phe Asn Val Thr Val 115 120 125	384
acc ttc tca gga cag tat aat atc tcc tgg cgc tca gat tac gaa gac Thr Phe Ser Gly Gln Tyr Asn Ile Ser Trp Arg Ser Asp Tyr Glu Asp 130 135 140	432
cct gcc ttc tac atg ctg aag ggc aag ctt cag tat gag ctg cag tac Pro Ala Phe Tyr Met Leu Lys Gly Lys Leu Gln Tyr Glu Leu Gln Tyr 145 150 155 160	480
agg aac cgg gga gac ccc tgg gct gtg agt ccg agg aga aag ctg atc Arg Asn Arg Gly Asp Pro Trp Ala Val Ser Pro Arg Arg Lys Leu Ile 165 170 175	528
tca gtg gac tca aga agt gtc tcc ctc ctc ccc ctg gag ttc cgc aaa Ser Val Asp Ser Arg Ser Val Ser Leu Leu Pro Leu Glu Phe Arg Lys 180 185 190	576
gac tcg agc tat gag ctg cag gtg cgg gca ggg ccc atg cct ggc tcc Asp Ser Ser Tyr Glu Leu Gln Val Arg Ala Gly Pro Met Pro Gly Ser 195 200 205	624
tcc tac cag ggg acc tgg agt gaa tgg agt gac ccg gtc atc ttt cag Ser Tyr Gln Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln 210 215 220	672
acc cag tca gag gag tta aag gaa ggc tgg aac cct cac ctg ctg ctt Thr Gln Ser Glu Glu Leu Lys Glu Gly Trp Asn Pro His Leu Leu Leu 225 230 235 240	720
ctc ctc ctg ctt gtc ata gtc ttc att cct gcc ttc tgg agc ctg aag Leu Leu Leu Leu Val Ile Val Phe Ile Pro Ala Phe Trp Ser Leu Lys 245 250 255	768
acc cat cca ttg tgg agg cta tgg aag aag ata tgg gcc gtc ccc agc Thr His Pro Leu Trp Arg Leu Trp Lys Lys Ile Trp Ala Val Pro Ser 260 265 270	816
cct gag cgg ttc ttc atg ccc ctg tac aag ggc tgc agc gga gac ttc Pro Glu Arg Phe Phe Met Pro Leu Tyr Lys Gly Cys Ser Gly Asp Phe 275 280 285	864
aag aaa tgg gtg ggt gca ccc ttc act ggc tcc agc ctg gag ctg gga Lys Lys Trp Val Gly Ala Pro Phe Thr Gly Ser Ser Leu Glu Leu Gly 290 295 300	912
ccc tgg agc cca gag gtg ccc tcc acc ctg gag gtg tac agc tgc cac Pro Trp Ser Pro Glu Val Pro Ser Thr Leu Glu Val Tyr Ser Cys His 305 310 315 320	960

158c

cca cca cgg agc ccg gcc aag agg ctg cag ctc acg gag cta caa gaa	1008
Pro Pro Arg Ser Pro Ala Lys Arg Leu Gln Leu Thr Glu Leu Gln Glu	
325 330 335	
cca gca gag ctg gtg gag tct gac ggt gtg ccc aag ccc agc ttc tgg	1056
Pro Ala Glu Leu Val Glu Ser Asp Gly Val Pro Lys Pro Ser Phe Trp	
340 345 350	
ccg aca gcc cag aac tcg ggg ggc tca gct tac agt gag gag agg gat	1104
Pro Thr Ala Gln Asn Ser Gly Gly Ser Ala Tyr Ser Glu Glu Arg Asp	
355 360 365	
cgg cca tac ggc ctg gtg tcc att gac aca gtg act gtg cta gat gca	1152
Arg Pro Tyr Gly Leu Val Ser Ile Asp Thr Val Thr Val Leu Asp Ala	
370 375 380	
gag ggg cca tgc acc tgg ccc tgc agc tgt gag gat gac ggc tac cca	1200
Glu Gly Pro Cys Thr Trp Pro Cys Ser Cys Glu Asp Asp Gly Tyr Pro	
385 390 395 400	
gcc ctg gac ctg gat gct ggc ctg gag ccc agc cca ggc cta gag gac	1248
Ala Leu Asp Leu Asp Ala Gly Leu Glu Pro Ser Pro Gly Leu Glu Asp	
405 410 415	
cca ctc ttg gat gca ggg acc aca gtc ctg tcc tgt ggc tgt gtc tca	1296
Pro Leu Leu Asp Ala Gly Thr Thr Val Leu Ser Cys Gly Cys Val Ser	
420 425 430	
gct ggc agc cct ggg cta gga ggg ccc ctg gga agc ctc ctg gac aga	1344
Ala Gly Ser Pro Gly Leu Gly Gly Pro Leu Gly Ser Leu Leu Asp Arg	
435 440 445	
cta aag cca ccc ctt gca gat ggg gag gac tgg gct ggg gga ctg ccc	1392
Leu Lys Pro Pro Leu Ala Asp Gly Glu Asp Trp Ala Gly Gly Leu Pro	
450 455 460	
tgg ggt ggc cgg tca cct gga ggg gtc tca gag agt gag gcg ggc tca	1440
Trp Gly Gly Arg Ser Pro Gly Gly Val Ser Glu Ser Glu Ala Gly Ser	
465 470 475 480	
ccc ctg gcc ggc ctg gat atg gac acg ttt gac agt ggc ttt gtg ggc	1488
Pro Leu Ala Gly Leu Asp Met Asp Thr Phe Asp Ser Gly Phe Val Gly	
485 490 495	
tct gac tgc agc agc cct gtg gag tgt gac ttc acc agc ccc ggg gac	1536
Ser Asp Cys Ser Ser Pro Val Glu Cys Asp Phe Thr Ser Pro Gly Asp	
500 505 510	
gaa gga ccc ccc cgg agc tac ctc cgc cag tgg gtg gtc att cct ccg	1584
Glu Gly Pro Pro Arg Ser Tyr Leu Arg Gln Trp Val Val Ile Pro Pro	
515 520 525	
cca ctt tcg agc cct gga ccc cag gcc agc	1614
Pro Leu Ser Ser Pro Gly Pro Gln Ala Ser	
530 535	

158d

<210> 2
 <211> 538
 <212> PRT
 <213> Homo sapiens

<400> 2
 Met Pro Arg Gly Trp Ala Ala Pro Leu Leu Leu Leu Leu Leu Gln Gly
 1 5 10 15
 Gly Trp Gly Cys Pro Asp Leu Val Cys Tyr Thr Asp Tyr Leu Gln Thr
 20 25 30
 Val Ile Cys Ile Leu Glu Met Trp Asn Leu His Pro Ser Thr Leu Thr
 35 40 45
 Leu Thr Trp Gln Asp Gln Tyr Glu Glu Leu Lys Asp Glu Ala Thr Ser
 50 55 60
 Cys Ser Leu His Arg Ser Ala His Asn Ala Thr His Ala Thr Tyr Thr
 65 70 75 80
 Cys His Met Asp Val Phe His Phe Met Ala Asp Asp Ile Phe Ser Val
 85 90 95
 Asn Ile Thr Asp Gln Ser Gly Asn Tyr Ser Gln Glu Cys Gly Ser Phe
 100 105 110
 Leu Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Phe Asn Val Thr Val
 115 120 125
 Thr Phe Ser Gly Gln Tyr Asn Ile Ser Trp Arg Ser Asp Tyr Glu Asp
 130 135 140
 Pro Ala Phe Tyr Met Leu Lys Gly Lys Leu Gln Tyr Glu Leu Gln Tyr
 145 150 155 160
 Arg Asn Arg Gly Asp Pro Trp Ala Val Ser Pro Arg Arg Lys Leu Ile
 165 170 175
 Ser Val Asp Ser Arg Ser Val Ser Leu Leu Pro Leu Glu Phe Arg Lys
 180 185 190
 Asp Ser Ser Tyr Glu Leu Gln Val Arg Ala Gly Pro Met Pro Gly Ser
 195 200 205
 Ser Tyr Gln Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln
 210 215 220
 Thr Gln Ser Glu Glu Leu Lys Glu Gly Trp Asn Pro His Leu Leu Leu
 225 230 235 240
 Leu Leu Leu Leu Val Ile Val Phe Ile Pro Ala Phe Trp Ser Leu Lys
 245 250 255
 Thr His Pro Leu Trp Arg Leu Trp Lys Lys Ile Trp Ala Val Pro Ser
 260 265 270
 Pro Glu Arg Phe Phe Met Pro Leu Tyr Lys Gly Cys Ser Gly Asp Phe
 275 280 285
 Lys Lys Trp Val Gly Ala Pro Phe Thr Gly Ser Ser Leu Glu Leu Gly
 290 295 300
 Pro Trp Ser Pro Glu Val Pro Ser Thr Leu Glu Val Tyr Ser Cys His
 305 310 315 320
 Pro Pro Arg Ser Pro Ala Lys Arg Leu Gln Leu Thr Glu Leu Gln Glu
 325 330 335
 Pro Ala Glu Leu Val Glu Ser Asp Gly Val Pro Lys Pro Ser Phe Trp
 340 345 350
 Pro Thr Ala Gln Asn Ser Gly Gly Ser Ala Tyr Ser Glu Glu Arg Asp
 355 360 365
 Arg Pro Tyr Gly Leu Val Ser Ile Asp Thr Val Thr Val Leu Asp Ala
 370 375 380
 Glu Gly Pro Cys Thr Trp Pro Cys Ser Cys Glu Asp Asp Gly Tyr Pro
 385 390 395 400

```
<210> 3
<211> 696
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (1)...(696)
```

<400> 3																
ctg	aac	acg	aca	att	ctg	acg	ccc	aat	ggg	aat	gaa	gac	acc	aca	gct	48
Leu	Asn	Thr	Thr	Ile	Leu	Thr	Pro	Asn	Gly	Asn	Glu	Asp	Thr	Thr	Ala	
1				5					10					15		
gat	ttc	ttc	ctg	acc	act	atg	ccc	act	gac	tcc	ctc	agt	gtt	tcc	act	96
Asp	Phe	Phe	Leu	Thr	Thr	Met	Pro	Thr	Asp	Ser	Leu	Ser	Val	Ser	Thr	
			20					25					30			
ctg	ccc	ctc	cca	gag	gtt	cag	tgt	ttt	gtg	ttc	aat	gtc	gag	tac	atg	144
Leu	Pro	Leu	Pro	Glu	Val	Gln	Cys	Phe	Val	Phe	Asn	Val	Glu	Tyr	Met	
		35					40					45				
aat	tgc	act	tgg	aac	agc	agc	tct	gag	ccc	cag	cct	acc	aac	ctc	act	192
Asn	Cys	Thr	Trp	Asn	Ser	Ser	Ser	Glu	Pro	Gln	Pro	Thr	Asn	Leu	Thr	
	50					55					60					
ctg	cat	tat	tgg	tac	aag	aac	tcg	gat	aat	gat	aaa	gtc	cag	aag	tgc	240
Leu	His	Tyr	Trp	Tyr	Lys	Asn	Ser	Asp	Asn	Asp	Lys	Val	Gln	Lys	Cys	
65					70					75					80	
agc	cac	tat	cta	ttc	tct	gaa	gaa	atc	act	tct	ggc	tgt	cag	ttg	caa	288
Ser	His	Tyr	Leu	Phe	Ser	Glu	Glu	Ile	Thr	Ser	Gly	Cys	Gln	Leu	Gln	
				85					90					95		

158f

aaa aag gag atc cac ctc tac caa aca ttt gtt gtt cag ctc cag gac	336
Lys Lys Glu Ile His Leu Tyr Gln Thr Phe Val Val Gln Leu Gln Asp	
100 105 110	
cca cgg gaa ccc agg aga cag gcc aca cag atg cta aaa ctg cag aat	384
Pro Arg Glu Pro Arg Arg Gln Ala Thr Gln Met Leu Lys Leu Gln Asn	
115 120 125	
ctg gtg atc ccc tgg gct cca gag aac cta aca ctt cac aaa ctg agt	432
Leu Val Ile Pro Trp Ala Pro Glu Asn Leu Thr Leu His Lys Leu Ser	
130 135 140	
gaa tcc cag cta gaa ctg aac tgg aac aac aga ttc ttg aac cac tgt	480
Glu Ser Gln Leu Glu Leu Asn Trp Asn Asn Arg Phe Leu Asn His Cys	
145 150 155 160	
ttg gag cac ttg gtg cag tac cgg act gac tgg gac cac agc tgg act	528
Leu Glu His Leu Val Gln Tyr Arg Thr Asp Trp Asp His Ser Trp Thr	
165 170 175	
gaa caa tca gtg gat tat aga cat aag ttc tcc ttg cct agt gtg gat	576
Glu Gln Ser Val Asp Tyr Arg His Lys Phe Ser Leu Pro Ser Val Asp	
180 185 190	
ggg cag aaa cgc tac acg ttt cgt gtt cgg agc cgc ttt aac cca ctc	624
Gly Gln Lys Arg Tyr Thr Phe Arg Val Arg Ser Arg Phe Asn Pro Leu	
195 200 205	
tgt gga agt gct cag cat tgg agt gaa tgg agc cac cca atc cac tgg	672
Cys Gly Ser Ala Gln His Trp Ser Glu Trp Ser His Pro Ile His Trp	
210 215 220	
ggg agc aat act tca aaa gag aat	696
Gly Ser Asn Thr Ser Lys Glu Asn	
225 230	

<210> 4
 <211> 232
 <212> PRT
 <213> Homo sapiens

<400> 4
 Leu Asn Thr Thr Ile Leu Thr Pro Asn Gly Asn Glu Asp Thr Thr Ala
 1 5 10 15
 Asp Phe Phe Leu Thr Thr Met Pro Thr Asp Ser Leu Ser Val Ser Thr
 20 25 30
 Leu Pro Leu Pro Glu Val Gln Cys Phe Val Phe Asn Val Glu Tyr Met
 35 40 45
 Asn Cys Thr Trp Asn Ser Ser Ser Glu Pro Gln Pro Thr Asn Leu Thr
 50 55 60
 Leu His Tyr Trp Tyr Lys Asn Ser Asp Asn Asp Lys Val Gln Lys Cys
 65 70 75 80
 Ser His Tyr Leu Phe Ser Glu Glu Ile Thr Ser Gly Cys Gln Leu Gln
 85 90 95

158g

Lys Lys Glu Ile His Leu Tyr Gln Thr Phe Val Val Gln Leu Gln Asp
 100 105 110
 Pro Arg Glu Pro Arg Arg Gln Ala Thr Gln Met Leu Lys Leu Gln Asn
 115 120 125
 Leu Val Ile Pro Trp Ala Pro Glu Asn Leu Thr Leu His Lys Leu Ser
 130 135 140
 Glu Ser Gln Leu Glu Leu Asn Trp Asn Asn Arg Phe Leu Asn His Cys
 145 150 155 160
 Leu Glu His Leu Val Gln Tyr Arg Thr Asp Trp Asp His Ser Trp Thr
 165 170 175
 Glu Gln Ser Val Asp Tyr Arg His Lys Phe Ser Leu Pro Ser Val Asp
 180 185 190
 Gly Gln Lys Arg Tyr Thr Phe Arg Val Arg Ser Arg Phe Asn Pro Leu
 195 200 205
 Cys Gly Ser Ala Gln His Trp Ser Glu Trp Ser His Pro Ile His Trp
 210 215 220
 Gly Ser Asn Thr Ser Lys Glu Asn
 225 230

<210> 5
 <211> 654
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (1)...(654)

<400> 5
 tgc ccc gac ctc gtc tgc tac acc gat tac ctc cag acg gtc atc tgc 48
 Cys Pro Asp Leu Val Cys Tyr Thr Asp Tyr Leu Gln Thr Val Ile Cys
 1 5 10 15
 atc ctg gaa atg tgg aac ctc cac ccc agc acg ctc acc ctt acc tgg 96
 Ile Leu Glu Met Trp Asn Leu His Pro Ser Thr Leu Thr Leu Thr Trp
 20 25 30
 caa gac cag tat gaa gag ctg aag gac gag gcc acc tcc tgc agc ctc 144
 Gln Asp Gln Tyr Glu Glu Leu Lys Asp Glu Ala Thr Ser Cys Ser Leu
 35 40 45
 cac agg tcg gcc cac aat gcc acg cat gcc acc tac acc tgc cac atg 192
 His Arg Ser Ala His Asn Ala Thr His Ala Thr Tyr Thr Cys His Met
 50 55 60
 gat gta ttc cac ttc atg gcc gac gac att ttc agt gtc aac atc aca 240
 Asp Val Phe His Phe Met Ala Asp Asp Ile Phe Ser Val Asn Ile Thr
 65 70 75 80
 gac cag tct ggc aac tac tcc cag gag tgt ggc agc ttt ctc ctg gct 288
 Asp Gln Ser Gly Asn Tyr Ser Gln Glu Cys Gly Ser Phe Leu Leu Ala
 85 90 95

158h

gag agc atc aag ccg gct ccc cct ttc aac gtg act gtg acc ttc tca	336
Glu Ser Ile Lys Pro Ala Pro Pro Phe Asn Val Thr Val Thr Phe Ser	
100 105 110	
gga cag tat aat atc tcc tgg cgc tca gat tac gaa gac cct gcc ttc	384
Gly Gln Tyr Asn Ile Ser Trp Arg Ser Asp Tyr Glu Asp Pro Ala Phe	
115 120 125	
tac atg ctg aag ggc aag ctt cag tat gag ctg cag tac agg aac cgg	432
Tyr Met Leu Lys Gly Lys Leu Gln Tyr Glu Leu Gln Tyr Arg Asn Arg	
130 135 140	
gga gac ccc tgg gct gtg agt ccg agg aga aag ctg atc tca gtg gac	480
Gly Asp Pro Trp Ala Val Ser Pro Arg Arg Lys Leu Ile Ser Val Asp	
145 150 155 160	
tca aga agt gtc tcc ctc ctc ccc ctg gag ttc cgc aaa gac tcg agc	528
Ser Arg Ser Val Ser Leu Leu Pro Leu Glu Phe Arg Lys Asp Ser Ser	
165 170 175	
tat gag ctg cag gtg cgg gca ggg ccc atg cct ggc tcc tcc tac cag	576
Tyr Glu Leu Gln Val Arg Ala Gly Pro Met Pro Gly Ser Ser Tyr Gln	
180 185 190	
ggg acc tgg agt gaa tgg agt gac ccg gtc atc ttt cag acc cag tca	624
Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln Thr Gln Ser	
195 200 205	
gag gag tta aag gaa ggc tgg aac cct cac	654
Glu Glu Leu Lys Glu Gly Trp Asn Pro His	
210 215	

<210> 6
 <211> 218
 <212> PRT
 <213> Homo sapiens

<400> 6

Cys Pro Asp Leu Val Cys Tyr Thr Asp Tyr Leu Gln Thr Val Ile Cys	
1 5 10 15	
Ile Leu Glu Met Trp Asn Leu His Pro Ser Thr Leu Thr Leu Thr Trp	
20 25 30	
Gln Asp Gln Tyr Glu Glu Leu Lys Asp Glu Ala Thr Ser Cys Ser Leu	
35 40 45	
His Arg Ser Ala His Asn Ala Thr His Ala Thr Tyr Thr Cys His Met	
50 55 60	
Asp Val Phe His Phe Met Ala Asp Asp Ile Phe Ser Val Asn Ile Thr	
65 70 75 80	
Asp Gln Ser Gly Asn Tyr Ser Gln Glu Cys Gly Ser Phe Leu Leu Ala	
85 90 95	
Glu Ser Ile Lys Pro Ala Pro Pro Phe Asn Val Thr Val Thr Phe Ser	
100 105 110	
Gly Gln Tyr Asn Ile Ser Trp Arg Ser Asp Tyr Glu Asp Pro Ala Phe	
115 120 125	

158i

```

Tyr Met Leu Lys Gly Lys Leu Gln Tyr Glu Leu Gln Tyr Arg Asn Arg
 130                               135                               140
Gly Asp Pro Trp Ala Val Ser Pro Arg Arg Lys Leu Ile Ser Val Asp
145                               150                               155                               160
Ser Arg Ser Val Ser Leu Leu Pro Leu Glu Phe Arg Lys Asp Ser Ser
                               165                               170                               175
Tyr Glu Leu Gln Val Arg Ala Gly Pro Met Pro Gly Ser Ser Tyr Gln
                               180                               185                               190
Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln Thr Gln Ser
                               195                               200                               205
Glu Glu Leu Lys Glu Gly Trp Asn Pro His
 210                               215

```

```

<210> 7
<211> 654
<212> DNA
<213> Artificial Sequence

```

```

<220>
<223> Degenerate polynucleotide sequence of soluble
      zalphal1 Receptor polypeptide as shown in SEQ ID
      NO:6

```

```

<221> misc_feature
<222> (1)...(654)
<223> n = A,T,C or G

```

```

<400> 7
tgyccngayy tngtntgyta yacngaytay ytnacaracng tnathtgyat hytngaratg      60
tggaayytnc ayccnwsnac nytnacnytn acntggcarg aycartayga rgarytnaar      120
gaygargcna cnwsntgyws nytncaymgn wsngcncaya aygcnaacna ygcnaacntay      180
acntgycaya tggaygtntt ycayttatg gcngaygaya thttywsngt naayathacn      240
gaycarwsng gnaaytayws ncargartgy ggnwsntt yy tnytngcnga rwsnathaar      300
cengncncnc cnttyaaygt nacngtnacn ttywsnggnc artayaayat hwsntggmgn      360
wsngaytayg argayccngc nttytayatg ytnaarggna arytncarta ygarytncar      420
taymgnaaym gnggngaycc ntgggcngtn wsncnmgmnm gnaarytnat hwsngtngay      480
wsnmgnwsng tnwsnytnyt nccnytngar ttymgnaarg aywsnwsnta ygarytncar      540
gtnmgnngcng gncnatgcc nggnwsnwsn taycarggna cntggwsnga rtggwsngay      600
cngtnatht tyacaracna rwsngargar ytnaargarg gntggaaycc ncay      654

```

```

<210> 8
<211> 696
<212> DNA
<213> Artificial Sequence

```

```

<220>
<223> Degenerate polynucleotide sequence of IL-2Rgamma
      polypeptide as shown in SEQ ID NO:4

```

```

<221> misc_feature
<222> (1)...(696)
<223> n = A,T,C or G

```

158j

<400> 8

ytnaayacna	cnathytnac	nccnaayggn	aaygargaya	cnacngcnga	yttyttyytn	60
acnacnatgc	cnacngayws	nytnwsngtn	wsnacnytn	cnytnccnga	rgtncartgy	120
ttygtnttya	aygtngarta	yatgaaytgy	acntggaayw	snwsnwsnga	rcncarccn	180
acnaayytna	cnytncayta	ytggtayaar	aaywsngaya	aygayaargt	ncaraartgy	240
wsncaytayy	tnntywsnga	rgarathacn	wsnggntgyc	arytncaraa	raargarath	300
cayytntayc	aracnttygt	ngtn Carytn	cargayccnm	gngarccnmg	nmgncargcn	360
acncaratgy	tnaarytnca	raayytngtn	athccntggg	cncngaraa	yytnacnytn	420
cayaarytnw	sngarwsnca	rytngarytn	aaytggaaya	aymgnttyyt	naaycaytgy	480
ytngarcayy	tngtncarta	ymgnaacngay	tgggaycayw	sntggacnga	rcarwsngtn	540
gaytaymgnc	ayaarttyws	nytnccnwsn	gtngayggnc	araarmgnta	yacnttymgn	600
gtnmgnwsnm	gnttyaaycc	nytn tgyggn	wsngcncarc	aytg gwsnga	rtggwsncay	660
ccnathcayt	ggggnwsnaa	yacnwsnaar	garaay			696

<210> 9

<211> 486

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)...(486)

<400> 9

atg	aga	tcc	agt	cct	ggc	aac	atg	gag	agg	att	gtc	atc	tgt	ctg	atg	48
Met	Arg	Ser	Ser	Pro	Gly	Asn	Met	Glu	Arg	Ile	Val	Ile	Cys	Leu	Met	
1				5				10						15		
gtc	atc	ttc	ttg	ggg	aca	ctg	gtc	cac	aaa	tca	agc	tcc	caa	ggg	caa	96
Val	Ile	Phe	Leu	Gly	Thr	Leu	Val	His	Lys	Ser	Ser	Ser	Gln	Gly	Gln	
			20					25					30			
gat	cgc	cac	atg	att	aga	atg	cgt	caa	ctt	ata	gat	att	gtt	gat	cag	144
Asp	Arg	His	Met	Ile	Arg	Met	Arg	Gln	Leu	Ile	Asp	Ile	Val	Asp	Gln	
		35					40					45				
ctg	aaa	aat	tat	gtg	aat	gac	ttg	gtc	cct	gaa	ttt	ctg	cca	gct	cca	192
Leu	Lys	Asn	Tyr	Val	Asn	Asp	Leu	Val	Pro	Glu	Phe	Leu	Pro	Ala	Pro	
	50					55				60						
gaa	gat	gta	gag	aca	aac	tgt	gag	tgg	tca	gct	ttt	tcc	tgt	ttt	cag	240
Glu	Asp	Val	Glu	Thr	Asn	Cys	Glu	Trp	Ser	Ala	Phe	Ser	Cys	Phe	Gln	
65				70				75						80		
aag	gcc	caa	cta	aag	tca	gca	aat	aca	gga	aac	aat	gaa	agg	ata	atc	288
Lys	Ala	Gln	Leu	Lys	Ser	Ala	Asn	Thr	Gly	Asn	Asn	Glu	Arg	Ile	Ile	
			85					90						95		
aat	gta	tca	att	aaa	aag	ctg	aag	agg	aaa	cca	cct	tcc	aca	aat	gca	336
Asn	Val	Ser	Ile	Lys	Lys	Leu	Lys	Arg	Lys	Pro	Pro	Ser	Thr	Asn	Ala	
			100					105					110			
ggg	aga	aga	cag	aaa	cac	aga	cta	aca	tgc	cct	tca	tgt	gat	tct	tat	384
Gly	Arg	Arg	Gln	Lys	His	Arg	Leu	Thr	Cys	Pro	Ser	Cys	Asp	Ser	Tyr	
	115						120					125				

158k

gag aaa aaa cca ccc aaa gaa ttc cta gaa aga ttc aaa tca ctt ctc 432
 Glu Lys Lys Pro Pro Lys Glu Phe Leu Glu Arg Phe Lys Ser Leu Leu
 130 135 140

caa aag atg att cat cag cat ctg tcc tct aga aca cac gga agt gaa 480
 Gln Lys Met Ile His Gln His Leu Ser Ser Arg Thr His Gly Ser Glu
 145 150 155 160

gat tcc 486
 Asp Ser

<210> 10
 <211> 162
 <212> PRT
 <213> Homo sapiens

<400> 10
 Met Arg Ser Ser Pro Gly Asn Met Glu Arg Ile Val Ile Cys Leu Met
 1 5 10 15
 Val Ile Phe Leu Gly Thr Leu Val His Lys Ser Ser Ser Gln Gly Gln
 20 25 30
 Asp Arg His Met Ile Arg Met Arg Gln Leu Ile Asp Ile Val Asp Gln
 35 40 45
 Leu Lys Asn Tyr Val Asn Asp Leu Val Pro Glu Phe Leu Pro Ala Pro
 50 55 60
 Glu Asp Val Glu Thr Asn Cys Glu Trp Ser Ala Phe Ser Cys Phe Gln
 65 70 75 80
 Lys Ala Gln Leu Lys Ser Ala Asn Thr Gly Asn Asn Glu Arg Ile Ile
 85 90 95
 Asn Val Ser Ile Lys Lys Leu Lys Arg Lys Pro Pro Ser Thr Asn Ala
 100 105 110
 Gly Arg Arg Gln Lys His Arg Leu Thr Cys Pro Ser Cys Asp Ser Tyr
 115 120 125
 Glu Lys Lys Pro Pro Lys Glu Phe Leu Glu Arg Phe Lys Ser Leu Leu
 130 135 140
 Gln Lys Met Ile His Gln His Leu Ser Ser Arg Thr His Gly Ser Glu
 145 150 155 160
 Asp Ser

<210> 11
 <211> 1735
 <212> DNA
 <213> mus musculus

<220>
 <221> CDS
 <222> (143)...(1729)

<400> 11
 ctgcccacct caaaccttca cctcccacca ccaccactcc gagtcccgct gtgactccca 60
 cgcccaggag accacccaag tgccccagcc taaagaatgg ctttctgaga aagaccctga 120

1581

aggagtaggt ctgggacaca gc atg ccc cgg ggc cca gtg gct gcc tta ctc	172
Met Pro Arg Gly Pro Val Ala Ala Leu Leu	
1 5 10	
ctg ctg att ctc cat gga gct tgg agc tgc ctg gac ctc act tgc tac	220
Leu Leu Ile Leu His Gly Ala Trp Ser Cys Leu Asp Leu Thr Cys Tyr	
15 20 25	
act gac tac ctc tgg acc atc acc tgt gtc ctg gag aca cgg agc ccc	268
Thr Asp Tyr Leu Trp Thr Ile Thr Cys Val Leu Glu Thr Arg Ser Pro	
30 35 40	
aac ccc agc ata ctc agt ctc acc tgg caa gat gaa tat gag gaa ctt	316
Asn Pro Ser Ile Leu Ser Leu Thr Trp Gln Asp Glu Tyr Glu Glu Leu	
45 50 55	
cag gac caa gag acc ttc tgc agc cta cac agg tct ggc cac aac acc	364
Gln Asp Gln Glu Thr Phe Cys Ser Leu His Arg Ser Gly His Asn Thr	
60 65 70	
aca cat ata tgg tac acg tgc cat atg cgc ttg tct caa ttc ctg tcc	412
Thr His Ile Trp Tyr Thr Cys His Met Arg Leu Ser Gln Phe Leu Ser	
75 80 85 90	
gat gaa gtt ttc att gtc aat gtg acg gac cag tct ggc aac aac tcc	460
Asp Glu Val Phe Ile Val Asn Val Thr Asp Gln Ser Gly Asn Asn Ser	
95 100 105	
caa gag tgt ggc agc ttt gtc ctg gct gag agc atc aaa cca gct ccc	508
Gln Glu Cys Gly Ser Phe Val Leu Ala Glu Ser Ile Lys Pro Ala Pro	
110 115 120	
ccc ttg aac gtg act gtg gcc ttc tca gga cgc tat gat atc tcc tgg	556
Pro Leu Asn Val Thr Val Ala Phe Ser Gly Arg Tyr Asp Ile Ser Trp	
125 130 135	
gac tca gct tat gac gaa ccc tcc aac tac gtg ctg agg ggc aag cta	604
Asp Ser Ala Tyr Asp Glu Pro Ser Asn Tyr Val Leu Arg Gly Lys Leu	
140 145 150	
caa tat gag ctg cag tat cgg aac ctc aga gac ccc tat gct gtg agg	652
Gln Tyr Glu Leu Gln Tyr Arg Asn Leu Arg Asp Pro Tyr Ala Val Arg	
155 160 165 170	
ccg gtg acc aag ctg atc tca gtg gac tca aga aac gtc tct ctt ctc	700
Pro Val Thr Lys Leu Ile Ser Val Asp Ser Arg Asn Val Ser Leu Leu	
175 180 185	
cct gaa gag ttc cac aaa gat tct agc tac cag ctg cag gtg cgg gca	748
Pro Glu Glu Phe His Lys Asp Ser Ser Tyr Gln Leu Gln Val Arg Ala	
190 195 200	
gcg cct cag cca ggc act tca ttc agg ggg acc tgg agt gag tgg agt	796
Ala Pro Gln Pro Gly Thr Ser Phe Arg Gly Thr Trp Ser Glu Trp Ser	
205 210 215	

158m

gac ccc gtc atc ttt cag acc cag gct ggg gag ccc gag gca ggc tgg	844
Asp Pro Val Ile Phe Gln Thr Gln Ala Gly Glu Pro Glu Ala Gly Trp	
220 225 230	
gac cct cac atg ctg ctg ctc ctg gct gtc ttg atc att gtc ctg gtt	892
Asp Pro His Met Leu Leu Leu Leu Ala Val Leu Ile Ile Val Leu Val	
235 240 245 250	
ttc atg ggt ctg aag atc cac ctg cct tgg agg cta tgg aaa aag ata	940
Phe Met Gly Leu Lys Ile His Leu Pro Trp Arg Leu Trp Lys Lys Ile	
255 260 265	
tgg gca cca gtg ccc acc cct gag agt ttc ttc cag ccc ctg tac agg	988
Trp Ala Pro Val Pro Thr Pro Glu Ser Phe Phe Gln Pro Leu Tyr Arg	
270 275 280	
gag cac agc ggg aac ttc aag aaa tgg gtt aat acc cct ttc acg gcc	1036
Glu His Ser Gly Asn Phe Lys Lys Trp Val Asn Thr Pro Phe Thr Ala	
285 290 295	
tcc agc ata gag ttg gtg cca cag agt tcc aca aca aca tca gcc tta	1084
Ser Ser Ile Glu Leu Val Pro Gln Ser Ser Thr Thr Thr Ser Ala Leu	
300 305 310	
cat ctg tca ttg tat cca gcc aag gag aag aag ttc ccg ggg ctg ccg	1132
His Leu Ser Leu Tyr Pro Ala Lys Glu Lys Lys Phe Pro Gly Leu Pro	
315 320 325 330	
ggt ctg gaa gag caa ctg gag tgt gat gga atg tct gag cct ggt cac	1180
Gly Leu Glu Glu Gln Leu Glu Cys Asp Gly Met Ser Glu Pro Gly His	
335 340 345	
tgg tgc ata atc ccc ttg gca gct ggc caa gcg gtc tca gcc tac agt	1228
Trp Cys Ile Ile Pro Leu Ala Ala Gly Gln Ala Val Ser Ala Tyr Ser	
350 355 360	
gag gag aga gac cgg cca tat ggt ctg gtg tcc att gac aca gtg act	1276
Glu Glu Arg Asp Arg Pro Tyr Gly Leu Val Ser Ile Asp Thr Val Thr	
365 370 375	
gtg gga gat gca gag ggc ctg tgt gtc tgg ccc tgt agc tgt gag gat	1324
Val Gly Asp Ala Glu Gly Leu Cys Val Trp Pro Cys Ser Cys Glu Asp	
380 385 390	
gat ggc tat cca gcc atg aac ctg gat gct ggc cga gag tct ggc cct	1372
Asp Gly Tyr Pro Ala Met Asn Leu Asp Ala Gly Arg Glu Ser Gly Pro	
395 400 405 410	
aat tca gag gat ctg ctc ttg gtc aca gac cct gct ttt ctg tct tgc	1420
Asn Ser Glu Asp Leu Leu Leu Val Thr Asp Pro Ala Phe Leu Ser Cys	
415 420 425	
ggc tgt gtc tca ggt agt ggt ctc agg ctt gga ggc tcc cca ggc agc	1468
Gly Cys Val Ser Gly Ser Gly Leu Arg Leu Gly Gly Ser Pro Gly Ser	
430 435 440	

158n

cta	ctg	gac	agg	ttg	agg	ctg	tca	ttt	gca	aag	gaa	ggg	gac	tgg	aca	1516
Leu	Leu	Asp	Arg	Leu	Arg	Leu	Ser	Phe	Ala	Lys	Glu	Gly	Asp	Trp	Thr	
		445					450					455				
gca	gac	cca	acc	tgg	aga	act	ggg	tcc	cca	gga	ggg	ggc	tct	gag	agt	1564
Ala	Asp	Pro	Thr	Trp	Arg	Thr	Gly	Ser	Pro	Gly	Gly	Gly	Ser	Glu	Ser	
	460					465					470					
gaa	gca	ggt	tcc	ccc	cct	ggt	ctg	gac	atg	gac	aca	ttt	gac	agt	ggc	1612
Glu	Ala	Gly	Ser	Pro	Pro	Gly	Leu	Asp	Met	Asp	Thr	Phe	Asp	Ser	Gly	
475					480					485					490	
ttt	gca	ggt	tca	gac	tgt	ggc	agc	ccc	gtg	gag	act	gat	gaa	gga	ccc	1660
Phe	Ala	Gly	Ser	Asp	Cys	Gly	Ser	Pro	Val	Glu	Thr	Asp	Glu	Gly	Pro	
			495					500						505		
cct	cga	agc	tat	ctc	cgc	cag	tgg	gtg	gtc	agg	acc	cct	cca	cct	gtg	1708
Pro	Arg	Ser	Tyr	Leu	Arg	Gln	Trp	Val	Val	Arg	Thr	Pro	Pro	Pro	Val	
			510				515						520			
gac	agt	gga	gcc	cag	agc	agc	tagcat									1735
Asp	Ser	Gly	Ala	Gln	Ser	Ser										
		525														

<210> 12
 <211> 529
 <212> PRT
 <213> mus musculus

<400> 12

Met	Pro	Arg	Gly	Pro	Val	Ala	Ala	Leu	Leu	Leu	Leu	Ile	Leu	His	Gly
1				5				10					15		
Ala	Trp	Ser	Cys	Leu	Asp	Leu	Thr	Cys	Tyr	Thr	Asp	Tyr	Leu	Trp	Thr
			20					25					30		
Ile	Thr	Cys	Val	Leu	Glu	Thr	Arg	Ser	Pro	Asn	Pro	Ser	Ile	Leu	Ser
		35					40					45			
Leu	Thr	Trp	Gln	Asp	Glu	Tyr	Glu	Glu	Leu	Gln	Asp	Gln	Glu	Thr	Phe
	50					55					60				
Cys	Ser	Leu	His	Arg	Ser	Gly	His	Asn	Thr	Thr	His	Ile	Trp	Tyr	Thr
65				70					75					80	
Cys	His	Met	Arg	Leu	Ser	Gln	Phe	Leu	Ser	Asp	Glu	Val	Phe	Ile	Val
			85					90					95		
Asn	Val	Thr	Asp	Gln	Ser	Gly	Asn	Asn	Ser	Gln	Glu	Cys	Gly	Ser	Phe
			100				105						110		
Val	Leu	Ala	Glu	Ser	Ile	Lys	Pro	Ala	Pro	Pro	Leu	Asn	Val	Thr	Val
	115						120					125			
Ala	Phe	Ser	Gly	Arg	Tyr	Asp	Ile	Ser	Trp	Asp	Ser	Ala	Tyr	Asp	Glu
	130					135					140				
Pro	Ser	Asn	Tyr	Val	Leu	Arg	Gly	Lys	Leu	Gln	Tyr	Glu	Leu	Gln	Tyr
145				150						155					160
Arg	Asn	Leu	Arg	Asp	Pro	Tyr	Ala	Val	Arg	Pro	Val	Thr	Lys	Leu	Ile
			165					170						175	
Ser	Val	Asp	Ser	Arg	Asn	Val	Ser	Leu	Leu	Pro	Glu	Glu	Phe	His	Lys
			180					185					190		

1580

Asp	Ser	Ser	Tyr	Gln	Leu	Gln	Val	Arg	Ala	Ala	Pro	Gln	Pro	Gly	Thr
		195					200					205			
Ser	Phe	Arg	Gly	Thr	Trp	Ser	Glu	Trp	Ser	Asp	Pro	Val	Ile	Phe	Gln
	210					215					220				
Thr	Gln	Ala	Gly	Glu	Pro	Glu	Ala	Gly	Trp	Asp	Pro	His	Met	Leu	Leu
225					230					235					240
Leu	Leu	Ala	Val	Leu	Ile	Ile	Val	Leu	Val	Phe	Met	Gly	Leu	Lys	Ile
			245							250				255	
His	Leu	Pro	Trp	Arg	Leu	Trp	Lys	Lys	Ile	Trp	Ala	Pro	Val	Pro	Thr
			260				265						270		
Pro	Glu	Ser	Phe	Phe	Gln	Pro	Leu	Tyr	Arg	Glu	His	Ser	Gly	Asn	Phe
		275					280					285			
Lys	Lys	Trp	Val	Asn	Thr	Pro	Phe	Thr	Ala	Ser	Ser	Ile	Glu	Leu	Val
	290					295					300				
Pro	Gln	Ser	Ser	Thr	Thr	Thr	Ser	Ala	Leu	His	Leu	Ser	Leu	Tyr	Pro
305					310					315					320
Ala	Lys	Glu	Lys	Lys	Phe	Pro	Gly	Leu	Pro	Gly	Leu	Glu	Glu	Gln	Leu
			325						330					335	
Glu	Cys	Asp	Gly	Met	Ser	Glu	Pro	Gly	His	Trp	Cys	Ile	Ile	Pro	Leu
			340					345					350		
Ala	Ala	Gly	Gln	Ala	Val	Ser	Ala	Tyr	Ser	Glu	Glu	Arg	Asp	Arg	Pro
		355					360					365			
Tyr	Gly	Leu	Val	Ser	Ile	Asp	Thr	Val	Thr	Val	Gly	Asp	Ala	Glu	Gly
	370					375					380				
Leu	Cys	Val	Trp	Pro	Cys	Ser	Cys	Glu	Asp	Asp	Gly	Tyr	Pro	Ala	Met
385					390					395					400
Asn	Leu	Asp	Ala	Gly	Arg	Glu	Ser	Gly	Pro	Asn	Ser	Glu	Asp	Leu	Leu
			405						410					415	
Leu	Val	Thr	Asp	Pro	Ala	Phe	Leu	Ser	Cys	Gly	Cys	Val	Ser	Gly	Ser
			420					425					430		
Gly	Leu	Arg	Leu	Gly	Gly	Ser	Pro	Gly	Ser	Leu	Leu	Asp	Arg	Leu	Arg
		435					440					445			
Leu	Ser	Phe	Ala	Lys	Glu	Gly	Asp	Trp	Thr	Ala	Asp	Pro	Thr	Trp	Arg
	450					455					460				
Thr	Gly	Ser	Pro	Gly	Gly	Gly	Ser	Glu	Ser	Glu	Ala	Gly	Ser	Pro	Pro
465					470					475					480
Gly	Leu	Asp	Met	Asp	Thr	Phe	Asp	Ser	Gly	Phe	Ala	Gly	Ser	Asp	Cys
			485					490						495	
Gly	Ser	Pro	Val	Glu	Thr	Asp	Glu	Gly	Pro	Pro	Arg	Ser	Tyr	Leu	Arg
			500					505					510		
Gln	Trp	Val	Val	Arg	Thr	Pro	Pro	Pro	Val	Asp	Ser	Gly	Ala	Gln	Ser
		515					520					525			

Ser

<210> 13

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> WSXWS polypeptide consensus motif

<221> VARIANT

<222> (1)...(5)

<223> Xaa = Any Amino Acid

158p

<400> 13
 Trp Ser Xaa Trp Ser
 1 5

<210> 14
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Glu-Glu (CEE) Tag amino acid sequence

<400> 14
 Glu Tyr Met Pro Met Glu
 1 5

<210> 15
 <211> 1701
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> soluble zalpha11R/IgGgamma1 construct

<221> CDS
 <222> (1)...(1701)

<400> 15
 atg ccg cgt ggc tgg gcc gcc ccc ttg ctc ctg ctg ctg ctc cag gga 48
 Met Pro Arg Gly Trp Ala Ala Pro Leu Leu Leu Leu Leu Gln Gly
 1 5 10 15

ggc tgg ggc tgc ccc gac ctc gtc tgc tac acc gat tac ctc cag acg 96
 Gly Trp Gly Cys Pro Asp Leu Val Cys Tyr Thr Asp Tyr Leu Gln Thr
 20 25 30

gtc atc tgc atc ctg gaa atg tgg aac ctc cac ccc agc acg ctc acc 144
 Val Ile Cys Ile Leu Glu Met Trp Asn Leu His Pro Ser Thr Leu Thr
 35 40 45

ctt acc tgg caa gac cag tat gaa gag ctg aag gac gag gcc acc tcc 192
 Leu Thr Trp Gln Asp Gln Tyr Glu Glu Leu Lys Asp Glu Ala Thr Ser
 50 55 60

tgc agc ctc cac agg tcg gcc cac aat gcc acg cat gcc acc tac acc 240
 Cys Ser Leu His Arg Ser Ala His Asn Ala Thr His Ala Thr Tyr Thr
 65 70 75 80

tgc cac atg gat gta ttc cac ttc atg gcc gac gac att ttc agt gtc 288
 Cys His Met Asp Val Phe His Phe Met Ala Asp Asp Ile Phe Ser Val
 85 90 95

158q

aac atc aca gac cag tct ggc aac tac tcc cag gag tgt ggc agc ttt	336
Asn Ile Thr Asp Gln Ser Gly Asn Tyr Ser Gln Glu Cys Gly Ser Phe	
100 105 110	
ctc ctg gct gag agc atc aag ccg gct ccc cct ttc aac gtg act gtg	384
Leu Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Phe Asn Val Thr Val	
115 120 125	
acc ttc tca gga cag tat aat atc tcc tgg cgc tca gat tac gaa gac	432
Thr Phe Ser Gly Gln Tyr Asn Ile Ser Trp Arg Ser Asp Tyr Glu Asp	
130 135 140	
cct gcc ttc tac atg ctg aag ggc aag ctt cag tat gag ctg cag tac	480
Pro Ala Phe Tyr Met Leu Lys Gly Lys Leu Gln Tyr Glu Leu Gln Tyr	
145 150 155 160	
agg aac cgg gga gac ccc tgg gct gtg agt ccg agg aga aag ctg atc	528
Arg Asn Arg Gly Asp Pro Trp Ala Val Ser Pro Arg Arg Lys Leu Ile	
165 170 175	
tca gtg gac tca aga agt gtc tcc ctc ctc ccc ctg gag ttc cgc aaa	576
Ser Val Asp Ser Arg Ser Val Ser Leu Leu Pro Leu Glu Phe Arg Lys	
180 185 190	
gac tcg agc tat gag ctg cag gtg cgg gca ggg ccc atg cct ggc tcc	624
Asp Ser Ser Tyr Glu Leu Gln Val Arg Ala Gly Pro Met Pro Gly Ser	
195 200 205	
tcc tac cag ggg acc tgg agt gaa tgg agt gac ccg gtc atc ttt cag	672
Ser Tyr Gln Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln	
210 215 220	
acc cag tca gag gag tta aag gaa ggc tgg aac cct cac gct agc acc	720
Thr Gln Ser Glu Glu Leu Lys Glu Gly Trp Asn Pro His Ala Ser Thr	
225 230 235 240	
aag ggc cca tcg gtc ttc ccc ctg gca ccc tcc tcc aag agc acc tct	768
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser	
245 250 255	
ggg ggc aca gcg gcc ctg ggc tgc ctg gtc aag gac tac ttc ccc gaa	816
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu	
260 265 270	
ccg gtg acg gtg tcg tgg aac tca ggc gcc ctg acc agc ggc gtg cac	864
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His	
275 280 285	
acc ttc ccg gct gtc cta cag tcc tca gga ctc tac tcc ctc agc agc	912
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser	
290 295 300	
gtg gtg acc gtg ccc tcc agc agc ttg ggc acc cag acc tac atc tgc	960
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys	
305 310 315 320	

158r

aac gtg aat cac aag ccc agc aac acc aag gtg gac aag aaa gtt gag	1008
Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu	
325 330 335	
ccc aaa tct tgt gac aaa act cac aca tgc cca ccg tgc cca gca cct	1056
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro	
340 345 350	
gaa ctc ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag	1104
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys	
355 360 365	
gac acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg	1152
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val	
370 375 380	
gac gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac	1200
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp	
385 390 395 400	
ggc gtg gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac	1248
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr	
405 410 415	
aac agc acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac	1296
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp	
420 425 430	
tgg ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc	1344
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu	
435 440 445	
cca gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga	1392
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg	
450 455 460	
gaa cca cag gtg tac acc ctg ccc cca tcc ccg gat gag ctg acc aag	1440
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys	
465 470 475 480	
aac cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac	1488
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp	
485 490 495	
atc gcc gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag	1536
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys	
500 505 510	
acc acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc	1584
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser	
515 520 525	
aag ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca	1632
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser	
530 535 540	

158s

tgc	tcc	gtg	atg	cat	gag	gct	ctg	cac	aac	cac	tac	acg	cag	aag	agc	1680
Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	
545					550					555					560	

ctc	tcc	ctg	tct	ccg	ggt	aaa										1701
Leu	Ser	Leu	Ser	Pro	Gly	Lys										
				565												

<210> 16
 <211> 567
 <212> PRT
 <213> Artificial Sequence

<400> 16

Met	Pro	Arg	Gly	Trp	Ala	Ala	Pro	Leu	Leu	Leu	Leu	Leu	Leu	Gln	Gly	
1				5				10						15		
Gly	Trp	Gly	Cys	Pro	Asp	Leu	Val	Cys	Tyr	Thr	Asp	Tyr	Leu	Gln	Thr	
			20					25					30			
Val	Ile	Cys	Ile	Leu	Glu	Met	Trp	Asn	Leu	His	Pro	Ser	Thr	Leu	Thr	
		35					40					45				
Leu	Thr	Trp	Gln	Asp	Gln	Tyr	Glu	Glu	Leu	Lys	Asp	Glu	Ala	Thr	Ser	
	50					55					60					
Cys	Ser	Leu	His	Arg	Ser	Ala	His	Asn	Ala	Thr	His	Ala	Thr	Tyr	Thr	
65				70						75					80	
Cys	His	Met	Asp	Val	Phe	His	Phe	Met	Ala	Asp	Asp	Ile	Phe	Ser	Val	
				85					90					95		
Asn	Ile	Thr	Asp	Gln	Ser	Gly	Asn	Tyr	Ser	Gln	Glu	Cys	Gly	Ser	Phe	
			100					105					110			
Leu	Leu	Ala	Glu	Ser	Ile	Lys	Pro	Ala	Pro	Pro	Phe	Asn	Val	Thr	Val	
		115					120					125				
Thr	Phe	Ser	Gly	Gln	Tyr	Asn	Ile	Ser	Trp	Arg	Ser	Asp	Tyr	Glu	Asp	
	130					135					140					
Pro	Ala	Phe	Tyr	Met	Leu	Lys	Gly	Lys	Leu	Gln	Tyr	Glu	Leu	Gln	Tyr	
145					150					155					160	
Arg	Asn	Arg	Gly	Asp	Pro	Trp	Ala	Val	Ser	Pro	Arg	Arg	Lys	Leu	Ile	
				165					170					175		
Ser	Val	Asp	Ser	Arg	Ser	Val	Ser	Leu	Leu	Pro	Leu	Glu	Phe	Arg	Lys	
			180					185					190			
Asp	Ser	Ser	Tyr	Glu	Leu	Gln	Val	Arg	Ala	Gly	Pro	Met	Pro	Gly	Ser	
		195					200					205				
Ser	Tyr	Gln	Gly	Thr	Trp	Ser	Glu	Trp	Ser	Asp	Pro	Val	Ile	Phe	Gln	
	210					215					220					
Thr	Gln	Ser	Glu	Glu	Leu	Lys	Glu	Gly	Trp	Asn	Pro	His	Ala	Ser	Thr	
225					230					235					240	
Lys	Gly	Pro	Ser	Val	Phe	Pro	Leu	Ala	Pro	Ser	Ser	Lys	Ser	Thr	Ser	
				245					250					255		
Gly	Gly	Thr	Ala	Ala	Leu	Gly	Cys	Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu	
			260					265					270			
Pro	Val	Thr	Val	Ser	Trp	Asn	Ser	Gly	Ala	Leu	Thr	Ser	Gly	Val	His	
		275					280						285			
Thr	Phe	Pro	Ala	Val	Leu	Gln	Ser	Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	
	290					295					300					
Val	Val	Thr	Val	Pro	Ser	Ser	Ser	Leu	Gly	Thr	Gln	Thr	Tyr	Ile	Cys	
305					310					315					320	

158t

```

Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
      325      330      335
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
      340      345      350
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
      355      360      365
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
      370      375      380
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
      385      390      395      400
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
      405      410      415
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp
      420      425      430
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu
      435      440      445
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
      450      455      460
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
      465      470      475      480
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
      485      490      495
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
      500      505      510
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
      515      520      525
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
      530      535      540
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
      545      550      555      560
Leu Ser Leu Ser Pro Gly Lys
      565

```

```

<210> 17
<211> 1083
<212> DNA
<213> Artificial Sequence

```

```

<220>
<223> soluble human IL-2Rgamma/human kappa light chain
construct

```

```

<221> CDS
<222> (1)...(1083)

```

```

<400> 17
atg ttg aag cca tca tta cca ttc aca tcc ctc tta ttc ctg cag ctg      48
Met Leu Lys Pro Ser Leu Pro Phe Thr Ser Leu Leu Phe Leu Gln Leu
  1              5              10              15

ccc ctg ctg gga gtg ggg ctg aac acg aca att ctg acg ccc aat ggg      96
Pro Leu Leu Gly Val Gly Leu Asn Thr Thr Ile Leu Thr Pro Asn Gly
      20              25              30

```

158u

aat gaa gac acc aca gct gat ttc ttc ctg acc act atg ccc act gac	144
Asn Glu Asp Thr Thr Ala Asp Phe Phe Leu Thr Thr Met Pro Thr Asp	
35 40 45	
tcc ctc agt gtt tcc act ctg ccc ctc cca gag gtt cag tgt ttt gtg	192
Ser Leu Ser Val Ser Thr Leu Pro Leu Pro Glu Val Gln Cys Phe Val	
50 55 60	
ttc aat gtc gag tac atg aat tgc act tgg aac agc agc tct gag ccc	240
Phe Asn Val Glu Tyr Met Asn Cys Thr Trp Asn Ser Ser Ser Glu Pro	
65 70 75 80	
cag cct acc aac ctc act ctg cat tat tgg tac aag aac tcg gat aat	288
Gln Pro Thr Asn Leu Thr Leu His Tyr Trp Tyr Lys Asn Ser Asp Asn	
85 90 95	
gat aaa gtc cag aag tgc agc cac tat cta ttc tct gaa gaa atc act	336
Asp Lys Val Gln Lys Cys Ser His Tyr Leu Phe Ser Glu Glu Ile Thr	
100 105 110	
tct ggc tgt cag ttg caa aaa aag gag atc cac ctc tac caa aca ttt	384
Ser Gly Cys Gln Leu Gln Lys Lys Glu Ile His Leu Tyr Gln Thr Phe	
115 120 125	
gtt gtt cag ctc cag gac cca cgg gaa ccc agg aga cag gcc aca cag	432
Val Val Gln Leu Gln Asp Pro Arg Glu Pro Arg Arg Gln Ala Thr Gln	
130 135 140	
atg cta aaa ctg cag aat ctg gtg atc ccc tgg gct cca gag aac cta	480
Met Leu Lys Leu Gln Asn Leu Val Ile Pro Trp Ala Pro Glu Asn Leu	
145 150 155 160	
aca ctt cac aaa ctg agt gaa tcc cag cta gaa ctg aac tgg aac aac	528
Thr Leu His Lys Leu Ser Glu Ser Gln Leu Glu Leu Asn Trp Asn Asn	
165 170 175	
aga ttc ttg aac cac tgt ttg gag cac ttg gtg cag tac cgg act gac	576
Arg Phe Leu Asn His Cys Leu Glu His Leu Val Gln Tyr Arg Thr Asp	
180 185 190	
tgg gac cac agc tgg act gaa caa tca gtg gat tat aga cat aag ttc	624
Trp Asp His Ser Trp Thr Glu Gln Ser Val Asp Tyr Arg His Lys Phe	
195 200 205	
tcc ttg cct agt gtg gat ggg cag aaa cgc tac acg ttt cgt gtt cgg	672
Ser Leu Pro Ser Val Asp Gly Gln Lys Arg Tyr Thr Phe Arg Val Arg	
210 215 220	
agc cgc ttt aac cca ctc tgt gga agt gct cag cat tgg agt gaa tgg	720
Ser Arg Phe Asn Pro Leu Cys Gly Ser Ala Gln His Trp Ser Glu Trp	
225 230 235 240	
agc cac cca atc cac tgg ggg agc aat act tca aaa gag aat act gtg	768
Ser His Pro Ile His Trp Gly Ser Asn Thr Ser Lys Glu Asn Thr Val	
245 250 255	

158v

gct gca cca tct gtc ttc atc ttc ccg cca tct gat gag cag ttg aaa	816
Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys	
260 265 270	
tct ggt acc gcc tct gtt gtg tgc ctg ctg aat aac ttc tat ccc aga	864
Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg	
275 280 285	
gag gcc aaa gta cag tgg aag gtg gat aac gcc ctc caa tcg ggt aac	912
Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn	
290 295 300	
tcc cag gag agt gtc aca gag cag gac agc aag gac agc acc tac agc	960
Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser	
305 310 315 320	
ctc agc agc acc ctg acg ctg agc aaa gca gac tac gag aaa cac aaa	1008
Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys	
325 330 335	
gtc tac gcc tgc gaa gtc acc cat cag ggc ctg agc tcg ccc gtc aca	1056
Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr	
340 345 350	
aag agc ttc aac agg gga gag tgt tag	1083
Lys Ser Phe Asn Arg Gly Glu Cys *	
355 360	

<210> 18
 <211> 360
 <212> PRT
 <213> Artificial Sequence

<400> 18
Met Leu Lys Pro Ser Leu Pro Phe Thr Ser Leu Leu Phe Leu Gln Leu
1 5 10 15
Pro Leu Leu Gly Val Gly Leu Asn Thr Thr Ile Leu Thr Pro Asn Gly
20 25 30
Asn Glu Asp Thr Thr Ala Asp Phe Phe Leu Thr Thr Met Pro Thr Asp
35 40 45
Ser Leu Ser Val Ser Thr Leu Pro Leu Pro Glu Val Gln Cys Phe Val
50 55 60
Phe Asn Val Glu Tyr Met Asn Cys Thr Trp Asn Ser Ser Ser Glu Pro
65 70 75 80
Gln Pro Thr Asn Leu Thr Leu His Tyr Trp Tyr Lys Asn Ser Asp Asn
85 90 95
Asp Lys Val Gln Lys Cys Ser His Tyr Leu Phe Ser Glu Glu Ile Thr
100 105 110
Ser Gly Cys Gln Leu Gln Lys Lys Glu Ile His Leu Tyr Gln Thr Phe
115 120 125
Val Val Gln Leu Gln Asp Pro Arg Glu Pro Arg Arg Gln Ala Thr Gln
130 135 140
Met Leu Lys Leu Gln Asn Leu Val Ile Pro Trp Ala Pro Glu Asn Leu
145 150 155 160

158w

Thr Leu His Lys Leu Ser Glu Ser Gln Leu Glu Leu Asn Trp Asn Asn
 165 170 175
 Arg Phe Leu Asn His Cys Leu Glu His Leu Val Gln Tyr Arg Thr Asp
 180 185 190
 Trp Asp His Ser Trp Thr Glu Gln Ser Val Asp Tyr Arg His Lys Phe
 195 200 205
 Ser Leu Pro Ser Val Asp Gly Gln Lys Arg Tyr Thr Phe Arg Val Arg
 210 215 220
 Ser Arg Phe Asn Pro Leu Cys Gly Ser Ala Gln His Trp Ser Glu Trp
 225 230 235 240
 Ser His Pro Ile His Trp Gly Ser Asn Thr Ser Lys Glu Asn Thr Val
 245 250 255
 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys
 260 265 270
 Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg
 275 280 285
 Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn
 290 295 300
 Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser
 305 310 315 320
 Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys
 325 330 335
 Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr
 340 345 350
 Lys Ser Phe Asn Arg Gly Glu Cys
 355 360

<210> 19
 <211> 36
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligonucleotide primer ZC19905

<400> 19
 acaggatccg tcagcatgcc gcgtggctgg gccgcc

36

<210> 20
 <211> 33
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligonucleotide primer ZC19906

<400> 20
 acagaattct tagctggcct ggggtccagg cgt

33

158x

<210> 21
 <211> 36
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligonucleotide primer ZC19931

<400> 21
 gggtggtacc gcaagatgcc gcgtggctgg gccgcc 36

<210> 22
 <211> 29
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligonucleotide primer ZC19932

<400> 22
 cggaggatcc gtgagggttc cagccttcc 29

<210> 23
 <211> 8
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> FLAG tag amino acid sequence

<400> 23
 Asp Tyr Lys Asp Asp Asp Asp Lys
 1 5

<210> 24
 <211> 66
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligonucleotide primer spanning vector flanking
 region and the 5' end of the zalphall

<400> 24
 tccactttgc ctttctctcc acaggtgtcc agggaattca tcgataatgc cgcgtggctg 60
 ggccgc 66

158y

<210> 25
 <211> 699
 <212> DNA
 <213> Homo sapiens

<400> 25
 gagcccagat cttcagacaa aactcacaca tgcccaccgt gcccagcacc tgaagccgag 60
 ggggcaccgt cagtcttcct cttcccccca aaaccacaagg acaccctcat gatctcccgg 120
 acccctgagg tcacatgcgt ggtggtggac gtgagccacg aagaccctga ggtcaagttc 180
 aactggtacg tggacggcgt ggaggtgcat aatgccaaaga caaagccgcg ggaggagcag 240
 tacaacagca cgtaccgtgt ggtcagcgtc ctcaccgtcc tgcaccagga ctggctgaat 300
 ggcaaggagt acaagtgcaa ggtctccaac aaagccctcc catcctccat cgagaaaacc 360
 atctccaaag ccaaagggca gccccgagaa ccacaggtgt acaccctgcc cccatcccgg 420
 gatgagctga ccaagaacca ggtcagcctg acctgcctgg tcaaaggctt ctatcccagc 480
 gacatcgccg tggagtggga gagcaatggg cagccggaga acaactacaa gaccacgcct 540
 cccgtgctgg actccgacgg ctccttcttc ctctacagca agctcaccgt ggacaagagc 600
 aggtggcagc aggggaacgt cttctcatgc tccgtgatgc atgaggctct gcacaaccac 660
 tacacgcaga agagcctctc cctgtctccg ggtaaataa 699

<210> 26
 <211> 62
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> First Oligonucleotide primer spanning 3' end of
 the zalphall extracellular domain and the 5' end
 of Fc4

<400> 26
 gcacggtggg catgtgtgag ttttgtctga agatctgggc tcgtgagggt tccagccttc 60
 ct 62

<210> 27
 <211> 61
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Second Oligonucleotide primer spanning 3' end of
 the zalphall extracellular domain and the 5' end
 of Fc4

<400> 27
 agaccagtc agaggagtta aaggaaggct ggaaccctca cgagcccaga tcttcagaca 60
 a 61

<210> 28
 <211> 67
 <212> DNA
 <213> Artificial Sequence

158z

<220>

<223> Oligonucleotide primer spanning the 3' end of Fc4
and the vector flanking region

<400> 28

gtgggcctct ggggtgggta caaccccaga gctgttttaa tctagattat ttacccggag 60
acaggga 67

<210> 29

<211> 1821

<212> DNA

<213> Artificial Sequence

<220>

<223> Polynucleotide encoding MBP-human zalphall soluble
receptor fusion

<221> CDS

<222> (1)...(1821)

<400> 29

atg	aaa	atc	gaa	gaa	ggt	aaa	ctg	gta	atc	tgg	att	aac	ggc	gat	aaa	48
Met	Lys	Ile	Glu	Glu	Gly	Lys	Leu	Val	Ile	Trp	Ile	Asn	Gly	Asp	Lys	
1			5					10						15		
ggc	tat	aac	ggt	ctc	gct	gaa	gtc	ggt	aag	aaa	ttc	gag	aaa	gat	acc	96
Gly	Tyr	Asn	Gly	Leu	Ala	Glu	Val	Gly	Lys	Lys	Phe	Glu	Lys	Asp	Thr	
			20					25						30		
gga	att	aaa	gtc	acc	gtt	gag	cat	ccg	gat	aaa	ctg	gaa	gag	aaa	ttc	144
Gly	Ile	Lys	Val	Thr	Val	Glu	His	Pro	Asp	Lys	Leu	Glu	Glu	Lys	Phe	
		35				40						45				
cca	cag	gtt	gcg	gca	act	ggc	gat	ggc	cct	gac	att	atc	ttc	tgg	gca	192
Pro	Gln	Val	Ala	Ala	Thr	Gly	Asp	Gly	Pro	Asp	Ile	Ile	Phe	Trp	Ala	
	50					55					60					
cac	gac	cgc	ttt	ggt	ggc	tac	gct	caa	tct	ggc	ctg	ttg	gct	gaa	atc	240
His	Asp	Arg	Phe	Gly	Gly	Tyr	Ala	Gln	Ser	Gly	Leu	Leu	Ala	Glu	Ile	
65				70				75						80		
acc	ccg	gac	aaa	gcg	ttc	cag	gac	aag	ctg	tat	ccg	ttt	acc	tgg	gat	288
Thr	Pro	Asp	Lys	Ala	Phe	Gln	Asp	Lys	Leu	Tyr	Pro	Phe	Thr	Trp	Asp	
			85					90						95		
gcc	gta	cgt	tac	aac	ggc	aag	ctg	att	gct	tac	ccg	atc	gct	gtt	gaa	336
Ala	Val	Arg	Tyr	Asn	Gly	Lys	Leu	Ile	Ala	Tyr	Pro	Ile	Ala	Val	Glu	
			100					105					110			
gcg	tta	tcg	ctg	att	tat	aac	aaa	gat	ctg	ctg	ccg	aac	ccg	cca	aaa	384
Ala	Leu	Ser	Leu	Ile	Tyr	Asn	Lys	Asp	Leu	Leu	Pro	Asn	Pro	Pro	Lys	
		115					120					125				

158aa

acc tgg gaa gag atc ccg gcg ctg gat aaa gaa ctg aaa gcg aaa ggt	432
Thr Trp Glu Glu Ile Pro Ala Leu Asp Lys Glu Leu Lys Ala Lys Gly	
130 135 140	
aag agc gcg ctg atg ttc aac ctg caa gaa ccg tac ttc acc tgg ccg	480
Lys Ser Ala Leu Met Phe Asn Leu Gln Glu Pro Tyr Phe Thr Trp Pro	
145 150 155 160	
ctg att gct gct gac ggg ggt tat gcg ttc aag tat gaa aac ggc aag	528
Leu Ile Ala Ala Asp Gly Gly Tyr Ala Phe Lys Tyr Glu Asn Gly Lys	
165 170 175	
tac gac att aaa gac gtg ggc gtg gat aac gct ggc gcg aaa gcg ggt	576
Tyr Asp Ile Lys Asp Val Gly Val Asp Asn Ala Gly Ala Lys Ala Gly	
180 185 190	
ctg acc ttc ctg gtt gac ctg att aaa aac aaa cac atg aat gca gac	624
Leu Thr Phe Leu Val Asp Leu Ile Lys Asn Lys His Met Asn Ala Asp	
195 200 205	
acc gat tac tcc atc gca gaa gct gcc ttt aat aaa ggc gaa aca gcg	672
Thr Asp Tyr Ser Ile Ala Glu Ala Ala Phe Asn Lys Gly Glu Thr Ala	
210 215 220	
atg acc atc aac ggc ccg tgg gca tgg tcc aac atc gac acc agc aaa	720
Met Thr Ile Asn Gly Pro Trp Ala Trp Ser Asn Ile Asp Thr Ser Lys	
225 230 235 240	
gtg aat tat ggt gta acg gta ctg ccg acc ttc aag ggt caa cca tcc	768
Val Asn Tyr Gly Val Thr Val Leu Pro Thr Phe Lys Gly Gln Pro Ser	
245 250 255	
aaa ccg ttc gtt ggc gtg ctg agc gca ggt att aac gcc gcc agt ccg	816
Lys Pro Phe Val Gly Val Leu Ser Ala Gly Ile Asn Ala Ala Ser Pro	
260 265 270	
aac aaa gag ctg gca aaa gag ttc ctc gaa aac tat ctg ctg act gat	864
Asn Lys Glu Leu Ala Lys Glu Phe Leu Glu Asn Tyr Leu Leu Thr Asp	
275 280 285	
gaa ggt ctg gaa gcg gtt aat aaa gac aaa ccg ctg ggt gcc gta gcg	912
Glu Gly Leu Glu Ala Val Asn Lys Asp Lys Pro Leu Gly Ala Val Ala	
290 295 300	
ctg aag tct tac gag gaa gag ttg gcg aaa gat cca cgt att gcc gcc	960
Leu Lys Ser Tyr Glu Glu Glu Leu Ala Lys Asp Pro Arg Ile Ala Ala	
305 310 315 320	
acc atg gaa aac gcc cag aaa ggt gaa atc atg ccg aac atc ccg cag	1008
Thr Met Glu Asn Ala Gln Lys Gly Glu Ile Met Pro Asn Ile Pro Gln	
325 330 335	
atg tcc gct ttc tgg tat gcc gtg cgt act gcg gtg atc aac gcc gcc	1056
Met Ser Ala Phe Trp Tyr Ala Val Arg Thr Ala Val Ile Asn Ala Ala	
340 345 350	

158bb

agc ggt cgt cag act gtc gat gaa gcc ctg aaa gac gcg cag act aat	1104
Ser Gly Arg Gln Thr Val Asp Glu Ala Leu Lys Asp Ala Gln Thr Asn	
355 360 365	
tcg agc tcc cac cat cac cat cac cac gcg aat tcg gta ccg ctg gtt	1152
Ser Ser Ser His His His His His His Ala Asn Ser Val Pro Leu Val	
370 375 380	
ccg cgt gga tcc tgc ccc gac ctc gtc tgc tac acc gat tac ctc cag	1200
Pro Arg Gly Ser Cys Pro Asp Leu Val Cys Tyr Thr Asp Tyr Leu Gln	
385 390 395 400	
acg gtc atc tgc atc ctg gaa atg tgg aac ctc cac ccc agc acg ctc	1248
Thr Val Ile Cys Ile Leu Glu Met Trp Asn Leu His Pro Ser Thr Leu	
405 410 415	
acc ctt acc tgg caa gac cag tat gaa gag ctg aag gac gag gcc acc	1296
Thr Leu Thr Trp Gln Asp Gln Tyr Glu Glu Leu Lys Asp Glu Ala Thr	
420 425 430	
tcc tgc agc ctc cac agg tcg gcc cac aat gcc acg cat gcc acc tac	1344
Ser Cys Ser Leu His Arg Ser Ala His Asn Ala Thr His Ala Thr Tyr	
435 440 445	
acc tgc cac atg gat gta ttc cac ttc atg gcc gac gac att ttc agt	1392
Thr Cys His Met Asp Val Phe His Phe Met Ala Asp Asp Ile Phe Ser	
450 455 460	
gtc aac atc aca gac cag tct ggc aac tac tcc cag gag tgt ggc agc	1440
Val Asn Ile Thr Asp Gln Ser Gly Asn Tyr Ser Gln Glu Cys Gly Ser	
465 470 475 480	
ttt ctc ctg gct gag agc atc aag ccg gct ccc cct ttc aac gtg act	1488
Phe Leu Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Phe Asn Val Thr	
485 490 495	
gtg acc ttc tca gga cag tat aat atc tcc tgg cgc tca gat tac gaa	1536
Val Thr Phe Ser Gly Gln Tyr Asn Ile Ser Trp Arg Ser Asp Tyr Glu	
500 505 510	
gac cct gcc ttc tac atg ctg aag ggc aag ctt cag tat gag ctg cag	1584
Asp Pro Ala Phe Tyr Met Leu Lys Gly Lys Leu Gln Tyr Glu Leu Gln	
515 520 525	
tac agg aac cgg gga gac ccc tgg gct gtg agt ccg agg aga aag ctg	1632
Tyr Arg Asn Arg Gly Asp Pro Trp Ala Val Ser Pro Arg Arg Lys Leu	
530 535 540	
atc tca gtg gac tca aga agt gtc tcc ctc ctc ccc ctg gag ttc cgc	1680
Ile Ser Val Asp Ser Arg Ser Val Ser Leu Leu Pro Leu Glu Phe Arg	
545 550 555 560	
aaa gac tcg agc tat gag ctg cag gtg cgg gca ggg ccc atg cct ggc	1728
Lys Asp Ser Ser Tyr Glu Leu Gln Val Arg Ala Gly Pro Met Pro Gly	
565 570 575	

158cc

tcc	tcc	tac	cag	ggg	acc	tgg	agt	gaa	tgg	agt	gac	ccg	gtc	atc	ttt	1776
Ser	Ser	Tyr	Gln	Gly	Thr	Trp	Ser	Glu	Trp	Ser	Asp	Pro	Val	Ile	Phe	
			580					585					590			

cag	acc	cag	tca	gag	gag	tta	aag	gaa	ggc	tgg	aac	cct	cac	tag		1821
Gln	Thr	Gln	Ser	Glu	Glu	Leu	Lys	Glu	Gly	Trp	Asn	Pro	His	*		
		595					600					605				

<210> 30
 <211> 606
 <212> PRT
 <213> Artificial Sequence

<400> 30

Met	Lys	Ile	Glu	Glu	Gly	Lys	Leu	Val	Ile	Trp	Ile	Asn	Gly	Asp	Lys	
1			5						10					15		
Gly	Tyr	Asn	Gly	Leu	Ala	Glu	Val	Gly	Lys	Lys	Phe	Glu	Lys	Asp	Thr	
			20					25					30			
Gly	Ile	Lys	Val	Thr	Val	Glu	His	Pro	Asp	Lys	Leu	Glu	Glu	Lys	Phe	
		35					40					45				
Pro	Gln	Val	Ala	Ala	Thr	Gly	Asp	Gly	Pro	Asp	Ile	Ile	Phe	Trp	Ala	
	50					55					60					
His	Asp	Arg	Phe	Gly	Gly	Tyr	Ala	Gln	Ser	Gly	Leu	Leu	Ala	Glu	Ile	
65				70					75					80		
Thr	Pro	Asp	Lys	Ala	Phe	Gln	Asp	Lys	Leu	Tyr	Pro	Phe	Thr	Trp	Asp	
			85					90					95			
Ala	Val	Arg	Tyr	Asn	Gly	Lys	Leu	Ile	Ala	Tyr	Pro	Ile	Ala	Val	Glu	
			100				105						110			
Ala	Leu	Ser	Leu	Ile	Tyr	Asn	Lys	Asp	Leu	Leu	Pro	Asn	Pro	Pro	Lys	
		115					120					125				
Thr	Trp	Glu	Glu	Ile	Pro	Ala	Leu	Asp	Lys	Glu	Leu	Lys	Ala	Lys	Gly	
	130					135					140					
Lys	Ser	Ala	Leu	Met	Phe	Asn	Leu	Gln	Glu	Pro	Tyr	Phe	Thr	Trp	Pro	
145				150					155					160		
Leu	Ile	Ala	Ala	Asp	Gly	Gly	Tyr	Ala	Phe	Lys	Tyr	Glu	Asn	Gly	Lys	
			165					170					175			
Tyr	Asp	Ile	Lys	Asp	Val	Gly	Val	Asp	Asn	Ala	Gly	Ala	Lys	Ala	Gly	
		180						185					190			
Leu	Thr	Phe	Leu	Val	Asp	Leu	Ile	Lys	Asn	Lys	His	Met	Asn	Ala	Asp	
	195					200						205				
Thr	Asp	Tyr	Ser	Ile	Ala	Glu	Ala	Ala	Phe	Asn	Lys	Gly	Glu	Thr	Ala	
	210					215					220					
Met	Thr	Ile	Asn	Gly	Pro	Trp	Ala	Trp	Ser	Asn	Ile	Asp	Thr	Ser	Lys	
225				230						235				240		
Val	Asn	Tyr	Gly	Val	Thr	Val	Leu	Pro	Thr	Phe	Lys	Gly	Gln	Pro	Ser	
			245					250					255			
Lys	Pro	Phe	Val	Gly	Val	Leu	Ser	Ala	Gly	Ile	Asn	Ala	Ala	Ser	Pro	
		260						265					270			
Asn	Lys	Glu	Leu	Ala	Lys	Glu	Phe	Leu	Glu	Asn	Tyr	Leu	Leu	Thr	Asp	
		275					280					285				
Glu	Gly	Leu	Glu	Ala	Val	Asn	Lys	Asp	Lys	Pro	Leu	Gly	Ala	Val	Ala	
	290					295				300						
Leu	Lys	Ser	Tyr	Glu	Glu	Glu	Leu	Ala	Lys	Asp	Pro	Arg	Ile	Ala	Ala	
305					310					315					320	

158dd

Thr	Met	Glu	Asn	Ala	Gln	Lys	Gly	Glu	Ile	Met	Pro	Asn	Ile	Pro	Gln
				325					330					335	
Met	Ser	Ala	Phe	Trp	Tyr	Ala	Val	Arg	Thr	Ala	Val	Ile	Asn	Ala	Ala
			340					345					350		
Ser	Gly	Arg	Gln	Thr	Val	Asp	Glu	Ala	Leu	Lys	Asp	Ala	Gln	Thr	Asn
		355					360					365			
Ser	Ser	Ser	His	His	His	His	His	His	Ala	Asn	Ser	Val	Pro	Leu	Val
	370					375					380				
Pro	Arg	Gly	Ser	Cys	Pro	Asp	Leu	Val	Cys	Tyr	Thr	Asp	Tyr	Leu	Gln
385					390					395					400
Thr	Val	Ile	Cys	Ile	Leu	Glu	Met	Trp	Asn	Leu	His	Pro	Ser	Thr	Leu
				405					410						415
Thr	Leu	Thr	Trp	Gln	Asp	Gln	Tyr	Glu	Glu	Leu	Lys	Asp	Glu	Ala	Thr
			420					425					430		
Ser	Cys	Ser	Leu	His	Arg	Ser	Ala	His	Asn	Ala	Thr	His	Ala	Thr	Tyr
		435					440					445			
Thr	Cys	His	Met	Asp	Val	Phe	His	Phe	Met	Ala	Asp	Asp	Ile	Phe	Ser
	450					455					460				
Val	Asn	Ile	Thr	Asp	Gln	Ser	Gly	Asn	Tyr	Ser	Gln	Glu	Cys	Gly	Ser
465					470					475					480
Phe	Leu	Leu	Ala	Glu	Ser	Ile	Lys	Pro	Ala	Pro	Pro	Phe	Asn	Val	Thr
				485					490					495	
Val	Thr	Phe	Ser	Gly	Gln	Tyr	Asn	Ile	Ser	Trp	Arg	Ser	Asp	Tyr	Glu
			500					505					510		
Asp	Pro	Ala	Phe	Tyr	Met	Leu	Lys	Gly	Lys	Leu	Gln	Tyr	Glu	Leu	Gln
		515					520					525			
Tyr	Arg	Asn	Arg	Gly	Asp	Pro	Trp	Ala	Val	Ser	Pro	Arg	Arg	Lys	Leu
	530					535					540				
Ile	Ser	Val	Asp	Ser	Arg	Ser	Val	Ser	Leu	Leu	Pro	Leu	Glu	Phe	Arg
545					550					555					560
Lys	Asp	Ser	Ser	Tyr	Glu	Leu	Gln	Val	Arg	Ala	Gly	Pro	Met	Pro	Gly
				565					570					575	
Ser	Ser	Tyr	Gln	Gly	Thr	Trp	Ser	Glu	Trp	Ser	Asp	Pro	Val	Ile	Phe
			580					585					590		
Gln	Thr	Gln	Ser	Glu	Glu	Leu	Lys	Glu	Gly	Trp	Asn	Pro	His		
		595					600					605			

<210> 31
 <211> 657
 <212> DNA
 <213> Artificial Sequence

<400> 31
 tgccccgacc tcgtctgcta caccgattac ctccagacgg tcatctgcat cctggaaatg 60
 tggaacctcc accccagcac gctcaccctt acctggcaag accagtatga agagctgaag 120
 gacgaggcca cctcctgcag cctccacagg tcggcccaca atgccacgca tgccacctac 180
 acctgccaca tggatgtatt ccacttcatg gccgacgaca ttttcagtgt caacatcaca 240
 gaccagtctg gcaactactc ccaggagtgt ggcagctttc tcctggctga gagcatcaag 300
 ccggctcccc ctttcaacgt gactgtgacc ttctcaggac agtataatat ctctggcgc 360
 tcagattacg aagaccctgc cttctacatg ctgaagggca agcttcagta tgagctgcag 420
 tacaggaacc ggggagaccc ctgggctgtg agtccgagga gaaagctgat ctcagtggac 480
 tcaagaagtg tctccctcct ccccctggag ttccgcaaag actcgagcta tgagctgcag 540
 gtgcgggcag ggcccatgcc tggctcctcc taccagggga cctggagtga atggagtgc 600
 ccggtcatct ttcagaccca gtcagaggag ttaaagggaag gctggaaccc tcactag 657

158ee

<210> 32
 <211> 65
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligonucleotide primerZC20187

<400> 32
 tcaccacgcg aattcgggtac cgctgggttcc gcgtggatcc tgccccgacc tcgtctgcta 60
 caccg 65

<210> 33
 <211> 68
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligonucleotide primerZC20185

<400> 33
 tctgtatcag gctgaaaatc ttatctcatc cgccaaaaca ctagtgaggg ttccagcctt 60
 cctttaac 68

<210> 34
 <211> 40
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligonucleotide primerZC19372

<400> 34
 tgtcgatgaa gccctgaaag acgcgcagac taattcgagc 40

<210> 35
 <211> 60
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligonucleotide primerZC19351

<400> 35
 acgcgcagac taattcgagc tcccaccatc accatcacca cgcgaaattcg gtaccgctgg 60

158ff

<210> 36
<211> 60
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primerZC19352

<400> 36
actcactata gggcgaattg cccgggggat ccacgcggaa ccagcggtac cgaattcgcg 60

<210> 37
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primerZC19371

<400> 37
acggccagtg aattgtaata cgactcacta tagggcgaat tg 42

<210> 38
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primerZC19907

<400> 38
atggatgtat tccacttcat ggcc 24

<210> 39
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primerZC19908

<400> 39
actgtcaaac gtgtccatat ccag 24

<210> 40
<211> 20
<212> DNA
<213> Artificial Sequence

158gg

<220>
<223> Oligonucleotide primerZC22277

<400> 40
ccaggagtgt ggcagctttc 20

<210> 41
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primerZC22276

<400> 41
gcttgccctt cagcatgtag a 21

<210> 42
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Zalphall TaqMan Probe, ZG31

<400> 42
cggctcccc tttcaacgtg act 23

<210> 43
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer, rRNA forward primer

<400> 43
cggctaccac atccaaggaa 20

<210> 44
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer, rRNA reverse primer

158hh

<400> 44
gctggaatta ccgcggct 18

<210> 45
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> rRNA TaqMan probe

<400> 45
tgctggcacc agacttgccc tc 22

<210> 46
<211> 3072
<212> DNA
<213> Mus musculus

<220>
<221> CDS
<222> (54)...(491)

<400> 46
gagaaccaga ccaaggccct gtcatacagct cctggagact cagttctggt ggc atg 56
Met
1

gag agg acc ctt gtc tgt ctg gta gtc atc ttc ttg ggg aca gtg gcc 104
Glu Arg Thr Leu Val Cys Leu Val Val Ile Phe Leu Gly Thr Val Ala
5 10 15

cat aaa tca agc ccc caa ggg cca gat cgc ctc ctg att aga ctt cgt 152
His Lys Ser Ser Pro Gln Gly Pro Asp Arg Leu Leu Ile Arg Leu Arg
20 25 30

cac ctt att gac att gtt gaa cag ctg aaa atc tat gaa aat gac ttg 200
His Leu Ile Asp Ile Val Glu Gln Leu Lys Ile Tyr Glu Asn Asp Leu
35 40 45

gat cct gaa ctt cta tca gct cca caa gat gta aag ggg cac tgt gag 248
Asp Pro Glu Leu Leu Ser Ala Pro Gln Asp Val Lys Gly His Cys Glu
50 55 60 65

cat gca gct ttt gcc tgt ttt cag aag gcc aaa ctc aag cca tca aac 296
His Ala Ala Phe Ala Cys Phe Gln Lys Ala Lys Leu Lys Pro Ser Asn
70 75 80

cct gga aac aat aag aca ttc atc att gac ctc gtg gcc cag ctc agg 344
Pro Gly Asn Asn Lys Thr Phe Ile Ile Asp Leu Val Ala Gln Leu Arg
85 90 95

158ii

agg agg ctg cct gcc agg agg gga gga aag aaa cag aag cac ata gct	392
Arg Arg Leu Pro Ala Arg Arg Gly Gly Lys Lys Gln Lys His Ile Ala	
100 105 110	
aaa tgc cct tcc tgt gat tgc tat gag aaa agg aca ccc aaa gaa ttc	440
Lys Cys Pro Ser Cys Asp Ser Tyr Glu Lys Arg Thr Pro Lys Glu Phe	
115 120 125	
cta gaa aga cta aaa tgg ctc ctt caa aag atg att cat cag cat ctc	488
Leu Glu Arg Leu Lys Trp Leu Leu Gln Lys Met Ile His Gln His Leu	
130 135 140 145	
tcc tagaacacat aggacccgaa gattcctgag gatccgagaa gattccccgag	541
Ser	
gactgaggag acgccggaca ctatagacgc tcacgaatgc aggagtacat cttgcctctt	601
gggattgcaa gtggagaagt acgatacgtt atgataagaa caactcagaa aagctatagg	661
ttaagatcct ttcgcccatt aactaagcag acattgtggt tccctgcaca gactccatgc	721
tgtcaacatg gaaaatctca actcaacaag agcccagctt cccgtgtcag ggattttctgg	781
tgctttctcaa gctgtggctt catcttattg cccaactgtg acattctttg attggaagg	841
gaaaactaaa gcttttagca aaaatacagc tagggaattt gtcgatctgc gagagtaaga	901
cctcttatga tcctaacgga atgatgtaag ctggaaataa taagcataag atgaaattga	961
aaattgaagt ctttattctt taagaaaaac tttgtacttg aaagcatgtc tgaagagttt	1021
actcattacc acaaacatct agcatattga taactaacat ctttatactc tacaagagag	1081
gctttccaga taggtacagt ttttcttctc tattaggtct atcaaaattt aacctattat	1141
gagggtcacc cctggctttc actgtttttc taaagaggca aggggtgtagt aagaagcagg	1201
cttaagttgc cttcctccca atgtcaagtt cttttataag ctaatagttt aatcttgtga	1261
agatggcaat gaaagcctgt ggaagtgcaa acctcactat cttctggagc caagtagaat	1321
tttcaagttt gtagctctca cctcaagtgg ttatgggtgt cctgtgatga atctgctagc	1381
tccagcctca gtctcctctc ccacatcctt tcctttcttt cctctttgaa acttctaaga	1441
aaaagcaatc caaacaagtt cagcacttaa gacacattgc atgcacactt ttgataagtt	1501
aaatccaacc atctatttaa aatcaaaatc aggagatgag ccaagagacc agaggttctg	1561
ttccagtttt aaacagactt ttactgaaca tccaatctt ttaaccacag aggctaaatt	1621
gagcaaatag ttttgccatt tgatataatt tccaacagta tgtttcaatg tcaagttaaa	1681
aagtctacaa agctattttc cctggagtgg tatcatcgct ttgagaattt cttatggtta	1741
aaatggatct gagatccaag catggcctgg gggatggttt tgatctaagg aaaaaggtgt	1801
ctgtacctca cagtgccttt aaaacaagca gagatcccgt gtaccgccct aagatagcac	1861
agactagtgt taactgattc ccagaaaagt gtcacaatca gaaccaacgc atttctcttaa	1921
actttaaaaa tatgtattgc aaagaacttg tgtaactgta aatgtgtgac tgttgatgac	1981
attatacaca catagcccac gtaagtgtcc aatgggtgcta gcattgggtg ctgagtttgc	2041
tgctcgaaag ctgaagcaga gatgcagtcc ttcacaaagc aatgatggac agagagggga	2101
gtctccatgt tttattcttt tgttggtttc ggctgtgtaa ctgttgactt cttgacattg	2161
tgatttttat atttaagaca atgtatttat tttgggtgtg ttattgttct agccttttaa	2221
atcactgaca atttctaata aagaagtaca aataattcaa tgcagcacag gctaagagct	2281
tgtatcgttt ggaaaagcca gtgaaggctt ctccactagc catgggaaag ctacgcttta	2341
gagtaaacta gacaaaattg cacagcagtc ttgaacctct ctgtgctcaa gactcagcca	2401
gtcctttgac attattgttc actgtgggtg ggaacacatt ggacctgaca cactgttgtg	2461
tgtccatgaa ggttgccact ggtgtaagct ttttttggtt ttcattctct tatctgtaga	2521
acaagaatgt ggggctttcc taagtctatt ctgtatttta ttctgaactt cgtatgtctg	2581
agtttttaatg ttttgagtac tcttacagga acacctgacc acacttttga gttaaatttt	2641
atcccaagtg tgatatttag ttgttcaaaa aggggaaggga tatacatata tacatacata	2701
catacatata tatatatata tatatatata tatatatata tatatatatg tatatatata	2761
tatatataga gagagagaga gagagagaga gagaaagaga gagaggttgt tgtagggtcat	2821
aggagttcag aggaaatcag ttatggccgt taatactgta gctgaaagtg ttttctttgt	2881
gaataaattc atagcattat tgatctatgt tattgctctg ttttatttac agtcacacct	2941
gagaatttag ttttaatatg aatgatgtac tttataactt aatgattatt tattatgtat	3001
ttgggttttga atgttttgtgt tcatggcttc ttatttaaga cctgatcata ttaaagtcta	3061

158jj

cccagtcgga a

3072

<210> 47
 <211> 146
 <212> PRT
 <213> Mus musculus

<400> 47
 Met Glu Arg Thr Leu Val Cys Leu Val Val Ile Phe Leu Gly Thr Val
 1 5 10 15
 Ala His Lys Ser Ser Pro Gln Gly Pro Asp Arg Leu Leu Ile Arg Leu
 20 25 30
 Arg His Leu Ile Asp Ile Val Glu Gln Leu Lys Ile Tyr Glu Asn Asp
 35 40 45
 Leu Asp Pro Glu Leu Leu Ser Ala Pro Gln Asp Val Lys Gly His Cys
 50 55 60
 Glu His Ala Ala Phe Ala Cys Phe Gln Lys Ala Lys Leu Lys Pro Ser
 65 70 75 80
 Asn Pro Gly Asn Asn Lys Thr Phe Ile Ile Asp Leu Val Ala Gln Leu
 85 90 95
 Arg Arg Arg Leu Pro Ala Arg Arg Gly Gly Lys Lys Gln Lys His Ile
 100 105 110
 Ala Lys Cys Pro Ser Cys Asp Ser Tyr Glu Lys Arg Thr Pro Lys Glu
 115 120 125
 Phe Leu Glu Arg Leu Lys Trp Leu Leu Gln Lys Met Ile His Gln His
 130 135 140
 Leu Ser
 145

<210> 48
 <211> 100
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligonucleotide primer ZC12749

<400> 48
 gtaccttccc gtaaattccct ccccttcccg gaattacacc cgcgtatttc ccagaaaagg 60
 aactgtagat ttctaggaat tcaatccttg gccacgcgtc 100

<210> 49
 <211> 100
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligonucleotide primer ZC12748

158kk

<400> 49
tcgagacgcg tggccaagga ttgaattcct agaaatctac agttcctttt ctgggaaata 60
cgcggtgtga attccgggaa ggggagggat ttacgggaag 100

<210> 50
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer ZC11450

<400> 50
acttgtggaa ttcgctagca ccaagggccc atcgggt 36

<210> 51
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer ZC11443

<400> 51
gcctagaacg cggttcattta cccggagaca gg 32

<210> 52
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer ZC11440

<400> 52
aattgaga 8

<210> 53
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer ZC11441

<400> 53
cgcggtctc 8

15811

<210> 54
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer ZC11501

<400> 54
gtcacttgaa ttcggtaccg cctctgttgt gtgcctg 37

<210> 55
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer ZC11451

<400> 55
gacctgaacg cgtctaacac tctcccctgt tg 32

<210> 56
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer ZC24052

<400> 56
tcagtcggaa ttcgcagaag ccatgccgcg tggctgggcc g 41

<210> 57
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer ZC24053

<400> 57
ctgtgacgct agcgtgaggg ttccagcctt cctt 34

<210> 58
<211> 41
<212> DNA
<213> Artificial Sequence

158mm

<220>

<223> Oligonucleotide primer ZC12834

<400> 58

tcagtcggaa ttgcgagaag ccatgttgaa gccatcatta c

41

<210> 59

<211> 90

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer ZC12831

<400> 59

aagacggtac cagatttcaa ctgctcatca gatggcggga agatgaagac agatggtgca
gccacagtag gattctcttt tgaagtattg

60

90

<210> 60

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer ZC23684

<400> 60

tcacccttac ctggcaagac

20

<210> 61

<211> 43

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer ZC23656

<400> 61

taatacgact cactataggg agggggagac acttcttgag tcc

43

<210> 62

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer ZC23685

158nn

<400> 62
aggtctgaat cccgactctg 20

<210> 63
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer ZC23657

<400> 63
taatacgact cactataggg aggacgtaat tgggtgtttaa taa 43

<210> 64
<211> 1707
<212> DNA
<213> homo sapiens

<220>
<221> CDS
<222> (1)...(1707)

<400> 64
atg ccg cgt ggc tgg gcc gcc ccc ttg ctc ctg ctg ctg ctc cag gga 48
Met Pro Arg Gly Trp Ala Ala Pro Leu Leu Leu Leu Leu Leu Gln Gly
1 5 10 15

gcc ctc gag ggg atg gag agg aag ctc tgc agt ccc aag cca ccc ccc 96
Ala Leu Glu Gly Met Glu Arg Lys Leu Cys Ser Pro Lys Pro Pro Pro
20 25 30

acc aag gcc tct ctc ccc act gac cct cca ggc tgg ggc tgc ccc gac 144
Thr Lys Ala Ser Leu Pro Thr Asp Pro Pro Gly Trp Gly Cys Pro Asp
35 40 45

ctc gtc tgc tac acc gat tac ctc cag acg gtc atc tgc atc ctg gaa 192
Leu Val Cys Tyr Thr Asp Tyr Leu Gln Thr Val Ile Cys Ile Leu Glu
50 55 60

atg tgg aac ctc cac ccc agc acg ctc acc ctt acc tgg ata ctt tct 240
Met Trp Asn Leu His Pro Ser Thr Leu Thr Leu Thr Trp Ile Leu Ser
65 70 75 80

aat aat act ggg tgc tat atc aag gac aga aca ctg gac ctc agg caa 288
Asn Asn Thr Gly Cys Tyr Ile Lys Asp Arg Thr Leu Asp Leu Arg Gln
85 90 95

gac cag tat gaa gag ctg aag gac gag gcc acc tcc tgc agc ctc cac 336
Asp Gln Tyr Glu Glu Leu Lys Asp Glu Ala Thr Ser Cys Ser Leu His
100 105 110

15800

agg	tcg	gcc	cac	aat	gcc	acg	cat	gcc	acc	tac	acc	tgc	cac	atg	gat	384
Arg	Ser	Ala	His	Asn	Ala	Thr	His	Ala	Thr	Tyr	Thr	Cys	His	Met	Asp	
		115					120					125				
gta	ttc	cac	ttc	atg	gcc	gac	gac	att	ttc	agt	gtc	aac	atc	aca	gac	432
Val	Phe	His	Phe	Met	Ala	Asp	Asp	Ile	Phe	Ser	Val	Asn	Ile	Thr	Asp	
	130					135					140					
cag	tct	ggc	aac	tac	tcc	cag	gag	tgt	ggc	agc	ttt	ctc	ctg	gct	gag	480
Gln	Ser	Gly	Asn	Tyr	Ser	Gln	Glu	Cys	Gly	Ser	Phe	Leu	Leu	Ala	Glu	
145					150					155					160	
agc	aga	cag	tat	aat	atc	tcc	tgg	cgc	tca	gat	tac	gaa	gac	cct	gcc	528
Ser	Arg	Gln	Tyr	Asn	Ile	Ser	Trp	Arg	Ser	Asp	Tyr	Glu	Asp	Pro	Ala	
				165				170						175		
ttc	tac	atg	ctg	aag	ggc	aag	ctt	cag	tat	gag	ctg	cag	tac	agg	aac	576
Phe	Tyr	Met	Leu	Lys	Gly	Lys	Leu	Gln	Tyr	Glu	Leu	Gln	Tyr	Arg	Asn	
			180					185						190		
cgg	gga	gac	ccc	tgg	gct	gtg	agt	ccg	agg	aga	aag	ctg	atc	tca	gtg	624
Arg	Gly	Asp	Pro	Trp	Ala	Val	Ser	Pro	Arg	Arg	Lys	Leu	Ile	Ser	Val	
		195					200					205				
gac	tca	aga	agt	gtc	tcc	ctc	ctc	ccc	ctg	gag	ttc	cgc	aaa	gac	tcg	672
Asp	Ser	Arg	Ser	Val	Ser	Leu	Leu	Pro	Leu	Glu	Phe	Arg	Lys	Asp	Ser	
	210					215					220					
agc	tat	gag	ctg	cag	gtg	cgg	gca	ggg	ccc	atg	cct	ggc	tcc	tcc	tac	720
Ser	Tyr	Glu	Leu	Gln	Val	Arg	Ala	Gly	Pro	Met	Pro	Gly	Ser	Ser	Tyr	
225					230					235					240	
cag	ggg	acc	tgg	agt	gaa	tgg	agt	gac	ccg	gtc	atc	ttt	cag	acc	cag	768
Gln	Gly	Thr	Trp	Ser	Glu	Trp	Ser	Asp	Pro	Val	Ile	Phe	Gln	Thr	Gln	
				245				250						255		
tca	gag	gag	tta	aag	gaa	ggc	tgg	aac	cct	cac	ctg	ctg	ctt	ctc	ctc	816
Ser	Glu	Glu	Leu	Lys	Glu	Gly	Trp	Asn	Pro	His	Leu	Leu	Leu	Leu	Leu	
			260					265						270		
ctg	ctt	gtc	ata	gtc	ttc	att	cct	gcc	ttc	tgg	agc	ctg	aag	acc	cat	864
Leu	Leu	Val	Ile	Val	Phe	Ile	Pro	Ala	Phe	Trp	Ser	Leu	Lys	Thr	His	
		275					280					285				
cca	ttg	tgg	agg	cta	tgg	aag	aag	ata	tgg	gcc	gtc	ccc	agc	cct	gag	912
Pro	Leu	Trp	Arg	Leu	Trp	Lys	Lys	Ile	Trp	Ala	Val	Pro	Ser	Pro	Glu	
	290					295					300					
cgg	ttc	ttc	atg	ccc	ctg	tac	aag	ggc	tgc	agc	gga	gac	ttc	aag	aaa	960
Arg	Phe	Phe	Met	Pro	Leu	Tyr	Lys	Gly	Cys	Ser	Gly	Asp	Phe	Lys	Lys	
305					310					315					320	
tgg	gtg	ggt	gca	ccc	ttc	act	ggc	tcc	agc	ctg	gag	ctg	gga	ccc	tgg	1008
Trp	Val	Gly	Ala	Pro	Phe	Thr	Gly	Ser	Ser	Leu	Glu	Leu	Gly	Pro	Trp	
				325				330						335		

158pp

agc cca gag gtg ccc tcc acc ctg gag gtg tac agc tgc cac cca cca	1056
Ser Pro Glu Val Pro Ser Thr Leu Glu Val Tyr Ser Cys His Pro Pro	
340 345 350	
cgg agc ccg gcc aag agg ctg cag ctc acg gag cta caa gaa cca gca	1104
Arg Ser Pro Ala Lys Arg Leu Gln Leu Thr Glu Leu Gln Glu Pro Ala	
355 360 365	
gag ctg gtg gag tct gac ggt gtg ccc aag ccc agc ttc tgg ccg aca	1152
Glu Leu Val Glu Ser Asp Gly Val Pro Lys Pro Ser Phe Trp Pro Thr	
370 375 380	
gcc cag aac tcg ggg ggc tca gct tac agt gag gag agg gat ccg cca	1200
Ala Gln Asn Ser Gly Gly Ser Ala Tyr Ser Glu Glu Arg Asp Arg Pro	
385 390 395 400	
tac ggc ctg gtg tcc att gac aca gtg act gtg cta gat gca gag ggg	1248
Tyr Gly Leu Val Ser Ile Asp Thr Val Thr Val Leu Asp Ala Glu Gly	
405 410 415	
cca tgc acc tgg ccc tgc agc tgt gag gat gac ggc tac cca gcc ctg	1296
Pro Cys Thr Trp Pro Cys Ser Cys Glu Asp Asp Gly Tyr Pro Ala Leu	
420 425 430	
gac ctg gat gct ggc ctg gag ccc agc cca ggc cta gag gac cca ctc	1344
Asp Leu Asp Ala Gly Leu Glu Pro Ser Pro Gly Leu Glu Asp Pro Leu	
435 440 445	
ttg gat gca ggg acc aca gtc ctg tcc tgt ggc tgt gtc tca gct ggc	1392
Leu Asp Ala Gly Thr Thr Val Leu Ser Cys Gly Cys Val Ser Ala Gly	
450 455 460	
agc cct ggg cta gga ggg ccc ctg gga agc ctc ctg gac aga cta aag	1440
Ser Pro Gly Leu Gly Gly Pro Leu Gly Ser Leu Leu Asp Arg Leu Lys	
465 470 475 480	
cca ccc ctt gca gat ggg gag gac tgg gct ggg gga ctg ccc tgg ggt	1488
Pro Pro Leu Ala Asp Gly Glu Asp Trp Ala Gly Gly Leu Pro Trp Gly	
485 490 495	
ggc cgg tca cct gga ggg gtc tca gag agt gag gcg ggc tca ccc ctg	1536
Gly Arg Ser Pro Gly Gly Val Ser Glu Ser Glu Ala Gly Ser Pro Leu	
500 505 510	
gcc ggc ctg gat atg gac acg ttt gac agt ggc ttt gtg ggc tct gac	1584
Ala Gly Leu Asp Met Asp Thr Phe Asp Ser Gly Phe Val Gly Ser Asp	
515 520 525	
tgc agc agc cct gtg gag tgt gac ttc acc agc ccc ggg gac gaa gga	1632
Cys Ser Ser Pro Val Glu Cys Asp Phe Thr Ser Pro Gly Asp Glu Gly	
530 535 540	
ccc ccc cgg agc tac ctc cgc cag tgg gtg gtc att cct ccg cca ctt	1680
Pro Pro Arg Ser Tyr Leu Arg Gln Trp Val Val Ile Pro Pro Pro Leu	
545 550 555 560	

158qq

tcg agc cct gga ccc cag gcc agc taa
 Ser Ser Pro Gly Pro Gln Ala Ser *
 565

1707

<210> 65
 <211> 568
 <212> PRT
 <213> homo sapiens

<400> 65
 Met Pro Arg Gly Trp Ala Ala Pro Leu Leu Leu Leu Leu Leu Gln Gly
 1 5 10 15
 Ala Leu Glu Gly Met Glu Arg Lys Leu Cys Ser Pro Lys Pro Pro Pro
 20 25 30
 Thr Lys Ala Ser Leu Pro Thr Asp Pro Pro Gly Trp Gly Cys Pro Asp
 35 40 45
 Leu Val Cys Tyr Thr Asp Tyr Leu Gln Thr Val Ile Cys Ile Leu Glu
 50 55 60
 Met Trp Asn Leu His Pro Ser Thr Leu Thr Leu Thr Trp Ile Leu Ser
 65 70 75 80
 Asn Asn Thr Gly Cys Tyr Ile Lys Asp Arg Thr Leu Asp Leu Arg Gln
 85 90 95
 Asp Gln Tyr Glu Glu Leu Lys Asp Glu Ala Thr Ser Cys Ser Leu His
 100 105 110
 Arg Ser Ala His Asn Ala Thr His Ala Thr Tyr Thr Cys His Met Asp
 115 120 125
 Val Phe His Phe Met Ala Asp Asp Ile Phe Ser Val Asn Ile Thr Asp
 130 135 140
 Gln Ser Gly Asn Tyr Ser Gln Glu Cys Gly Ser Phe Leu Leu Ala Glu
 145 150 155 160
 Ser Arg Gln Tyr Asn Ile Ser Trp Arg Ser Asp Tyr Glu Asp Pro Ala
 165 170 175
 Phe Tyr Met Leu Lys Gly Lys Leu Gln Tyr Glu Leu Gln Tyr Arg Asn
 180 185 190
 Arg Gly Asp Pro Trp Ala Val Ser Pro Arg Arg Lys Leu Ile Ser Val
 195 200 205
 Asp Ser Arg Ser Val Ser Leu Leu Pro Leu Glu Phe Arg Lys Asp Ser
 210 215 220
 Ser Tyr Glu Leu Gln Val Arg Ala Gly Pro Met Pro Gly Ser Ser Tyr
 225 230 235 240
 Gln Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln Thr Gln
 245 250 255
 Ser Glu Glu Leu Lys Glu Gly Trp Asn Pro His Leu Leu Leu Leu Leu
 260 265 270
 Leu Leu Val Ile Val Phe Ile Pro Ala Phe Trp Ser Leu Lys Thr His
 275 280 285
 Pro Leu Trp Arg Leu Trp Lys Lys Ile Trp Ala Val Pro Ser Pro Glu
 290 295 300
 Arg Phe Phe Met Pro Leu Tyr Lys Gly Cys Ser Gly Asp Phe Lys Lys
 305 310 315 320
 Trp Val Gly Ala Pro Phe Thr Gly Ser Ser Leu Glu Leu Gly Pro Trp
 325 330 335
 Ser Pro Glu Val Pro Ser Thr Leu Glu Val Tyr Ser Cys His Pro Pro
 340 345 350

158rr

Arg Ser Pro Ala Lys Arg Leu Gln Leu Thr Glu Leu Gln Glu Pro Ala
 355 360 365
 Glu Leu Val Glu Ser Asp Gly Val Pro Lys Pro Ser Phe Trp Pro Thr
 370 375 380
 Ala Gln Asn Ser Gly Gly Ser Ala Tyr Ser Glu Glu Arg Asp Arg Pro
 385 390 395 400
 Tyr Gly Leu Val Ser Ile Asp Thr Val Thr Val Leu Asp Ala Glu Gly
 405 410 415
 Pro Cys Thr Trp Pro Cys Ser Cys Glu Asp Asp Gly Tyr Pro Ala Leu
 420 425 430
 Asp Leu Asp Ala Gly Leu Glu Pro Ser Pro Gly Leu Glu Asp Pro Leu
 435 440 445
 Leu Asp Ala Gly Thr Thr Val Leu Ser Cys Gly Cys Val Ser Ala Gly
 450 455 460
 Ser Pro Gly Leu Gly Gly Pro Leu Gly Ser Leu Leu Asp Arg Leu Lys
 465 470 475 480
 Pro Pro Leu Ala Asp Gly Glu Asp Trp Ala Gly Gly Leu Pro Trp Gly
 485 490 495
 Gly Arg Ser Pro Gly Gly Val Ser Glu Ser Glu Ala Gly Ser Pro Leu
 500 505 510
 Ala Gly Leu Asp Met Asp Thr Phe Asp Ser Gly Phe Val Gly Ser Asp
 515 520 525
 Cys Ser Ser Pro Val Glu Cys Asp Phe Thr Ser Pro Gly Asp Glu Gly
 530 535 540
 Pro Pro Arg Ser Tyr Leu Arg Gln Trp Val Val Ile Pro Pro Pro Leu
 545 550 555 560
 Ser Ser Pro Gly Pro Gln Ala Ser
 565

<210> 66
 <211> 741
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Degenerate polynucleotide sequence of SEQ ID NO:69

<221> misc_feature
 <222> (1)...(741)
 <223> n = A,T,C or G

<400> 66
 atggarmgna arytnhtgyws nccnaarccn ccnccnacna argcnwsnyt nccnacngay 60
 ccnccnggnt ggggntgycc ngayytngtn tgytayacng aytayytnc racngtnath 120
 tgyathytng aratgtggaa yytncaayccn wsnacnytna cnytnacntg gathytnwsn 180
 aayaayacng gntgytayat haargaymgn acnytngayy tnmgncarga ycartaygar 240
 garytnaarg aygargcnac nwsntgywsn ytncaymgnw sngcncayaa ygcnacncay 300
 gcnacntaya cntgycayat ggaygtntty cayttyatgg cngaygayat httywsngtn 360
 aayathacng aycarwsngg naaytaywsn cargartgyg gnwsnttyyt nytngcngar 420
 wsnmgncart ayaayathws ntggmgwnsn gaytaygarg ayccngcntt ytayatgytn 480
 aarggnaary tncartayga rytncartay mgnaaymgng gngayccntg ggcngtnwsn 540
 ccnmgmngna arytnathws ngtngaywsn mgnwsngtnw snytnytnc nytngartty 600
 mgnaargayw snwsntayga rytncargtn mgngcnggnc cnatgccngg nwsnwsntay 660
 carggnacnt ggwsngartg gwsngayccn gtnathttyc aracncarws ngargarytn 720
 aargarggnt ggaayccnca y 741

158ss

<210> 67
 <211> 4
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> WXXW motif

<221> VARIANT
 <222> (1)...(4)
 <223> Xaa = Any Amino Acid

<400> 67
 Trp Xaa Xaa Trp
 1

<210> 68
 <211> 741
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (1)...(741)

<400> 68
 atg gag agg aag ctc tgc agt ccc aag cca ccc ccc acc aag gcc tct 48
 Met Glu Arg Lys Leu Cys Ser Pro Lys Pro Pro Pro Thr Lys Ala Ser
 1 5 10 15

ctc ccc act gac cct cca ggc tgg ggc tgc ccc gac ctc gtc tgc tac 96
 Leu Pro Thr Asp Pro Pro Gly Trp Gly Cys Pro Asp Leu Val Cys Tyr
 20 25 30

acc gat tac ctc cag acg gtc atc tgc atc ctg gaa atg tgg aac ctc 144
 Thr Asp Tyr Leu Gln Thr Val Ile Cys Ile Leu Glu Met Trp Asn Leu
 35 40 45

cac ccc agc acg ctc acc ctt acc tgg ata ctt tct aat aat act ggg 192
 His Pro Ser Thr Leu Thr Leu Thr Trp Ile Leu Ser Asn Asn Thr Gly
 50 55 60

tgc tat atc aag gac aga aca ctg gac ctc agg caa gac cag tat gaa 240
 Cys Tyr Ile Lys Asp Arg Thr Leu Asp Leu Arg Gln Asp Gln Tyr Glu
 65 70 75 80

gag ctg aag gac gag gcc acc tcc tgc agc ctc cac agg tcg gcc cac 288
 Glu Leu Lys Asp Glu Ala Thr Ser Cys Ser Leu His Arg Ser Ala His
 85 90 95

aat gcc acg cat gcc acc tac acc tgc cac atg gat gta ttc cac ttc 336
 Asn Ala Thr His Ala Thr Tyr Thr Cys His Met Asp Val Phe His Phe
 100 105 110

158tt

atg gcc gac gac att ttc agt gtc aac atc aca gac cag tct ggc aac	384
Met Ala Asp Asp Ile Phe Ser Val Asn Ile Thr Asp Gln Ser Gly Asn	
115 120 125	
tac tcc cag gag tgt ggc agc ttt ctc ctg gct gag agc aga cag tat	432
Tyr Ser Gln Glu Cys Gly Ser Phe Leu Leu Ala Glu Ser Arg Gln Tyr	
130 135 140	
aat atc tcc tgg cgc tca gat tac gaa gac cct gcc ttc tac atg ctg	480
Asn Ile Ser Trp Arg Ser Asp Tyr Glu Asp Pro Ala Phe Tyr Met Leu	
145 150 155 160	
aag ggc aag ctt cag tat gag ctg cag tac agg aac cgg gga gac ccc	528
Lys Gly Lys Leu Gln Tyr Glu Leu Gln Tyr Arg Asn Arg Gly Asp Pro	
165 170 175	
tgg gct gtg agt ccg agg aga aag ctg atc tca gtg gac tca aga agt	576
Trp Ala Val Ser Pro Arg Arg Lys Leu Ile Ser Val Asp Ser Arg Ser	
180 185 190	
gtc tcc ctc ctc ccc ctg gag ttc cgc aaa gac tcg agc tat gag ctg	624
Val Ser Leu Leu Pro Leu Glu Phe Arg Lys Asp Ser Ser Tyr Glu Leu	
195 200 205	
cag gtg cgg gca ggg ccc atg cct ggc tcc tcc tac cag ggg acc tgg	672
Gln Val Arg Ala Gly Pro Met Pro Gly Ser Ser Tyr Gln Gly Thr Trp	
210 215 220	
agt gaa tgg agt gac ccg gtc atc ttt cag acc cag tca gag gag tta	720
Ser Glu Trp Ser Asp Pro Val Ile Phe Gln Thr Gln Ser Glu Glu Leu	
225 230 235 240	
aag gaa ggc tgg aac cct cac	741
Lys Glu Gly Trp Asn Pro His	
245	

<210> 69
 <211> 247
 <212> PRT
 <213> Homo sapiens

<400> 69
 Met Glu Arg Lys Leu Cys Ser Pro Lys Pro Pro Pro Thr Lys Ala Ser
 1 5 10 15
 Leu Pro Thr Asp Pro Pro Gly Trp Gly Cys Pro Asp Leu Val Cys Tyr
 20 25 30
 Thr Asp Tyr Leu Gln Thr Val Ile Cys Ile Leu Glu Met Trp Asn Leu
 35 40 45
 His Pro Ser Thr Leu Thr Leu Thr Trp Ile Leu Ser Asn Asn Thr Gly
 50 55 60
 Cys Tyr Ile Lys Asp Arg Thr Leu Asp Leu Arg Gln Asp Gln Tyr Glu
 65 70 75 80
 Glu Leu Lys Asp Glu Ala Thr Ser Cys Ser Leu His Arg Ser Ala His
 85 90 95

158uu

```

Asn Ala Thr His Ala Thr Tyr Thr Cys His Met Asp Val Phe His Phe
      100      105      110
Met Ala Asp Asp Ile Phe Ser Val Asn Ile Thr Asp Gln Ser Gly Asn
      115      120      125
Tyr Ser Gln Glu Cys Gly Ser Phe Leu Leu Ala Glu Ser Arg Gln Tyr
      130      135      140
Asn Ile Ser Trp Arg Ser Asp Tyr Glu Asp Pro Ala Phe Tyr Met Leu
145      150      155      160
Lys Gly Lys Leu Gln Tyr Glu Leu Gln Tyr Arg Asn Arg Gly Asp Pro
      165      170      175
Trp Ala Val Ser Pro Arg Arg Lys Leu Ile Ser Val Asp Ser Arg Ser
      180      185      190
Val Ser Leu Leu Pro Leu Glu Phe Arg Lys Asp Ser Ser Tyr Glu Leu
      195      200      205
Gln Val Arg Ala Gly Pro Met Pro Gly Ser Ser Tyr Gln Gly Thr Trp
      210      215      220
Ser Glu Trp Ser Asp Pro Val Ile Phe Gln Thr Gln Ser Glu Glu Leu
225      230      235      240
Lys Glu Gly Trp Asn Pro His
      245

```

```

<210> 70
<211> 4
<212> PRT
<213> Artificial Sequence

```

```

<220>
<223> Domain linker motif; PAPP motif

```

```

<400> 70
Pro Ala Pro Pro
1

```

```

<210> 71
<211> 261
<212> PRT
<213> Artificial Sequence

```

```

<220>
<223> Representative variant soluble receptor with
domain linker

```

```

<221> VARIANT
<222> (1)...(261)
<223> Xaa = Any Amino Acid

```

```

<400> 71
Met Glu Arg Lys Leu Cys Ser Pro Lys Pro Pro Pro Thr Lys Ala Ser
1      5      10      15
Leu Pro Thr Asp Pro Pro Gly Trp Gly Cys Pro Asp Leu Val Cys Tyr
      20      25      30
Thr Asp Tyr Leu Gln Thr Val Ile Cys Ile Leu Glu Met Trp Asn Leu
      35      40      45

```

158vv

His	Pro	Ser	Thr	Leu	Thr	Leu	Thr	Trp	Ile	Leu	Ser	Asn	Asn	Thr	Gly	
	50					55				60						
Cys	Tyr	Ile	Lys	Asp	Arg	Thr	Leu	Asp	Leu	Arg	Gln	Asp	Gln	Tyr	Glu	
65				70				75							80	
Glu	Leu	Lys	Asp	Glu	Ala	Thr	Ser	Cys	Ser	Leu	His	Arg	Ser	Ala	His	
			85					90						95		
Asn	Ala	Thr	His	Ala	Thr	Tyr	Thr	Cys	His	Met	Asp	Val	Phe	His	Phe	
			100					105					110			
Met	Ala	Asp	Asp	Ile	Phe	Ser	Val	Asn	Ile	Thr	Asp	Gln	Ser	Gly	Asn	
		115					120					125				
Tyr	Ser	Gln	Glu	Cys	Gly	Ser	Phe	Leu	Leu	Ala	Glu	Ser	Xaa	Xaa	Pro	
	130					135					140					
Ala	Pro	Pro	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Arg	Gln	Tyr	Asn	Ile	
145				150				155							160	
Ser	Trp	Arg	Ser	Asp	Tyr	Glu	Asp	Pro	Ala	Phe	Tyr	Met	Leu	Lys	Gly	
				165				170						175		
Lys	Leu	Gln	Tyr	Glu	Leu	Gln	Tyr	Arg	Asn	Arg	Gly	Asp	Pro	Trp	Ala	
			180					185					190			
Val	Ser	Pro	Arg	Arg	Lys	Leu	Ile	Ser	Val	Asp	Ser	Arg	Ser	Val	Ser	
		195					200					205				
Leu	Leu	Pro	Leu	Glu	Phe	Arg	Lys	Asp	Ser	Ser	Tyr	Glu	Leu	Gln	Val	
	210					215					220					
Arg	Ala	Gly	Pro	Met	Pro	Gly	Ser	Ser	Tyr	Gln	Gly	Thr	Trp	Ser	Glu	
225					230					235					240	
Trp	Ser	Asp	Pro	Val	Ile	Phe	Gln	Thr	Gln	Ser	Glu	Glu	Leu	Lys	Glu	
				245					250					255		
Gly	Trp	Asn	Pro	His												
			260													

<210> 72
 <211> 1461
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Mouse zalpahl1 extracellular domain murine
 immunoglobulin gamma 2a heavy chain Fc region
 fusion protein (zalpahl1m-mG2a) Polynucleotide

<221> CDS
 <222> (1)...(1461)

<400> 72																
atg	gat	gca	atg	aag	aga	ggg	ctc	tgc	tgt	gtg	ctg	ctg	ctg	tgt	ggc	48
Met	Asp	Ala	Met	Lys	Arg	Gly	Leu	Cys	Cys	Val	Leu	Leu	Leu	Cys	Gly	
1				5				10						15		
gcc	gtc	ttc	gtt	tcg	ctc	agc	cag	aaa	atc	cat	gcc	gag	ttg	aga	cgc	96
Ala	Val	Phe	Val	Ser	Leu	Ser	Gln	Lys	Ile	His	Ala	Glu	Leu	Arg	Arg	
			20					25					30			
ttc	cgg	aga	tgc	ctg	gac	ctc	act	tgc	tac	act	gac	tac	ctc	tgg	acc	144
Phe	Arg	Arg	Cys	Leu	Asp	Leu	Thr	Cys	Tyr	Thr	Asp	Tyr	Leu	Trp	Thr	
			35				40					45				

158ww

atc acc tgt gtc ctg gag aca cgg agc ccc aac ccc agc ata ctc agt Ile Thr Cys Val Leu Glu Thr Arg Ser Pro Asn Pro Ser Ile Leu Ser 50 55 60	192
ctc acc tgg caa gat gaa tat gag gaa ctt cag gac caa gag acc ttc Leu Thr Trp Gln Asp Glu Tyr Glu Glu Leu Gln Asp Gln Glu Thr Phe 65 70 75 80	240
tgc agc cta cac agg tct ggc cac aac acc aca cat ata tgg tac acg Cys Ser Leu His Arg Ser Gly His Asn Thr Thr His Ile Trp Tyr Thr 85 90 95	288
tgc cat atg cgc ttg tct caa ttc ctg tcc gat gaa gtt ttc att gtc Cys His Met Arg Leu Ser Gln Phe Leu Ser Asp Glu Val Phe Ile Val 100 105 110	336
aat gtg acg gac cag tct ggc aac aac tcc caa gag tgt ggc agc ttt Asn Val Thr Asp Gln Ser Gly Asn Asn Ser Gln Glu Cys Gly Ser Phe 115 120 125	384
gtc ctg gct gag agc atc aaa cca gct ccc ccc ttg aac gtg act gtg Val Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Leu Asn Val Thr Val 130 135 140	432
gcc ttc tca gga cgc tat gat atc tcc tgg gac tca gct tat gac gaa Ala Phe Ser Gly Arg Tyr Asp Ile Ser Trp Asp Ser Ala Tyr Asp Glu 145 150 155 160	480
ccc tcc aac tac gtg ctg agg ggc aag cta caa tat gag ctg cag tat Pro Ser Asn Tyr Val Leu Arg Gly Lys Leu Gln Tyr Glu Leu Gln Tyr 165 170 175	528
cgg aac ctc aga gac ccc tat gct gtg agg ccg gtg acc aag ctg atc Arg Asn Leu Arg Asp Pro Tyr Ala Val Arg Pro Val Thr Lys Leu Ile 180 185 190	576
tca gtg gac tca aga aac gtc tct ctt ctc cct gaa gag ttc cac aaa Ser Val Asp Ser Arg Asn Val Ser Leu Leu Pro Glu Glu Phe His Lys 195 200 205	624
gat tct agc tac cag ctg cag gtg cgg gca gcg cct cag cca ggc act Asp Ser Ser Tyr Gln Leu Gln Val Arg Ala Ala Pro Gln Pro Gly Thr 210 215 220	672
tca ttc agg ggg acc tgg agt gag tgg agt gac ccc gtc atc ttt cag Ser Phe Arg Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln 225 230 235 240	720
acc cag gct ggg gag ccc gag gca ggc tgg gac cct cac gag ccc aga Thr Gln Ala Gly Glu Pro Glu Ala Gly Trp Asp Pro His Glu Pro Arg 245 250 255	768
tct ccc aca atc aag ccc tgt cct cca tgc aaa tgc cca gca cct aac Ser Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn 260 265 270	816

[illegible]

158yy

<210> 73
 <211> 486
 <212> PRT
 <213> Artificial Sequence

<400> 73
 Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly
 1 5 10 15
 Ala Val Phe Val Ser Leu Ser Gln Lys Ile His Ala Glu Leu Arg Arg
 20 25 30
 Phe Arg Arg Cys Leu Asp Leu Thr Cys Tyr Thr Asp Tyr Leu Trp Thr
 35 40 45
 Ile Thr Cys Val Leu Glu Thr Arg Ser Pro Asn Pro Ser Ile Leu Ser
 50 55 60
 Leu Thr Trp Gln Asp Glu Tyr Glu Glu Leu Gln Asp Gln Glu Thr Phe
 65 70 75 80
 Cys Ser Leu His Arg Ser Gly His Asn Thr Thr His Ile Trp Tyr Thr
 85 90 95
 Cys His Met Arg Leu Ser Gln Phe Leu Ser Asp Glu Val Phe Ile Val
 100 105 110
 Asn Val Thr Asp Gln Ser Gly Asn Asn Ser Gln Glu Cys Gly Ser Phe
 115 120 125
 Val Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Leu Asn Val Thr Val
 130 135 140
 Ala Phe Ser Gly Arg Tyr Asp Ile Ser Trp Asp Ser Ala Tyr Asp Glu
 145 150 155 160
 Pro Ser Asn Tyr Val Leu Arg Gly Lys Leu Gln Tyr Glu Leu Gln Tyr
 165 170 175
 Arg Asn Leu Arg Asp Pro Tyr Ala Val Arg Pro Val Thr Lys Leu Ile
 180 185 190
 Ser Val Asp Ser Arg Asn Val Ser Leu Leu Pro Glu Glu Phe His Lys
 195 200 205
 Asp Ser Ser Tyr Gln Leu Gln Val Arg Ala Ala Pro Gln Pro Gly Thr
 210 215 220
 Ser Phe Arg Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln
 225 230 235 240
 Thr Gln Ala Gly Glu Pro Glu Ala Gly Trp Asp Pro His Glu Pro Arg
 245 250 255
 Ser Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn
 260 265 270
 Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp
 275 280 285
 Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp
 290 295 300
 Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn
 305 310 315 320
 Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn
 325 330 335
 Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp
 340 345 350
 Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro
 355 360 365
 Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala
 370 375 380
 Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys
 385 390 395 400

158zz

Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile
 405 410 415
 Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn
 420 425 430
 Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys
 435 440 445
 Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys
 450 455 460
 Ser Val Val His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe
 465 470 475 480
 Ser Arg Thr Pro Gly Lys
 485

<210> 74
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligonucleotide primer ZC26644

<400> 74
 ggggtcgacg gccggccacc atg

23

<210> 75
 <211> 35
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligonucleotide primer ZC26641

<400> 75
 caagtgaggt ccaggcatct ccggaagcgt ctcaa

35

<210> 76
 <211> 35
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligonucleotide primer ZC26642

<400> 76
 ttgagacgct tccggagatg cctggacctc acttg

35

<210> 77
 <211> 36
 <212> DNA
 <213> Artificial Sequence

158aaa

<220>
 <223> Oligonucleotide primer ZC26662

<400> 77
 tgtgggagat ctgggctcgt gaggggccca gcctgc 36

<210> 78
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligonucleotide primer ZC26643

<400> 78
 gagcccagat ctcccacaat caagccctgt 30

<210> 79
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligonucleotide primer ZC26645

<400> 79
 aaacgcggcc gcggatccgg c 21

<210> 80
 <211> 35
 <212> PRT
 <213> Homo sapeins

<400> 80
 Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly
 1 5 10 15
 Ala Val Phe Val Ser Leu Ser Gln Glu Ile His Ala Glu Leu Arg Arg
 20 25 30
 Phe Arg Arg
 35

<210> 81
 <211> 966
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (1)...(966)

158bbb

<400> 81

ggg ggc ggg ggc gcc gcg cct acg gaa act cag cca cct gtg aca aat	48
Gly Gly Gly Gly Ala Ala Pro Thr Glu Thr Gln Pro Pro Val Thr Asn	
1 5 10 15	
ttg agt gtc tct gtt gaa aac ctc tgc aca gta ata tgg aca tgg aat	96
Leu Ser Val Ser Val Glu Asn Leu Cys Thr Val Ile Trp Thr Trp Asn	
20 25 30	
cca ccc gag gga gcc agc tca aat tgt agt cta tgg tat ttt agt cat	144
Pro Pro Glu Gly Ala Ser Ser Asn Cys Ser Leu Trp Tyr Phe Ser His	
35 40 45	
ttt ggc gac aaa caa gat aag aaa ata gct ccg gaa act cgt cgt tca	192
Phe Gly Asp Lys Gln Asp Lys Lys Ile Ala Pro Glu Thr Arg Arg Ser	
50 55 60	
ata gaa gta ccc ctg aat gag agg att tgt ctg caa gtg ggg tcc cag	240
Ile Glu Val Pro Leu Asn Glu Arg Ile Cys Leu Gln Val Gly Ser Gln	
65 70 75 80	
tgt agc acc aat gag agt gag aag cct agc att ttg gtt gaa aaa tgc	288
Cys Ser Thr Asn Glu Ser Glu Lys Pro Ser Ile Leu Val Glu Lys Cys	
85 90 95	
atc tca ccc cca gaa ggt gat cct gag tct gct gtg act gag ctt caa	336
Ile Ser Pro Pro Glu Gly Asp Pro Glu Ser Ala Val Thr Glu Leu Gln	
100 105 110	
tgc att tgg cac aac ctg agc tac atg aag tgt tct tgg ctc cct gga	384
Cys Ile Trp His Asn Leu Ser Tyr Met Lys Cys Ser Trp Leu Pro Gly	
115 120 125	
agg aat acc agt ccc gac act aac tat act ctc tac tat tgg cac aga	432
Arg Asn Thr Ser Pro Asp Thr Asn Tyr Thr Leu Tyr Tyr Trp His Arg	
130 135 140	
agc ctg gaa aaa att cat caa tgt gaa aac atc ttt aga gaa ggc caa	480
Ser Leu Glu Lys Ile His Gln Cys Glu Asn Ile Phe Arg Glu Gly Gln	
145 150 155 160	
tac ttt ggt tgt tcc ttt gat ctg acc aaa gtg aag gat tcc agt ttt	528
Tyr Phe Gly Cys Ser Phe Asp Leu Thr Lys Val Lys Asp Ser Ser Phe	
165 170 175	
gaa caa cac agt gtc caa ata atg gtc aag gat aat gca gga aaa att	576
Glu Gln His Ser Val Gln Ile Met Val Lys Asp Asn Ala Gly Lys Ile	
180 185 190	
aaa cca tcc ttc aat ata gtg cct tta act tcc cgt gtg aaa cct gat	624
Lys Pro Ser Phe Asn Ile Val Pro Leu Thr Ser Arg Val Lys Pro Asp	
195 200 205	
cct cca cat att aaa aac ctc tcc ttc cac aat gat gac cta tat gtg	672
Pro Pro His Ile Lys Asn Leu Ser Phe His Asn Asp Asp Leu Tyr Val	
210 215 220	

158ccc

caa tgg gag aat cca cag aat ttt att agc aga tgc cta ttt tat gaa	720
Gln Trp Glu Asn Pro Gln Asn Phe Ile Ser Arg Cys Leu Phe Tyr Glu	
225 230 235 240	
gta gaa gtc aat aac agc caa act gag aca cat aat gtt ttc tac gtc	768
Val Glu Val Asn Asn Ser Gln Thr Glu Thr His Asn Val Phe Tyr Val	
245 250 255	
caa gag gct aaa tgt gag aat cca gaa ttt gag aga aat gtg gag aat	816
Gln Glu Ala Lys Cys Glu Asn Pro Glu Phe Glu Arg Asn Val Glu Asn	
260 265 270	
aca tct tgt ttc atg gtc cct ggt gtt ctt cct gat act ttg aac aca	864
Thr Ser Cys Phe Met Val Pro Gly Val Leu Pro Asp Thr Leu Asn Thr	
275 280 285	
gtc aga ata aga gtc aaa aca aat aag tta tgc tat gag gat gac aaa	912
Val Arg Ile Arg Val Lys Thr Asn Lys Leu Cys Tyr Glu Asp Asp Lys	
290 295 300	
ctc tgg agt aat tgg agc caa gaa atg agt ata ggt aag aag cgc aat	960
Leu Trp Ser Asn Trp Ser Gln Glu Met Ser Ile Gly Lys Lys Arg Asn	
305 310 315 320	
tcc aca	966
Ser Thr	

<210> 82
 <211> 322
 <212> PRT
 <213> Homo sapiens

<400> 82

Gly Gly Gly Gly Ala Ala Pro Thr Glu Thr Gln Pro Pro Val Thr Asn	
1 5 10 15	
Leu Ser Val Ser Val Glu Asn Leu Cys Thr Val Ile Trp Thr Trp Asn	
20 25 30	
Pro Pro Glu Gly Ala Ser Ser Asn Cys Ser Leu Trp Tyr Phe Ser His	
35 40 45	
Phe Gly Asp Lys Gln Asp Lys Lys Ile Ala Pro Glu Thr Arg Arg Ser	
50 55 60	
Ile Glu Val Pro Leu Asn Glu Arg Ile Cys Leu Gln Val Gly Ser Gln	
65 70 75 80	
Cys Ser Thr Asn Glu Ser Glu Lys Pro Ser Ile Leu Val Glu Lys Cys	
85 90 95	
Ile Ser Pro Pro Glu Gly Asp Pro Glu Ser Ala Val Thr Glu Leu Gln	
100 105 110	
Cys Ile Trp His Asn Leu Ser Tyr Met Lys Cys Ser Trp Leu Pro Gly	
115 120 125	
Arg Asn Thr Ser Pro Asp Thr Asn Tyr Thr Leu Tyr Tyr Trp His Arg	
130 135 140	
Ser Leu Glu Lys Ile His Gln Cys Glu Asn Ile Phe Arg Glu Gly Gln	
145 150 155 160	
Tyr Phe Gly Cys Ser Phe Asp Leu Thr Lys Val Lys Asp Ser Ser Phe	
165 170 175	

158ddd

Glu Gln His Ser Val Gln Ile Met Val Lys Asp Asn Ala Gly Lys Ile
 180 185 190
 Lys Pro Ser Phe Asn Ile Val Pro Leu Thr Ser Arg Val Lys Pro Asp
 195 200 205
 Pro Pro His Ile Lys Asn Leu Ser Phe His Asn Asp Asp Leu Tyr Val
 210 215 220
 Gln Trp Glu Asn Pro Gln Asn Phe Ile Ser Arg Cys Leu Phe Tyr Glu
 225 230 235 240
 Val Glu Val Asn Asn Ser Gln Thr Glu Thr His Asn Val Phe Tyr Val
 245 250 255
 Gln Glu Ala Lys Cys Glu Asn Pro Glu Phe Glu Arg Asn Val Glu Asn
 260 265 270
 Thr Ser Cys Phe Met Val Pro Gly Val Leu Pro Asp Thr Leu Asn Thr
 275 280 285
 Val Arg Ile Arg Val Lys Thr Asn Lys Leu Cys Tyr Glu Asp Asp Lys
 290 295 300
 Leu Trp Ser Asn Trp Ser Gln Glu Met Ser Ile Gly Lys Lys Arg Asn
 305 310 315 320
 Ser Thr

<210> 83
 <211> 951
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (1)...(951)

<400> 83
 gac acc gag ata aaa gtt aac cct cct cag gat ttt gag ata gtg gat 48
 Asp Thr Glu Ile Lys Val Asn Pro Pro Gln Asp Phe Glu Ile Val Asp
 1 5 10 15
 ccc gga tac tta ggt tat ctc tat ttg caa tgg caa ccc cca ctg tct 96
 Pro Gly Tyr Leu Gly Tyr Leu Tyr Leu Gln Trp Gln Pro Pro Leu Ser
 20 25 30
 ctg gat cat ttt aag gaa tgc aca gtg gaa tat gaa cta aaa tac cga 144
 Leu Asp His Phe Lys Glu Cys Thr Val Glu Tyr Glu Leu Lys Tyr Arg
 35 40 45
 aac att ggt agt gaa aca tgg aag acc atc att act aag aat cta cat 192
 Asn Ile Gly Ser Glu Thr Trp Lys Thr Ile Ile Thr Lys Asn Leu His
 50 55 60
 tac aaa gat ggg ttt gat ctt aac aag ggc att gaa gcg aag ata cac 240
 Tyr Lys Asp Gly Phe Asp Leu Asn Lys Gly Ile Glu Ala Lys Ile His
 65 70 75 80
 acg ctt tta cca tgg caa tgc aca aat gga tca gaa gtt caa agt tcc 288
 Thr Leu Leu Pro Trp Gln Cys Thr Asn Gly Ser Glu Val Gln Ser Ser
 85 90 95

158eee

tgg gca gaa act act tat tgg ata tca cca caa gga att cca gaa act	336
Trp Ala Glu Thr Thr Tyr Trp Ile Ser Pro Gln Gly Ile Pro Glu Thr	
100 105 110	
aaa gtt cag gat atg gat tgc gta tat tac aat tgg caa tat tta ctc	384
Lys Val Gln Asp Met Asp Cys Val Tyr Tyr Asn Trp Gln Tyr Leu Leu	
115 120 125	
tgt tct tgg aaa cct ggc ata ggt gta ctt ctt gat acc aat tac aac	432
Cys Ser Trp Lys Pro Gly Ile Gly Val Leu Leu Asp Thr Asn Tyr Asn	
130 135 140	
ttg ttt tac tgg tat gag ggc ttg gat cat gca tta cag tgt gtt gat	480
Leu Phe Tyr Trp Tyr Glu Gly Leu Asp His Ala Leu Gln Cys Val Asp	
145 150 155 160	
tac atc aag gct gat gga caa aat ata gga tgc aga ttt ccc tat ttg	528
Tyr Ile Lys Ala Asp Gly Gln Asn Ile Gly Cys Arg Phe Pro Tyr Leu	
165 170 175	
gag gca tca gac tat aaa gat ttc tat att tgt gtt aat gga tca tca	576
Glu Ala Ser Asp Tyr Lys Asp Phe Tyr Ile Cys Val Asn Gly Ser Ser	
180 185 190	
gag aac aag cct atc aga tcc agt tat ttc act ttt cag ctt caa aat	624
Glu Asn Lys Pro Ile Arg Ser Ser Tyr Phe Thr Phe Gln Leu Gln Asn	
195 200 205	
ata gtt aaa cct ttg ccg cca gtc tat ctt act ttt act cgg gag agt	672
Ile Val Lys Pro Leu Pro Pro Val Tyr Leu Thr Phe Thr Arg Glu Ser	
210 215 220	
tca tgt gaa att aag ctg aaa tgg agc ata cct ttg gga cct att cca	720
Ser Cys Glu Ile Lys Leu Lys Trp Ser Ile Pro Leu Gly Pro Ile Pro	
225 230 235 240	
gca agg tgt ttt gat tat gaa att gag atc aga gaa gat gat act acc	768
Ala Arg Cys Phe Asp Tyr Glu Ile Glu Ile Arg Glu Asp Asp Thr Thr	
245 250 255	
ttg gtg act gct aca gtt gaa aat gaa aca tac acc ttg aaa aca aca	816
Leu Val Thr Ala Thr Val Glu Asn Glu Thr Tyr Thr Leu Lys Thr Thr	
260 265 270	
aat gaa acc cga caa tta tgc ttt gta gta aga agc aaa gtg aat att	864
Asn Glu Thr Arg Gln Leu Cys Phe Val Val Arg Ser Lys Val Asn Ile	
275 280 285	
tat tgc tca gat gac gga att tgg agt gag tgg agt gat aaa caa tgc	912
Tyr Cys Ser Asp Asp Gly Ile Trp Ser Glu Trp Ser Asp Lys Gln Cys	
290 295 300	
tgg gaa ggt gaa gac cta tcg aag aaa act ttg cta cgt	951
Trp Glu Gly Glu Asp Leu Ser Lys Lys Thr Leu Leu Arg	
305 310 315	

158fff

<210> 84
 <211> 317
 <212> PRT
 <213> Homo sapiens

<400> 84
 Asp Thr Glu Ile Lys Val Asn Pro Pro Gln Asp Phe Glu Ile Val Asp
 1 5 10 15
 Pro Gly Tyr Leu Gly Tyr Leu Tyr Leu Gln Trp Gln Pro Pro Leu Ser
 20 25 30
 Leu Asp His Phe Lys Glu Cys Thr Val Glu Tyr Glu Leu Lys Tyr Arg
 35 40 45
 Asn Ile Gly Ser Glu Thr Trp Lys Thr Ile Ile Thr Lys Asn Leu His
 50 55 60
 Tyr Lys Asp Gly Phe Asp Leu Asn Lys Gly Ile Glu Ala Lys Ile His
 65 70 75 80
 Thr Leu Leu Pro Trp Gln Cys Thr Asn Gly Ser Glu Val Gln Ser Ser
 85 90 95
 Trp Ala Glu Thr Thr Tyr Trp Ile Ser Pro Gln Gly Ile Pro Glu Thr
 100 105 110
 Lys Val Gln Asp Met Asp Cys Val Tyr Tyr Asn Trp Gln Tyr Leu Leu
 115 120 125
 Cys Ser Trp Lys Pro Gly Ile Gly Val Leu Leu Asp Thr Asn Tyr Asn
 130 135 140
 Leu Phe Tyr Trp Tyr Glu Gly Leu Asp His Ala Leu Gln Cys Val Asp
 145 150 155 160
 Tyr Ile Lys Ala Asp Gly Gln Asn Ile Gly Cys Arg Phe Pro Tyr Leu
 165 170 175
 Glu Ala Ser Asp Tyr Lys Asp Phe Tyr Ile Cys Val Asn Gly Ser Ser
 180 185 190
 Glu Asn Lys Pro Ile Arg Ser Ser Tyr Phe Thr Phe Gln Leu Gln Asn
 195 200 205
 Ile Val Lys Pro Leu Pro Pro Val Tyr Leu Thr Phe Thr Arg Glu Ser
 210 215 220
 Ser Cys Glu Ile Lys Leu Lys Trp Ser Ile Pro Leu Gly Pro Ile Pro
 225 230 235 240
 Ala Arg Cys Phe Asp Tyr Glu Ile Glu Ile Arg Glu Asp Asp Thr Thr
 245 250 255
 Leu Val Thr Ala Thr Val Glu Asn Glu Thr Tyr Thr Leu Lys Thr Thr
 260 265 270
 Asn Glu Thr Arg Gln Leu Cys Phe Val Val Arg Ser Lys Val Asn Ile
 275 280 285
 Tyr Cys Ser Asp Asp Gly Ile Trp Ser Glu Trp Ser Asp Lys Gln Cys
 290 295 300
 Trp Glu Gly Glu Asp Leu Ser Lys Lys Thr Leu Leu Arg
 305 310 315

<210> 85
 <211> 519
 <212> DNA
 <213> Homo sapeins

<220>
 <221> CDS
 <222> (1)...(519)

158ggg

<400> 85
 atc acg tgc cct ccc ccc atg tcc gtg gaa cac gca gac atc tgg gtc 48
 Ile Thr Cys Pro Pro Pro Met Ser Val Glu His Ala Asp Ile Trp Val
 1 5 10 15

aag agc tac agc ttg tac tcc agg gag cgg tac att tgt aac tct ggt 96
 Lys Ser Tyr Ser Leu Tyr Ser Arg Glu Arg Tyr Ile Cys Asn Ser Gly
 20 25 30

ttc aag cgt aaa gcc ggc acg tcc agc ctg acg gag tgc gtg ttg aac 144
 Phe Lys Arg Lys Ala Gly Thr Ser Ser Leu Thr Glu Cys Val Leu Asn
 35 40 45

aag gcc acg aat gtc gcc cac tgg aca acc ccc agt ctc aaa tgc att 192
 Lys Ala Thr Asn Val Ala His Trp Thr Thr Pro Ser Leu Lys Cys Ile
 50 55 60

aga gac cct gcc ctg gtt cac caa agg cca gcg cca ccc tcc aca gta 240
 Arg Asp Pro Ala Leu Val His Gln Arg Pro Ala Pro Pro Ser Thr Val
 65 70 75 80

acg acg gca ggg gtg acc cca cag cca gag agc ctc tcc cct tct gga 288
 Thr Thr Ala Gly Val Thr Pro Gln Pro Glu Ser Leu Ser Pro Ser Gly
 85 90 95

aaa gag ccc gca gct tca tct ccc agc tca aac aac aca gcg gcc aca 336
 Lys Glu Pro Ala Ala Ser Ser Pro Ser Ser Asn Asn Thr Ala Ala Thr
 100 105 110

aca gca gct att gtc ccg ggc tcc cag ctg atg cct tca aaa tca cct 384
 Thr Ala Ala Ile Val Pro Gly Ser Gln Leu Met Pro Ser Lys Ser Pro
 115 120 125

tcc aca gga acc aca gag ata agc agt cat gag tcc tcc cac ggc acc 432
 Ser Thr Gly Thr Thr Glu Ile Ser Ser His Glu Ser Ser His Gly Thr
 130 135 140

ccc tct cag aca aca gcc aag aac tgg gaa ctc aca gca tcc gcc tcc 480
 Pro Ser Gln Thr Thr Ala Lys Asn Trp Glu Leu Thr Ala Ser Ala Ser
 145 150 155 160

cac cag ccg cca ggt gtg tat cca cag ggc cac agc gac 519
 His Gln Pro Pro Gly Val Tyr Pro Gln Gly His Ser Asp
 165 170

<210> 86
 <211> 173
 <212> PRT
 <213> Homo sapeins

<400> 86
 Ile Thr Cys Pro Pro Pro Met Ser Val Glu His Ala Asp Ile Trp Val
 1 5 10 15
 Lys Ser Tyr Ser Leu Tyr Ser Arg Glu Arg Tyr Ile Cys Asn Ser Gly
 20 25 30

158hhh

Phe	Lys	Arg	Lys	Ala	Gly	Thr	Ser	Ser	Leu	Thr	Glu	Cys	Val	Leu	Asn
		35					40					45			
Lys	Ala	Thr	Asn	Val	Ala	His	Trp	Thr	Thr	Pro	Ser	Leu	Lys	Cys	Ile
	50					55					60				
Arg	Asp	Pro	Ala	Leu	Val	His	Gln	Arg	Pro	Ala	Pro	Pro	Ser	Thr	Val
65					70					75					80
Thr	Thr	Ala	Gly	Val	Thr	Pro	Gln	Pro	Glu	Ser	Leu	Ser	Pro	Ser	Gly
				85					90					95	
Lys	Glu	Pro	Ala	Ala	Ser	Ser	Pro	Ser	Ser	Asn	Asn	Thr	Ala	Ala	Thr
			100					105					110		
Thr	Ala	Ala	Ile	Val	Pro	Gly	Ser	Gln	Leu	Met	Pro	Ser	Lys	Ser	Pro
		115					120					125			
Ser	Thr	Gly	Thr	Thr	Glu	Ile	Ser	Ser	His	Glu	Ser	Ser	His	Gly	Thr
	130					135					140				
Pro	Ser	Gln	Thr	Thr	Ala	Lys	Asn	Trp	Glu	Leu	Thr	Ala	Ser	Ala	Ser
145					150					155					160
His	Gln	Pro	Pro	Gly	Val	Tyr	Pro	Gln	Gly	His	Ser	Asp			
				165					170						

CLAIMS:

1. An isolated polynucleotide encoding a heterodimeric or multimeric receptor complex comprising soluble receptor subunits, wherein the receptor complex comprises a sequence of amino acid residues that is at least 90% identical to the amino acid sequence as shown in SEQ ID NO:6, and a soluble IL-2R γ receptor polypeptide as shown in SEQ ID NO:4.
2. The isolated polynucleotide of claim 1, wherein the sequence of amino acid residues is as shown in SEQ ID NO:6.
3. The isolated polynucleotide of claim 1 or 2, wherein the receptor complex comprises a WSXWS motif as shown in SEQ ID NO:13.
4. The isolated polynucleotide of claim 2, wherein the sequence of amino acids as shown in SEQ ID NO:6 is encoded by the polynucleotide as shown in SEQ ID NO:7.
5. An isolated polynucleotide of claim 1 or 2, encoding a multimeric receptor complex, wherein the multimeric receptor complex further comprises a soluble Class I cytokine receptor.
6. An isolated polynucleotide of any one of claims 1-5, wherein the soluble receptor complex further comprises an affinity tag.
7. An expression vector comprising:
 - (a) a transcription promoter; a first DNA segment encoding a soluble receptor polypeptide having an amino acid sequence as shown in SEQ ID NO:6; and a transcription terminator, wherein said promoter, DNA segment and terminator are operably linked; and

(b) a second transcription promoter; a second DNA segment encoding a soluble IL-2R γ receptor polypeptide as shown in SEQ ID NO:4; and a transcription terminator, wherein said promoter, DNA segment and terminator are operably linked.

8. Two expression vectors comprising:

(a) a transcription promoter; a first DNA segment encoding a soluble receptor polypeptide having an amino acid sequence as shown in SEQ ID NO:6; and a transcription terminator, wherein said promoter, DNA segment and terminator are operably linked; and

(b) a second transcription promoter; a second DNA segment encoding a soluble IL-2R γ receptor polypeptide as shown in SEQ ID NO:4; and a transcription terminator, wherein said promoter, DNA segment and terminator are operably linked;

wherein the first and second DNA segments are contained within independent expression vectors; and wherein the polypeptides expressed from said DNA segments associate to form a heterodimeric or multimeric receptor complex.

9. The expression vector of claim 7, or two expression vectors according to claim 8, further comprising a secretory signal sequence operably linked to the first and second DNA segments.

10. A cultured cell comprising one or more expression vectors comprising:

(a) a transcription promoter; a first DNA segment encoding a soluble receptor polypeptide having an amino acid sequence as shown in SEQ ID NO:6; and a transcription terminator, wherein said promoter, DNA segment and terminator are operably linked; and

(b) a second transcription promoter; a second DNA segment encoding a soluble IL-2R γ receptor polypeptide as shown in SEQ ID NO:4; and a transcription terminator, wherein said promoter, DNA segment and terminator are operably linked;

wherein the first and second DNA segments are contained within a single expression vector or are contained within independent expression vectors;

and wherein the cell expresses the polypeptides encoded by the DNA segments.

11. The cultured cell of claim 10, wherein the first and second DNA segments are located on independent expression vectors and are co-transfected into the cell.

12. The cultured cell of claim 10, wherein the cell expresses a heterodimeric or multimeric soluble receptor complex encoded by the DNA segments.

13. The cell of claim 10, wherein the cell secretes a soluble receptor polypeptide heterodimeric or multimeric receptor complex.

14. The cell of claim 10, wherein the cell secretes a soluble receptor polypeptide heterodimer or multimeric complex that binds a ligand comprising a polypeptide of SEQ ID NO:10 or SEQ ID NO:47, or antagonizes the ligand activity.

15. A DNA construct encoding a fusion protein comprising:
a first DNA segment encoding a polypeptide having a sequence of amino acid residues as shown in SEQ ID NO:6; and
at least one other DNA segment encoding a soluble IL-2R γ receptor polypeptide as shown in SEQ ID NO:4,
wherein the first and other DNA segments are connected in-frame; and
wherein the first and other DNA segments encode the fusion protein.

16. An expression vector comprising the following operably linked elements:
a transcription promoter;
a DNA construct encoding a fusion protein according to claim 15; and
a transcription terminator,
wherein the promoter is operably linked to the DNA construct, and the DNA construct is operably linked to the transcription terminator.

17. A cultured cell comprising an expression vector according to claim 16, wherein the cell expresses a polypeptide encoded by the DNA construct.

18. A method of producing a fusion protein encoded by a DNA construct according to claim 15, comprising:

culturing a cell according to claim 17 such that the cell expresses the polypeptide encoded by the DNA construct; and

isolating the polypeptide produced by the cell.

19. An isolated heterodimeric or multimeric receptor complex comprising soluble receptor subunits, wherein at least one of the soluble receptor subunits comprises a sequence of amino acid residues that is at least 90% identical to an amino acid sequence as shown in SEQ ID NO:6, and wherein the receptor complex further comprises a soluble IL-2R γ receptor polypeptide as shown in SEQ ID NO:4.

20. The isolated heterodimeric or multimeric soluble receptor complex of claim 19, wherein at least one of the soluble receptor subunits comprises a soluble receptor polypeptide comprising a sequence of amino acid residues as shown in SEQ ID NO:6.

21. The isolated heterodimeric or multimeric receptor complex of claim 19 or 20, comprising a WSXWS motif as shown in SEQ ID NO:13.

22. The isolated multimeric soluble receptor complex according to any one of claims 19-21, wherein at least one of the soluble receptor subunits consists of a soluble receptor polypeptide comprising SEQ ID NO:6, and wherein at least one other of the soluble receptor subunits consists of a soluble receptor polypeptide comprising soluble IL-2R γ receptor polypeptide as shown in SEQ ID NO:4.

23. The isolated multimeric receptor complex according to any one of claims 19-22, further comprising a soluble Class I cytokine receptor.

24. The isolated heterodimeric receptor complex according to any one of claims 19-21, comprising a sequence of amino acid residues as shown in SEQ ID NO:6 and a soluble IL-2R γ receptor polypeptide as shown in SEQ ID NO:4.

25. The isolated heterodimeric receptor complex according to any one of claims 19-21 or 24, consisting of two soluble receptor subunits, wherein the first soluble receptor subunit consists of a soluble receptor polypeptide comprising a sequence of amino acid residues as shown in SEQ ID NO:6, and the second receptor subunit consists of a soluble receptor polypeptide comprising soluble IL-2R γ receptor polypeptide as shown in SEQ ID NO:4.

26. The isolated heterodimeric or multimeric receptor complex according to any one of claims 19-21, or the isolated multimeric receptor complex according to any one of claims 22-23, or the isolated heterodimeric receptor complex according to any one of claims 24-25, wherein the heterodimeric receptor complex binds a ligand comprising a polypeptide of SEQ ID NO:10 or SEQ ID NO:47, or antagonizes the ligand activity.

27. The isolated heterodimeric or multimeric receptor complex according to any one of claims 19-21 or 26, or the isolated multimeric receptor complex according to any one of claims 22-23 or 26, or the isolated heterodimeric receptor complex according to any one of claims 24-26, wherein at least one of the soluble receptor subunits further comprises an affinity tag, label, chemical moiety, toxin, biotin/avidin label, radionuclide, enzyme, substrate, cofactor, inhibitor, fluorescent marker, chemiluminescent marker, toxin, cytotoxic molecule or an immunoglobulin Fc domain.

28. A method of producing a soluble heterodimeric or multimeric complex comprising:

culturing a cell according to any of claims 10-14 or 17; and
isolating the soluble receptor polypeptides produced by the cell.

29. A method of producing an antibody to a soluble heterodimeric or multimeric receptor complex, wherein the inoculated soluble heterodimeric or multimeric receptor complex comprises SEQ ID NO:6 and a soluble IL-2R γ receptor polypeptide as shown in SEQ ID NO: 4;

wherein the complex elicits an immune response to produce the antibody;
and

wherein the antibody specifically binds to a heterodimeric or multimeric receptor complex comprising SEQ ID NO:6 and a soluble IL-2R γ receptor polypeptide as shown in SEQ ID NO:4.

30. An *in vitro* method for inhibiting a ligand comprising a polypeptide of SEQ ID NO:10 or SEQ ID NO:47, or for antagonizing the ligand activity-induced proliferation of hematopoietic cells and hematopoietic cell progenitors, comprising:

culturing bone marrow or peripheral blood cells with a composition comprising a heterodimeric or multimeric receptor complex comprising soluble receptor subunits, wherein at least one of the subunits comprises a sequence of amino acid residues that is at least 90% identical to SEQ ID NO:6, and wherein the receptor complex further comprises a soluble IL-2R γ receptor polypeptide as shown in SEQ ID NO: 4;

wherein the composition reduces proliferation of the hematopoietic cells in the bone marrow or peripheral blood cells as compared to bone marrow or peripheral blood cells cultured in the absence of soluble receptor complex.

31. An *in vitro* method for inhibiting a ligand comprising a polypeptide of SEQ ID NO:10, or for antagonizing the ligand activity-induced proliferation of hematopoietic cells and hematopoietic cell progenitors, comprising:

culturing bone marrow or peripheral blood cells with a composition comprising a soluble receptor, wherein the soluble receptor comprises a heterodimeric receptor complex comprising soluble receptor subunits, wherein the first soluble receptor subunit comprises a soluble receptor polypeptide comprising a sequence of amino acid residues that is at least 90% identical to SEQ ID NO:6, and wherein the second soluble

receptor subunit comprises a soluble IL-2R γ receptor polypeptide as shown in SEQ ID NO:4;

wherein the composition reduces proliferation of the hematopoietic cells in the bone marrow or peripheral blood cells as compared to bone marrow or peripheral blood cells cultured in the absence of soluble receptor.

32. An *in vitro* method for inhibiting a ligand comprising a polypeptide of SEQ ID NO:10 or antagonizing the ligand activity-induced proliferation of hematopoietic cells and hematopoietic cell progenitors comprising:

culturing bone marrow or peripheral blood cells with a composition comprising a soluble receptor, wherein the soluble receptor comprises a multimeric soluble receptor complex comprising soluble receptor subunits, wherein at least one of soluble receptor subunits comprises a soluble receptor polypeptide comprising a sequence of amino acid residues that is at least 90% identical to SEQ ID NO:6, and wherein at least one other of the soluble receptor subunits comprises a soluble receptor polypeptide comprising soluble IL-2R γ receptor polypeptide as shown in SEQ ID NO:4;

wherein the composition reduces proliferation of the hematopoietic cells in the bone marrow or peripheral blood cells as compared to bone marrow or peripheral blood cells cultured in the absence of soluble receptor.

33. The *in vitro* method according to any one of claims 30-32, wherein at least one of the soluble receptor subunits comprises a soluble receptor polypeptide comprising a sequence of amino acids as shown in SEQ ID NO:6.

34. The *in vitro* method according to any one of claims 30-33, wherein the hematopoietic cells and hematopoietic progenitor cells are lymphoid cells.

35. The *in vitro* method according to claim 34, wherein the lymphoid cells are NK cells or cytotoxic T cells.

36. Use of a soluble heterodimeric or multimeric receptor complex comprising soluble receptor subunits, wherein at least one of the subunits comprises a sequence of amino acids that is at least 90% identical to SEQ ID NO:6, and wherein the receptor complex further comprises a soluble IL-2R γ receptor polypeptide as shown in SEQ ID NO: 4, in an acceptable pharmaceutical vehicle, for the manufacture of a medicament for suppressing an immune response in a mammal exposed to an antigen or pathogen.

37. Use of a soluble heterodimeric or multimeric receptor complex comprising soluble receptor subunits, wherein at least one of the subunits comprises a sequence of amino acids that is at least 90% identical to SEQ ID NO:6, and wherein the receptor complex further comprises a soluble IL-2R γ receptor polypeptide as shown in SEQ ID NO:4, for the manufacture of a medicament for reducing proliferation of neoplastic B or T cells in a mammal with a B or T cell neoplasm.

38. The use of claim 36 or 37, wherein the soluble heterodimeric receptor complex comprises a first soluble receptor subunit comprising a sequence of amino acid residues as shown in SEQ ID NO:6, and a second soluble receptor subunit comprising a soluble IL-2R γ receptor polypeptide as shown in SEQ ID NO:4.

39. The use of claim 36 or 37, wherein at least one of the soluble receptor subunits comprises a soluble receptor polypeptide comprising a sequence of amino acid residues as shown in SEQ ID NO:6, and wherein at least one other of the soluble receptor subunits comprises a soluble receptor polypeptide comprising soluble IL-2R γ receptor polypeptide as shown in SEQ ID NO:4.

40. The use of any one of claims 36-37 or 39, wherein the soluble multimeric receptor complex further comprises a Class I cytokine receptor polypeptide.

41. Use of a soluble heterodimeric or multimeric receptor complex comprising soluble receptor subunits, wherein at least one of the subunits comprises a sequence of amino acids that is at least 90% identical to SEQ ID NO:6, and wherein the receptor

complex further comprises a soluble IL-2R γ receptor polypeptide as shown in SEQ ID NO: 4, in an acceptable pharmaceutical vehicle, for suppressing an immune response in a mammal exposed to an antigen or pathogen.

42. Use of a soluble heterodimeric or multimeric receptor complex comprising soluble receptor subunits, wherein at least one of the subunits comprises a sequence of amino acids that is at least 90% identical to SEQ ID NO:6, and wherein the receptor complex further comprises a soluble IL-2R γ receptor polypeptide as shown in SEQ ID NO:4, for reducing proliferation of neoplastic B or T cells in a mammal with a B or T cell neoplasm.

43. The use of claim 41 or 42, wherein the soluble heterodimeric receptor complex comprises a first soluble receptor subunit comprising a sequence of amino acid residues as shown in SEQ ID NO:6, and a second soluble receptor subunit comprising a soluble IL-2R γ receptor polypeptide as shown in SEQ ID NO:4.

44. The use of claim 41 or 42, wherein at least one of the soluble receptor subunits comprises a soluble receptor polypeptide comprising a sequence of amino acid residues as shown in SEQ ID NO:6, and wherein at least one other of the soluble receptor subunits comprises a soluble receptor polypeptide comprising soluble IL-2R γ receptor polypeptide as shown in SEQ ID NO:4.

45. The use of any one of claims 41, 42 or 44, wherein the soluble multimeric receptor complex further comprises a Class I cytokine receptor polypeptide.

46. An isolated heterodimeric or multimeric receptor complex that is capable of intracellular signaling, wherein said receptor complex comprises:

(i) a first receptor subunit comprising the extracellular domain of the $\alpha 11$ receptor, as shown in SEQ ID NO:6, and an intracellular domain of a class I cytokine receptor; and

(ii) a second receptor subunit comprising the extracellular domain of the IL-2R γ receptor, as shown in SEQ ID NO: 4, and an intracellular domain from a class I cytokine receptor.

47. The heterodimeric or multimeric receptor complex of claim 46, wherein the first receptor subunit comprises the intracellular domain of the zalpha11 receptor, as shown in residues 256 (Lys) to 538 (Ser) of SEQ ID NO:2.

48. The isolated heterodimeric or multimeric receptor complex of claim 46, wherein the second receptor subunit comprises the intracellular domain of the zalpha11 receptor, as shown in residues 256 (Lys) to 538 (Ser) of SEQ ID NO:2.

49. The isolated heterodimeric or multimeric receptor complex of claim 46, wherein the first receptor subunit comprises an intracellular domain from a class I cytokine receptor other than the zalpha11 receptor; and wherein the first receptor subunit further comprises a transmembrane domain from either: (i) the zalpha11 receptor, as shown in residues 238 (Leu) to 255 (Leu) of SEQ ID NO:2; or (ii) the class I cytokine receptor other than the zalpha11 receptor.